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Abstract 
The innate immune system is known to play a significant role in the pathogenesis of 
Huntington’s disease (HD). However, whether the myeloid cell activation and 
inflammation associated with neurodegeneration and disease progression in HD is 
protective or damaging remains to be clearly defined. Here, neuronal-myeloid cell 
interactions were examined in novel co-culture models of HD, with the aim of 
investigating the contribution of myeloid cells to neurotoxicity or neuroprotection in the 
pathogenesis of HD. HD and non-HD human NSC-derived neuronal cell lines 
expressing human huntingtin (HTT; full-length or exon 1) were developed and 
characterised. These cell lines can be differentiated into mature neuronal cultures, and 
HD neuronal cultures expressing mutant HTT exon 1 exhibit several characteristics of 
pathologically affected neurons in the HD patient brain. Additionally, a novel technique 
was discovered for the induced differentiation of primary blood monocyte cultures, from 
healthy volunteers or HD patients, into microglia-like cells (BMD-microglia). BMD-
microglia are similar to human brain-resident microglia in vivo by both morphological 
and antigenic criteria. In co-culture, BMD-microglia rescued HD neurons from mutant 
HTT-induced neurotoxicity and reduced neuronal death. This was associated with 
elevated levels of brain-derived neurotrophic factor (BDNF) release and M2 
polarisation shift. During chronic stimulation, HD patient BMD-microglia became more 
M2-polarised than healthy volunteer BMD-microglia and released BDNF at three-fold 
higher levels. In contrast, BMD-macrophages, differentiated from primary monocyte 
cultures from healthy volunteers or HD patients, were neurotoxic in co-culture with HD 
or non-HD neurons, and this was associated with increased release of the 
proinflammatory cytokines interleukin (IL)-1β, IL-6 and tumour necrosis factor (TNF)α. 
Inherent dysfunctional upregulation of cytokine release was also demonstrated in HD 
patient monocytes. Overall, the findings presented in this Thesis highlight myeloid cell 
phenotypes as an important modulator of neurotoxicity in HD, and harnessing the 
innate immune system in order to promote neuroprotective myeloid cell phenotypes 
whilst inhibiting neurotoxic phenotypes is an attractive therapeutic target. Laquinimod, 
a novel immunomodulatory drug which has been shown to have beneficial effects in 
multiple sclerosis patients, was shown here to dampen hyper-reactive cytokine 
production in HD patient monocytes. Modulation of peripheral immune responses has 
previously been demonstrated to impact on central pathology and disease progression 
in HD, and therefore laquinimod may be a promising candidate for dampening the 
harmful effects of a dysfunctional innate immune system in HD. 
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1 Introduction 
1.1 Huntington’s disease 
Huntington’s disease (HD) is a genetic neurodegenerative disorder characterised by 
pathology in the brain and peripheral tissues, along with progressive motor, cognitive 
and neuropsychiatric symptoms. HD is a highly debilitating and fatal condition which 
displays a pattern of progressive decline over approximately twenty years from when 
symptoms become manifest, which is usually in middle-age (Walker 2007). The 
condition was first described in detail by George Huntington in 1872 as a hereditary 
chorea with a psychiatric component and age-onset (Huntington 1872). Approximately 
12 per 100,000 persons suffer from HD in the United Kingdom (UK) (Evans et al. 2013) 
and there is currently no cure, nor are there any treatments which can delay onset or 
slow progression of the disease. 
1.1.1 Clinical features of HD 
Symptoms of HD display delayed onset despite presence of the disease-causing gene, 
mutant huntingtin (mHTT), and protein (mHTT) throughout the entire lifetime. 
Symptoms usually become manifest at 35-44 years of age, but can begin at any time 
from infancy to senescence (Walker 2007). 
Motor abnormalities include involuntary movement disturbances (chorea), such as 
hyperkinetic, irregular and uncontrollable movements. With disease progression, motor 
symptoms become more severe with abnormal posturing and writhing motions, until 
rigidity-akinesia ensues in the final stages (Wild and Tabrizi 2007). Cognitive 
dysfunction in HD includes deficits in attention, executive functioning and working 
memory, and ultimately dementia (Montoya et al. 2006). The most commonly reported 
neuropsychiatric symptoms in HD patients are depressed mood, anxiety, irritability, and 
apathy (van Duijn et al. 2007). 
HD gene carriers can present with one or all of the symptom domains comprising the 
HD triad (motor, cognitive and neuropsychiatric), and in any order (Victorson et al. 
2014). Being such a clinically heterogeneous disease, it can be difficult to clearly 
discern symptom onset. While many patients display evidence of cognitive and 
psychiatric problems before any manifestation of motor symptoms, a definitive 
Introduction 
27 
 
diagnosis of HD is usually only made when motor abnormalities are noted on 
examination (Wild and Tabrizi 2007).  
Approximately 7 % of HD patients become manifest at under twenty years of age and 
are diagnosed with Juvenile HD. Disease progression is generally faster in Juvenile 
HD, and symptoms differ from the adult onset disease in that akinetic-rigidity, rather 
than chorea, is the dominant motor abnormality and many individuals additionally suffer 
with seizure disorder (Nance and Myers 2001). 
Life expectancy of HD patients is around twenty years from symptom onset, and the 
most common primary causes of death are aspiration pneumonia and cardiovascular 
diseases (Heemskerk and Roos 2012; Sørensen and Fenger 1992). Suicide rates are 
also much higher in HD patients than in the general population (Schoenfeld et al. 1984; 
Sørensen and Fenger 1992). 
1.1.2 HD genetics and other contributing factors 
HD is an autosomal dominantly inherited condition caused by a cytosine-adenine-
guanine (CAG) trinucleotide repeat expansion in exon 1 of the HTT gene, which is 
located on the short arm of chromosome 4 at 4p16.3 (The Huntington’s Disease 
Collaborative Research Group 1993). The CAG codons are translated into a poly-
glutamine (polyQ) stretch of amino acids in the HTT protein, which is ubiquitously 
expressed (van der Burg et al. 2009; Ellrichmann et al. 2013). 
The CAG repeat region in HTT can vary in length between individuals and is very 
closely related to HD manifestation and phenotype (Harper 1999; Walker 2007). In HD 
patients, CAG repeat length accounts for approximately 60 % of the variation in age at 
onset (AAO) and rate of disease progression; individuals with longer repeats become 
manifest at a younger age and progress faster (Andrew et al. 1993; Snell et al. 1993; 
Harper 1999; Walker 2007). Less than 27 CAG repeats is normal and individuals do 
not develop HD. HTT with 27-35 repeats is considered an intermediate genotype as 
individuals are generally unaffected but there is a potential risk of expansion and 
inheritance of the mutant gene by offspring (Ha et al. 2012). Trinucleotide CAG repeats 
in the intermediate range or longer become increasingly unstable with length during 
replication, especially in spermatogenesis, leading to dynamic mutations and an 
increased likelihood of expansions over generations (Snell et al. 1993; Walker 2007). 
Repeats of 36-40 give a mutant gene which has reduced penetrance and symptoms 
may not appear until late in adult life, if at all (Rubinsztein et al. 1996; Walker 2007). 
With CAG repeats of more than 40 a fully penetrant mutant gene is produced and 
carriers will be affected by HD (Walker 2007). If the mHTT gene has 60 or more 
repeats, the individual will manifest with Juvenile HD (Nance and Myers 2001). 
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The majority of HD patients are heterozygous gene carriers, and the chance of HD 
inheritance by offspring is 50 %. Some individuals, however, are homozygous for the 
mutant gene, increasing heritability to 100 %. Interestingly, AAO remains within the 
same range as heterozygotes carrying similar repeat lengths to the homozygote allele 
with the longest CAG repeat (Squitieri et al. 2003). Rate of progression in homozygous 
HD gene carriers is, however, more rapid, suggesting that there may be different 
mechanisms underlying AAO and disease progression (Squitieri et al. 2003).  
CAG-repeat length accounts for some, but not all, of the variation in AAO and 
progression rate in HD, and other contributors such as genetic modifiers and 
environmental factors are attributable for the remaining variation in HD pathogenesis 
(Wexler et al. 2004; Gusella et al. 2014; Sun et al. 2016). Recently, analysis of a 
genome-wide association study (GWAS) revealed variants in genes associated with 
deoxyribonucleic acid (DNA) handling and repair mechanisms to be significant 
modifiers of HD AAO (Genetic Modifiers of Huntington’s Disease (GeM-HD) 
Consortium 2015). This could be linked to CAG-repeat somatic expansion, particularly 
in brain regions that are targets for neurodegeneration, which has been found to occur 
at a higher rate in individuals with earlier AAO (Swami et al. 2009). Environmental 
factors which may influence AAO include poverty, diet, exposure to pollutants and poor 
sanitation (Wexler et al. 2004). 
Since identification of the HD gene, individuals who are at risk can choose to undergo 
genetic testing, preceded by genetic counselling, to confirm whether or not they have 
inherited the defective gene. The most common reasons for genetic testing are family 
planning and making career choices (Walker 2007). For example, HD gene carriers 
may opt for in vitro fertilisation (IVF) along with preimplantation genetic diagnostics to 
select for unaffected embryos (Stern 2014). Genetic testing in HD also offers a unique 
opportunity for researchers to study the processes of neurodegenerative disease in the 
pre-manifest stages, potentially opening up avenues of therapeutic intervention before 
the onset of symptoms. 
1.1.3 HD neuropathology 
Neuropathology in HD is hallmarked by neuronal dysfunction and atrophy of the dorsal 
striatum, resulting in extreme shrinkage of the caudate nucleus and putamen and 
expansion of the frontal horns of the lateral ventricles (Vonsattel et al. 1985) (Figure 
1.1). Gamma-amino butyric acid (GABA)ergic medium spiny neurons (MSNs) are 
particularly vulnerable, leading to loss of inhibitory input to the indirect pathway of basal 
ganglia-thalamocortical circuitry involved with movement initiation, and consequently 
manifestation of hyperkinesis and chorea (Purves et al. 2001). Other brain areas 
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particularly affected in HD include the substantia nigra, cortical layers 3, 5, and 6, the 
CA1 region of the hippocampus, the angular gyrus in the parietal lobe, Purkinje cells of 
the cerebellum, lateral tuberal nuclei of the hypothalamus, and the centromedial-
parafascicular complex of the thalamus (Walker 2007). There is also profound white 
matter loss in manifest patients, with basal ganglia-cortical connectivity being 
particularly affected (Novak et al. 2015), in addition to progressive astrogliosis and 
accumulation of reactive microglia in affected brain regions (Vonsattel et al. 1985; Sapp 
et al. 2001). Structural and functional brain changes throughout the disease course 
correlate with symptom manifestation and severity, with the specific regions affected 
relating to associated motor, cognitive and neuropsychiatric symptoms (Kuwert et al. 
1989; Mayberg et al. 1992; Montoya et al. 2006; Novak et al. 2015). 
 
Figure 1.1: Large-scale progressive neuropathology in the HD brain 
Volumetric magnetic resonance imaging (MRI) scans in a healthy volunteer (HV), a pre-manifest 
HD gene carrier (preHD) and a manifest HD patient (manHD) in the early stages of clinical 
symptomatic disease, reveal progressive regional and whole-brain atrophy in HD (Tabrizi et al. 
2009). Striking changes, which can be observed in the images above, include expansion of the 
lateral ventricles, atrophy of the caudate and putamen, and thinning of the cortex. (Re-printed 
with minor amendments from Lancet Neurology, Volume 8, Issue 9, ‘Biological and clinical 
manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional 
analysis of baseline data’, Page 795, Figure 1, Tabrizi et al., ©2009, with permission granted by 
Elsevier Health Science Journals via Copyright Clearance Center, License ID: 
3931970923439). 
Neuropathology at the cellular level is characterised by presence of nuclear and 
cytoplasmic inclusion bodies containing ubiquitinated mHTT aggregates (Davies et al. 
1997; DiFiglia et al. 1997). The full-length HTT protein is proteolytically cleaved into 
several smaller N-terminal fragments all containing the polyQ region, and in HD the 
smallest fragments, including an exon 1 only HTT protein, accumulate into a detergent-
insoluble complex (Landles et al. 2010). It is thought that the polyQ expansion in mHTT 
alters the physiochemical properties of the final protein structure, especially in the 
shorter fragments, such that the final proteins do not fold normally and are instead 
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drawn together by their highly polar polyQ tracts to form hydrogen-bonded 
accumulating aggregates (Arrasate and Finkbeiner 2012). Other cellular 
neuropathology includes dysfunction of synapses, cytoskeletal integrity and axonal 
transport (Walker 2007). 
1.1.4 Normal HTT function 
HTT is a very large protein, approximately 350 kilodaltons (KDa) in its full-length form 
(Cattaneo et al. 2005), which is expressed in all human and mammalian cells (Walker 
2007; Ellrichmann et al. 2013). The HTT gene sequence is also highly conserved 
phylogenetically (Cattaneo et al. 2001) suggesting a fundamental role of HTT in cellular 
function. 
HTT is transcribed widely during embryogenesis (Buraczynska et al. 1995) and 
homozygous Htt knock-out is embryonic lethal in mouse models (Duyao et al. 1995; 
Nasir et al. 1995; Zeitlin et al. 1995), indicating an essential role of HTT in 
development. HTT interacts with numerous other proteins involved with a variety of 
biological functions including transcriptional regulation, endocytosis, intracellular 
trafficking and vesicle transport, cell viability and apoptosis, cell signalling, and 
morphogenesis (Cattaneo et al. 2001; Harjes and Wanker 2003), suggesting that HTT 
is also involved with these processes. 
Highest concentrations of HTT are found in the brain and testes (Walker 2007), and 
several identified roles of the protein relate specifically to neuronal function. HTT 
regulates fast axonal trafficking, vesicle transport and synaptic transmission, and 
protects neurons from excitotoxicity (Cattaneo et al. 2001; Cattaneo et al. 2005). HTT 
is also required for normal excitatory synapse development in the cortex and striatum 
(McKinstry et al. 2014), and is involved in the production and transport of brain-derived 
neurotrophic factor (BDNF), a neurotrophin which protects neurons and regulates 
neurogenesis (Cattaneo et al. 2005). HTT is therefore crucial for normal brain function. 
1.1.5 Mutant huntingtin and cellular pathogenesis 
It is unlikely that HD pathogenesis is caused by a loss of normal HTT function, but 
rather a toxic gain of function by the mutant protein. It is known that expression of 
mHTT causes neuronal dysfunction and degeneration, and there is accumulating 
evidence that fragments of mHTT exon 1 are the toxic species. HD pathology could, 
however, be caused by soluble misfolded mHTT, mHTT-containing inclusion bodies, or 
any species that exist inbetween (compact β-sheet structures, protofibrils, fibrils, 
aggregation foci or visible aggregates) (Bates 2003; Rubinsztein and Carmichael 
2003). Full-length HTT and/or smaller N-terminal fragments could be involved, and 
even mHTT messenger ribonucleic acid (mRNA)-mediated mechanisms of 
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neurotoxicity have been implicated (Nalavade et al. 2013). Any of these species could 
be toxic, redundant or even protective.  
Accumulation of aggregates, especially nuclear inclusions, may cause mechanistic 
interference with normal cell signalling, and have been shown to correlate with toxicity 
in several animal and cell models (Rubinsztein and Carmichael 2003). Aggregation 
inhibition by specific antibodies directed at HTT has been shown to prevent death in an 
HD cell culture model, and antibodies which stimulated aggregation increased 
apoptotic cell death (Khoshnan et al. 2002). Aggregates may also sequester HTT-
interaction proteins and normal HTT into inclusions via retained binding sites and polar 
polyQ interactions, resulting in a dominant negative effect by interfering with normal 
HTT function (Walker 2007). However, it has also been argued that the development of 
inclusions is a protective mechanism implemented by cells to compartmentalise toxic 
mHTT species to reduce their overall concentration and toxicity. Cells which form 
inclusion bodies have been shown to survive longer than those that don’t (Arrasate et 
al. 2004), and a compound which enhances aggregate formation may even lessen 
some aspects of cellular pathology (Bodner et al. 2006). In transgenic HD mouse 
models the most toxic species seems to be mHTT exon 1, as these fragment models 
display the most aggressive disease phenotype, much more so than full-length mHTT 
or larger N-terminal fragments (Heng et al. 2008). 
Whatever the toxic species, mHTT expression has been shown to cause cellular 
pathogenesis via several mechanisms. These include excitotoxicity, mitochondrial 
dysfunction, metabolic impairment, increased production of free radicals, oxidative 
stress, impairment of autophagy and proteasomal degradation systems, transcriptional 
dysregulation, caspase activation, calcium homeostasis dysregulation, apoptosis, and 
inflammatory processes (Rubinsztein and Carmichael 2003; Ross and Tabrizi 2011; 
Soulet and Cicchetti 2011; Ellrichmann et al. 2013).  
The reasons for specific vulnerability of striatal and cortical neurons to mHTT in HD 
pathogenesis are not known. One theory is that the connectivity properties of striatal 
MSNs with the neocortex leave these cells more susceptible to hyper-excitation and 
excitotoxicity is aggravated. Therefore, by non-cell-autonomous neuronal circuit-
mediated effects, these cells have a heightened vulnerability to the cell-autonomous 
toxicity of mHTT (Saxena and Caroni 2011). Another explanation for selective 
vulnerability in HD could be that mHTT interacts with Ras homologue enriched in 
striatum (Rhes), a protein localised selectively to the striatum which has been shown to 
greatly enhance toxicity by eliciting mHTT sumoylation, disaggregation and cell death 
(Subramaniam et al. 2009).  
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1.1.6 Peripheral pathology in HD 
Despite the primary pathology in HD occurring in the brain, numerous reports have now 
described abnormalities in peripheral tissues of HD patients. These include weight loss, 
skeletal muscle wasting, cardiac failure, testicular atrophy, osteoporosis, diabetes, and 
dysfunction of blood-derived cells (van der Burg et al. 2009) (Figure 1.2). It seems that 
dysfunction in peripheral tissues can be partly accounted for as secondary effects of 
central nervous system (CNS) pathology, or due to general sickness. However, there is 
a growing body of evidence which indicates peripheral pathologies are directly caused 
by cell-autonomous effects of mHTT expression. 
 
Figure 1.2: Peripheral pathology in HD patients 
In addition to neurological symptoms, HD patients also suffer with non-neurological symptoms 
as a result of dysfunction in peripheral tissues caused by the ubiquitous expression of mHTT. 
(Re-printed from Lancet Neurology, Volume 8, Issue 8, ‘Beyond the brain: widespread 
pathology in Huntington’s disease’, Page 768, Figure 2, van der Burg et al., ©2009, with 
permission granted by Elsevier Health Science Journals via Copyright Clearance Center, 
License ID: 3931941045883). 
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Intracellular mHTT aggregates are present in peripheral organs of transgenic HD 
mouse models (Sathasivam et al. 1999; Orth et al. 2003) and peripheral cells isolated 
from HD patients are dysfunctional when in isolation (van der Burg et al. 2009), 
indicating cell intrinsic effects of mHTT which are not secondary to pathological brain 
function. For example, monocytes isolated from HD patients are hyper-reactive in 
response to a pathogenic stimulus (Björkqvist et al. 2008). Weight loss and skeletal 
muscle atrophy may result from increased metabolic rate and altered muscle energy 
metabolism in HD patient cells, and osteoporosis has been linked to disrupted 
endocrine signalling, such as increased cortisol concentrations (van der Burg et al. 
2009). 
Blood-derived cells are dysfunctional in HD patients (van der Burg et al. 2009) and 
evidence is increasing for an active role of the immune system in HD (Ellrichmann et al. 
2013). Blood plasma levels of proinflammatory cytokines are elevated in HD patients 
on average sixteen years before onset of clinical symptoms and peripheral blood 
mononuclear cells (PBMCs) have altered inflammatory signalling (Björkqvist et al. 
2008). This could occur in reaction to cellular pathology such as aggregate formation, 
oxidative damage or necrotic cell death, however there is also evidence to suggest a 
direct role of intrinsic mHTT expression in disrupted PBMC inflammatory signalling 
(Träger et al. 2014a). It is possible that both cell-autonomous and non-cell-autonomous 
mechanisms of hyperactive inflammatory processes are at play, leading to a cycle of 
chronic inflammation. An elevated inflammatory state may additionally contribute to 
further neuropathology and peripheral pathology in HD, including neuroinflammation, 
weight loss and muscle wasting (van der Burg et al. 2009). 
It is important to study peripheral pathologies in HD because some contribute 
significantly to mortality, and treating non-neurological symptoms could reduce 
morbidity and improve quality of life. Peripheral tissues may also offer valuable insight 
for molecular and cellular pathogenic disease mechanisms that are shared with the 
CNS. Peripheral cells, such as PBMCs, are easier and less invasive to sample from 
HD patients, and are less expensive to study than CNS-derived cells. As they can be 
isolated from living HD patients, they can be used to monitor pathogenesis over the 
disease course, and could serve as a window into central pathogenic events. There is 
also potential for peripheral biomarkers which track disease progression (Strand et al. 
2005; Dalrymple et al. 2007; Björkqvist et al. 2008; Weiss et al. 2012). 
1.2 The innate immune system 
The innate immune system is an evolutionarily conserved, non-specific branch of the 
immune system which provides a broad first line of defence against invading microbial 
Chapter 1 
34 
 
pathogens, endogenous cellular and tissue damage, and other potential threats. The 
innate immune system comprises physical and chemical barriers against infectious 
agents as well as innate leukocytes which destroy and clear pathogens and other 
dangerous molecules via a variety of different mechanisms. When a local threat or 
cellular damage is detected by tissue-resident leukocytes, a process of acute 
inflammation is initiated. The cells become activated and release inflammatory 
mediators such as histamine, bradykinin, leukotrienes and prostaglandins, which 
induce vasodilation, increase vascular permeability, and have chemotactic effects on 
other circulating leukocytes (Yoshikai 2001). Phagocytes, such as neutrophils and 
macrophages, migrate towards the chemoattractant stimuli and are recruited into the 
inflammatory response, where they can additionally engulf and phagocytose smaller 
pathogens, damaged cells and dangerous molecules. Activated phagocytes release 
cytokines and chemokines which recruit other leukocytes and mediate the inflammatory 
response. Another important function of innate immune cell activation is the 
subsequent initiation of a pathogen-specific adaptive immune response, via antigen 
presentation, for long-lasting immunological memory through B and T lymphocytes 
(Hoebe et al. 2004; Iwasaki and Medzhitov 2015). 
1.2.1 Myeloid cells 
Myeloid cells of the innate immune system include basophils, dendritic cells, 
eosinophils, monocytes, macrophages (and microglia), mast cells, natural killer (NK) 
cells and neutrophils. 
Neutrophils are circulating granular polymorphonuclear leukocytes which are generally 
the first cells to be recruited to an inflammatory site, and can kill microorganisms by 
production of toxic antimicrobial molecules, or by phagocytosis (Kolaczkowska and 
Kubes 2013). Basophils and eosinophils are also polymorphonuclear granulocytes, and 
they play important roles in parasite infections by activating the release of chemical 
mediators such as histamine, which also implicates these cells as initiators of chronic 
allergy responses (Karasuyama et al. 2009; Rosenberg et al. 2013). Mast cells share 
similar characteristics with basophils, but unlike their circulating counterparts they are 
tissue-resident (Karasuyama et al. 2009). Mast cells contain secretory granules 
harbouring pre-formed immunomodulatory and vasoactive compounds, and when 
appropriately activated they undergo degranulation whereby these compounds are 
rapidly released into the extracellular surroundings (Wernersson and Pejler 2014). NK 
cells are mononuclear leukocytes that produce immunomodulatory cytokines as well as 
cytotoxic molecules which can directly destroy infected, damaged or cancer cells via 
cytolytic processes (Vivier et al. 2008). Monocytes are peripheral blood circulating 
mononuclear cells which migrate into tissues where they produce inflammatory 
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mediators and terminally differentiate into macrophage or dendritic cell populations (Shi 
and Pamer 2011). Tissue-resident macrophages have important roles in the 
maintenance of homeostasis by sensing and responding to local infection or tissue 
injury. They produce inflammatory mediators and present antigens to T cells for 
initiation of a secondary adaptive immune response. They also employ specialised 
phagocytic mechanisms to engulf and degrade pathogens, lipoproteins, debris and 
dead cells (Lavin et al. 2015). Microglia are a specialised population of CNS-resident 
macrophages which are the primary responding cells for pathogen infection and injury 
in the CNS. They release inflammatory mediators and engage in phagocytosis in 
response to a threat, but also function in maintenance of normal tissue homeostasis 
and play important roles in the development and remodelling of the CNS (Saijo and 
Glass 2011). Both monocytes and macrophages (and their sub-populations) also play 
roles in tissue repair following infection and injury, and are essential for wound healing 
processes. Dendritic cells are the major antigen-presenting cells and their main 
function is to process and present pathogenic antigens to T cells and promote their 
activation (Gabrilovich et al. 2012). 
1.2.1.1 Monocytes and macrophages 
Monocytes originate from self-renewing multipotent haematopoietic stem cells in the 
bone marrow which differentiate over sequential steps to produce mature, specialised 
myeloid cells (Gabrilovich et al. 2012). Circulating human monocytes can be classified 
into three subsets based on their expression of cluster of differentiation (CD) cell 
surface markers and phenotypes: classical monocytes (CD14hiCD16-), intermediate 
monocytes (CD14hiCD16+), and non-classical monocytes (CD14lowCD16+) (Ziegler-
Heitbrock et al. 2010). Classical monocytes are inflammatory and phagocytic, produce 
inflammatory cytokines such as interleukin (IL)-6 and tumour necrosis factor (TNF)α, 
generate reactive oxygen species (ROS), and migrate into tissues where they 
differentiate into inflammatory M1 classified macrophages which are involved in 
mediation of an inflammatory response, phagocytosis, proteolysis, antigen presentation 
and T cell activation (Yang et al. 2014). Non-classical monocytes are anti-inflammatory 
and patrolling, produce anti-inflammatory cytokines such as IL-10, and migrate into 
tissues where they differentiate into anti-inflammatory M2 classified macrophages 
which are involved in wound healing, tissue fibrosis and angiogenesis (Yang et al. 
2014). During steady state, circulating pools of monocytes in the blood are 
predominantly of the classical or non-classical definition, and their expression and 
phenotypic profiles can change between these two major subtypes, via the 
intermediate monocyte group, to maintain a steady composition of monocyte subsets 
(Ziegler-Heitbrock et al. 2010; Yang et al. 2014). 
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While tissue-resident macrophages can be produced by differentiation of infiltrating 
monocytes (Figure 1.3), it has recently been discovered that the majority of 
macrophage populations originate from erythromyeloid precursors which migrate from 
yolk sac into specific tissues during early embryogenesis, and terminally differentiate 
into specialised macrophage sub-populations with tissue-specific phenotypes (Lavin et 
al. 2015). Tissue-specific functional specialisation is thought to occur in response to 
cytokines and metabolites that are released by the stroma and drive the expression of 
unique transcription factors (Lavin et al. 2015). Under normal homeostatic conditions 
most tissue macrophage populations are maintained by self-renewing embryonic 
precursors independently of monocytes, but following local innate immune responses 
macrophage numbers can be replenished by differentiation of infiltrating monocytes 
(Lavin et al. 2015). 
Macrophage activation has been historically classified as classical or alternative, ‘M1’ 
or ‘M2’ respectively. Classical activation can be triggered by inflammatory cytokines 
such as interferon gamma (IFNү), which is produced by T helper type 1 (Th1) cells, and 
alternative activation can be triggered by IL-4 or IL-13, which are produced by T helper 
type 2 (Th2) cells, hence the respective M1 versus M2 macrophage activation 
nomenclature (Martinez and Gordon 2014). M1 macrophages have increased 
proinflammatory cytokine, inducible nitric oxide synthase (iNOS) and ROS production; 
increased expression of major histocompatibility complex (MHC) class II molecules and 
CD68; increased antigen presentation; and increased microbicidal activity (Gordon and 
Taylor 2005). M2 macrophages have increased endocytic activity; increased 
expression of mannose receptor, dectin-1 and arginase; increased cell growth; 
increased tissue repair; and increased parasite killing (Gordon and Taylor 2005). An 
additional ‘M0’ activation state may also be considered, whereby macrophages are 
deactivated by anti-inflammatory IL-10 or transforming growth factor beta (TGFβ) 
leading to increased production of IL-10, TGFβ and prostaglandin E2 (PGE2); and 
reduced expression of MHC class II molecules (Gordon and Taylor 2005). 
While the M1 versus M2 classification of macrophages may still be used to describe 
the extreme phenotypes of macrophage function, it is now more generally accepted 
that these cells are highly plastic and exist in a dynamic continuum between M1 and 
M2 activation states (Martinez and Gordon 2014). Based on a growing body of 
evidence, it is now considered that macrophage markers and function reflect their 
tissue microenvironment and these cells are highly sensitive to local deviations from 
homeostasis, adapting their phenotypes accordingly (Gabrilovich et al. 2012; Yang et 
al. 2014).  
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1.2.1.2 Microglia 
Microglia are CNS-resident macrophages which are derived by primitive 
haematopoiesis in the foetal yolk sac and seed CNS tissue during early embryogenesis 
(Ginhoux et al. 2010; Saijo and Glass 2011; Goldmann et al. 2016). Yolk sac-derived 
embryonic myeloid precursors are exposed to factors in CNS tissue which drive the 
expression of specific genes for differentiation into functionally specialised microglia 
(Saijo and Glass 2011; Lavin et al. 2015) (Figure 1.3). Recent studies have shown that 
the molecular signatures of microglia define them as a distinct cell population 
compared to other cells of myeloid lineage (Michell-Robinson et al. 2015). Unlike other 
tissue macrophages, none of the microglia sub-populations originate from 
haematopoietic stem cells in the bone marrow, and under normal physiological 
conditions circulating monocytes do not contribute to the myeloid cell pool in the CNS 
(Ginhoux et al. 2010; Saijo and Glass 2011). Rather, maintenance and local expansion 
of microglia is solely dependent on self-renewing CNS-resident microglial progenitors 
(Ajami et al. 2007). Under neuroinflammatory conditions, however, circulating 
monocytes may be recruited to a CNS lesion site where they differentiate into 
macrophages or dendritic cells (Mildner et al. 2007; Greter et al. 2015). 
 
Figure 1.3: Microglia and BMD-macrophage differentiation  
Microglia (top) are derived from primitive haematopoiesis and migrate from the foetal yolk sac to 
the brain during the early days of embryonic (E[days]) development. Microglia differentiation 
and proliferation is initiated by colony-stimulating factor 1 (CSF1) and its receptor (CSF1R), 
CD34 and transcription factor PU.1. Blood monocyte-derived (BMD)-macrophages (bottom) 
originate from haematopoietic stem cells in the bone marrow, enter the circulation as 
monocytes, and take up residence in peripheral tissues as macrophages. BMD-macrophage 
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differentiation and proliferation is initiated by CSF1-CSF1R and transcription factors PU.1, 
CCAAT/enhancer-binding proteins (C/EBPs) and activator protein 1 (AP1). (Re-printed with 
minor amendments from Nature Reviews Immunology, Volume 11, Issue 11, ‘Microglial cell 
origin and phenotypes in health and disease’, Page 776, Figure 1, Saijo and Glass, ©2011, with 
permission granted by Nature Publishing Group (Permissions) via Copyright Clearance Center, 
License ID: 3932010960492). 
Microglia remove damaged neurons and infections as well as playing important roles in 
brain development, tissue maintenance and repair. Neuron-microglia cross-talk occurs 
throughout CNS development via soluble factors, physical regulation of the number of 
neural progenitor cells, and direct interaction with developing synapses (Michell-
Robinson et al. 2015). Microglia also modulate neurite outgrowth and myelin formation 
in the developing and adult brain. Under normal homeostatic conditions, microglia 
exhibit a different morphology than peripheral macrophages, with ramified branches 
which extend from the cell body and dynamically survey the local environment and 
communicate with neurons and other glial cells. In response to infection or traumatic 
stimuli, microglia rapidly adopt an amoeboid morphology and become migratory and 
phagocytic, releasing proinflammatory mediators such as cytokines, chemokines, ROS 
and nitric oxide (NO) (Saijo and Glass 2011) (Figure 1.4). Microglia hyperactivity or 
chronic activation, however, is associated with neurotoxicity and myelin loss and can 
contribute to the progression of neurodegenerative and neoplastic diseases (Saijo and 
Glass 2011). 
Like peripheral macrophages, it is considered that microglia can exist in a dynamic 
continuum between M1 and M2 polarised states (Figure 1.4), and microenvironmental 
conditions can selectively modify unique microglia phenotypes and functions (Michell-
Robinson et al. 2015). Microglia morphology is also highly variable depending on the 
developmental and functional state as well as anatomical location. The structural and 
functional signatures of primary microglia can be modulated by the local 
microenvironment, and peripheral blood monocyte-derived (BMD)-macrophages and 
microglia show morphological and functional similarities when cultivated under identical 
conditions (Gordon et al. 1988; Schmid et al. 2009; Butovsky et al. 2014). Under 
neuroinflammatory conditions in vivo, there is a large phenotypic overlap between 
microglia and recruited BMD-macrophages, introducing technical difficulty for the 
definition of microglia-specific functions in inflammation. Microglia and certain BMD-
cells have even been deemed phenotypically indistinguishable (Enose et al. 2005; 
Greter et al. 2015). It is possible that BMD-macrophages recruited to a site of 
neuroinflammation adopt a functional and morphological state similar to resident 
microglia due to an equal response to the same environmental stimuli (O’Koren et al. 
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2016). Therefore, whilst recent studies have presented unique molecular signatures as 
a means of reliably distinguishing between populations of resident microglia and 
infiltrating myeloid cells (Greter et al. 2015; Michell-Robinson et al. 2015), these cell 
types are highly dynamic and become almost phenotypically indistinguishable when 
exposed to the same microenvironment. 
 
Figure 1.4: Microglial morphology and activation phenotypes 
A) Schematic representations (top panel) and photomicrographs (Iba1 microglial-marker 
immunohistochemistry, bottom panel) of human brain microglia, depicted at various 
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morphological stages of activation. Ramified/resting microglia have long, ramified processes 
with small cell bodies; hyper-ramified microglia are mildly activated and display longer 
processes with increased branching in addition to proinflammatory cytokine production; bushy 
microglia are intermediate in their activation state and are characterised by swollen, truncated 
processes and enlarged cell bodies; amoeboid/phagocytic microglia display rounded, 
macrophage-like morphology with no/few processes and are associated with maximal 
proinflammatory activation, ROS production, and microglial apoptosis (Crews and Vetreno 
2016). (Re-printed from Psychopharmacology, Volume 233, Issue 9, ‘Mechanisms of 
neuroimmune gene induction in alcoholism’, Page 1544, Figure 1, Crews and Vetreno, ©2016, 
with permission granted by Springer-Verlag Berlin/Heidelberg via Copyright Clearance Center, 
License ID: 3932500986976). B) Microglial/macrophage activation is a dynamic process 
existing between M1 (classical activation) and M2 (alternative activation) poles. M1 populations 
release proinflammatory mediators and free radicals which promote neuroinflammation and 
removal of pathogens but impair brain repair and regeneration. M2 populations promote brain 
repair and regeneration by increasing phagocytosis, releasing trophic factors and resolving 
neuroinflammation (Hu et al. 2015). (Re-printed from Nature Reviews Neurology, Volume 11, 
Issue 1, ‘Microglial and macrophage polarization—new prospects for brain repair’, Page 57, 
Figure 1, Hu et al., ©2015, with permission granted by Nature Publishing Group (Permissions) 
via Copyright Clearance Center, License ID: 3932500035088). Abbreviations not yet stated: 
CD206, also known as mannose receptor; IL-1R, interleukin 1 receptor; Ym, chitinase-like 
proteins. 
1.2.2 Myeloid cell signalling 
1.2.2.1 Pattern recognition receptors (PRRs) 
Monocyte-, macrophage- and microglia-mediated inflammatory responses can be 
activated through stimulation of a diverse and extensive array of pattern recognition 
receptors (PRRs) expressed by these myeloid cells. PRRs recognise pathogen-
associated molecular patterns (PAMPs) and damage-associated molecular patterns 
(DAMPs). PAMPs are structures conserved amongst microbial species such as 
flagellin (flagellated bacteria), zymosan (certain fungi), double-stranded RNA (dsRNA) 
(viruses) and lipopolysaccharide (LPS) (Gram-negative bacterial cell wall component) 
(Akira et al. 2006). DAMPs are endogenous danger signals including components from 
damaged, necrotic or dying cells such as intracellular proteins, protein fragments from 
the extracellular matrix and pathologically aggregated proteins (for example, heat-
shock proteins, fibrinogen and mHTT) (Akira et al. 2006). PRRs are germ-line encoded, 
evolutionarily conserved molecules, and include Toll-like receptors (TLRs), for example 
TLR4 which recognises LPS, nucleotide-binding oligomerization domain (NOD)-like 
receptors (NLRs), Retinoic acid-inducible gene 1 (RIG-I)-like receptors (RLRs), 
cytosolic DNA sensors (CDS) and C-type lectin receptors (CLRs) (Takeuchi and Akira 
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2010; Mahla et al. 2013). Activation of different PRRs leads to initiation of different 
signalling cascades resulting in upregulated transcription of genes involved in 
inflammatory responses, such as proinflammatory cytokines, type I IFNs, chemokines 
and antimicrobial proteins, proteins involved in the modulation of PRR signalling, and 
many uncharacterised proteins (Takeuchi and Akira 2010). 
1.2.2.2 Toll-like receptors (TLRs) 
TLRs are characterised by N-terminal leucine-rich repeats and a transmembrane 
region followed by a cytoplasmic Toll/IL-1 receptor homology (TIR) domain (Medzhitov 
et al. 1997; Rock et al. 1998). Ten different types of TLR (TLR1-10) have been 
identified in humans and twelve in mice, all recognising a variety of different PAMPs 
and DAMPs (Takeuchi and Akira 2010). When stimulated, each TLR activates shared 
but distinct signalling pathways via different adaptor molecules which are recruited to 
the TIR domain (Akira et al. 2006). Stimulation of TLR signalling leads to the activation 
of transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B 
cells (NFκB) and interferon regulatory factors (IRFs), and the induction of various 
cellular immune responses such as production of proinflammatory cytokines, 
chemokines and IFNs (Mahla et al. 2013).  
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Figure 1.5: TLR4 signalling cascades triggered by LPS stimulation 
When TLR4 recognises LPS, an LPS-multireceptor assembles at the plasma membrane with 
the recruitment of CD14, MD-2 and LBP. Depending on the associated adaptor proteins 
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involved, a signalling cascade is initiated via the MyD88-dependent pathway (TIRAP/Mal and 
MyD88) or MyD88-independent pathway (TRAM and TRIF). MyD88 recruitment to the TIR-
domain induces formation of a complex of IRAKs, the E3 ubiquitin ligase TRAF6, and IRF-5. 
TRAF6 catalyses the ubiquitination of itself and NEMO/IKKү with Ubc13 and Uev1a, and via 
interaction with the complex formed by TAK1, TAB1 and TAB 2/3 regulates phosphorylation and 
subsequent activation of the IKK complex. Phosphorylated IκB undergoes ubiquitination and is 
targeted for degradation by the proteasome, allowing freed NFκB to translocate to the nucleus 
and induce transcription of proinflammatory cytokine genes. TAK1 is released into the 
cytoplasm directing additional activation of MAPK (ERK, JNK and p38) cascades, ultimately 
leading to the activation of AP-1 which is critical for the induction of cytokine genes. MKK 
phosphorylates MAPKs which in turn initiates the heterodimerisation of c-Fos and c-Jun and the 
formation of AP-1 complex. TRAM recruitment to the TIR-domain triggers translocation of the 
LPS-multireceptor into endosomes, which is controlled by CD14. From endosomes, TLR4 is 
able to interact with the modulator protein TRIF which activates NFκB and IRF-3, inducing their 
nuclear translocation and induction of proinflammatory and type I IFN gene transcription, 
respectively. TRIF regulates formation of a complex of TRAF6 and RIP1 which leads to NFκB 
activation, and TRAF3 which is responsible for phosphorylation of IRF-3 by TBK1/IKKi, inducing 
its translocation. NAP1 and SINTBAD are required for the activation of TBK1/IKKi. (Akira et al. 
2006; Takeuchi and Akira 2010; Brubaker et al. 2015). Abbreviations not yet stated: c-Fos, 
cellular Fos; c-Jun, cellular Jun; ERK, extracellular signal-regulated kinase; IKK, IκB kinase; 
IRAK, interleukin-1 receptor-associated kinase; IκB, inhibitor of kappa-light-chain-enhancer of 
activated B cells; JNK, c-Jun N-terminal kinases; MAPK, mitogen-activated protein kinase; 
MKK, mitogen-activated protein kinase kinase; NAP1, NFκB-activating kinase-associated 
protein 1; NEMO, NFκB essential modulator (also known as IKKү subunit); P, phosphorylated 
(phosphate group); RIP1, receptor-interacting serine/threonine-protein kinase 1; SINTBAD, 
similar to NAP1 TBK1 adaptor; TAB, TGFβ-activated kinase 1-binding protein; TAK1, TGFβ-
activated kinase 1; TBK1, TANK-binding kinase 1; TRAF, TNF receptor-associated factor; Ub, 
ubiquitin; Ubc13, ubiquitin-conjugating enzyme E2 13; Uev1a, ubiquitin-conjugating enzyme E2 
variant 1A. 
There are five TLR TIR domain-containing adaptor molecules: Myeloid differentiation 
primary response gene 88 (MyD88), TIR domain-containing adaptor inducing IFNβ 
(TRIF), TIR domain-containing adaptor protein (TIRAP)/MyD88 adaptor-like (Mal), 
TRIF-related adaptor molecule (TRAM), and Sterile-alpha and Armadillo motif-
containing protein (SARM) (Takeuchi and Akira 2010). TLR signalling can be divided 
into two distinct pathways depending on the usage of MyD88 or TRIF adaptor 
molecules. MyD88 is essential for the induction of inflammatory cytokines triggered by 
all TLRs except TLR3, and TRIF is implicated in the TLR3- and TLR4-mediated 
MyD88-independent pathway (Takeda and Akira 2004; Takeuchi and Akira 2010). 
TLR4 is expressed on the plasma membrane and on endosomes. It is the principle 
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LPS receptor but also recognises other PAMPs such as viral proteins and 
polysaccharide, and DAMPs such as low-density lipoprotein, β-defensins, heat shock 
proteins and pathologically aggregated proteins (Walter et al. 2007; Brubaker et al. 
2015). The TLR4 response to LPS requires a multireceptor complex consisting of LPS-
binding protein (LBP), CD14, and myeloid differentiation protein 2 (MD-2), which act 
sequentially to extract LPS from bacteria and promote TLR4 signalling (Brubaker et al. 
2015). TLR4 activation triggers both the MyD88-dependent and TRIF-dependent 
signalling pathways, although unlike TLR3, TLR4 requires another adaptor, TRAM, for 
activating TRIF (Takeuchi and Akira 2010). Ultimately, the MyD88-dependent signalling 
cascade results in activation of NFκB, activator protein 1 (AP-1) and IRF-5 transcription 
factors and subsequent production of proinflammatory cytokines, and the TRIF-
dependent signalling cascade results in activation of NFκB and IRF-3 which induce 
production of proinflammatory cytokines and type I IFNs (Akira et al. 2006; Takeuchi 
and Akira 2010). Figure 1.5 shows details of the signalling pathways activated when 
TLR4 is stimulated with LPS. 
1.2.2.3 Cytokines 
Monocytes, macrophages and microglia produce both Th1- and Th2-type cytokines, 
depending on their phenotype. Th1- and Th2-type cytokines are so-called because 
they are also produced by Th1 and Th2 cells, respectively. Th1-type cytokines, such as 
IFNү, IL-1β, IL-6, IL-8, IL-12 and TNFα, promote classical inflammation and tend to 
produce proinflammatory responses like activation of phagocytosis and cytotoxic T 
cells. Th2-type cytokines, such as IL-4, IL-5, IL-10 and IL-13, are produced in 
alternative activation states and are involved in T cell-dependent activation of B cells 
and promotion of immunoglobulin (Ig) E and eosinophilic responses. Excessive Th1-
type proinflammatory responses can lead to chronic inflammation-related tissue 
damage, and Th2-type cytokines can counteract some Th1-mediated actions to 
achieve an optimal, balanced immune reaction (Berger 2000). See Table 1.1 for details 
of specific IFN, interleukin and TNF cytokines. 
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Table 1.1: Cytokines 
Interferons (IFNs) 
 Glycoprotein cytokines which activate immune cells via signal transducer and 
activator of transcription (STAT) signalling complexes (Brocker et al. 2010) 
 Predominantly known for their ability to mediate cellular responses to viral infection 
(Brocker et al. 2010) 
 Five classes of type I IFNs found in humans: IFNα, IFNβ, IFNε, IFNκ and IFNω 
(Pestka et al. 2004) 
 One class of type II IFN: IFNү (Pestka et al. 2004) 
Type I IFNs:  Activate intracellular antimicrobial programmes 
 Modulate cell fate, differentiation and migration 
 Regulate the development of almost every effector cell of the 
innate and adaptive immune responses 
(Hertzog and Williams 2013; Ivashkiv and Donlin 2014) 
Type II IFN 
(IFNү): 
 Principle Th1-type cytokine 
 Activates macrophages 
 Upregulates pathogen recognition, antigen processing and 
presentation 
 Directly inhibits viral replication 
 Inhibits cellular proliferation and modulates apoptosis 
 Activates microbicidal effector functions 
 Mediates leukocyte trafficking 
 General roles in immunomodulation 
(Schroder et al. 2003) 
 Ligand for the interferon-gamma receptor (IFNGR) - IFNGR 
activates Janus kinase (Jak)1 and Jak2, leading to the 
phosphorylation and activation of STAT1. This forms a 
transcription factor (STAT1α) which translocates to the nucleus 
and drives the expression of IFNγ-regulated genes (Pestka et al. 
2004) 
 STAT3 and STAT5 are also sometimes activated by IFNү, as well 
as phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), Akt 
(protein kinase B), NFκB and mitogen-activated protein kinases 
(MAPKs) (Pestka et al. 2004) 
Interleukins (ILs) 
 Cytokines which modulate growth, differentiation and activation during an immune 
response 
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 First observed as a number of secreted molecules produced by leukocytes 
(The information about interleukins in this table was acquired from a review written 
by Brocker and colleagues (Brocker et al. 2010)). 
IL-1β:  Th1-type cytokine 
 Rapidly induces transcription of hundreds of downstream targets, 
including other cytokines/chemokines, NOS and matrix 
metalloproteinases (MMPs) 
 Induces production of adhesion molecules to enable transmigration 
of leukocytes into inflamed tissues 
 Involved in the induction of fever 
IL-2:  Does not specifically promote a Th1- or Th2-type immune 
response 
 Along with the Th2-type cytokine IL-4, influences proliferation, 
differentiation and survival of innate and adaptive immune cells, 
including T cells, B cells, NK cells, natural killer T cells and 
dendritic cells 
IL-4:  Th2-type cytokine 
 Along with IL-5 and granulocyte macrophage colony-stimulating 
factor (GM-CSF), facilitates granulocyte maturation 
 Regulation of Ig class switching in B cells, for example, induction of 
IgE secretion 
 Mast cell recruitment 
 Multiple effects on the function and differentiation of monocytes 
and macrophages 
IL-5:  Th2-type cytokine 
 Along with IL-4 and GM-CSF, facilitates granulocyte maturation 
 Stimulates B cell growth and immunoglobulin secretion 
 Stimulates eosinophil production, activation and localisation 
IL-6:  Th1-type cytokine 
 Plays key roles in the acute phase immune response 
 Mediates systemic inflammation and fever 
 Induces differentiation and maturation of B cells into Ig-secreting 
plasma B cells 
 Initiates T cell activation, growth and differentiation 
IL-8:  Th1-type cytokine 
 Attracts neutrophils to the vascular endothelium during 
inflammation, behaving more like a chemokine than a cytokine 
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IL-10:  Th2-type cytokine 
 Key anti-inflammatory cytokine - an extremely important anti-
inflammatory and immunosuppressive cytokine in humans 
 Inhibits Th1-type cytokine expression 
 Potent suppressor of monocyte and macrophage functions 
 Regulates and terminates inflammatory responses 
 Enhances B cell survival, proliferation and antibody production 
IL-12p70:  Th1-type cytokine 
 The active heterodimer of IL-12 
 Promotes differentiation of naïve T cells into Th1 cells 
 Stimulates production of IFNγ and TNFα 
 Inhibits IL-4-induced proliferation of Th2 cells 
 Mediates cytotoxic activity of NK cells and cytotoxic T cells 
IL-13:  Th2-type cytokine 
 Closely related to IL-4 and shares similar effects 
 Regulation of Ig class switching in B cells, for example, induction of 
IgE secretion 
 Mast cell recruitment 
 Multiple effects on the function and differentiation of monocytes 
and macrophages 
Tumour necrosis factors (TNFs) 
 Cytotoxic cytokines which can induce cell death by apoptosis or regulated necrosis 
 Important molecules in the immune response to tumours 
TNFα:  Th1-type cytokine 
 Plays key roles in the acute phase immune response 
 Mediates systemic inflammation 
 Triggers multiple cell signalling pathways leading to apoptosis, 
proliferation, differentiation, chemoattraction and cytokine 
production 
(Aggarwal 2003) 
 
1.2.2.4 Neurotrophins 
Neurotrophins are a family of polypeptide growth factors that are essential for the 
development, function and maintenance of the nervous system. They promote 
neuronal growth and survival, have significant direct effects on synaptic transmission 
and plasticity, and any neurotrophin gene knock-out is embryonic lethal indicating their 
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essential roles in development (Chao 2003). The neurotrophin family includes nerve 
growth factor (NGF), BDNF, neurotrophin (NT)-3 and NT-4. They can bind to the low-
affinity p75 neurotrophin receptor (p75NTR), or the high-affinity tyrosine receptor 
kinase (Trk) receptors (TrkA, TrkB and TrkC). P75NTR is a member of the TNF 
receptor superfamily, and it is involved in the induction of pro-apoptotic programmes, 
the control of axonal regeneration, and mediates the migration of Schwann cells (Chao 
2003; Vega et al. 2003). P75NTR also acts as a regulator of Trk receptor activation by 
modulating the binding affinity and specificity of the receptors for their different 
neurotrophin ligands (Segal 2003). TrkA is the preferred receptor for NGF; TrkB for 
BDNF and NT-4; and TrkC for NT-3 (Vega et al. 2003). Neurotrophins and their 
receptors are widely expressed in the peripheral and CNS, as well as by cells of the 
immune system, and may be involved in mediating interactions between neurons and 
immune cells (Kleij and Bienenstock 2007). 
Monocytes, macrophages and microglia produce NGF and BDNF, and express their 
high affinity receptors (TrkA and TrkB, respectively) (Vega et al. 2003; Kleij and 
Bienenstock 2007). Both neurotrophins influence the expression profile and production 
of inflammatory mediators such as IFNү, IL-1β, IL-4, IL-5, TGFβ and TNFα (Vega et al. 
2003; Kleij and Bienenstock 2007); promote activation (Kleij and Bienenstock 2007; 
Mizoguchi et al. 2014); promote proliferation and differentiation (Kleij and Bienenstock 
2007; Gomes et al. 2013); induce chemotaxis and migration (De Simone et al. 2007; 
Zhang et al. 2014); and can have pro- or anti-inflammatory effects depending on the 
situation and concentration of the neurotrophin (Kleij and Bienenstock 2007). Microglia 
constitutively secrete low levels of BDNF during homeostasis, but during CNS 
inflammation or following injury, BDNF production is chronically upregulated and NGF 
production is induced (Nakajima et al. 2001; Kleij and Bienenstock 2007; Venkatesan 
et al. 2010; Gomes et al. 2013). The TrkA and TrkB receptors can behave as 
autoreceptors, regulating myeloid cell neurotrophin synthesis and release as well as 
responding to neurotrophins in the environment (Kleij and Bienenstock 2007; Zhang et 
al. 2014). Positive feedback loops of autocrine BDNF signalling may contribute to 
prolonged microglial activation and chronic neuroinflammation in CNS diseases (Zhang 
et al. 2014), however the neurotrophin has also been shown to have neuroprotective 
effects in several CNS injury and disease models (Linker et al. 2010; Lee et al. 2012). 
NGF can contribute to inflammatory hypersensitivity, but also suppresses inflammation 
by switching the immune response to an anti-inflammatory, suppressive mechanism 
(Kleij and Bienenstock 2007). 
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1.2.2.5 Complement 
The complement system is involved in rapid, non-specific sensing and responding to 
tissue alterations and pathogen antigens. It is an integral part of the innate immune 
response, but also acts as a bridge between the innate and adaptive immune systems. 
The complement system comprises approximately twenty-five proteins and peptides 
which are present in the plasma and on cell surfaces as inactive precursors, which can 
be activated at the site of inflammation. Via a coordinated sequential enzyme cascade, 
complement mediates responses to inflammatory triggers by enhancing recognition, 
opsonisation and lysis of foreign or damaged cells (Nesargikar et al. 2012). The system 
‘complements’ both innate and adaptive immune cell functions by attracting phagocytic 
cells, triggering cytokine expression, initiating cell lysis by the membrane attack 
complex, and can be activated by and work with IgG and IgM antibodies produced by B 
cells (Nesargikar et al. 2012). 
1.3 Neural-immune interactions 
The CNS and immune system are intimately linked, and neural-immune interactions 
are bi-directional. The complex communication between these systems occurs at 
multiple levels, from whole system to cellular interactions and sub-cellular and 
molecular mechanisms. Neuroendocrine and neuronal pathways control humoral and 
cellular immune responses via the hypothalamic–pituitary–adrenal (HPA) axis and 
direct sympathetic innervation of the lymphoid organs, respectively; and the immune 
system influences the CNS via immune mediators and cytokines (Eskandari and 
Sternberg 2002; Wrona 2006). At cellular and molecular levels, neurons and immune 
cells interact via hormones, neurotransmitters, neuropeptides, cytokines and growth 
factors, and their receptors (Wrona 2006). 
1.3.1 Healthy neural-immune interactions 
1.3.1.1 Communication between the CNS and immune system 
CNS control of the immune system is primarily mediated via the HPA axis and 
sympathetic nervous system (SNS). HPA axis activity results in the production of 
glucocorticoids which regulate a wide variety of immune cell functions, including 
production of cytokines and other inflammatory mediators, maturation and 
differentiation, chemoattraction and migration, and expression of adhesion molecules, 
as well as causing a Th1- to Th2-type shift in immune responses (Eskandari and 
Sternberg 2002). Immune organs, including the thymus, spleen and lymph nodes, are 
innervated by the SNS, and immune cells express adrenergic receptors which allow 
them to respond to the catecholamine neurotransmitters released by sympathetic 
nerves. Like glucocorticoids, systemic adrenaline and noradrenaline promote a Th2-
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type immune response over a Th1-type response by inhibiting production of 
proinflammatory cytokines such as IFNү, IL-12 and TNFα, and stimulating the 
production of anti-inflammatory cytokines like IL-10 and TGFβ (Eskandari and 
Sternberg 2002). In certain local responses, however, catecholamines may also 
promote a proinflammatory immune reaction by inducing IL-1β, IL-8 and TNFα 
production (Eskandari and Sternberg 2002). 
Peripheral immune cells can also regulate activity in the CNS, and this is primarily 
mediated by cytokines. Peripherally-derived cytokines can affect the CNS via several 
mechanisms: they can cross the blood-brain barrier (BBB) at ‘leaky’ sites, for example, 
at the organum vasculosum lamina terminalis or median eminence; they can cross the 
BBB by carrier-mediated transport mechanisms; they can trigger the production of 
CNS-derived mediators in the brain parenchyma via a relay involving endothelial cells 
and circumventricular organs at the internal milieu-brain interface; or they can signal 
the CNS by stimulating peripheral afferent neurons such as those of the vagus nerve 
(Eskandari and Sternberg 2002; Wrona 2006). In general, the peripheral immune 
system signals the CNS to influence feedback regulation of systemic immune 
responses, as well as to induce or suppress the physiological (for example; fever) and 
behavioural (for example; anorexia, immobility, social withdrawal, depressed mood, 
disturbed sleep) symptoms of sickness (Eskandari and Sternberg 2002; Poon et al. 
2015). 
Cytokines produced by peripheral monocytes and macrophages and CNS-resident 
microglia can have direct effects on neurons in the CNS by activating their neuronal 
receptors. The proinflammatory cytokines IL-1β, IL-6 and TNFα have been shown to 
have neuromodulatory properties by impacting synaptic transmission and neuronal 
excitability: the activation of their neuronal receptors rapidly alters neuronal excitability 
via post-translational modifications of either voltage-gated or receptor-coupled ion 
channels, and by promoting presynaptic changes in neurotransmission (Vezzani and 
Viviani 2015). IL-2 and the Th1-type cytokines granulocyte-colony stimulating factor (G-
CSF), IFNγ IL-1α, IL-1β, IL-6, IL-12 and TNFα regulate numerous pathways in 
neurons, including cytokine–receptor interactions, MAPKs, TLRs, apoptosis, 
peroxisome proliferator-activated receptor (PPAR) signalling, cell adhesion molecules, 
antigen processing and Jak-STAT signalling (Benjamins 2013). These cytokines also 
upregulate production of certain neurotransmitters and their receptors, elements of the 
ubiquitin-proteasome pathway, iNOS, superoxide dismutase (SOD)2 and genes 
involved in the Wnt and Notch signalling pathways (Benjamins 2013). The Th2-type 
cytokines IL-4, IL-5, IL-10 and TGF-β regulate genes related to neuroactive ligand-
receptors, calcium and long-term potentiation, upregulate arginase 1 expression 
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leading to decreased NO generation and enhanced neurite outgrowth, and 
downregulate the gene for nuclear receptor co-repressor 2 (NCOR2) which could 
potentially lead to inhibition of histone demethylases and promotion of neuronal 
differentiation (Benjamins 2013). 
1.3.1.2 Neuronal-microglial cell interactions 
Neurons and microglia engage in dynamic communication essential for CNS 
development and maintenance, as well as to produce appropriate immune responses 
in the event of injury or infection. Neurons secrete factors such as chemokines, classic 
neurotransmitters and purines which modulate or maintain microglial activation states, 
properties and behaviours. Microglia produce cytokines, neurotrophic factors and other 
mediators, as well as making direct physical contact with neuronal elements, playing 
important roles in neurodevelopment, neuronal cell fate, the function and maintenance 
of neuronal synapses and circuitry, and the surveillance and resolution of neuronal 
injury or infection. 
CD200 and the chemokine fractalkine (CX3CL1) are expressed on the surface of 
neurons in the CNS, and are unique ligands for their receptors CD200R and CX3CR1, 
respectively, which are expressed by microglia in the CNS parenchyma. When CD200 
activates CD200R, microglia are maintained in a quiescent and unactivated state. 
When CX3CL1 activates CX3CR1 in models of inflammation, microglia are maintained 
in a non-neurotoxic, quiescent state and basal microglial process dynamism, motility 
and surveillance activities are promoted (Eyo and Wu 2013). It has also been 
suggested that neurons suppress the activation of microglia through cell-to-cell contact 
via interaction between the neuronal cell-surface proteins CD47 and CD22 and their 
respective microglial cell receptors CD172 and CD45 (Saijo and Glass 2011). 
Microglial activity is also affected by local neurotransmission, whereby motility is 
decreased by GABAergic inhibitory neurotransmission and increased by glutamatergic 
excitatory neurotransmission (Eyo and Wu 2013). GABA and glutamate have also been 
shown to have direct effects on microglial activation state and phenotype via interaction 
with their microglia-expressed neurotransmitter receptors (Mead et al. 2012). When 
injured, neurons release purines including adenosine triphosphate (ATP) and its 
degradation products; adenosine diphosphate (ADP) and adenosine. Purines diffuse 
into the extracellular space where they can activate P1 (A3) and P2 (P2Y12) microglial 
purinergic receptors, leading to ATP-induced microglial chemotaxis, migration and 
branch extension towards the injury site. Following microglial activation, adenosine can 
also activate A2a receptors that mediate microglial branch retraction (Eyo and Wu 
2013). 
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During homeostasis, microglia secrete neurotrophic factors, such as BDNF, insulin-like 
growth factor (IGF)1, NGF and TGFβ, which support neuronal survival, function and 
tissue repair and maintain CNS homeostasis (Saijo and Glass 2011). Microglial 
processes also make transient direct physical contact with synaptic neuronal dendritic 
spines, suggesting neuro-modulatory roles for microglia during normal physiology (Eyo 
and Wu 2013). Microglia regulate the development and maintenance of neuronal 
synapses and circuitry through various signalling pathways including fractalkine, 
complement receptor, and the DNAX activation protein 12 (DAP12)/triggering receptor 
expressed on myeloid cells 2 (TREM2) signalling complex (Eyo and Wu 2013). 
DAP12/TREM2 is also involved in the maintenance of microglia in a quiescent, 
unactivated state (Saijo and Glass 2011). Microglia also play key roles in synaptic 
pruning during development, and their phagocytic functions support neurogenesis 
(Saijo and Glass 2011). In response to local injury or infection, microglia are activated 
to a proinflammatory, phagocytic, M1-type state which although in principle is 
neuroprotective, can be neurotoxic, especially if the inflammation becomes chronic. 
There are therefore several mechanisms which actively regulate the transition of 
microglia from the activated state to a quiescent, neuroprotective phenotype, and some 
of these are through direct communication with neurons. IL-10, TGFβ, steroid 
hormones, fatty acid metabolites and various nuclear receptor ligands have been 
shown to contribute to the restoration of the resting microglial cell phenotype and the 
resolution of microglial cell-mediated inflammation (Saijo and Glass 2011). For 
example, IL-10 induces the expression of 17β-hydroxysteroid dehydrogenase type 14 
(17β-HSD14), which mediates the conversion of dehydroepiandrosterone (DHEA) to 5-
androstene-3β,17β-diol (∆5-ADIOL), an anti-inflammatory ligand of oestrogen receptor-
β (ERβ). 17β-HSD14 can also be suppressed by TLR4 signalling, allowing acute 
inflammatory activation to occur during a threat and resolution of the inflammatory 
response when the threat is no longer present; an integrated response mediated by the 
ERβ nuclear receptor (Saijo and Glass 2011).  
1.3.2 Neural-immune interactions in neurodegenerative diseases 
In principle, inflammation is a protective, natural response to tissue damage or 
infection. However, chronic activation of the immune system or incomplete resolution of 
the immune response can trigger tissue pathology. Neuroinflammation, along with 
upregulation of peripheral immune responses, is a hallmark of several 
neurodegenerative diseases, including HD, Alzheimer’s disease (AD), Parkinson’s 
disease (PD) and amyotrophic lateral sclerosis (ALS). The extent to which inflammation 
is protective or deleterious in these neurodegenerative diseases, and whether immune 
activity is not only a consequence of but also a contributor to neuropathology, is 
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currently not well understood. Dissecting the complex mechanisms underlying neural-
immune interaction have recently become a key focus of research in 
neurodegenerative diseases as there is potential for immunomodulation as a beneficial 
therapeutic target. 
Neurodegenerative diseases share common features, including the aggregation, 
accumulation and deposition of certain misfolded proteins; progressive dysfunction and 
loss of specific CNS neuronal populations leading to related cognitive, psychiatric or 
motor dysfunction; age-dependent symptom onset and progressive disability until 
directly or indirectly fatal; chronic innate immune activation; and neuroinflammation. It 
may therefore be considered that neurodegenerative diseases share common 
mechanisms of pathology, including those underlying the bidirectional communication 
between neurons and immune cells and their roles in disease progression. Discoveries 
in the context of AD, PD and ALS can shed light on similar mechanisms which may be 
at play in HD; and as a dominantly inherited genetic condition, HD may serve as a 
model for studying neural-immune interactions over the entire disease-course, 
including a unique opportunity to investigate the pre-symptomatic phase of a 
neurodegenerative disease in patients. In this section, the role of neural-immune 
interactions in neurodegenerative diseases is discussed, with a particular focus on AD, 
PD and ALS. Immune system dysfunction and neural-immune interactions in HD are 
discussed in more detail in section 1.4. 
1.3.2.1 Characteristics of neurodegenerative diseases 
AD is both the most common neurodegenerative disease and the most common 
dementing illness, and is characterised by the parenchymal deposition of amyloid-beta 
(Aβ) peptides into Aβ plaques, the formation of neurofibrillary tangles composed largely 
of hyperphosphorylated microtubule-associated tau protein, and the progressive 
atrophy of hippocampus and neocortex leading to progressive memory decline and 
cognitive dysfunction (Amor et al. 2014; Heneka et al. 2014; Doty et al. 2015). PD is 
the second-most common neurodegenerative disorder. It is characterised by abnormal 
accumulation of α-synuclein aggregates in neurons, nerve fibres or glial cells, and the 
formation of Lewy bodies composed of intracellular proteinaceous inclusions containing 
α-synuclein and ubiquitin. PD is hallmarked by neurodegeneration of extrapyramidal 
motor neurons, in particular the loss of dopaminergic neurons of the basal ganglia from 
the substantia nigra pars compacta to the striatum (caudate and putamen). This results 
in movement disturbances such as resting tremor, bradykinesia, rigidity and gait 
dysfunction (Amor et al. 2014; Doty et al. 2015). ALS is characterised by ubiquitin-
positive cytoplasmic inclusions containing transactive response DNA binding protein 43 
(TDP-43) in pathologic neurons, and selective degeneration and loss of upper and 
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lower motor neurons in the motor cortex, brainstem and spinal cord. This leads to 
corticospinal tract signs such as hyper-reflexia and fasciculations, and the wasting and 
atrophy of targeted muscles, ultimately resulting in complete paralysis (Heneka et al. 
2014; Doty et al. 2015).  
1.3.2.2 Microglial activation and chronic neuroinflammation in neurodegenerative 
diseases 
While neuronal dysfunction and death are the main phenomena leading to cognitive, 
psychiatric and physical disability in neurodegenerative diseases, there is a growing 
body of evidence for a key role of innate immune activation and neuroinflammation in 
pathogenesis. In HD, AD, PD and ALS, neuroinflammation is routinely documented in 
pathologically affected areas of the CNS, and involves microgliosis (activation, 
proliferation and migration of microglia at/to a site of injury or infection); astrogliosis 
(altered molecular expression, cellular hypertrophy and proliferation of astrocytes, 
potentially leading to glial scar formation); elevated production of proinflammatory 
cytokines, chemokines and complement; increased expression of PRRs including 
TLRs; and in some cases activation and infiltration of peripherally-derived immune cells 
like T cells, NK cells and BMD-macrophages (Amor et al. 2014; Heneka et al. 2014; 
Doty et al. 2015). Neuroinflammation and immune activation develop early in the 
course of the disease, often prior to symptom onset and large-scale neuronal loss, and 
neuronal injury occurs in an inflammatory environment (Doty et al. 2015). Complex 
interplay occurs between different immune cells and degenerating neurons, and 
polymorphisms of several common immunomodulators involved in this cross-talk have 
been associated with increased risk of neurodegeneration or altered rate of disease 
progression in recent GWASs (Durrenberger et al. 2014; Heneka et al. 2014; Doty et 
al. 2015). 
In neurodegenerative diseases, neuroinflammation can be triggered via stimulation of 
PRRs on different brain cell types (including microglia, astrocytes, neurons and 
endothelial cells) by disease-associated DAMPs such as misfolded proteins, 
aggregated peptides or mislocalised nucleic acids (including mHTT, Aβ and α-
synuclein aggregates) (Saijo and Glass 2011; Heneka et al. 2014; Doty et al. 2015). 
Other DAMPs occurring as a result of neuronal injury or death can also trigger 
neuroinflammation, such as heat-shock proteins, high-mobility group box 1 protein 
(HMGB1), histones and ATP (Saijo and Glass 2011; Amor et al. 2014). A continued 
presence of high levels of DAMPs in the diseased brain leads to chronic microglial 
activation and production of proinflammatory factors which can have autocrine effects 
to reinforce and maintain the inflammatory phenotype (Doty et al. 2015). Such factors 
may also stimulate responses from astrocytes, which feedback to microglia driving 
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recruitment and neuroinflammatory modulation, as well as having both neurotrophic or 
neurotoxic effects on neurons (Saijo and Glass 2011; Doty et al. 2015). Neurotoxic 
effects of mediators released by microglia and astrocytes in the neuroinflammatory 
milieu leads to further neuronal injury and death and the subsequent release of more 
DAMPs which activate microglia. Additionally, due to the damage and loss of neuronal 
populations in neurodegenerative diseases, there is a reduction in the 
neuroimmunoregulatory molecules normally expressed by these cells to provide 
inhibitory input to maintain or restore microglial quiescence and regulatory functions, 
indirectly driving a pro-activation state in local microglia (Amor et al. 2014). As a 
consequence, a chronic cycle of neuroinflammation is initiated (Figure 1.6).  
 
Figure 1.6: Generation of a feed-forward cycle of chronic neuroinflammation in 
neurodegenerative diseases 
Degenerating neurons release DAMPs which are detected by PRRs and purinergic receptors on 
microglia, leading to their activation. Disease-associated protein aggregates may also be 
recognised as DAMPs. The fibril form of Aβ has also been reported to stimulate the activity of 
the NLRP3 inflammasome in microglia, which promotes the maturation of IL-1β. Classically 
activated microglia release proinflammatory mediators such as cytokines, ROS and NO which 
maintain the proinflammatory state by activating other microglial cells and astrocytes, which 
amplify neuroinflammatory signals by releasing their own inflammatory mediators. This causes 
further neuronal damage, resulting in the release of more DAMPs (Saijo and Glass 2011). (Re-
printed from Nature Reviews Immunology, Volume 11, Issue 11, ‘Microglial cell origin and 
phenotypes in health and disease’, Page 782, Figure 4, Saijo and Glass, ©2011, with 
permission granted by Nature Publishing Group (Permissions) via Copyright Clearance Center, 
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License ID: 3932560951122). Abbreviations not yet stated: NLRP3, NOD-, LRR- and pyrin 
domain-containing 3; RAGE, Receptor for advanced glycation end-products. 
Neuroinflammation can be directly neurotoxic because inflammatory mediators such as 
cytokines, free radicals and proteolytic enzymes cause neuronal damage (Amor et al. 
2014; Doty et al. 2015). Alternatively, neuroinflammation can result in indirect 
neurotoxicity due to the shift in microglial phenotypes away from quiescent microglia 
performing homeostatic and beneficial functions, such as the production of 
neurotrophic factors and supporting normal neuronal function (Heneka et al. 2014). For 
example, the sustained release of proinflammatory mediators has been shown to 
suppress axonal transport, adult neurogenesis and synaptic plasticity, and this is 
thought to be a combined effect of the directly suppressive effects of cytokines and NO 
along with the phenotypic change in microglia away from the ramified form which has 
been associated with synapse remodelling via direct neuronal contact through 
microglial processes (Heneka et al. 2014). Additionally, when microglia become 
excessively and chronically activated, they cease to engage in beneficial 
communication with neurons, and microglial cytokine production can become 
dysregulated. This promotes harmful actions of the defence mechanisms leading to 
neurotoxicity, and disturbance of normal neural cell functions due to the sensitivity of 
neurons to cytokine signalling (Hanisch 2002). Prolonged activation of microglia has 
also been shown to reduce their phagocytic functions, restricting their abilities to 
degrade and clear misfolded and aggregated proteins (Heneka et al. 2014).  
Neurons which are injured in neurodegenerative diseases may be more vulnerable to 
progressive damage caused by both direct and indirect mechanisms of inflammation-
related neurotoxicity. In support of a toxic role for inflammation in neurodegenerative 
diseases, epidemiologic studies have shown long-term use of non-steroidal anti-
inflammatory drugs (NSAIDs) reduce the risk of developing AD or PD by approximately 
fifty percent (Lucin and Wyss-Coray 2009; Heneka et al. 2014), and anti-inflammatory 
agents have been reported to reduce microglial activation in association with reduced 
neuronal loss in experimental animal models of PD (Doty et al. 2015). Also, by 
visualising ongoing proinflammatory microglial activity using positron emission 
tomography (PET), high levels of neuroinflammation predicts development of clinical 
AD in patients experiencing mild cognitive impairment (MCI), and the extent of 
microglial cell activation positively correlates with the severity of clinical symptoms in 
ALS (Heneka et al. 2014). A recent study demonstrated that classical NFκB activation 
leading to proinflammatory cytokine production occurs in microglia in the spinal cord of 
ALS patients, and constitutive activation of this pathway alone was enough to induce 
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the pathological hallmarks of ALS in wild-type mice. Conversely, the selective inhibition 
of microglial NFκB signalling rescued motor neurons from microglial-mediated death by 
dampening proinflammatory microglia activation, and the consequence of this was to 
extend survival and delay disease progression by almost fifty percent in a mouse 
model of ALS (Frakes et al. 2014). This study highlights the significance of microglia-
mediated neurotoxicity in this neurodegenerative disease.  
Alternatively, there are many cases in which innate immune activation and 
neuroinflammation have been shown to be protective in neurodegenerative diseases, 
especially in early phases of the neurodegeneration process. For example, phagocytic 
microglia can clear Aβ aggregates and promote efflux of amyloid from the brain to the 
blood stream (Doty et al. 2015). This has been shown to reverse amyloid burden and 
prevent amyloid deposition in animal models of AD (Cagnin et al. 2006). Also, microglia 
populations existing on the continuum between the classically activated and quiescent 
poles have important functions in healing and supporting neuronal survival. It is 
possible that in the early stages of neurodegenerative diseases activated microglia 
perform neuroprotective functions, and in later stages become neurotoxic in their role 
on account of dysregulated neural-immune communication and damage to microglial 
populations themselves as a result of prolonged stimulation over years of the disease 
course. In support of this, ex vivo microglia from an ALS mouse model in early-stage 
disease were shown to be alternatively activated (M2 phenotype) and neuroprotective, 
whereas microglia from late-stage animals were more classically activated (M1 
phenotype) and neurotoxic to motor neurons in co-culture (Doty et al. 2015). Moreover, 
an increased ratio of M1 to M2 markers has been observed in the mid-brain of aged 
mice and blocking microglial polarisation to the M2 phenotype in substantia nigra 
dramatically exacerbated the death of dopaminergic neurons in a mouse model of PD 
(Tang et al. 2014). This suggests that ageing is a factor in switching microglial 
phenotypes away from protective M2-type microglia to neurotoxic M1-type microglia in 
PD. In addition, microglia may be driven to a more toxic phenotype in later stages of 
the neurodegenerative process as a result of chronic activation. For example, 
prolonged stimulation of microglia has been demonstrated to induce aberrant and 
uncontrolled production of proinflammatory mediators and cause restricted abilities to 
phagocytose and clear protein aggregates (Cagnin et al. 2006; Heneka et al. 2014). 
1.3.2.3 Cytokines and neurotrophins in the pathogenesis of neurodegenerative 
diseases 
Cytokines are essential mediators for neural-immune communication in the 
pathogenesis of neurodegenerative diseases, and their functions have been shown to 
have both beneficial and deleterious effects.  
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Elevated levels of the proinflammatory cytokines IL-1β, IL-6, IL-8, IL-12 and TNFα have 
been detected in cerebrospinal fluid (CSF), in areas surrounding Aβ plaque formation 
and neuronal damage, and in plaque-associated microglia in AD patients (Heneka et 
al. 2014; Doty et al. 2015). IL-1β signalling initiates activation of NFκB which drives 
proinflammatory gene expression and production of NO and ROS which can promote 
bystander neuronal death. Over-expression of IL-1β in AD brain has been directly 
linked to plaque progression and tangle formation (Doty et al. 2015). IL-6 drives gliosis 
in response to Aβ and promotes tau hyperphosphorylation, as well as having roles in 
immune resolution and behaving as a neurotrophic factor. Inhibiting IL-12 or TNFα in 
AD mouse models leads to decreased levels of Aβ and reduced pre-plaque pathology 
along with fewer learning and memory deficits (Czirr and Wyss-Coray 2012; Heneka et 
al. 2014; Doty et al. 2015).  
In PD, elevated levels of IFNү, IL-1β, IL-2, IL-4, IL-6, TGFα, TGFβ and TNFα, along 
with an upregulation of NFκB activation, have been reported in patient CSF and in the 
substantia nigra and striatum (Nagatsu et al. 2000a; Reale et al. 2009a; Doty et al. 
2015). TGFβ1 and TGFβ2 may serve to protect against neuronal cell damage in the 
brain parenchyma (Reale et al. 2009a). Blocking TNFα in mouse models of PD 
prevents microglial activation and attenuates the progressive degeneration of 
dopaminergic neurons (Nagatsu et al. 2000a; Czirr and Wyss-Coray 2012; Reale 
2015), however TNFα has been shown to have neuroprotective as well as toxic effects. 
Chronic low expression of TNFα levels reduced the nigrostriatal neurodegeneration in a 
mouse model of PD, while chronic expression of high levels of TNFα induced a slow 
and progressive neurodegeneration accompanied by gliosis and an infiltration of 
peripheral monocytes and macrophages (Chertoff et al. 2011). This suggests that the 
level and time of expression of a particular cytokine can determine whether it causes 
CNS damage or protection.  
Cytokines detected in ALS spinal cord and CSF are similar to AD and PD, and include 
IL-1β, TNFα, and IL-6. The excessive production and release of IL-1β is a common 
feature of neurodegenerative disease, and as a result of the proinflammatory cascades 
it induces, IL-1β is considered to be a major driver of chronic neuroinflammation in AD, 
PD and ALS (Heneka et al. 2014; Doty et al. 2015).  
Neurodegenerative diseases are also associated with dysregulation and altered 
distribution of neurotrophins and their receptors. Neurotrophins are produced by 
neurons, astrocytes, microglia and peripheral myeloid cells, and they can directly 
impact neuronal function and survival. In neurodegenerative diseases, levels of NGF 
and BDNF and their primary high affinity receptors TrkA and TrkB, respectively, have 
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been reported to be increased, decreased or displaying no change in patient brain, 
CSF and serum. There are several potential reasons for these conflicting results, 
including variations in neurotrophin levels over the disease course, large patient-to-
patient variability, medication or supplements used by patients which affect 
neurotrophin levels and lead to confounding results, or even differences in 
methodology. Whilst disease-related changes in the levels of NGF and BDNF still 
remain to be clearly defined, the general consensus is that lower levels of NGF or 
BDNF in disease-associated brain areas, CSF or serum correlate with worse outcome 
and higher levels correlate with better outcome in measures such as neuronal fate, 
brain atrophy rate, disease progression, and symptoms or behaviours in patients and 
animal models of various neurodegenerative diseases (Howells et al. 2000; Nagatsu et 
al. 2000b; Lorigados Pedre et al. 2002; Schindowski et al. 2008; Salehi and 
Mashayekhi 2009; Weinstein et al. 2014; Budni et al. 2015; Forlenza et al. 2015; 
Passaro et al. 2015; Wang et al. 2016). 
1.3.2.4 The role of peripheral immune cells in the pathogenesis of neurodegenerative 
diseases 
While it is clear that a strong link has been defined between neuroinflammation and 
neurodegeneration, peripherally-derived innate immune cells may also play a 
significant role in disease progression, either directly by infiltration to sites of 
neurodegeneration in the CNS, or indirectly via the release of inflammatory mediators. 
CNS infiltration of T cells has been shown to modulate microglial phenotypes and 
neuroinflammation, and affects disease progression in PD and ALS (Park et al. 2016). 
In AD, circulating monocytes have been demonstrated to play a role in the elimination 
of Aβ, whereby they are attracted to and crawl onto the luminal wall of Aβ-positive 
veins and carry Aβ back into the peripheral blood stream (Michaud et al. 2013). 
Increases in the concentrations of inflammatory mediators in the periphery, which can 
occur as a result of obesity, reduced physical activity or a history of systemic infection, 
are known risk factors for AD (Heneka et al. 2014). Also, AD patients who experience 
an acute systemic infection display accelerated cognitive decline which has been 
correlated with peripheral levels of IL-1β and TNFα (Holmes et al. 2003; Holmes et al. 
2009), and there is a strong correlation between peripheral proinflammatory cytokine 
levels and rate of disease progression in PD (Reale 2015). IL-2, IL-1β, IL-6 and TNFα 
have all been reported to be elevated in the periphery in AD and PD. IFNү, IL-4, IL-8 
and IL-10 are also increased in PD, and TGFβ is increased in AD (Brodacki et al. 2008; 
Reale et al. 2009a). This indicates that neurodegenerative diseases are not only 
hallmarked by neuroinflammation, but are associated with a more widespread 
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inflammatory state, and PBMCs are a likely source of enhanced and dysregulated 
cytokine production in the periphery (Reale et al. 2009b).  
While sustained microglial activation is most likely triggered by disease-associated and 
neuronal injury-related DAMPs in neurodegenerative diseases, it is possible that 
peripheral proinflammatory events may also contribute directly to the chronic cycle of 
neuroinflammation ongoing in the CNS by amplifying microglial responses and 
exacerbating neurodegeneration. For example, pre-symptomatic ALS animal models 
show an accelerated course of disease development in response to chronic peripheral 
LPS exposure (Heneka et al. 2014). In PD high plasma concentrations of IL-6 result in 
an increased risk of developing the disease (Chen et al. 2008), and people with high 
levels of circulating IL-1β or TNFα produced by PBMCs are more likely to develop AD 
(Tan et al. 2007). Also, CNS entry of peripherally-derived proinflammatory factors such 
as TNFα has been shown to directly activate microglia and induce their production of 
more inflammatory factors (including TNFα, monocyte chemoattractant protein-1 (MCP-
1), IL-1β and NFκB p65) leading to progressive neurodegeneration of dopaminergic 
neurons in the substantia nigra of adult wild-type mice (Qin et al. 2007). This suggests 
that peripheral proinflammatory cytokines do not only contribute to chronic 
neuroinflammation leading to neurodegeneration, but may also trigger it. 
While there is substantial evidence that peripheral inflammatory events can impact on 
the development and progression of neurodegenerative diseases, there is also scope 
for the injured CNS affecting the peripheral immune system. Delivery of an 
inflammatory stimulus, such as Aβ, IL-1β or an endotoxin, by intracerebroventricular 
injection, induces production of cytokines such as IL-6, which are secreted from the 
brain and directly contribute to the pool of systemic cytokines, or stimulate cytokine 
production by peripheral immune cells via the HPA axis (De Simoni et al. 1990; 
Romero et al. 1996; Song et al. 2001; Reale et al. 2009a). It may therefore be 
considered that the peripheral immune alterations observed in neurodegenerative 
diseases occur as a consequence of brain immune activation as well as contributing to 
it. Hence, when attempting to dissect the complex neural-immune interactions in the 
self-propagating cycle of chronic inflammation and neuronal injury in 
neurodegenerative diseases, it is important to include the roles of peripheral immune 
cells. 
1.3.2.5 Intervention by immunomodulation in neurodegenerative diseases 
Studying the immune components of neurodegenerative diseases has yielded common 
themes, and by unifying these concepts there is increased potential for the 
development of immune-based therapeutics for treatment of HD, AD, PD and ALS. 
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Chronic neuroinflammation and associated neurotoxicity is a characteristic of all of 
these diseases, and it could be argued that directly inhibiting proinflammatory 
processes with an anti-inflammatory agent would be neuroprotective. There is a large 
body of evidence in support of this theory, including epidemiological studies which have 
shown long-term use of NSAIDs to reduce the risk of developing AD or PD (Lucin and 
Wyss-Coray 2009; Heneka et al. 2014). However, increasing expression of the key ant-
inflammatory cytokine, IL-10, in AD mouse models was recently shown to suppress 
microglial Aβ phagocytosis, increase Aβ plaque accumulation and exacerbate memory 
impairment (Chakrabarty et al. 2015). Conversely, suppression of IL-10 has been 
shown to be beneficial, promoting Aβ clearance and mitigating synaptic and cognitive 
deficits in AD mice (Guillot-Sestier et al. 2015). The IL-10 signalling pathway is 
abnormally elevated in AD patient brains, and it is thought that suppressing IL-10 may 
rebalance innate immunity and mitigate AD pathology (Guillot-Sestier et al. 2015). 
Expression of proinflammatory molecules has also been demonstrated to improve 
disease-relevant outcomes in several animal models of neurodegenerative disease 
(Doty et al. 2015). From these studies, it can be considered that due to the complexity 
of neural-immune interactions, and the dual roles of inflammation in both 
neuroprotection and neurotoxicity, a general dampening of all immune responses is 
unlikely to yield a beneficial treatment for neurodegenerative diseases. Rather, a 
targeted immunomodulatory approach should aim to dampen neurotoxic aspects of 
immune cell activation and neuroinflammation whilst promoting beneficial immune cell 
behaviours. To achieve this, a better understanding of the communication between 
neurons and immune cells during homeostasis and in neurodegenerative diseases is 
required. 
1.4 Innate immune system dysfunction in the pathogenesis of 
HD 
As in other neurodegenerative diseases, the innate immune system is now recognised 
to play a significant role in the pathogenesis of HD. Neuroinflammation, involving 
microglial activation, astrogliosis and elevated levels of proinflammatory factors, is an 
early and active component of the disease course, and is accompanied by parallel 
inflammatory events in the periphery mediated by monocytes and macrophages. 
Chronic inflammation and aberrant myeloid cell behaviour accelerate alongside 
progressive neurodegeneration and peripheral pathology. This is likely due, in part, to 
cell-autonomous dysfunction caused by the expression of mHTT in immune cells. As is 
the case in other neurodegenerative disease like AD, PD and ALS, it is also probable 
that cell-to-cell interaction mechanisms involving neurons, immune cells and astrocytes 
play a role in generating a ‘feed-forward’ cycle of myeloid cell activation and chronic 
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inflammation; triggered by DAMPs produced by damaged and degenerating neurons 
and sustained by the accumulating presence of proinflammatory and neurotoxic factors 
which affect all interacting cells.  
Evidence suggests that peripheral innate immune cell dysfunction and systemic 
inflammation in HD may serve as a window into central pathological events, or could 
even directly modulate neuroinflammation and impact on neurodegenerative processes 
in the brain. Whether the myeloid cell activation and inflammation associated with 
neurodegeneration in HD is protective or damaging remains to be clearly defined, and 
the extent to which innate immune system dysfunction in HD is a reactive process or 
has an active influence on disease progression has not yet been fully elucidated. 
Recent evidence, however, indicates that targeting immune disruption, centrally or 
peripherally, may modify disease onset and/or progression. Therefore, it is important 
that we develop further understanding of the influence of inflammation on HD 
pathogenesis, as innate immune cells hold potential as a meaningful therapeutic target 
to slow disease progression or forestall the onset of disease. 
1.4.1 Microglial activation and chronic neuroinflammation in HD 
HD is characterised by cellular and molecular features of neuroinflammation, including 
microgliosis, astrogliosis, elevated levels of proinflammatory cytokines and 
chemokines, strong activation of the complement system, and production of ROS and 
reactive nitrogen species (RNS); and microglia are the main effector cells.  
Post-mortem study of HD brain tissue and PET analyses in living HD patients (using a 
ligand for the peripheral benzodiazepine receptor (PBR), PK11195, expressed 
selectively by activated microglia in the CNS), have shown an early and progressive 
accumulation of activated microglia in affected regions of the HD brain, such as the 
cortex and striatum, and this correlated with loss of neuronal function, brain atrophy, 
and disease severity (Sapp et al. 2001; Pavese et al. 2006; Politis et al. 2011). 
Microglial activation has also been detected in pre-symptomatic HD gene carriers up to 
fifteen years before predicted AAO, and this correlated with striatal neuronal 
dysfunction and rate of disease progression (Tai et al. 2007a; Tai et al. 2007b; Politis et 
al. 2011). Interestingly, a higher level of microglia activation correlated with a lower 
level of dopamine D2 receptor binding sites and this was associated with a higher 
probability of developing HD in five years (Tai et al. 2007b). Additionally, activated 
microglia can be observed in degenerating white matter, which is a key early 
pathological event in HD (Tabrizi et al. 2013). Taken together, these findings indicate 
that microglial activation is an early event in HD pathogenesis and shares a spatial and 
progressive temporal relationship with neuropathology, suggesting an active role of 
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microglial activation in neurodegeneration, including subclinical disease progression. 
Indeed, activated microglia have been shown to proliferate in the vicinity of 
degenerating neurites in HD brain slice cultures and mHTT-expressing neuronal cell 
models of HD (Kraft et al. 2012), indicating a direct association between microgliosis 
and neuronal damage in an isolated in vitro setting. 
Microglial activation is accompanied by a distinct profile of inflammatory mediators in 
HD patient CSF and post-mortem HD brain tissue (Silvestroni et al. 2009). IL-1β and 
TNFα were found to be increased only in the striatum, while IL-6, IL-8 and MMP-9 were 
also upregulated in cortex and cerebellum (Silvestroni et al. 2009). The mRNA levels of 
IL-6, IL-8, IL-10, MCP-1 and TNFα are also increased in the CSF and diseased brains 
of HD patients (Björkqvist et al. 2008; Silvestroni et al. 2009) (Figure 1.7). Elevated 
levels of inflammatory mediators can similarly be observed in the brains of well-
established HD transgenic mouse models, such as the R6/2 model which expresses 
human mHTT exon 1 driven by the human huntingtin promoter (Mangiarini et al. 1996), 
and the BACHD and YAC128 models which express full-length human mHTT from the 
human genomic locus on a bacterial artificial chromosome (BAC) (Gray et al. 2008) or 
yeast artificial chromosome (YAC) (Hodgson et al. 1999; Slow et al. 2003; Van 
Raamsdonk et al. 2007), respectively. Like in human HD patient brain, microglial 
accumulation has been observed in the striatum of HD mouse models (Simmons et al. 
2007), and this is associated with elevated levels of proinflammatory cytokines such as 
IL-1β, IL-6 and TNFα (Ona et al. 1999; Björkqvist et al. 2008; Bouchard et al. 2012; 
Alto et al. 2014). Analysis of striatal tissue gene expression in symptomatic R6/2 mice 
has revealed Th1-type cytokines as potential regulators of disease (Crocker et al. 
2006), and both IL-6 and TNFα have been demonstrated to influence the disease 
course in HD (Bouchard et al. 2012; Hsiao et al. 2014). Administration of an IL-6 
neutralising antibody into R6/2 mice diminished weight loss and partially rescued motor 
deficits (Bouchard et al. 2012). Intracranial infusion of a TNFα inhibitor into R6/2 mice 
decreased the elevated levels of TNFα in the cortex and striatum, decreased gliosis 
and reduced caspase activation, and this was associated with fewer mHTT aggregates, 
increased neuronal density and improved motor function (Hsiao et al. 2014). These 
studies indicate a pathological role of the proinflammatory cytokines IL-6 and TNFα in 
HD, and findings suggest they are key mediators of disease progression. IL-1β is 
another proinflammatory cytokine which is elevated in the brains of HD patients and in 
the R6/2 mouse model (Ona et al. 1999; Ellrichmann et al. 2013). IL-1β is known to 
augment inflammatory signals in the CNS, including direct stimulation of astrogliosis, 
and is involved in neuronal cell death (Ona et al. 1999).  
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Other aspects of neuroinflammation, such as astrogliosis and increased complement 
biosynthesis and activation, can also be observed in affected regions of HD patient 
brains (Singhrao et al. 1999). Astrocytes expressing mHTT are more prone to support 
neuroinflammation and may amplify proinflammatory signalling initiated by microglia 
(Crotti and Glass 2015). Complement activators and regulators have been shown to be 
constitutively expressed at much higher levels in the HD brain compared with normal 
brain; and in the striatum, neurons, astrocytes and myelin show deposition of 
complement components on their surface (Singhrao et al. 1999). It is thought that 
complement production is elevated in local microglia and activated on neuronal 
membranes, contributing to neuronal necrosis and proinflammatory activities (Singhrao 
et al. 1999). The complement peptide receptor mRNAs, C5a receptor and C3a 
receptor, are strongly expressed in HD caudate (Singhrao et al. 1999). These receptors 
may be involved in the recruitment and stimulation of glial cells and phagocytes bearing 
specific complement receptors, and have been shown to activate microglia and induce 
their migration in vitro (Nolte et al. 1996; Möller et al. 1997). 
Recently, magnetic resonance imaging (MRI) techniques and post-mortem tissue 
analyses have been used to assess blood vessel impairments in HD patients, and it 
was discovered that there were alterations in the cerebral vasculature leading to BBB 
leakage (Drouin-Ouellet et al. 2015). The BBB was also found to be compromised in 
the R6/2 mouse model (Drouin-Ouellet et al. 2015). This suggests that there may be 
uncontrolled passage of innate immune cells and blood-borne factors between the 
brain and periphery, however, CNS influx of peripherally-derived immune cells has not 
been reported in neuropathological studies of HD (Silvestroni et al. 2009; Möller 2010). 
Therefore, neuroinflammation in HD appears to be mediated solely via cellular 
interactions between microglia, neurons and astrocytes. There may, however, be 
communication between central and peripheral inflammatory events mediated via 
molecular messengers, such as cytokines. 
1.4.2 Peripheral innate immune system dysfunction in HD 
Like in the CNS, peripherally, inflammatory molecules are elevated in plasma up to 
sixteen years prior to AAO (Björkqvist et al. 2008; Dalrymple et al. 2007; Wild et al. 
2011; Chang et al. 2015), providing further evidence for a possible active role of the 
innate immune system during progression to symptomatic disease. Plasma levels of IL-
6, IL-8, TNFα and clusterin (a protein associated with the clearance of cellular debris 
and apoptosis) are elevated in pre-manifest HD, become more abundant with clinical 
manifestation, and continue to increase in correlation with disease severity (Dalrymple 
et al. 2007; Björkqvist et al. 2008; Heneka et al. 2014) (Figure 1.7). Plasma levels of 
other cytokines and chemokines, including chemokine (C-C motif) ligand (CCL)4, 
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CCL11, CCL26, IFNү, IL-1β, IL-4 and IL-10 also increase with disease progression 
(Björkqvist et al. 2008; Wild et al. 2011; Ellrichmann et al. 2013). Similarly, serum levels 
of inflammatory molecules have been shown to be elevated in several HD mouse 
models (Björkqvist et al. 2008; Nguyen et al. 2010; Chang et al. 2015). As is the case 
in the CNS, several members of the complement cascade have also been detected in 
HD patient plasma samples (Dalrymple et al. 2007). These studies indicate a 
peripheral immune response in HD which occurs in parallel to microglial activation and 
neuroinflammation in the CNS.  
Peripheral myeloid cells are the likely source of elevated systemic levels of 
inflammatory molecules in HD. Monocytes and macrophages isolated from HD patients 
are hyper-reactive in response to external proinflammatory stimulation (Björkqvist et al. 
2008; Träger et al. 2014a), exhibit increased levels of phagocytosis (Träger et al. 
2014b), and are impaired in their ability to migrate towards chemo-attractant stimuli 
(Kwan et al. 2012b). The intrinsic phenotype of T cells, however, is not altered in HD 
patients (Miller et al. 2015). HD monocytes from pre-manifest HD gene carriers, up to 
sixteen years prior to AAO, produce elevated levels of IL-6 compared to healthy 
volunteer monocytes when stimulated with IFNү and LPS ex vivo, and this can 
additionally be observed in both microglia and macrophages isolated from HD mouse 
models (Björkqvist et al. 2008). Increased IL-6, IL-8 and TNFα production has also 
been observed in stimulated pre-manifest and manifest HD patient monocytes and 
BMD-macrophages differentiated in vitro (Träger et al. 2014a) (Figure 1.7). These 
responses, observed in myeloid cells ex vivo, account for elevated levels of 
proinflammatory cytokines in the brain, CSF and plasma of HD patients over the 
disease course. 
The extent to which central and peripheral inflammation in the pathogenesis of HD are 
independent and parallel events, or occur in synchronisation as a consequence of 
interactive communication, is not entirely understood. For example, HD patient 
peripheral myeloid cells (Björkqvist et al. 2008; Weiss et al. 2012; Träger et al. 2014a), 
like microglia (Shin et al. 2005; Simmons et al. 2007), express mHTT, and this results 
in immune cell dysfunction (Kwan et al. 2012b; Träger et al. 2014a) which could 
promote equivalent hyper-reactive proinflammatory molecule secretion in the CNS and 
plasma (Björkqvist et al. 2008). As microglia respond to DAMPs produced by neuronal 
injury, peripheral myeloid cells may also encounter DAMPs produced by mHTT-
induced peripheral tissue pathology or mHTT itself (van der Burg et al. 2009), possibly 
leading to initiation and maintenance of chronic inflammation in the periphery as occurs 
in the CNS. In these cases, cell-autonomous mHTT-induced immune cell dysfunction 
and hyper-reactive responses to progressive pathology in the CNS and periphery 
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would occur in parallel, but independently, and these events would accelerate with 
disease progression. Alternatively, microglial activation and neuroinflammation could 
directly impact peripheral immune behaviour (Eskandari and Sternberg 2002; Saleh et 
al. 2009) and/or peripheral inflammatory events could contribute to neuroinflammation 
and neurodegenerative processes in the CNS (Eskandari and Sternberg 2002; Wrona 
2006). It is probable that both independent cell-autonomous mechanisms and 
synchronised CNS-peripheral immune system interactions play roles in the generation 
and maintenance of chronic neuroinflammation and systemic inflammation in HD. 
 
 
Figure 1.7: Central, peripheral and cellular inflammatory events in the HD patient 
Levels of key proinflammatory cytokines, including IL-6, IL-8 and TNFα, are elevated in the CNS 
and blood plasma of HD patients, up to sixteen years prior to expected AAO. This is strongly 
linked to disease progression. Degenerating neurons stimulate microglial activation in the brain 
parenchyma leading to cytokine production. The cell-autonomous expression of mHTT by 
microglia and peripheral monocytes (and macrophages) also leads to hyper-reactive 
proinflammatory cytokine production by these cells. This is due, in part, to direct transcriptional 
dysregulation caused by mHTT expression, as well as interaction of mHTT with elements of the 
NFκB pathway (and key myeloid-lineage determining factors in microglia) which up-regulates 
proinflammatory responses. (Björkqvist et al. 2008). (Re-printed from The Journal of 
Experimental Medicine, Volume 205, Issue 8, ‘A novel pathogenic pathway of immune 
activation detectable before clinical onset in Huntington's disease’, Page 1874, Figure 4, 
Björkqvist et al., 2008). 
Evidence for parallel cell-autonomous effects of mHTT-induced immune cell 
dysfunction comes from studies examining central and peripheral myeloid cell 
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behaviour ex vivo. The expression of mHTT was shown to compromise cell migration 
and the motility of cellular processes in microglia and monocytes derived from HD 
mouse models and HD patients (Kwan et al. 2012b). Monocytes isolated from HD 
patient blood were also shown to release elevated levels of proinflammatory cytokines 
when stimulated, compared with healthy volunteer monocytes, and this was reversed 
after delivery of small interfering (si)RNAs which lowered HTT expression (Träger et al. 
2014a).  
There has been very little research into the direct effects of neuroinflammation on the 
peripheral immune system in HD. However, there is some evidence to suggest that the 
HPA axis may be altered in HD patients. Levels of cortisol, a major 
immunosuppressant and the main glucocorticoid produced by the adrenal cortex in 
humans, were found to be higher in HD patient blood than in healthy volunteers (Saleh 
et al. 2009). However, this was independent of adrenocorticotropic hormone levels 
which stimulates the adrenal cortex to produce cortisol, indicating alterations in the 
HPA axis in HD, possibly due to chronic stress (Saleh et al. 2009). These findings may 
indicate dysfunction of a major pathway of communication between the CNS and the 
peripheral immune system in HD. 
Multiple studies have shown peripheral immune dysfunction as a key modifier of 
neuroinflammation and central pathogenesis in HD. Peripheral administration of LPS at 
doses unlikely to penetrate the CNS induces changes such as increased microglial 
activation in the brains of YAC128 mice (Franciosi et al. 2012). The dampening of 
peripheral immune responses has also been shown to confer benefits in the brains of 
HD mouse models. For example, peripherally-restricted inhibition of kynurenine 3-
monooxygenase (KMO), an enzyme highly expressed in peripheral immune cells, 
ameliorates neurodegeneration in R6/2 mice by raising CNS levels of neuroprotective 
metabolite kynurenic acid (KYNA) and consequently preventing hyperactive microglial 
activity (Zwilling et al. 2011). Transplantation of wild-type bone marrow into YAC128 
and BACHD mice resulted in normalisation of circulating proinflammatory cytokine 
levels, increased synaptic connections in the cortex, and partial suppression of motor 
and neuropathological defects (Kwan et al. 2012a). Conversely, signalling through 
cannabinoid receptor 2 (CB2) dampens immune activation, and genetic deletion of 
these receptors in BACHD mice accelerated the onset of motor deficits and 
exacerbated their severity (Bouchard et al. 2012). Treatment of R6/2 mice with a CB2 
agonist extended life-span and suppressed motor deficits, synapse loss, and 
neuroinflammation, while a peripherally restricted CB2 antagonist blocked these effects 
(Bouchard et al. 2012). Inhibition of systemic IL-6 also partially rescues motor deficits 
and weight loss in R6/2 mice (Bouchard et al. 2012). These studies provide evidence 
Chapter 1 
68 
 
that peripheral immune cell dysfunction is an important modifier of HD pathogenesis, 
and plays active roles in central pathology, including microglial activation, 
neuroinflammation and neurodegeneration, and impacts on disease onset, progression 
and severity. 
1.4.3 Cellular mechanisms of myeloid cell dysfunction in HD  
Myeloid cells are known to be dysfunctional in HD, and there is evidence that both cell-
autonomous and non-cell-autonomous cellular mechanisms play a role. In HD patients, 
the mHTT protein is constitutively and ubiquitously expressed, however mHTT mRNA 
expression in immune cells is approximately three-fold higher than in other cell-types 
(Genomics Institute of Novartis Research Foundation, transcript 202389_s_at) (Soulet 
and Cicchetti 2011). Mutant HTT levels measured in PBMCs isolated from HD patients 
were also found to correlate with markers of disease progression such as disease 
stage, disease burden score and caudate atrophy rates (Weiss et al. 2012). It is 
therefore considered that mHTT expression causes cell-autonomous dysfunction in 
myeloid cells, contributing to HD pathogenesis. In support of this, it has been revealed 
in a recent study that HD patient monocytes display innate transcriptional dysregulation 
associated with proinflammatory pathway activation in their basal, unstimulated state 
(Miller et al. 2016), indicating a cell-autonomous mechanism in myeloid cells for the 
elevated release of proinflammatory molecules in HD. Miller et al. found increased 
resting expression of numerous proinflammatory cytokines and abnormal basal 
activation of the NFκB pathway was thought to play a key role in mediating these 
transcriptional changes (Miller et al. 2016). Indeed, others have demonstrated mHTT to 
directly interact with components of the NFκB pathway leading to upregulation of 
proinflammatory gene expression in monocytes and macrophages (Träger et al. 
2014a). Similarly, mHTT has been shown to enhance the transcriptional activities of 
myeloid lineage-determining factors in microglia, resulting in increased production of 
proinflammatory cytokines (Crotti et al. 2014). Mutant HTT also directly impairs immune 
cell migration, and it is proposed that this is due to interaction with components of the 
actin machinery (Kwan et al. 2012b).  
Non-cell-autonomous mechanisms of myeloid cell dysfunction in HD include chronic 
inflammation induced and sustained by hyper-reactive responses to mHTT-induced 
DAMPs produced by other cells, and mHTT itself. It is possible that mHTT expression 
primes immune cells in their resting state, leading to an exaggerated inflammatory 
response when a stimulus is encountered. Therefore, myeloid cells are not only in an 
abnormal diseased environment which promotes inflammatory responses, but are also 
maladaptive to this environment due to the cell-autonomous expression of mHTT. In 
support of this, the addition of mHTT-expressing microglia to wild-type neuronal 
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cultures has been shown to cause neuronal apoptosis, and the extent of this 
neurotoxicity is considerably increased under conditions of sterile inflammation (Crotti 
et al. 2014). 
 
Figure 1.8: Cellular and molecular mechanisms of the immune response in HD 
Myeloid cells may contribute to HD pathogenesis by cell-to-cell interaction mechanisms as well 
as cell-autonomous mechanisms. In the former case, degenerating neurons release DAMPs 
and mHTT which activate microglia and trigger neuroinflammation. In the latter case, 
constitutive expression of mHTT by microglia and peripheral myeloid cells primes, or even 
triggers, a heightened immune response. This includes the release of proinflammatory 
cytokines and ROS, and activation of the complement system. Induction of the kynurenine 
pathway also leads to the release of ROS and production of neurotoxic metabolite quinolinic 
acid (QA), which causes excitotoxicity by over-stimulating neuronal glutamatergic N-methyl-ᴅ-
aspartate (NMDA) receptors. All of these inflammatory mediators can cause further damage to 
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neurons (black arrows). Microglial QA release, in combination with astrocytic deficiencies in 
glutamate reuptake, exacerbate excitotoxicity in neurons. Mutant HTT expression in astrocytes 
also leads to downregulation of CCL5, attenuating its beneficial effects on neurite development 
and neuronal activity. Reactive microglia, however, also release neurotrophic factors such as 
BDNF, which may promote neuroprotection (dashed arrows). Modulation of CB2 signalling can 
alter myeloid cell inflammatory phenotypes; signalling through this receptor can downregulate 
inflammatory responses and promote neuroprotection. Finally, cell-specific, differential 
proteasome activity may negatively correlate with the toxicity of the soluble form of mHtt. (Soulet 
and Cicchetti 2011). (Re-printed from Molecular Psychiatry, Volume 16, Issue 9, ‘The role of 
immunity in Huntington's disease’, Page 893, Figure 3, Soulet and Cicchetti, ©2011, with 
permission granted by Nature Publishing Group (Permissions) via Copyright Clearance Center, 
License ID: 3934220747498) 
1.4.3.1 Non-cell-autonomous mechanisms of myeloid cell activation in HD 
When cells are damaged or killed by mHTT-induced toxicity, DAMPs are released and 
detected by myeloid cells as immunogenic molecules, triggering an inflammatory 
response (Soulet and Cicchetti 2011; Crotti and Glass 2015) (Figure 1.8). It is possible 
that extracellular soluble or aggregated forms of mHTT could also be detected as 
DAMPs and induce immune responses, as occurs when Aβ is taken up by 
macrophages via phagocytic or receptor-mediated endocytic processes (Morten et al. 
2007). It has been demonstrated that immortalised cell lines in culture are capable of 
ingesting synthetic polyQ peptides from the extracellular space, which then translocate 
to the nucleus and induce cytotoxicity (Yang et al. 2002). Internalised fibrillar 
aggregates have also been shown to interact with soluble cytoplasmic proteins (Ren et 
al. 2009). It is therefore plausible that mHTT fragments could be detected and trigger 
similar processes in myeloid cells. Mutant HTT mRNA may also serve as a trigger for 
immune cell activation. CAG trinucleotide repeats can form hybrid dsRNAs which are 
subsequently cleaved by the ribonuclease, Dicer, into single-stranded (ss)RNA CAG 
repeat septamers, that can activate intracellular TLRs and cause cell death (Richards 
et al. 2013; Heneka et al. 2014). This mechanism was shown to drive neurotoxicity in a 
Drosophila melanogaster model of HD (Richards et al. 2013; Samaraweera et al. 
2013). 
1.4.3.2 NFκB pathway dysregulation in HD myeloid cells 
Hyper-reactivity of the innate immune response in HD is due partly to NFκB pathway 
dysregulation (Khoshnan et al. 2004; Hsiao et al. 2013; Träger et al. 2014a) (Figure 
1.7). In HD myeloid cells, dysregulation is observed upon activation of TLRs using LPS, 
implicating a possible mechanism of dysfunctional signalling downstream of TLR4, the 
principal LPS receptor (Poltorak et al. 1998; Qureshi et al. 1999). Signalling down-
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stream of TLR4 is highly complex, including activation of the NFκB signalling pathway, 
as well as MAPKs and IRFs (Figure 1.5). Aberrant NFκB signalling has been 
demonstrated in cultured cells expressing mHTT and striatal cells from HD patients 
and HD mouse models, where mHTT was shown to interact with the IKKү subunit, 
leading to elevated NFκB activity and increased NFκB-dependent gene expression 
(Khoshnan et al. 2004; Hsiao et al. 2013). This was also observed in peripheral 
myeloid cells isolated from HD patients, along with a more rapid degradation of IκB 
following LPS stimulation in HD patient monocytes compared to healthy volunteer 
monocytes (Träger et al. 2014a). Under baseline conditions, IκB binds NFκB 
transcription factors such as p65 (RELA) and RelB, thereby preventing their nuclear 
translocation. When a stimulus activates TLR4, the MyD88-dependent and/or MyD88-
independent signalling cascades are triggered, leading to assembly of the IKK complex 
which phosphorylates IκB. The subsequent degradation of IκB liberates NFκB 
transcription factors for nuclear translocation where they initiate gene transcription for 
production of proinflammatory cytokines and type I IFNs (Akira et al. 2006; Takeuchi 
and Akira 2010; Brubaker et al. 2015). In HD patient myeloid cells, mHTT directly 
interacts with the ү subunit of the IKK complex, resulting in enhanced degradation of 
IκB, increased and prolonged NFκB translocation, and elevated production of 
proinflammatory cytokines (including IL-1β, IL-6, IL-8 and TNFα) following stimulation 
(Khoshnan et al. 2004; Björkqvist et al. 2008; Träger et al. 2014a) (Figure 1.9). 
Moreover, IKK has been shown to phosphorylate mHTT at amino acid S13, enhancing 
the clearance of mHTT via the ubiquitin-proteasome and autophagy degradation 
systems and regulating its neurotoxicity (Thompson et al. 2009; Steffan 2010). 
In addition, mHTT-induced transcriptional dysregulation affects key inflammatory 
signalling pathways, including elements of the NFκB pathway, in HD patient myeloid 
cells (Figure 1.7). Basal, resting RNA expression levels of several genes downstream 
of TLR4 activation are increased, including Akt, c-Fos, c-Jun, IRAK-1, MyD88 and 
TRAM (Träger et al. 2014a) (Figure 1.5). When HTT expression was knocked-down by 
delivery of anti-HTT siRNAs, the observed transcriptional dysregulation in HD myeloid 
cells was reversed, and the elevated production of IL-6, IL-8 and TNFα was also 
decreased (Träger et al. 2014a). Immortalised human monocyte and rat microglial cell 
lines could also be induced to release elevated levels of proinflammatory cytokines in 
response to stimulation (Träger et al. 2014a), and elevated proinflammatory gene 
transcripts (Crotti et al. 2014), respectively, by transduction with mHTT. These findings 
provide further evidence for HD myeloid cells existing in a cell-autonomous, mHTT-
induced primed state leading to hyper-reactive responses when a stimulus is 
encountered. 
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Figure 1.9: NFκB pathway dysfunction in HD patient myeloid cells 
Cell-autonomous mHTT expression in HD patient microglia, monocytes and macrophages leads 
to hyper-reactive proinflammatory cytokine production in response to LPS stimulation. Mutant 
HTT directly interacts with the ү subunit of the IKK complex (also known as NEMO) leading to 
increased IκB degradation, and subsequently nuclear translocation of NFκB is enhanced and 
prolonged. NFκB initiates transcription of genes for proinflammatory cytokines and type I IFNs 
which are released from the cell at elevated levels. 
1.4.3.3 mHTT promotes microglial activation via myeloid lineage-determining factors 
While mHTT has been shown to promote autonomous hyper-reactivity in myeloid cells 
by enhancing the activities of the transcription factor NFκB (Träger et al. 2014a), mHTT 
has also been demonstrated to promote microglial activation in a basal, resting state 
via myeloid lineage-determining factors (Crotti et al. 2014) (Figure 1.7). The expression 
of mHTT in a rat microglial cell line conferred a cell-autonomous increase in 
proinflammatory gene expression associated with the increased expression and 
transcriptional activities of myeloid lineage-determining factors PU.1 and 
CCAAT/enhancer-binding protein (C/EBP) (Crotti et al. 2014). Binding sites for PU.1 
and C/EBPs were highly enriched in enhancers and promoters associated with genes 
exhibiting constitutive upregulation in primary microglia isolated from HD mouse 
models, and enhanced binding of the two transcription factors in combination was 
observed nearby genes such as Il6 and Tnfa, correlating with their increased 
expression. Microglia in the striatum and cortex of HD patient brains were also shown 
to express elevated levels of PU.1 (Crotti et al. 2014). This molecular mechanism of 
mHTT-induced enhanced basal proinflammatory activation was reported to be 
microglia-specific, as it was not observed in peripheral macrophages isolated from HD 
mouse models or in HD patient monocytes (Crotti et al. 2014). 
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1.4.3.4 Signalling through CB2 dampens proinflammatory activation and promotes 
neuroprotective phenotypes in HD myeloid cells  
CB2 is expressed by microglia and peripheral myeloid cells (Palazuelos et al. 2009; 
Bouchard et al. 2012), and its expression is increased in striatal microglia in the brains 
of HD patients and HD mouse models (Palazuelos et al. 2009). It has been 
demonstrated that signalling through this receptor both suppresses proinflammatory 
activation of immune cells and confers a neuroprotective phenotype (Figure 1.8). 
Administration of CB2 agonists to transgenic and chemical HD animal models reduces 
neuroinflammation, systemic levels of proinflammatory cytokines, brain oedema, 
striatal neuronal loss, synapse loss and motor deficits, and extends life-span 
(Palazuelos et al. 2009; Sagredo et al. 2009; Bouchard et al. 2012). Conversely, 
genetic ablation of CB2 or administration of CB2 antagonists in HD animal models 
enhances microglial activation, increases disease-related neurotoxicity, accelerates the 
onset of motor deficits, increases severity of motor symptomatology, and reduces life-
span (Palazuelos et al. 2009; Sagredo et al. 2009; Bouchard et al. 2012). A 
peripherally-restricted CB2 antagonist was also shown to have these effects (Bouchard 
et al. 2012). These studies demonstrate a link between CB2 signalling in peripheral and 
central myeloid cells and the onset and severity of neurodegeneration in HD, and 
indicate an association between the attenuation of myeloid cell activation and the 
prevention neurodegeneration. 
1.4.3.5 Kynurenine pathway modulation in HD myeloid cells 
The kynurenine pathway, for the metabolism of L-tryptophan and formation of 
nicotinamide adenine dinucleotide (NAD+) (Moroni 1999), has received interest in the 
study of HD pathogenesis because it generates several metabolites with neuroactive 
properties (Amori et al. 2009; Schwarcz et al. 2010). KYNA has a neuroprotective 
effect through modulation of mitochondrial function (Beal et al. 1990), while 3-
hydroxykynurenine (3-HK) and quinolinic acid (QA) are neurotoxic because they induce 
oxidative stress via generation of ROS (Crotti and Glass 2015), and cause 
excitotoxicity by over-stimulating neuronal glutamatergic N-methyl-ᴅ-aspartate (NMDA) 
receptors (Schwarcz and Pellicciari 2002), respectively. Several studies have 
investigated the levels of kynurenine pathway metabolites in HD patients and HD 
mouse models, and generally found increased levels of neurotoxic metabolites and 
decreased levels of neuroprotective metabolites (Möller 2010; Schwarcz et al. 2010). In 
a yeast suppressor screen, it was discovered that genetic deletion of KMO, the enzyme 
that converts kynurenine into 3-HK, suppresses mHTT toxicity (Giorgini et al. 2005). 
Inhibition of KMO decreases levels of neurotoxic metabolites and increases KYNA 
levels (Andre et al. 2016). In the CNS, KMO is mainly expressed by microglia, and is 
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not found in neurons (Guillemin et al. 2003; Giorgini et al. 2008), implicating a non-cell-
autonomous mechanism for microglia involvement in HD pathogenesis. A follow-up 
study by Giorgini et al. (2008) demonstrated that microglia isolated from R6/2 mice 
synthesise increased levels of neurotoxic metabolites via the kynurenine pathway, and 
that these increases can be reduced by histone deacetylase (HDAC) inhibitors 
(Giorgini et al. 2008). Interestingly, oral treatment with a peripherally-restricted KMO 
inhibitor has also been shown to protect against synaptic loss and improve behavioural 
defects in HD mice, implicating a role of peripheral immune cells, as well as microglia, 
in the modulation of neurodegeneration via the kynurenine pathway in HD (Zwilling et 
al. 2011) (Figure 1.8). 
1.4.3.6 Motility and migration deficits in HD myeloid cells 
Mutant HTT expression has been linked to impaired immune cell motility and migration. 
Microglia isolated from BACHD mice and monocytes and macrophages isolated from 
HD patient blood are defective in their ability to migrate towards chemoattractant stimuli 
(Kwan et al. 2012b). Microglia also displayed reduced process extension and increased 
process retraction, and a delayed response to injury in the brains of HD mice in vivo 
(Kwan et al. 2012b). These migration and motility deficits were reversed when mHTT 
expression was inhibited specifically in macrophages by conditional HTT deletion 
(Kwan et al. 2012b), demonstrating a cell-autonomous mechanism of immune cell 
dysfunction caused by expression of mHTT. The authors proposed that mHTT directly 
interacts with cofilin, a component of the actin machinery, disrupting the dynamic 
turnover of cofilin/phosphorylated-cofilin which drives membrane alterations required 
for cell migration (Kwan et al. 2012b). 
1.4.4 Neurotoxic versus neuroprotective effects of innate immune system 
dysfunction in HD 
In the study of neurodegenerative diseases, the consequences of inflammation for 
neurodegenerative processes is an important area of research. The same is true for 
HD, where central and peripheral immune activation and inflammation is recognised to 
play key roles in the onset, progression and modulation of neuropathology. Exactly 
what these roles are, and to what extent they are beneficial or harmful, however, still 
need to be completely elucidated. A fully comprehensive understanding of the complex 
neural-immune interactions underpinning communication between the nervous and 
immune systems in HD is likely to reveal targets for appropriate therapeutic 
intervention with the aim of delaying disease onset and/or slowing disease progression. 
There is a huge body of evidence in support of microglial activation and 
neuroinflammation causing neurotoxicity in HD, and increased inflammation has been 
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clearly linked to a more severe disease phenotype and symptomatic progression 
(Heneka et al. 2014). In one study, induction of sterile inflammation by stereotactic 
injection of LPS into the striatum of mice expressing mHTT only in microglia, resulted in 
enhanced neuronal death compared to non-transgenic control mice (Crotti et al. 2014). 
This response was also observed in vitro when the addition of primary murine mHTT-
expressing microglia to wild-type murine neuronal-astrocyte cultures increased 
neuronal apoptosis (Crotti et al. 2014). Inflammatory changes in mHTT-expressing host 
microglia have also been shown to cause specific striatal projection neuron toxicity in 
non-HD grafts in human patients (Cicchetti et al. 2009). These results suggest that 
mHTT-expressing microglia have the capacity to initiate and/or amplify 
neuroinflammation, and that this is enough to cause neurotoxicity, even in non-HD 
neurons. 
Excessive proinflammatory cytokine release by microglia and peripheral myeloid cells 
have been demonstrated to contribute to neurotoxicity, and inhibition of IL-6 or TNFα, 
centrally or peripherally, has been shown to have beneficial therapeutic effects in HD 
(Bouchard et al. 2012; Hsiao et al. 2014). Chronic elevated proinflammatory cytokine 
release may also have direct impact on peripheral tissues, such as muscle and fat, 
leading to exacerbated symptoms of muscle wasting and weight loss in HD patients 
(van der Burg et al. 2009). 
The presence of mHTT is also a trigger of oxidative stress (Crotti and Glass 2015). 
Aggregates of mHTT have been shown to cause generation of ROS and RNS in 
neuronal and non-neuronal cells, including myeloid cells (Wyttenbach et al. 2002; 
Hands et al. 2011), and this is possibly due to mHTT-induced defects in mitochondrial 
metabolism (Crotti and Glass 2015). HTT is an iron-regulated protein (Hilditch-Maguire 
et al. 2000) and mHTT inclusions are iron-dependent centres of oxidative stress 
(Firdaus et al. 2006). This has been proposed as a direct mechanism of neuronal 
injury, as well as an indirect mechanism via microgliosis; which has been demonstrated 
to be attenuated, along with neurodegeneration, in rat models of iron deprivation 
(Shoham and Youdim 2000). Conversely, iron supplementation to iron deprivation rats 
increased microgliosis and neuronal damage, demonstrating a tight relationship 
between iron and neurotoxic microgliosis (Shoham and Youdim 2000). Abnormal 
accumulation of iron has been observed in HD brains (van den Bogaard et al. 2013), 
and while iron is required for normal mitochondrial function, when it is in excess this 
can lead to uncontrollable generation of ROS (Crotti and Glass 2015). Oxidative stress 
can cause neurotoxicity in HD by damaging neuronal DNA, lipids and proteins (Barja 
2004; Shirendeb et al. 2011). However, in addition to the excessive production of free 
radicals, over-expression of antioxidants, such as the glutathione peroxidases 
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peroxiredoxin 1 and peroxiredoxin 6, has also been observed in HD (Sorolla et al. 
2008; Mason et al. 2013), and it is suggested that this is an adaptive response to 
restore the balance of ROS and RNS (Sorolla et al. 2008). Glutathione peroxidase 
activity has even been shown to be neuroprotective in HD mouse models (Mason et al. 
2013). Ferritin, an iron storage protein with antioxidant properties, has been found to 
accumulate in mHTT aggregates in striatal microglia from R6/2 mice and in HD patient 
tissue, and ferritin accumulation increased with disease progression (Simmons et al. 
2007). It is considered that ferritin accumulation may be a protective response to 
reduce the free iron pool and consequently reduce oxidative stress (Möller 2010; Crotti 
and Glass 2015). 
While current evidence generally points to a neurotoxic role for immune cell activation 
and inflammation in HD (Andre et al. 2016), it is possible that myeloid cell phenotypes 
may shift throughout different stages of the disease course. For example, in early 
stages of disease, immune responses to neuronal damage may be protective and 
beneficial, but when neurodegeneration becomes extensive the inflammatory events 
may shift to become chronic, uncontrolled and neurotoxic. Surprisingly, however, a 
study looking at macrophage M1-M2 polarisation over the clinical disease course in 
HD, found pre-manifest and early-stage manifest HD patient macrophages to be 
predominantly of a proinflammatory M1 phenotype, and late-stage manifest HD patient 
macrophages displayed changes in the expression of surface markers in favour of an 
anti-inflammatory M2 phenotype (Di Pardo et al. 2013). This correlated with increased 
IL-12 and NFκB expression in pre-manifest HD macrophages and reduced levels of 
anti-inflammatory TGFβ1 in pre-manifest HD serum, all of which returned to normal 
levels along with an increase in IL-10-expressing macrophages in progressing 
symptomatic disease (Di Pardo et al. 2013). These findings suggest an active 
inflammatory state in pre-manifest and early-stage HD, which shifts to a more down-
regulated, neuroprotective state in late-stage disease, possibly outlining tissue 
repairing attempts. The authors suggested a possible M1/M2 polarisation shift 
dysfunction in HD macrophages, mediated by aberrant NFκB pathway signalling which 
changes due to altered microenvironment signals over the disease course (Di Pardo et 
al. 2013). 
Activated microglia are generally considered to be of a neurotoxic phenotype, however, 
microglial activation can also occur as a protective response to neuronal dysfunction 
and changes in the tissue microenvironment, and microglial provision of phagocytic 
clearance and trophic support could be beneficial during neurodegeneration (Andre et 
al. 2016). This has been demonstrated in HD brain slice cultures and a rodent HD cell 
culture model, where microglia became activated and proliferated in the vicinity of 
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degenerating neurites (Kraft et al. 2012). Co-culture of wild-type microglia with mHTT-
expressing neurons also increased neuronal survival (Kraft et al. 2012). Activated 
microglia can therefore be neuroprotective, however cell-autonomous dysfunction 
caused by expression of mHTT in HD patient immune cells may reduce these 
protective functions (Heneka et al. 2014). 
It has also been argued that microglial activation and neuroinflammation are simply 
reactive processes; responding to neurodegeneration but not contributing to it in either 
a beneficial or harmful capacity. For example, BACHD mice showed marked 
amelioration of disease with reduction of mHTT in cortical and striatal neurons, without 
affecting its expression in microglia (Wang et al. 2014a). The general consensus, 
however, is that cell-autonomous toxicity as well as cell-to-cell interactions, involving 
neurons, astrocytes and microglia, are necessary for the generation of striatal 
pathogenesis in HD (Gu et al. 2005; Gu et al. 2007; Bradford et al. 2009; Bradford et al. 
2010; Möller 2010; Crotti and Glass 2015). 
1.5 Therapeutic intervention in HD 
1.5.1 Management of symptoms in HD 
There are currently no curative treatments for HD, and no therapies which slow or 
delay disease progression (Mestre and Ferreira 2012; Pidgeon and Rickards 2013; 
Frank 2014; Killoran and Biglan 2014; Dayalu and Albin 2015). Pharmacological 
intervention aims at symptomatic relief (Pidgeon and Rickards 2013; Brett et al. 2014; 
Killoran and Biglan 2014; Dayalu and Albin 2015), and these treatments generally 
focus on the motor aspects of HD (Pidgeon and Rickards 2013; Frank 2014). For 
example, tetrabenazine, a dopamine-depleting agent and the only drug officially 
approved for the treatment of HD, is effective for reducing chorea (Mestre and Ferreira 
2012; Pidgeon and Rickards 2013; Frank 2014; Killoran and Biglan 2014). However, 
the use of this agent carries a risk of potentially serious adverse effects, so some 
newer neuroleptic agents, such as olanzapine and aripiprazole, are often administered 
as alternatives due to their adequate efficacy for treating chorea and psychosis with a 
more favourable adverse effect profile (Frank 2014; Killoran and Biglan 2014). For the 
management of psychiatric disturbances, selective serotonin reuptake inhibitors and 
mood stabilizers are often used (Killoran and Biglan 2014). No known effective 
treatment is available for cognitive dysfunction in HD (Killoran and Biglan 2014).  
Overall, the evidence base for the pharmacological management of HD is poor, with 
only tetrabenazine showing any clinically meaningful effect on chorea and few clinical 
studies focussing on pharmacotherapy for non-motor symptoms of HD (Pidgeon and 
Chapter 1 
78 
 
Rickards 2013). There is some evidence for the usefulness of physical therapy, 
occupational therapy and speech therapy, but such non-drug treatments are still limited 
in improving quality of life (Walker 2007). This highlights a significant need for high 
quality clinical trials and clinical research efforts with the aim of finding effective and 
safe treatments for motor, cognitive and neuropsychiatric symptoms of HD (Mestre and 
Ferreira 2012; Pidgeon and Rickards 2013). 
1.5.2 Current therapeutic strategies under investigation for treatment of HD 
In addition to ongoing clinical research into the treatment of symptoms in HD, multiple 
therapeutic strategies are currently under investigation with the aim of 
preventing/delaying disease onset and/or slowing disease progression. These potential 
therapies target a variety of biological aspects of this complex disease.  
Pharmacological approaches include administration of BDNF (Giampà et al. 2013) or 
dopamine stabilisers (Huntington Study Group HART Investigators 2013) to preserve 
remaining neural activity; cannabinoids which have anti-inflammatory, neuroprotective 
and neuroregenerative properties (Sagredo et al. 2012); KMO inhibitors to tip the 
balance of kynurenine pathway metabolites in the favour of neuroprotective KYNA 
production and away from neurotoxic 3-HK and QA production (Zwilling et al. 2011); 
phosphodiesterase (PDE) inhibitors targeting transcriptional dysregulation within the 
cyclic adenosine monophosphate (cAMP) and cAMP response element binding 
(CREB) signalling cascades in striatal neurons, and restoring synaptic function 
(DeMarch et al. 2008; Giampà et al. 2010); HDAC inhibitors which alter gene 
transcription and aberrant post-translational modifications of mHTT (Gray 2011); non-
allele specific RNA inhibitors (RNAi) (Manth et al. 2012) and antisense oligonucleotides 
(ASOs) (Lu and Yang 2012) to knock down expression of HTT; and allele-specific 
silencers which target single nucleotide polymorphisms (SNPs) in the mutant gene 
(Kay et al. 2014). 
Surgical approaches, which have already been shown to have some benefit in other 
neurodegenerative diseases, such as PD, involve the neurotransplantation of neural 
and mesenchymal stem cells in an attempt to replace neurons that have already 
succumbed to disease pathology and provide trophic support for remaining cells 
(Lescaudron et al. 2012; Maucksch et al. 2013; Kerkis et al. 2015). Pre-implantation 
genetic engineering of stem cells to over-express BDNF may also serve as a useful 
CNS delivery method for this neurotrophin (Pollock et al. 2016). Recent advances in 
induced pluripotent stem cell (iPSC) technology, in combination with emerging specific 
RNAi and ASO gene therapies to silence the mHTT gene, highlight potential for 
patient-specific cell replacement therapy which would provide a readily obtainable 
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source of graft material which can be differentiated into specific neuronal populations, 
and eliminate problems of immunological rejection (Liu et al. 2016). 
1.5.3 Potential therapies targeting the immune system in HD 
Numerous reports have described dysfunction of the innate immune system in HD, and 
an active role in neuropathology has been clearly demonstrated in HD mouse models 
and HD patients. Consequently, novel therapeutic approaches targeting immune cells 
and inflammation are under investigation for the treatment of HD.  
The first attempt to reduce neuronal damage by immunomodulation in HD was the use 
of minocycline (Ellrichmann et al. 2013). Minocycline displays high tolerance and 
excellent bioavailability to the brain and has been clinically tested for several disorders 
of the CNS, including ALS and PD, due to its widespread neuroprotective and anti-
inflammatory actions (Soulet and Cicchetti 2011). Minocycline is a caspase inhibitor, 
known to suppress microglial activation and IL-1β, TNFα and iNOS production, and has 
been demonstrated to significantly delay disease progression and mortality in the R6/2 
mouse model (Chen et al. 2000). In a small study, the drug was also shown to be safe 
and well tolerated in HD patients (Thomas et al. 2004), however the primary endpoint 
of a 25 % improvement in TFC score was not met in a subsequent futility study 
(Huntington Study Group DOMINO Investigators 2010).  
Taking a more general anti-inflammatory approach, treatments with two NSAID 
cyclooxygenase-2 (COX-2) inhibitors, acetylsalicylate and rofecoxib, already in 
widespread human use for the treatment of inflammation and pain, were analysed. 
Both drugs were administered to transgenic HD mouse models from weaning, at doses 
comparable to those tolerated in humans, but had no beneficial effects on weight loss, 
behavioural changes, or gross cerebral and striatal atrophy (Norflus et al. 2004). 
More recently, the fumaric acid ester, dimethylfumarate, an immunomodulator 
approved for the treatment of relapsing-remitting multiple sclerosis (MS) (Tecfidera, 
Biogen), has been shown to have beneficial effects on neuronal degeneration, motor 
functions, weight loss and length of survival in R6/2 and YAC128 mouse models 
(Ellrichmann et al. 2011). Dimethylfumarate has pronounced effects on macrophages 
(Schilling et al. 2006) and potentially exerts neuroprotective effects via induction of 
nuclear factor E2-related factor 2 (Nrf2), a transcription factor which activates 
detoxification pathways and subsequently protects against oxidative damage and free 
radicals triggered by inflammation (Ellrichmann et al. 2011; Linker et al. 2011). 
A more specific anti-cytokine approach also holds potential for reducing inflammation 
and modifying disease progression in HD. Administration of an IL-6 neutralising 
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antibody to R6/2 mice partially rescued motor deficits and prevented weight loss 
(Bouchard et al. 2012). Inhibition of TNFα, another proinflammatory cytokine which is 
elevated in HD, has also been demonstrated to have therapeutic effect in HD mouse 
models. Intracerebroventricular infusion of XPro1595, a dominant negative inhibitor of 
soluble TNFα, decreased elevated levels of TNFα in the cortex and striatum, improved 
motor function, reduced caspase activation, diminished the amount of mHTT 
aggregates, increased neuronal density and decreased gliosis in brains of R6/2 mice 
(Hsiao et al. 2014). Systemic injection of XPro1595 reduced the peripheral 
inflammatory response and improved motor function in R6/2 mice (Hsiao et al. 2014). 
Modulation of the kynurenine pathway in peripheral immune cells has also been shown 
to have potential as a therapeutic target in HD. Oral administration of JM6, a 
peripherally-restricted small-molecule prodrug inhibitor of KMO, into R6/2 mice, 
inhibited KMO (which is expressed at high levels in peripheral immune cells such as 
macrophages (Heyes et al. 1992)) in the blood, and increased KYNA levels and 
reduced extracellular glutamate in the brain (Zwilling et al. 2011). This was associated 
with extended life span, reduced loss of synapses and a decrease in abnormal 
microglial activation (Zwilling et al. 2011). It is thought that KYNA is neuroprotective by 
reducing glutamate receptor-mediated excitotoxicity and free radical formation (Zwilling 
et al. 2011). The Cure Huntington’s Disease Initiative (CHDI) foundation have recently 
developed a novel peripherally-acting KMO inhibitor, CHDI-340246, that may increase 
the levels of kynurenine and KYNA in the brains of rodent HD models and in the CSF 
of non-human primates (Mrzljak 2013). 
Signalling through the CB2 receptor dampens immune activation, and administration of 
the CB2 receptor agonist, GW405833, has been demonstrated to ameliorate motor 
deficits, synapse loss, and CNS inflammation, and prolong survival in the BACHD 
mouse model (Bouchard et al. 2012). Co-administration with a peripherally-restricted 
CB2 antagonist reversed these beneficial effects (Bouchard et al. 2012), suggesting 
that GW405833 acts peripherally, and providing further evidence for peripheral 
immunomodulation as a viable therapeutic target in the treatment of HD. 
Thus far, while anti-inflammatory strategies for the treatment of HD have shown 
potential at pre-clinical stages of research, few have led to meaningful benefits in 
patients (Soulet and Cicchetti 2011). A possible reason for this is that a general 
suppression of immune responses inhibits the beneficial roles of the immune system as 
well as the detrimental roles. Complex communication between neurons and immune 
cells in the degenerating brain include reparative and neuroprotective interactions, and 
these processes may need to be maintained or enhanced while damaging interactions 
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are inhibited. A specific immunomodulatory approach aiming to promote 
neuroprotective roles of the immune system while inhibiting its deleterious features, 
rather than a general anti-inflammatory approach, may therefore have more therapeutic 
value for the treatment of HD. 
1.5.4 Novel immunomodulatory drug laquinimod 
Laquinimod (Figure 1.10) is a novel orally-active immunomodulatory drug that has 
been shown to downregulate immune cell activation and inflammation in the CNS 
(Brück et al. 2012; Mishra et al. 2014) and periphery (Yang et al. 2004; Schulze-
Topphoff et al. 2012). The drug has already been studied in human immunomodulation 
and has been shown to affect neuropathological processes. Laquinimod was 
demonstrated to be safe and well-tolerated in humans, as well as having beneficial 
effects on inflammation, brain atrophy and disease progression in two Phase III clinical 
trials for the treatment of MS (Comi et al. 2012; Filippi et al. 2014; Vollmer et al. 2014). 
Inflammation has been implicated in myelin, axonal and neuronal loss in MS pathology, 
and the same is true for HD (Ellrichmann et al. 2013). It is therefore plausible that 
laquinimod could slow brain atrophy rate and disease progression in HD through 
central and peripheral immunomodulatory mechanisms, as it has been shown to do in 
MS. 
 
Figure 1.10: Compound summary for laquinimod 
Chemical structure, chemical name, molecular formula and molecular weight for novel orally-
active immunomodulatory drug laquinimod (National Center for Biotechnology Information; 
PubChem Compound Database; CID=54677946, 
https://pubchem.ncbi.nlm.nih.gov/compound/54677946; accessed Apr. 9, 2017). 
In cuprizone-treated mice (a model of MS), laquinimod administration reduced the 
proportion of astrocytes with nuclear NFκB (p65/RelA) immune-reactivity (Brück et al. 
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2012), and in ex vivo cultures of adult human microglia, laquinimod treatment 
decreased cytokine release in response to LPS stimulation (Mishra et al. 2014). In mice 
with induced experimental autoimmune encephalomyelitis (EAE), laquinimod markedly 
reduced demyelination, axonal damage and inflammation within the brain by 
suppressing T cell recruitment (Wegner et al. 2010). It may also restore BDNF levels 
(Aharoni et al. 2012). In the periphery, laquinimod has been shown to induce an 
immunomodulatory shift in immune cell phenotypes away from M1/Th1-type responses 
and towards M2/Th2-type responses. Primary cultures of human PBMCs released 
lower levels of IL-17, IL-3 and G-CSF following laquinimod treatment (Brück and 
Wegner 2011). Mononuclear cells isolated from the spleen of a laquinimod-treated MS 
rat model displayed evidence of a shift from proinflammatory Th1-type to anti-
inflammatory and regulatory Th2-type cytokine expression profiles, with a laquinimod-
induced change in favour of Th2-type cytokines IL-4, IL-10 and TGFβ and reductions in 
the Th1-type cytokines TNFα and IL-12 (Yang et al. 2004). Laquinimod has also been 
shown to promote splenic development of M2-polarised monocytes and dendritic cells 
in mice, leading to reduced cellular production of Th1-type cytokines IL-6, IL-12 and 
TNFα and a corresponding increase in production of anti-inflammatory Th2-type 
cytokine IL-10 (Schulze-Topphoff et al. 2012). As an immunomodulatory drug, rather 
than an anti-inflammatory drug, laquinimod may therefore have the potential to promote 
reparative and neuroprotective inflammatory phenotypes in immune cells whilst 
suppressing proinflammatory and neurotoxic phenotypes. 
The immunomodulatory effects of laquinimod in the periphery and CNS have recently 
been found to be mediated via induction of the aryl hydrocarbon receptor (AhR) (Berg 
et al. 2016; Kaye et al. 2016; Birnberg et al. 2017). The AhR pathway modulates the 
differentiation and function of several cell populations, many of which play an important 
role in neuroinflammation (Kaye et al. 2016). Laquinimod can bind and activate the 
AhR leading to downstream gene transcription (Berg et al. 2016; Kaye et al. 2016), and 
while laquinimod treatment has been shown to have a pronounced effect on clinical 
symptoms, CNS inflammation, leukocyte infiltration and demyelination in EAE-afflicted 
wild-type mice, these effects were abolished in AhR-deficient mice (Berg et al. 2016; 
Kaye et al. 2016). Interestingly, laquinimod treatment resulted in increased BDNF 
production associated with neuroprotection in AhR-deficient mice (Berg et al. 2016), 
suggesting that the immunomodulatory effects of laquinimod occur by different 
mechanisms than the neuroprotective effects in EAE. 
In addition to the AhR pathway, laquinimod has also been shown to modulate multiple 
genes within the NFκB pathway, including the downregulation of proinflammatory 
monocyte genes (Birnberg et al. 2017). In a high-throughput gene expression study 
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using DNA microarrays, laquinimod-treated human PBMC cultures were revealed to 
express increased IκB whilst downstream NFκB genes were decreased (Gurevich et al. 
2010). Imaging flow cytometry (IFC) experiments have also shown laquinimod-induced 
reduction of p65 translocation in primary murine astrocytes (Brück et al. 2012). IκB 
degradation is increased and NFκB translocation enhanced and prolonged in HD 
patient myeloid cells in response to stimulation (Träger et al. 2014a), and it is plausible 
that laquinimod could rescue this dysfunctional hyper-reactive phenotype and dampen 
the consequential elevated production of proinflammatory cytokines by these cells 
(Björkqvist et al. 2008). Laquinimod may also suppress another proinflammatory 
signalling pathway by reducing phosphorylation and activation of the MAPKs p38 and 
JNK (Mishra et al. 2012). 
While laquinimod has been shown to have both peripheral and central affects, when 
orally-administered the drug is quickly absorbed into the blood stream from where only 
a small percentage (7-8 %) crosses the BBB and penetrates the CNS. It is therefore 
likely that laquinimod acts primarily on peripheral immune cells. Intervention of 
peripheral inflammatory events has previously been shown to modulate central 
neuropathology and disease progression in HD (Zwilling et al. 2011; Bouchard et al. 
2012; Kwan et al. 2012a), therefore laquinimod has potential for slowing disease 
progression in HD patients by affecting peripheral immune cells. Indeed, laquinimod is 
currently under investigation for its potential effects in HD and a Phase II clinical trial 
(LEGATO-HD) aimed at evaluating the efficacy, safety and tolerability of laquinimod as 
a treatment in patients with HD is in progress (Teva Pharmaceutical Industries 2016). 
1.6 Thesis aims 
1.6.1 General research goals 
The overarching goal was to investigate the physiological and pathophysiological roles 
of inflammatory processes in HD. Aims were to examine neuroprotective and 
neurotoxic interactions between myeloid cells and neurons in HD, and to determine 
whether dysfunctional hyper-reactive and proinflammatory phenotypes in HD myeloid 
cells may be rescued by novel immunomodulatory drug, laquinimod. 
1.6.2 Specific aims 
1) Develop and characterise novel human neuronal-myeloid cell co-culture models of 
HD using three main experimental approaches: 
i. Develop and characterise novel human neural stem cell-derived neuronal cell 
models expressing human HTT exon 1 or full-length human HTT with varying 
CAG repeat lengths in the pathogenic and non-pathogenic range. 
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ii. Develop and characterise a novel primary human blood monocyte-derived 
microglia cell model, differentiated in vitro from ex vivo primary monocyte 
cultures (taken from healthy volunteers, pre-manifest HD gene carriers and 
manifest HD patients), using a novel technique. 
iii. Develop and characterise control and HD co-culture paradigms with neuronal 
cell lines, blood monocyte-derived macrophages and blood monocyte-derived 
microglia. 
2) Investigate neuronal-myeloid cell interactions in HD co-culture models 
i. Determine the effects of resting or activated (by acute or chronic stimulation) 
healthy volunteer and HD patient myeloid cells on wild-type and HD neuronal 
survival. 
ii. Analyse M1/Th1- and M2/Th2-type cytokines and neurotrophin production by 
healthy volunteer and HD patient myeloid cells and assess differential effects 
on wild-type and HD neurons in co-culture. 
3) Investigate the effects of laquinimod on rescuing hyper-reactive immune cell 
dysfunction in HD patient myeloid cells. 
i. Analyse M1/Th1- and M2/Th2-type cytokine production in untreated and 
laquinimod-treated healthy volunteer and HD patient monocytes. 
ii. Investigate modulation of the NFκB pathway as a potential mechanism of 
action for laquinimod in HD patient myeloid cells. 
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2 Materials and methods 
All materials and reagents were purchased from Sigma unless otherwise stated. Non-
sterile ultra-pure deionised distilled water (ddH2O) was obtained using a Milli-Q 
ultrapure water purification system (18 MΩ·cm resistivity at 25 °C) [Merck Millipore].  
2.1 Cell culture 
All cell cultures were maintained in Heracell 150i incubators [Thermo Scientific] at 37 
°C; 5 % CO2. Unless otherwise stated, all culture media and reagents were warmed to 
37 °C prior to use, in a digitally-controlled stable temperature water bath [Grant] 
designated for tissue culture. All cell culture procedures, including those involving work 
with viruses, were performed in Containment Level II Safety Cabinets in a designated 
tissue culture facility, and aseptic practices were followed in order to maintain sterile 
conditions and adhere to safety protocols. All work involving whole blood samples was 
carried out in a tissue culture facility specifically designated for handling human blood. 
Non-primary cells were subject to routine mycoplasma screening using LookOut 
Mycoplasma PCR Detection Kit. All biological material waste, including cells and 
viruses, was decontaminated in Virkon disinfectant for at least 2 h prior to disposal; 
other than waste from human primary cell culture which was decontaminated in 2 M 
sodium hydroxide for a minimum of 2 h, in accordance with safe disposal guidelines.  
2.1.1 Cell lines 
2.1.1.1 HEK293T, Phoenix-AMPHO and HeLa 
Human embryonic kidney cell line 293, containing the SV40 T antigen (HEK293T) and 
the second-generation Phoenix amphotropic cell line (Phoenix-AMPHO) based on 
HEK293T, were used for packaging lentiviral and retroviral plasmids, respectively. 
HEK293T were additionally used to test and titrate lentiviruses expressing HTT exon 1. 
Both cell lines were kind gifts from Prof. Parmjit S. Jat (Medical Research Council 
(MRC) Prion Unit, Institute of Neurology (IoN), London, UK). The HeLa cell line was 
derived from human cervical adenocarcinoma cells. The line was a kind gift from Dr 
Adrian M Isaacs (University College London (UCL) IoN, London, UK) and was used to 
test and titrate retroviruses expressing full-length HTT. 
These cell lines were cultured in sterile Nunclon cell culture-treated polystyrene flasks 
[Nunc] and maintained in DMEM/FBS culture medium (Appendix I-i) in the incubator. 
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Medium was changed 2-3 times per week, and once the cells reached 70-80 % 
confluence they were passaged into fresh culture flasks. To passage, medium was 
removed with a serological pipette [Corning] and cells were washed in Dulbecco’s 
Phosphate-Buffered Saline (DPBS) [Life Technologies]. Enough Trypzean-
Ethylenediaminetetraacetic acid (EDTA) [Lonza] was added to the cells to just cover 
the culture surface and cells were incubated at 37 °C; 5 % CO2 for 5 min. Fresh culture 
medium was then added to inhibit further trypsinisation, and then cells were triturated 
from the culture surface and collected into a 15 mL Falcon tube [BD Falcon] using a 
serological pipette. Cells were pelleted out of solution by centrifugation at 300 × g for 5 
minutes (min) at room temperature (RT) and re-suspended in fresh DMEM/FBS culture 
medium. Cells were counted using a haemocytometer and seeded at a minimum 
density of 1.4 × 104 cells/cm2 in fresh culture flasks. Cells were then returned to the 
incubator. 
When HEK293T or Phoenix-AMPHO cells were used for viral packaging, they were 
thawed from cryopreserved stocks which had undergone less than ten passages, and 
were expanded for only one passage in culture before use. 
2.1.1.2 N2a_R2 
Neuro-2a (N2a) is a murine neuroblastoma cell line of which R2 is a sub-clone made 
by, and a kind gift from, Dr. Peter C. Klöhn (MRC Prion Unit, IoN, London, UK). 
N2a_R2 cells were received as cryopreserved stocks at their third passage post-sub-
cloning. Once thawed, the cell line was used in experiments between one and three 
subsequent passages in culture. N2a_R2 were cultured in sterile Nunclon cell culture-
treated polystyrene flasks and maintained in OptiMEM/FBS culture medium (Appendix 
I-ii) in the incubator. Medium was changed every 3-4 days and once cells reached 80-
90 % confluence, they were passaged into fresh culture flasks. To passage, medium 
was removed and cells were gently washed in DPBS. Culture medium was added to 
the flask and cells were triturated from the culture surface using a serological pipette. 
The cell suspension was then added to fresh culture flasks containing pre-warmed 
medium, at a split of 1:10-1:7 densities. Cells were then returned to the incubator. 
2.1.1.3 ReNcell VM NSC culture 
The ReNcell VM neural stem cell (NSC) line was a kind gift from ReNeuron (Guilford, 
UK). ReNcell VM was derived from 10-week-old human foetal ventral mesencephalon 
immortalised by retroviral transduction with a v-myc oncogene and expanded long-term 
as undifferentiated NSCs. ReNcell VM can be routinely cultured in their replicating 
form, and stable karyotype has been confirmed for up to a minimum of 80 passages 
(ReNeuron). NSCs can be spontaneously differentiated into pan-neuronal cultures, and 
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some astrocytes, upon removal of the growth factors epidermal growth factor (EGF) 
and basic fibroblast growth factor (bFGF) from the culture medium (Donato et al. 2007). 
The NSCs were received as cryopreserved stocks at their seventeenth passage, and 
once thawed they were used in experiments between one and ten passages in culture. 
NSCs were plated in sterile laminin-coated Nunclon cell culture-treated polystyrene 
flasks. To laminin-coat, 10 μg/mL cold mouse laminin-1 PathClear [Trevigen] in cold 
DMEM: Nutrient Mixture F-12 (DMEM:F-12) [Life Technologies] was added to culture 
flasks at approx.130 μL/cm2 and incubated at 37 °C; 5 % CO2 for at least 2 hours (h). 
Before seeding NSCs, the laminin solution was removed and laminin-coated surfaces 
were washed in pre-warmed DMEM:F-12. For experiments, NSCs were seeded in a 
sterile laminin-coated 4-well, 6-well, 24-well or 96-well Nunclon cell culture-treated 
MultiDish [Nunc] at 5 × 104 cells/cm2. In some cases, NSCs were seeded onto sterile 
laminin-coated 13 mm diameter round glass coverslips [VWR International] at a density 
of 1 × 105 cells/coverslip. Coverslips were sterilised by baking in an electric oven at 200 
°C for 6 h. To laminin-coat, sterile coverslips were placed in a 4-well or 24-well cell 
culture dish and 200 μL 20 μg/mL cold mouse laminin-1 PathClear in 20 mM cold Tris-
HCl [Sigma], pH 7, was pipetted onto each coverslip. The culture dish was then placed 
in the incubator for at least 24 h. Before seeding NSCs, the laminin solution was 
removed and laminin-coated surfaces were washed in pre-warmed DMEM:F-12. 
NSCs were maintained in ReN/NSC culture medium (Appendix I-iii) with fresh media 
changes every 3-4 days, and were passaged on reaching 80-90 % confluence. To 
passage, medium was removed and cells were washed with Hank’s Balanced Salt 
Solution (HBSS) [Life Technologies]. Enough Trypzean-EDTA was added to the cells 
to just cover the culture surface and cells were incubated at 37 °C; 5 % CO2 for 5 min 
until cells had detached from the flask. Trypsinisation was inhibited by the addition of 
Defined Trypsin Inhibitor (DTI) solution [Life Technologies] at equal volume to 
Trypzean-EDTA, and then cells were triturated and collected into a 15 mL Falcon tube 
using a serological pipette. NSCs were pelleted out of solution by centrifugation at 300 
× g for 5 min at RT, and re-suspended in fresh ReN/NSC culture medium. Cells were 
counted using a haemocytometer and then plated as a monolayer in laminin-coated 
culture flasks at a density of 1.4 × 104 cells/cm2. Cells were then returned to the 
incubator. 
2.1.1.4 Cryopreservation and revival of cell lines 
Once cultures reached 80-90 % confluence, cells were collected from the culture flask 
as described above for the relevant cell line. Viable cells were counted by Trypan Blue 
exclusion (section 2.6.4) using a haemocytometer. Cultures with greater than 95 % cell 
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viability were taken forward for cryopreservation. Cells were pelleted out of solution by 
centrifugation, re-suspended in relevant culture medium supplemented with 8 % 
dimethyl sulfoxide (DMSO), to a density of 3 × 106 viable cells/mL, and aliquoted into 
1.6 mL cryovials [Nunc] at 1 mL per vial. Cryovials were then placed into a Mr Frosty 
Freezing Container [Thermo Scientific] and frozen to −80 °C. The following day, 
cryovials were placed in a liquid nitrogen tank under vapour-phase nitrogen for long-
term storage.  
To revive cell lines under cryopreservation, cryovials were taken from liquid nitrogen 
storage and immediately placed in a 37 °C water bath for rapid thawing. Cells were 
then quickly added to 10 mL pre-warmed relevant culture medium in a 15 mL Falcon 
tube and pelleted by centrifugation at 300 × g for 5 min at RT. Cells were re-suspended 
in 15 mL relevant culture medium and plated in 75 cm2 culture flasks. ReNcell VM 
NSCs were an exception, as they were added directly to laminin-coated culture flasks 
containing pre-warmed culture medium, immediately following rapid thaw and without 
undergoing centrifugation. This was due to the fragility of this cell line and vulnerability 
to lysis by centrifugation during revival. The following day, all cultures were given a 
fresh media change and thereafter received media changes every 2-3 days until they 
were ready to passage. 
2.1.2 Primary human cell cultures 
All human experiments were performed in accordance with the Declaration of Helsinki 
and approved by UCL/UCL Hospitals Joint Research Ethics Committee. All blood 
donors provided informed written consent for research on Huntington’s disease.  
2.1.2.1 Classification of human samples 
Blood samples were collected from healthy volunteers, pre-manifest HD gene carriers 
and manifest HD patients, who were recruited from the HD clinic at the National 
Hospital for Neurology and Neurosurgery (NHNN), London, UK. Healthy volunteers 
were generally spouses, partners and/or carers of HD patients. Pre-manifest HD were 
genetically diagnosed patients with a diagnostic confidence level (DCL) of less than 4 
on the standardised motor exam of the Unified Huntington’s Disease Rating Scale 
(UHDRS). Manifest HD were genetically diagnosed patients with early or moderate 
stage disease and a DCL of 4 with unequivocal extrapyramidal motor signs consistent 
with HD. Donors with inflammatory or infectious conditions, and/or taking anti-
inflammatory or immunomodulating medication were excluded. Samples were collected 
from both males and females, and average age and age range of participants were 
matched as much as possible between groups for each experiment. Each blood 
sample collected was designated an anonymised five-digit number for blinded analysis. 
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2.1.2.2 Isolation of primary human monocytes from whole blood 
Whole blood samples were collected from donors and decanted into 50 mL heparinised 
tubes (50 µL prescription grade heparin [CP Pharmaceuticals] in standard 50 mL 
Falcon tubes). Twenty-five millilitres whole blood was then carefully layered onto 20 mL 
Histopaque-1077. Histopaque-1077 is a solution of polysucrose and sodium 
diatrizoate, adjusted to a density of 1.077 g/mL. It is designed to facilitate recovery of 
viable peripheral blood mononuclear cells (PBMCs) from small volumes of whole blood. 
Whole blood was separated through the Histopaque-1077 gradient by centrifugation in 
a swinging bucket rotor at 400 × g for 30 min at RT with no brake. Erythrocytes are 
aggregated by polysucrose and rapidly sediment, and granulocytes become slightly 
hypertonic, increasing their sedimentation rate, resulting in pelleting of erythrocytes and 
granulocytes at the bottom of the centrifuge tube. PBMCs remain at the 
plasma/Histopaque-1077 interface and were isolated by removal with a Pasteur 
pipette. PBMCs were washed in magnetic-activated cell sorting (MACS) buffer 
(Appendix II-i) and pelleted out of wash solution by centrifugation at 350 × g for 10 min 
at 4 °C. Cells were re-suspended in 1 mL MACS buffer and 60 µL anti-CD14 MACS 
MicroBeads [Miltenyi Biotec] were added to the suspension. The MicroBeads are highly 
specific antibodies directed at the CD14 antigen, a plasma membrane receptor 
expressed by monocytes, conjugated to 50 nm superparamagnetic particles. The 
MicroBeads were mixed with PBMCs by quick vortex and the mixture was incubated for 
15 min at 4 °C. Cells were then pelleted by centrifugation at 350 × g for 5 min at 4 °C, 
and re-suspended in fresh MACS buffer before being applied to MACS columns 
[Miltenyi Biotec] mounted on a magnetic separator [Miltenyi Biotec]. MACS columns 
contain a matrix composed of ferromagnetic spheres, and when placed on a magnetic 
separator, they amplify the magnetic field by 10,000-fold, inducing a high gradient 
within the column. PBMCs run slowly through the column, and magnetically labelled 
CD14+ monocytes are held in suspension within the column, while unlabelled cells drip 
through and were discarded. Magnetically-isolated CD14+ monocytes were plunged 
out of the column into a separate collection tube, washed in DPBS by suspension and 
centrifugation, and re-suspended in RPMI/FBS culture medium (Appendix I-iv).  
2.1.2.3 Ex vivo culture of primary human monocytes 
A total cell count was made before seeding monocytes into 6-well or 24-well Primaria 
culture dishes [BD Falcon] at a density of 2.5 × 105 cells/cm2 and placing them in the 
incubator. For some experiments, monocytes were seeded onto sterile poly-ᴅ-lysine 
(PDL)-coated coverslips at a density of 1 × 105 cells/coverslip. Coverslips were 
sterilised using 100 % ethanol and were allowed to air-dry before placing into a 4-well 
or 24-well cell culture dish. To PDL-coat, 200 μL 0.1 mg/mL PDL in sterile tissue 
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culture grade distilled water [Life Technologies] was pipetted onto each coverslip and 
incubated for 5 min at RT. PDL solution was then removed and coverslips were 
thoroughly washed in sterile distilled water before being allowed to air-dry for at least 
two hours. If monocytes were differentiated in vitro the PDL-coating step was skipped, 
as following differentiation steps, the cells much better adhere to glass. Pre-testing 
using fluorescence-activated cell sorting (FACS) analysis has shown the purity of 
cultures described here to be at least 95 % CD14+ monocytes (Björkqvist et al. 2008), 
and they were used in experiments up to 4 days in vitro (DIV). 
2.1.2.4 Differentiation of human blood monocyte-derived (BMD) macrophages in vitro 
Ex vivo human monocyte cultures were prepared as described above (section 2.1.2.2) 
with the addition of 20 ng/mL GM-CSF to RPMI/FBS culture medium on seeding. Cells 
were given a complete medium change with addition of fresh GM-CSF at 3 DIV, and 
returned to the incubator. These cells have previously been confirmed by factor 
analysis to be fully differentiated macrophages at 6 DIV, and were used in experiments 
6-10 DIV. 
2.1.2.5 Differentiation of human BMD-microglia in vitro 
Primary human macrophage cultures were prepared as described above (section 
2.1.2.4). At 7 DIV, macrophages were given a complete medium change into neuronal 
medium (NM) (Appendix I-v) and returned to the incubator for a further 4 days. At 11 
DIV, cells displayed morphological and phenotypic characteristics of primary human 
microglia, as is shown later in this Thesis (sections 3.5.4.2 and 3.5.4.3), and were used 
in experiments at this stage.  
2.1.2.6 Stimulation of human myeloid cells 
Unless stated otherwise, where primary human myeloid cells (monocytes, BMD-
macrophages and BMD-microglia) are described as “stimulated” in this Thesis, cells 
were given a media change with the addition of 2 µg/mL LPS and 10 ng/mL IFNү [R&D 
Systems]. In “acute stimulation” paradigms cells were given a pulse stimulation for 1 h 
followed by a fresh media change, and in “chronic stimulation” paradigms cells were 
stimulated continuously for 24 or 48 h. Myeloid cells described as “non-stimulated” 
were given the same media changes without the addition of LPS and IFNү. In the 
investigation into the effects of laquinimod on rescuing hyperactive immune cell 
dysfunction in HD patient myeloid cells (Chapter 5), myeloid cells were stimulated with 
1 µg/mL LPS and 10 ng/mL IFNү for 24 h. Due to potential batch-to-batch variability in 
the potency and content of LPS, myeloid cells were stimulated with LPS from the same 
source and batch (Sigma, L6529, E. coli 055:B5) across all experiments.  
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2.1.3 ReNcell VM neuronal differentiation 
2.1.3.1 Spontaneous differentiation of ReNcell VM NSCs into neuronal cultures 
ReNcell VM NSCs can be spontaneously differentiated into mature neuronal cultures 
by removal of EGF and bFGF from the ReN/NSC culture medium (Neuronal medium 
(NM); Appendix I-v). Mature neuronal cultures also contained some glial cells, including 
astrocytes. ReNcell VM NSCs were seeded in sterile laminin-coated culture flasks, as 
described above (section 2.1.1.3), at a higher density of 5 × 105 cell/cm2. NSCs, which 
had undergone less than ten passages post-thawing, were maintained in ReN/NSC 
culture medium until reaching 90-100 % confluence (1-2 days), when they were given a 
complete media change into NM and returned to the incubator. Differentiating cultures 
were given fresh media changes every 4-5 days and were used at various stages of 
differentiation (days differentiation, DD), depending on the experiment. 
2.1.3.2 Induced differentiation of ReNcell VM NSCs into neuronal cultures 
In some cases, an alternative protocol was used to differentiate ReNcell VM NSCs, 
with the aim of achieving a higher neuronal yield and fewer glial cells in the mature 
cultures. The following optimised protocol was adapted from Donato et al. (2007). 
Following standard NSC passage, as described above (section 2.1.1.3), cells which 
had undergone less than ten passages post-thawing were cultured as neurospheres by 
seeding in non-laminin-coated culture flasks in standard ReN/NSC culture medium at a 
density of 3 × 104 cells/cm2. NSCs were then returned to the incubator and allowed to 
form neurospheres over 5-7 days. Once neurospheres had formed, they were pelleted 
out of culture medium by centrifugation at 300 × g for 5 min at RT, washed in DPBS, 
and disaggregated by incubation in Trypzean-EDTA for 15 min at 37 °C. Trypsinisation 
was then inhibited by 1:1 addition of DTI, and cells were pelleted out of solution by 
centrifugation at 300 × g for 5 min at RT. Cells were re-suspended in ReN/NSC culture 
medium, seeded in laminin-coated culture flasks at a density of 5 × 104 cells/cm2 and 
returned to the incubator. Once cells reached 90-100 % confluence (1-2 days post-
seeding), they were given a complete medium change into NM supplemented with 
dibutyryl-cAMP (db-cAMP) and glial-derived neurotrophic factor (GDNF) 
(NM/cAMP/GDNF; Appendix I-vi), and returned to the incubator. Differentiating cultures 
were given fresh media changes in supplemented NM every 4-5 days for the first 2 
weeks, and in standard NM (Appendix I-v) thereafter, and used in characterisation 
experiments from 10-25 DD. 
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2.1.4 Co-culture 
2.1.4.1 Preparation of conditioned media and myeloid cell lysates 
Primary human myeloid cells were cultured in 24-well plates and treated in 1 mL 
relevant culture medium per well, in accordance with the relevant experiment. Whole 
culture medium was harvested per well; monocyte-conditioned medium (MC-CM), 
macrophage-conditioned medium (Mφ-CM) or microglia-conditioned medium (MG-CM). 
Conditioned medium was transferred from culture wells to 0.5 mL microcentrifuge 
tubes [Eppendorf] using a 1000 μL pipette [Gilson], centrifuged at 400 × g for 5 minutes 
to deposit out any remaining cells, supernatant passed through a 0.22 µL cellulose 
acetate sterile syringe filter [Triple Red] to remove cell debris and any other potential 
contaminants, and aliquoted into separate fresh microcentrifuge tubes. Conditioned 
medium was then snap frozen in a dry ice/ethanol cooling bath and stored at −80 °C.  
For some experiments, analysis results for conditioned medium content were 
normalised to total protein. Therefore, upon removal of conditioned medium from a 
culture, cell lysates were prepared by adding 100 µL 4 °C radioimmunoprecipitation 
assay (RIPA) buffer (Appendix II-ii) directly to each well. Culture plates were then 
incubated at 4 °C for 15 min on a shaking platform set to 400 revolutions per minute 
(rpm). Cell lysates were homogenised by pipetting, collected into separate 0.5 mL 
microcentrifuge tubes and stored at −80 °C. 
This process was repeated on a routine basis as blood sample donations became 
available bi-monthly through the HD clinic, and was continued until relevant sample 
sizes had been processed and stored. Generally, 5-6 samples were processed at a 
time, with at least one sample per subject group processed together.  
2.1.4.2 Co-culture by conditioned media transfer 
ReNcell VM NSCs were seeded at 2 × 104 cells/well in sterile laminin-coated cell 
culture-treated Nunc MicroWell 96-well Microplates, and differentiated into mature 
neuronal cultures as described above (section 2.1.4.1). When neuronal cultures 
reached 10 or 25 DD, Mφ-CM or MG-CM was thawed slowly on ice and gradually 
warmed to 37 °C. Culture medium was removed from neuronal cultures and replaced 
with 100 μL Mφ-CM or MG-CM per well, in triplicate. Control wells were cultured in 100 
μL fresh non-conditioned NM, and Mφ-CM transfer co-culture experiments also had 
additional control wells cultured in 100 μL RPMI/FBS culture medium. Neuronal 
cultures were then returned to the incubator and maintained in conditioned media 
treatments for 24 h. All conditioned medium related to the same experiment was used 
to treat neuronal cultures at the same time. 
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2.1.4.3 Co-culture by medium shared concurrently 
Monocytes were cultured on 13 mm diameter glass coverslips in 24-well cell culture 
dishes and differentiated into macrophages until 5 DIV. ReNcell VM NSCs were 
cultured on coverslips in 24-well cell culture dishes and differentiated into 11 DD 
mature neuronal cultures by spontaneous differentiation. One coverslip of each cell 
type was then transferred into a 10 cm diameter sterile cell culture-treated petri-dish 
[Nunc] and both cell types were co-cultured in shared RPMI/FBS culture medium 
(Appendix I-iv) for a further 3 days.  
2.1.4.4 Co-culture by direct physical contact 
Monocytes were cultured in 6-well cell culture dishes and differentiated into BMD-
microglia. At 11 DIV, culture medium was removed and discarded, and BMD-microglia 
were lifted from the culture surface by scraping in ice-cold 2 mM EDTA in DPBS. Cells 
were transferred from culture dishes to 15 mL Falcon tubes using a pipette, pooling 
together cells from the same donor. A viable cell count was made using Trypan Blue 
exclusion (section 2.6.3) and a haemocytometer. BMD-microglia were then pelleted out 
of solution by centrifugation at 400 × g for 5 min at 4 °C, washed in pre-warmed DPBS, 
and re-suspended in pre-warmed NM to a density of 2 × 105 cells/mL. NSCs were 
cultured on coverslips in 24-well cell culture dishes and differentiated into mature 
neuronal cultures by induced differentiation to 18 DD. Half of the neuronal culture 
medium, 500 µL, was removed per well and replaced with 500 µL BMD-microglia cell 
suspension in NM, equivalent to 1 × 105 BMD-microglia per coverslip. Cells were then 
returned to the incubator in direct co-culture. 
2.2 Molecular biology 
Samples suspected to contain viral vectors were handled in a Class II Microbiological 
Safety Cabinet situated within an Advisory Committee on Dangerous Pathogens 
(ACDP) Containment Level II laboratory with strict adherence to local rules of safe 
working practice. Samples, and any waste from bacterial work, were decontaminated 
with Virkon disinfectant for at least 2 h and autoclaved prior to disposal.  
2.2.1 Viral plasmids 
2.2.1.1 Human HTT exon 1 lentiviral expression system plasmids 
Human HTT exon 1 lentiviral plasmids and related control vectors were a kind gift from 
Prof. Gillian P. Bates (King’s College London (KCL), London, UK), and made by Dr. 
Eva C. Sirinathsingh of the same research group. The entire coding sequence of 
human HTT exon 1 with 29 (normal genotype), 71 (expanded, HD genotype) or 129 
(highly expanded, HD genotype) CAG repeats, and the first 21 base pairs (bp) of HTT 
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intron 2, was cloned into a pHR-self-inactivating (SIN) lentivirus vector backbone under 
the bidirectional A2 ubiquitous chromatin opening element (A2UCOE) promoter. The 
A2UCOE element is a CpG island which confers resistance to DNA methylation-
mediated silencing of lentiviral vectors, for stable, reliable and sustained transgene 
expression (Zhang et al. 2010). Following HTT exon 1 is an internal ribosome entry site 
(IRES) controlling concurrent expression of reporter gene enhanced green fluorescent 
protein (eGFP). A central poly-purine tract (cPPT) and Woodchuck post-transcriptional 
regulatory element (WPRE) are incorporated to increase transduction efficiency and 
transgene expression (Barry et al. 2001). The entire sequence is flanked by long 
terminal repeats (LTRs) to facilitate integration into the host genome, with a deletion in 
the 3’ LTR rendering the virus self-inactivating after integration, in adherence with 
safety guidelines. An ampicillin resistance gene (ampr) is also present within the 
lentiviral backbone to allow for selection of expressing bacterial colonies during plasmid 
amplification. See Figure 2.1 for a schematic representation of the A2UCOE HTT exon 
1 constructs, and Figure 2.2 for detailed plasmid maps of the A2UCOE HTT exon 1 
constructs (HTT exon 1 129 CAG presented as an example) and an A2UCOE eGFP 
reporter only control vector, without the HTT exon 1 transgene, which was also cloned. 
 
 
Figure 2.1: Schematic representation of A2UCOE HTT Exon 1 constructs 
pHR-SIN backbone including cPPT and WPRE regulatory elements and flanking LTRs. Exon 1 
genes with 29, 71 or 129 CAG repeats have been inserted under control of the A2UCOE 
promoter, and are followed by an IRES initiating concurrent expression of eGFP.  
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Figure 2.2: Plasmid maps for A2UCOE HTT Exon 1 lentiviral vectors 
Full plasmid map for pHR-SIN-cPPT-A2UCOE-HTT exon 1-IRES-eGFP-WPRE (left), with 
mHTT 129 CAG construct presented as an example. Base pair (bp) numbers are indicated in 
black. An eGFP reporter only control construct was also created; pHR-SIN-cPPT-A2UCOE-
eGFP-linker-WPRE (right). Restriction enzyme sites are indicated in grey on both plasmids.  
2.2.1.2 Full-length human HTT retroviral expression system plasmids 
Full-length human HTT retroviral plasmids were a kind gift from Prof. Michael R. 
Hayden (University of British Columbia, Canada). Full-length human HTT 
complementary DNA (cDNA) with 15 CAG repeats was synthesised from the ~10 Kb 
transcript variant of HTT ribonucleic acid (RNA) by reverse transcription. This produced 
the control HTT gene, which was a 10,030 bp transcript including the entire coding 
DNA sequence, and a non-coding DNA region followed by a poly A tail. A highly 
expanded pathological length CAG repeat region was then sub-cloned into HTT (15 
CAG) to produce a HD mHTT gene with 138 CAG repeats (Goldberg et al. 1996). HTT 
(15 CAG) and mHTT (138 CAG) were cloned into the multiple cloning site (MCS) of 
Clontech murine stem cell virus (MSCV) vectors, with puromycin (puro) or hygromycin 
(hyg) antibiotic resistance genes, puror and hygr respectively, to produce 
MSCVpuro+full-length HTT (15 CAG) and MSCVhyg+full-length mHTT (138 CAG) 
(Figure 2.3). The MSCV expression systems are optimised for the introduction and 
expression of target genes in pluripotent stem cells, such as the ReNcell VM NSC line. 
Transgene expression is under the control of a retroviral promoter, Ψ+, and a 
phosphoglycerate kinase (PGK) promoter following the transgene induces concurrent 
expression of the puro or hyg antibiotic resistance gene. Ampr is also present in each 
construct to allow for selection of expressing bacterial colonies during plasmid 
amplification.  
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Figure 2.3: Plasmid maps for MSCV full-length HTT retroviral vectors 
MSCVpuro (left) and MSCVhyg (right) Clontech retroviral plasmid vectors. Full-length (FL) 
human HTT cDNA was inserted into the MCS at the HpaI site in both constructs, with the 
resulting ablation of the 3’ HpaI site (HTT (15 CAG) into MSCVpuro and mHTT (138 CAG) into 
pMSCVhyg).  
2.2.2 Amplification and purification of plasmid DNA 
Plasmid DNA (viral vectors and relevant viral packaging plasmids) was amplified in 
One Shot TOP10 Chemically Competent E. Coli [Invitrogen]. 100 ng plasmid DNA was 
added to one vial of One Shot cells and mixed gently. The vial was then incubated on 
ice for 30 min before heat-shocking the cells in a water bath for 30 seconds (s) at 42 °C 
and returning to ice for a further 2 min. 250 µL pre-warmed Super Optimal broth with 
Catabolite repression (SOC) medium was aseptically added to the vial to enhance 
transformation, and cells were shaken horizontally at 37 °C for 1 h at 225 rpm in a 
shaking incubator. Transformation mix was spread, at 200 µL per plate, on pre-warmed 
Luria-Bertani (LB) agar plates containing 50 ng/µL ampicillin, at 1:1, 1:10 or 1:100 
dilutions in LB Broth. Plates were inverted and incubated overnight at 37 °C. Single 
bacterial colonies were picked from plates on which the colonies were well spaced, and 
used to inoculate 2 mL LB Broth culture medium containing 100 µg/mL ampicillin. 
Transformed bacteria were expanded in increasing volumes of LB Broth (with 
ampicillin), up to a volume of 1.5 L per culture, over 24 h at 37 °C with horizontal 
shaking at 225 rpm. During expansion, small samples of the bacterial culture were 
taken to create glycerol stocks for long-term storage of DNA plasmids (section 2.2.2.1). 
E. Coli were harvested from the culture medium by centrifugation at 6000 × g for 15 
min at 4 °C, and plasmid DNA was isolated and purified using Qiagen Plasmid Maxi Kit 
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and the protocol for plasmid DNA purification using Qiagen Plasmid Midi and Maxi Kits 
[Qiagen], as per the manufacturer’s protocol. Briefly, the bacterial pellet was re-
suspended in lysis solution, and DNA was precipitated from the lysate. The lysate was 
cleared from the supernatant containing precipitated DNA by centrifugation and 
filtration steps, and then DNA was purified by wash steps through a Qiagen-tip 500 
column. Purified plasmid DNA was then eluted from the column, and precipitated in 
isopropanol before pelleting by centrifugation at 6000 × g for 1 h at 4 °C. The DNA 
pellet was washed in 5 mL ethanol and centrifuged at 6000 × g for 1 h at 4 °C. The 
pellet was then air-dried and re-dissolved in ddH2O. Plasmid DNA was assessed for 
concentration and purity by NanoDrop (section 2.2.7). 
2.2.2.1 Creating and using bacterial glycerol stocks 
For long-term storage of plasmids, samples of transformed bacterial cultures were 
taken during the amplification phase. Five hundred microlitres bacterial culture was 
added to 500 µL 50 % glycerol in a 2 mL cryovial [Nunc] and gently mixed before 
freezing at −80 °C. For revival of bacteria, glycerol stocks were removed from the 
freezer, and without thawing, a sterile loop was used to scrape frozen bacteria from the 
top of the glycerol stock. Bacteria was then streaked onto LB agar plates containing 50 
ng/µL ampicillin and colonies were grown overnight in an incubator at 37 °C. Bacterial 
glycerol stocks were returned to the freezer without thawing. 
2.2.3 DNA sequencing 
2.2.3.1 DNA sequencing primers and design 
DNA sequencing primers were designed using online tool Primer3 (Untergasser et al. 
2012), and selected based on their relative melting/annealing temperatures, low 
guanine-cytosine (G-C) bp percentage and minimal likelihood of complementary pair 
annealing between primers. See Table 2.1 for primers used to sequence ReNcell VM 
HTT exon 1 genomic DNA, HTT exon 1 transgenes in A2UCOE lentiviral plasmid 
vectors and full-length HTT transgenes in MSCV retroviral plasmid vectors. Forward 
and reverse primer sites for sequencing HTT exon 1 transgenes were within the 
A2UCOE plasmid backbone, 5’ and 3’ to the transgene inserts. The eGFP reporter only 
control A2UCOE vector was also sequenced using the same primers. Due to the large 
size of full-length HTT transgenes in MSCV, 17 primer pairs were designed to 
sequence shorter, overlapping fragments along the entire transgene, and these were 
matched up for analysis of the whole full-length transgene. These primer pairs were 
designed based on the Clontech plasmid sequences flanking the transgenes and the 
published National Center for Biotechnology Information (NCBI); nucleotide; 
RefSeqGene reference sequence NG_009378.1, for the ~10.3 Kb transcript variant of 
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full-length Homo sapiens HTT cDNA (IT15), chromosome 4. The same reference 
sequence was used to design forward and reverse primers for sequencing ReNcell VM 
genomic HTT exon 1.  
Table 2.1: DNA sequencing primers 
Primer name Sequence (5’ to 3’) 
ReNcell VM genomic DNA HTT exon 1 forward TGCTTCTCGCTGCACTAATC 
ReNcell VM genomic DNA HTT exon 1 reverse CTGAGGACCCCAAGTGTGAC 
A2UCOE HTT exon 1 forward  CCCGGGTCTAGAATCGATAA 
A2UCOE HTT exon 1 reverse TTTTCCACCATATTGCCGTC 
MSCV full-length HTT 681 forward ATGGTGCCCCTCGGAGTT 
MSCV full-length HTT 879 reverse GCAAAATTGCCAAAAGAAGC 
MSCV full-length HTT 1054 forward TGTCGAGGATGAACACTCCA 
MSCV full-length HTT 1264 reverse ATTGTGGTCTTGGTGCTGTG 
MSCV full-length HTT 1533 forward TCAGCAGCTCTGCCTTAACA 
MSCV full-length HTT 1736 reverse TATCCTCCTCATCCCCATCA 
MSCV full-length HTT 1993 forward GGAGGCCTTCAGGAACTCTT 
MSCV full-length HTT 2222 reverse AAGCAGATAAAAGGCGGACA 
MSCV full-length HTT 2522 forward ACATTTTCTTTGGCGGATTG 
MSCV full-length HTT 2799 reverse AAAAAGCTCACCAGCCTGAA 
MSCV full-length HTT 3193 forward CACATCAACCACCAGAGCAC 
MSCV full-length HTT 3409 reverse ATGGGCTGAGAGATCCAATG 
MSCV full-length HTT 3702 forward AGGGGAAGGAGAAAGAACCA 
MSCV full-length HTT 3931 reverse CGTGCTGTTCTGAAGATCCA 
MSCV full-length HTT 4295 forward GAGCAGGAGAACGACACCTC 
MSCV full-length HTT 4510 reverse CGCCAGCAAATCTAAAACCT 
MSCV full-length HTT 4849 forward CCAAAAAGAGGTGGTGGTGT 
MSCV full-length HTT 5008 reverse GGCTAACATTGGGAGGATGA 
MSCV full-length HTT 5435 forward GTGGAAATGAGTGAGCAGCA 
MSCV full-length HTT 5608 reverse GTTCAAGCTGTCCAGGGTGT 
MSCV full-length HTT 6011 forward ATCCAGGCAATTCAGTCTCG 
MSCV full-length HTT 6220 reverse ATTTGCAGCCAGAAGCATTT 
MSCV full-length HTT 6504 forward AAGGTGCAGAGCTGGTGAAT 
MSCV full-length HTT 6723 reverse TGGAAGACATGATGGACAGC 
MSCV full-length HTT 7061 forward GCCTGCTCCCTCATCTACTG 
MSCV full-length HTT 7247 reverse TTTCTGCCACCATCTCACAG 
MSCV full-length HTT 7609 forward GAGCCCACCAGAAGAAGACA 
MSCV full-length HTT 7821 reverse TCTTGCTCCACAATCCCTCT 
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MSCV full-length HTT 8292 forward GCAACCAGTTTGAGCTGATG 
MSCV full-length HTT 8530 reverse GTCGCACTCCAGCACATAGA 
MSCV full-length HTT 8846 forward CTGGTCAAGCTGAGTGTGGA 
MSCV full-length HTT 9028 reverse AGATACCCGCTCCATAGCAA 
MSCV full-length HTT 9262 forward GCTGTCCCTCTCCAACTTCA 
MSCV full-length HTT 9505 reverse CACCTCAAGCACAGACTGGA 
 
2.2.3.2 DNA sequencing polymerase chain reaction and analysis 
DNA sequencing polymerase chain reactions (PCR) were carried out in ThermoFast 
non-skirted 96-well microplates [Thermo Fisher Scientific]. One reaction (15 µL final 
volume) was prepared with 1 µL BigDye Terminator v1.1 (Cycle Sequencing Kit) 
[Applied Biosystems], 5 µL Better Buffer [Microzone Limited], 0.75 µL primer (5 µM), 1 
µL template DNA (150 ng/µL) and 7.25 μL ddH2O. Plates were covered and placed on 
a Tetrad 2 BioRad thermal cycler with the program outlined in Table 2.2. 
Table 2.2: Thermal cycling program for DNA sequencing PCR 
Step Temperature Duration Number of cycles
Initial denaturation 96 °C 1 min 1 
Denaturation 96 °C 30 s 
30 
Annealing/extension 60 °C 3 min 15 s 
Reaction stop 15 °C 5 min 1 
 
To purify extension products, 3.75 µL 0.125 M EDTA and 45 µL 100 % ethanol was 
added to each sequencing reaction and mixed by pipetting. Reactions were then 
incubated at RT for 15 min before centrifugation of the plate at 3000 × g for 30 min at 4 
°C to pellet precipitated DNA. Waste products were removed by gently inverting the 
plate onto tissue and centrifugation for 1 min at 100 × g. Sixty microlitres 70 % ethanol 
was added to each DNA pellet and the plate was centrifuged at 1650 × g for 15 min at 
4 °C. The plate was then inverted onto tissue and centrifuged again for 1 min at 185 × 
g to remove excess liquid. The plate was then placed, uncovered, on a thermocycler 
set to 37 °C for 5 min to allow any final traces of ethanol to evaporate. Dried DNA 
pellets were frozen to −20 °C and handed to Gary Adamson, Genetics and 
Diagnostics, MRC Prion Unit (IoN, London, UK), for sequencing. Samples were 
sequenced using the automated Applied Biosystems 3730xl DNA Analyser. 
Electropherograms for each sample were analysed in the forward and reverse 
directions using Geneious Pro (Biomatters Ltd.). 
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Sequencing results for ReNcell VM NSC genomic HTT exon 1, A2UCOE HTT exon 1 
transgenes and MSCV full-length HTT transgenes were assessed for homology against 
the NCBI; nucleotide; RefSeqGene reference sequence NG_009378.1, for the ~10.3 
Kb alternatively polyadenylated transcript variant of full-length Homo sapiens HTT 
cDNA (IT15), chromosome 4. DNA sequences were assessed for CAG repeat length, 
any mutations in exon 1, and any coding mutations in the rest of the full-length 
transgene. Genomic DNA was additionally assessed for SNPs in exon 1. 
2.2.4 HD genotyping by CAG repeat-sizing 
ReNcell VM NSCs were grown to approximately 80 % confluence in a 75 cm2 culture 
flask, removed from the culture surface and pelleted as per the usual protocol (section 
2.1.1.3). Cells were re-suspended in 200 µL 1× phosphate-buffered saline (PBS, 
prepared from 10× PBS solution diluted in ddH2O). ReNcell VM Genomic DNA was 
then extracted using Qiagen DNeasy Blood and Tissue Kit [Qiagen; #69504] according 
to the manufacturer’s Spin-Column Protocol for purification of total DNA from animal 
blood or cells. DNA was eluted in 200 µL Qiagen Buffer AE (10 mM Tris-Cl; 0.5mM 
EDTA; pH 9.0) and nucleic acid concentration and purity were determined using 
NanoDrop (section 2.2.7).  
ReNcell VM genomic DNA was then sent to Andrea Haworth (Neurogenetics, NHNN, 
London, UK) for CAG repeat sizing, using the same method as is used for HD patient 
diagnostics through the HD clinic. Two primer pairs (HD3F/HDE and HD3F/HD5; see 
Table 2.3) were used to amplify across the CAG repeat by PCR. The HD3 primer is 
conjugated to 6-Carboxyfluorescein (6-FAM) fluorophore (HD3F). The HD3F/HD5 
primer pair sequences across the polymorphic cytosine-cytosine-guanine (CCG) repeat 
region adjacent to the CAG repeat tract, and can be used to check for diploidy at the 
HTT gene site and HD gene homozygosity. Results from this PCR can also be used to 
confirm any positive results. One reaction was prepared with 12.5 µL Amplitaq Gold 
360 Master Mix, 2.5 µL GC enhancer, 5 pmol of each primer, 1 µL DNA (50 ng/µL) and 
ddH2O to a final volume of 25 µL. Two expansion positive controls, one with an 
expansion of 40-50 repeats and one with a large expansion of >70, were included in 
each analysis. A negative control was also included which was homozygous for a 
normal repeat size with HD3F/HDE, or heterozygous with HD3F/HD5. PCR was then 
performed according to the thermal cycling program outlined in Table 2.4.  
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Table 2.3: CAG repeat-sizing PCR primers 
PCR primer Sequence (5’ to 3’) 
HD3F 6-FAM-CCTTCGAGTCCCTCAAGTCCTT 
HDE GGCGGTGGCGGCTGTTGCTGCTGCTGCTGC 
HD5 CGGCTGAGGCAGCAGCGGCTGT 
 
Table 2.4: Thermal cycling program for HTT CAG repeat-sizing PCR 
Step Temperature Duration Number of cycles
Initial denaturation 95 °C 10 min 1 
Cycling 
95 °C 30 s 
30 58 °C 30 s 
72 °C 30 s 
Final extension 72 °C 7 min 1 
Reaction stop 4 °C - 1 
 
Ten microlitres PCR product was transferred to a 3.5 % agarose minigel and subjected 
to agarose gel electrophoresis (section 2.2.6). DNA was visualised by exposure to 
ultraviolet (UV) light using the Gene Genius gel documentation system. The agarose 
gel was used to check that the PCR had worked and that there was no contamination 
of the samples. Capillary electrophoresis of the PCR product was then performed. One 
microlitre PCR product was added to 12 µL highly deionised (Hi-Di) formamide and 0.3 
µL 500 Liz dye-labelled fragment size standard in a 96-well plate. The plate was then 
heat-sealed with plastic film using an Eppendorf Heat Sealer; before briefly spinning 
down the samples by centrifugation. Samples were heated at 95 °C for 3 min, 
immediately cooled on ice for 3 min, briefly spun down again, and then loaded onto an 
Applied Biosystems Incorporation (ABI) 3730 XL DNA Analyzer for capillary 
electrophoresis and fragment analysis. Sizing data was analysed using GeneMapper 
Software, and repeat sizes were calculated as shown in Table 2.5. The size, shape and 
peak height of PCR products was examined for interpretation of homozygosity and 
expanded alleles. The agarose gel was compared with capillary electrophoresis data to 
check for consistency of results.  
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Table 2.5: CAG repeat size calculation 
Primer pair CAG repeat number 
HD3F/HDE 
ẘↄↄⱡↄⱡ ݏⱪݖⱡ െ 39
3 േ 2 
HD3F/HD5 ẘↄↄⱡↄⱡ ݏⱪݖⱡ െ 1083 േ 2 
The range of normal alleles is 8-26 repeats, intermediate alleles sizes range from 27-35 
repeats, expanded alleles 36-75+ (36 to 39 reduced penetrance; ≥40 fully penetrant). Repeat 
allele sizes have been empirically ascertained to be accurate within a range of ± 2 repeats. 
2.2.5 Restriction enzyme digestion of DNA 
For each reaction, 1 µg plasmid DNA and 1 µL of each specific restriction enzyme was 
diluted in 1 × appropriate restriction enzyme buffer [NEBuffer; New England BioLabs], 
supplemented with 100 µg/mL bovine serum albumin (BSA) if specified by the 
manufacturer’s protocol for use of the specific restriction enzyme, to a final volume of 
10 µL in DNAse/RNAse free molecular biology grade water. Reactions were incubated 
for 1 h at 37 °C. DNA fragments were visualised by agarose gel electrophoresis 
(section 2.2.6). Restriction enzyme digests were used to size A2UCOE and MSCV 
plasmid backbones and their transgene inserts as confirmation of their presence at 
correct sizes and no contamination between transgenes. See Table 2.6 for details of 
restriction enzymes used for each digest and the conditions used. 
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Table 2.6: Restriction enzyme plasmid sites and reaction conditions 
Plasmid 
Restriction 
enzyme 
Reaction 
conditions 
Digestion sites 
A2UCOE+ 
HTT exon 1 
BamHI NEBuffer3 + 
BSA 
HTT exon 1 transgene + 
A2UCOE plasmid backbone 
Double cut in A2UCOE either side 
of transgene 
MSCV+ 
full-length HTT 
Double digest: 
EcoRI 
HpaI 
NEBuffer4 Fragmented full-length HTT 
transgene + MSCV plasmid 
backbone 
EcoRI: MCS 3’ to transgene, bp 
4698 and 5175 HTT cDNA, within 
hygr 
HpaI: MCS 5’ to transgene 
MSCV+ 
full-length HTT 
XhoI NEBuffer4 + 
BSA 
5’ fragment of full-length HTT 
transgene including CAG repeat 
MCS 5’ to transgene and bp 824 
HTT cDNA 
 
2.2.6 Agarose gel electrophoresis 
Zero point eight to one point two percent agarose gels were prepared by heating 0.8-
1.2 grams (g) UltraPure Agarose [Invitrogen] in 100 mL 1 × Tris/Borate/EDTA (TBE) 
buffer (Appendix II-iii) in a microwave, with occasional swirling, until the agarose was 
completely dissolved. The solution was allowed to cool to approximately 50 °C before 
adding ethidium bromide to 0.5 µg/mL final concentration and pouring into a casting 
tray where it was allowed to solidify. Once set, the agarose gel was removed from the 
casting tray and placed in an electrophoresis unit [Thermo Scientific]. The gel tray was 
filled with TBE buffer until the gel was completely covered. BlueJuice Gel Loading 
Buffer [Invitrogen] was added to each DNA digest, and samples were carefully loaded 
into wells of the agarose gel. HyperLadder I/IV DNA ladders (Bioline) were loaded 
alongside the samples. DNA fragments were electrophoresed at 100-120 Volts (V) for 
30-60 min, until the dye line had run approximately 80 % of the way through the gel. 
DNA fragments were visualised under UV light using the BioRad Gel Doc XR system 
with Quantity One software (version 4.5.1, BioRad). The size of DNA fragments was 
interpreted using the DNA ladders as a guide. 
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2.2.7 Determining concentration and purity of DNA 
Nucleic acid concentration was determined by measuring absorbance at 260 nm 
(A260) using a NanoDrop ND-1000 spectrophotometer [NanoDrop Technologies]. 
Absorbance measurement at 280 nm (A280) was used to determine protein 
concentration, and absorbance at 230 nm (A230) was used to determine presence of 
other contaminants within the sample. A260/A280 and A260/A230 ratios were 
calculated and used as a measure of purity in DNA samples, with an A260/A280 ratio 
of ~1.8 and an A260/A230 ratio of 2.0-2.2 being considered pure DNA. Deionised 
distilled H2O was used to blank the machine before each sample absorbance reading. 
2.3 Viral vectors and transduction of NSCs 
All procedures involving viruses or virus parts were performed under biosafety level 2 
conditions and appropriate risk assessments and safety measures were in place. All 
materials and waste associated with the use of viruses or virus parts were 
decontaminated for at least 2 h in 5 % Virkon disinfectant prior to disposal, as per the 
recommended safety guidelines.  
2.3.1 Packaging plasmids into viruses 
2.3.1.1 Packaging A2UCOE+HTT exon 1 into lentiviruses in HEK293T 
A2UCOE+HTT exon 1 with 29, 71 or 129 CAG repeats, and A2UCOE eGFP reporter 
only plasmids were packaged into lentiviral vectors with a Vesicular Stomatitis Virus 
glycoprotein G (VSV-G) envelope, encoded from VSV-G-expressing plasmid MD.G2. 
Group antigens (GAG) and pol (reverse transcriptase, RNase H and integrase 
functions) proteins were encoded from the packaging plasmid CMVRd8.74. MD.G2 and 
CMVRd8.74 plasmids were produced by Plasmid Factory, and the patent is held with 
Michael Antoniou, KCL, London, UK. 
HEK293T cells of low passage number were seeded at 12 × 106 cells per 175 cm−2 
culture flask and incubated at 37 °C for 24 h, as described above (section 2.1.1.1). For 
each flask of cultured cells, viral parts were prepared by adding 50 µg specific viral 
vector construct, 17.5 µg VSV-G envelope plasmid (MD.G2) and 32.5 µg GAG/pol 
packaging plasmid (pCMVRd8.47) to 5 mL serum-free Dulbecco’s modified Eagle 
medium (DMEM). Polyethylenimine (PEI) transfection reagent was prepared by adding 
1 µL 10 mM pH 7.0 PEI to 5 mL DMEM. Viral parts and PEI solution were sterilised by 
passing through a 0.22 µm cellulose acetate syringe filter before gently mixing them 
together and incubating for 20 min at RT. Culture medium was removed from HEK293T 
cultures, and the cells were washed in serum-free DMEM before transfection was 
initiated by adding 10 mL viral parts and PEI mixture to each flask. Cells were returned 
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to the incubator for 4 h. The transfection mixture was then replaced with 15 mL 
standard DMEM/FBS culture medium (Appendix I-i) and cells were incubated for a 
further 24 h. Following this, lentiviral supernatants were harvested, passed through a 
0.45 µm cellulose acetate syringe filter [Nalgene] into Falcon tubes to remove any cells 
or cellular debris, and promptly frozen in a −80 °C freezer where they were stored until 
ready for use.  
2.3.1.2 Packaging MSCV+full-length HTT into retroviruses in Phoenix-AMPHO 
MSCVpuro+full-length HTT (15 CAG) and MSCVhyg+full-length mHTT (138 CAG) 
were packaged into retroviral vectors with a pseudotyped dual 4070A (amphotropic) 
and VSV-G envelope. The additional VSV-G envelope protein was incorporated to 
increase the stability of retrovirus particles for the purpose of virus concentration by 
ultracentrifugation (section 2.3.2). The 4070A envelope and GAG/pol proteins were 
encoded from constructs carried by the second-generation Phoenix-AMPHO retrovirus 
producer cell line, and VSV-G was encoded from VSV-G-expressing plasmid MD.G2. 
Phoenix-AMPHO cells of low passage number were plated at 2.5 × 106 per 75 cm−2 
culture flask and grown to approximately 60 % confluence, as described above (section 
2.1.1.1). Cells were transfected with MSCVpuro+full-length HTT (15 CAG) or 
MSCVhyg+full-length mHTT (138 CAG) using FuGene HD Transfection Reagent 
[Promega], as was recommended by the manufacturer for use with this cell line. For 
each flask,16.3 µL transfection reagent and 7.5 µg VSV-G envelope plasmid (MD.G2) 
was added to 136 µL serum-free DMEM, and incubated at RT for 5 min. Thirteen point 
six micrograms specific viral vector construct was then added to the mixture and 
incubated at RT for a further 15 min. The mixture was added drop-wise to Phoenix-
AMPHO cells and swirled to mix evenly with the cells, before returning the cultures to 
the incubator for 24 h. The transfection medium was then removed from the cells and 
replaced with 10 mL fresh standard DMEM/FBS culture medium (Appendix I-i). After a 
further 48 h incubation, retroviral supernatants were harvested, passed through a 0.45 
µm cellulose acetate syringe filter and promptly frozen in a −80 °C freezer where they 
were stored until ready for use. 
2.3.2 Concentration of viruses 
Viral supernatants were concentrated to increase multiplicity of infection (MOI) when 
transducing cells (section 2.3.4; Stable transduction of NSCs), and to allow for re-
suspension of virus pellets in NSC-compatible culture media. A2UCOE+HTT exon 1 
lentivirus or MSCV+full-length HTT retrovirus frozen supernatants were rapidly thawed 
in a 37 °C water bath. Twenty millilitres supernatant was transferred into an 
ultracentrifuge tube [Polyallomer Konical 30 mL Beckman Coulter]. Virus supernatant 
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was underlain with 5 mL filter-sterilised [0.22 µm cellulose acetate filter and vacuum 
pump; Millipore] 25 % sucrose in PBS, then the remaining supernatant was added and 
tubes were topped up with serum-free DMEM. The virus suspension was then 
centrifuged through the sucrose gradient by ultracentrifugation in a Sorvall Ultra Pro 80 
centrifuge with a Sorvall Surespin 630 (36 mL) rotor, in a vacuum at 98,000 × g for 2 h 
at 4 °C, with fast acceleration and slow deacceleration. Supernatant was removed and 
discarded, and each viral pellet was re-suspended in 200 µL DMEM:F-12, aliquoted 
into cryovials [Nunc] and stored at −80 °C until ready for use. 
2.3.3 Virus viability testing and titration 
2.3.3.1 Testing and titrating A2UCOE+HTT exon 1 lentiviruses in HEK293T cells 
A2UCOE+HTT exon 1 with 29, 71 or 129 CAG repeats, and A2UCOE+eGFP reporter 
only lentiviral supernatants were tested for transduction viability in HEK293T cells, and 
the concentrated lentiviruses were titred in the same cell line.  
To test for presence of viable lentivirus in supernatants, HEK293T cells were seeded in 
25 cm−2 flasks at 3 × 105 cells per flask and incubated for 8 h, as described above 
(section 2.1.1.1). Lentivirus supernatants were removed from −80 °C freezer storage 
and rapidly thawed in a 37 °C water bath. Culture medium was then removed from 
HEK293T cell cultures and replaced with 5 mL 1:1 fresh culture medium: lentiviral 
supernatant and 8 µg/mL hexadimethrine bromide (polybrene). Polybrene is a cationic 
polymer which neutralises the charge repulsion between virus particles and sialic acid 
on the cell surface, increasing the efficiency of retroviral infection. Cell cultures were 
returned to the incubator for 24 h, given a fresh media change, then incubated for a 
further 48 h. Transduction efficiency was assessed by monitoring eGFP expression by 
live-cell fluorescence microscopy with a fluorescein isothiocyanate (FITC) filter (section 
2.7.2).  
To titrate concentrated lentiviruses, HEK293T cells were seeded in 24-well culture 
plates at 1 × 105 cells per well and incubated overnight, as described above (section 
2.1.1.1). Concentrated lentivirus was removed from −80 °C freezer storage and rapidly 
thawed in a 37 °C water bath. HEK293T cells were treated in duplicate with 
concentrated lentivirus at 1:100, 1:500, 1:1000, 1:5,000, or 1:10,000 dilution, or no 
lentivirus (control), in 500 µL standard culture medium with 8 µg/mL polybrene, for 24 
h. Cells were then given a fresh medium change and returned to the incubator for a 
further 48 h. Transduction efficiency was assessed by monitoring eGFP expression by 
live-cell fluorescence microscopy with a FITC filter, and calculating the average 
percentage eGFP-positive cell population across two repeats, per concentrated 
lentivirus dilution. The optimum lentivirus treatment was considered to be the dilution 
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which resulted in ~50 % average eGFP-positive cell population, as greater than 50 % 
infection increases the likelihood of multiple transductions per cell, and less than 50 % 
would yield low transduction efficiency. These optimum conditions were taken forward 
for the transduction of ReNcell VM NSCs with HTT exon 1.  
2.3.3.2 Testing and titrating MSCV+full-length HTT retroviruses in HeLa cells 
MSCVpuro+full-length HTT (15 CAG) and MSCVhyg+full-length mHTT (138 CAG) 
retroviral supernatants were tested for transduction viability in HeLa cells, and the 
concentrated retroviruses were titred in the same cell line.  
To test for presence of viable retrovirus in supernatants, HeLa cells were seeded in 6-
well culture plates at 5 × 104 cells per well and incubated overnight, as described 
above (section 2.1.1.1). Retrovirus supernatants were removed from −80 °C freezer 
storage and rapidly thawed in a 37 °C water bath. Culture medium was then removed 
from HeLa cell cultures and replaced with 2 mL 1:1 fresh culture medium: retroviral 
supernatant and 8 µg/mL polybrene. Cell cultures were returned to the incubator for 24 
h, given a fresh media change, then incubated for a further 48 h, reaching sub- 
confluence. Keeping all cells, transduced cultures were passaged into 75 cm−2 culture 
flasks, as previously described, and incubated overnight. Antibiotic selection of 
successfully transduced cells was then commenced by the addition of 0.2 μg/mL 
puromycin (puromycin dihydrochloride from Streptomyces alboniger) to the culture 
medium of cells infected with MSCVpuro+full-length HTT (15 CAG) retrovirus and 300 
μg/mL Hygromycin B (from Streptomyces hydroscopicus) [Invitrogen] to cultures 
infected with MSCVhyg+full-length mHTT (138 CAG). Culture medium changes with 
the addition of fresh antibiotics were performed every 48 h. The optimum conditions 
and concentrations of antibiotics used here for antibiotic selection were ascertained by 
performing puromycin or Hygromycin B antibiotic kill curves in HeLa cells (section 
2.3.4.1). Retrovirus viability was assessed by monitoring the number of surviving cells 
(cell density) after four days puromycin selection or seven days Hygromycin B 
selection. Infections with retroviral supernatants which resulted in at least 5 % surviving 
cells after 4 days puromycin selection or 7 days Hygromycin B selection, followed by 
an exponential growth phase under continued selection, were considered to contain 
viable retrovirus with reasonable transduction efficiency, and were subsequently taken 
forward for concentration. 
To titrate concentrated retroviruses, HeLa cells were seeded in 24-well culture plates at 
5 × 104 cells per well and incubated overnight, as described above (section 2.1.1.1). 
Concentrated retrovirus was removed from −80 °C freezer storage and rapidly thawed 
in a 37 °C water bath. HeLa cells were treated in duplicate with concentrated retrovirus 
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at 1:100, 1:1000 or 1:10,000 dilutions, or no retrovirus (control), in 500 µL standard 
culture medium with 8 µg/mL polybrene, for 24 h. Cells were then grown to confluence, 
passaged into 25 cm−2 culture flasks, and subjected to antibiotic selection, in the same 
way as is described above for testing retrovirus viability in supernatants. Transduction 
efficiency was assessed by monitoring the average number of surviving cells (cell 
density) after four days puromycin selection or seven days Hygromycin B selection, per 
retrovirus dilution, over two repeats. The optimum retrovirus treatment was considered 
to be the dilution which resulted in 15-20 % average surviving cell population after 4 
days puromycin selection or 7 days Hygromycin B selection (with the no retrovirus 
treatment control cultures reaching 100 % cell death alongside), followed by an 
exponential growth phase under continued selection. These optimum conditions were 
taken forward for the transduction of ReNcell VM NSCs with full-length HTT. 
As additional measures of MSCVpuro+full-length HTT (15 CAG) and MSCVhyg+full-
length mHTT (138 CAG) retrovirus viability and transduction success, HeLa cells which 
had survived antibiotic selection were expanded and presence of the full-length 
(m)HTT protein produced from the transgene was assessed by Western blotting and 
immunocytochemistry (ICC) techniques. Increased expression of HTT in transfected 
HeLa cells compared with non-transfected cells was considered to indicate presence of 
either transgene. Expression of mHTT in HeLa cells transfected with full-length mHTT 
(138 CAG) compared with non-transfected cells or cells transfected with full-length HTT 
(15 CAG) was considered to indicate presence of the full-length mHTT (138 CAG) 
transgene. 
2.3.4 Stable transduction of NSCs 
2.3.4.1 Antibiotic kill curves 
MSCVpuro+full-length HTT (15 CAG) and MSCVhyg+full-length mHTT (138 CAG) 
carry puror and hygr antibiotic resistance genes, respectively, which are co-expressed 
alongside the HTT transgene in transduced cells. Consequently, cells which carry the 
transgene can be selected for in a mixed culture by treatment with the relevant 
antibiotic. The optimum antibiotic selection concentration for each cell type was 
determined using kill curves. HeLa cells or ReNcell VM NSCs were seeded in 6-well 
culture plates at 5 × 104 cells per well and incubated overnight, as described above 
(sections 2.1.1.1 and 2.1.1.3). Cells were then given a media change with the addition 
of a range of antibiotic concentrations, each tested in triplicate. HeLa cells were treated 
with twelve different puromycin concentrations in the range of 0-15 µg/mL, or ten 
different Hygromycin B concentrations in the range of 0-500 µg/mL. ReNcell VM NSCs 
were treated with seventeen different puromycin concentrations in the range of 0-1 
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µg/mL, or ten different Hygromycin B concentrations in the range of 0-400 µg/mL. Cells 
were given a media change with the addition of fresh antibiotics every 2 days. 
Percentage surviving cells was monitored daily, and determined by direct visualisation 
of cell cultures under a light microscope (section 2.7.1), taking an average 
interpretation from three treatment repeats. The optimum antibiotic selection 
concentration was considered to be the minimum concentration required to give 100 % 
cell death after 3-4 days for puromycin, and 7-8 days for Hygromycin B.  
2.3.4.2 Transduction of ReNcell VM NSCs with HTT exon 1 or full-length HTT 
ReNcell VM NSCs which had undergone one passage post-thawing were seeded in 
24-well culture plates at 5 × 104 cells per well and incubated overnight, as previously 
described (section 2.1.1.3). Cells were then infected with concentrated A2UCOE+HTT 
exon 1 lentiviruses or MSCV+full-length HTT retroviruses at 1:100 dilutions, in 500 µL 
culture medium with 8 µg/mL polybrene per well, for 24 h. For full-length HTT 
transductions, cells were then given another consecutive 24 h infection with the aim of 
increasing MOI, because the concentrated retroviruses were of very low titre. All cells 
were then given a fresh medium change and returned to the incubator. Once cells had 
been allowed to grow to confluence, they were passaged into larger culture vessels, 
keeping all cells.  
2.3.4.3 Selecting for HTT transgenes in transduced NSCs 
Transgene expression was confirmed in A2UCOE+HTT exon 1-infected cells by 
screening for the eGFP reporter using live-cell fluorescence microscopy with a FITC 
filter (section 2.7.2). NSC+HTT exon 1 (29, 71 or 129 CAG) and NSC+eGFP reporter 
only cultures were then expanded, and cells carrying the transgene and co-expressing 
the eGFP reporter were selected for by FACS (section 2.5.4); performed by Dr. Eva C. 
Sirinathsingh, Prof. Gillian P. Bates’ research group, KCL, London, UK).  
NSC cultures which had been infected with MSCVpuro+full-length HTT (15 CAG) or 
MSCVhyg+full-length mHTT (138 CAG) retroviruses were treated with 0.125 µg/mL 
puromycin or 40 µg/mL Hygromycin B, respectively, to select for transduced cells. 
Culture medium was changed every 2 days with the addition of fresh antibiotics, and 
cultures were maintained under antibiotic selection for 1 week (puromycin) or 2 weeks 
(Hygromycin B).  
2.3.4.4 Confirmation and maintenance of ReNcell VM+HTT exon 1 and ReNcell 
VM+full-length HTT NSC lines 
ReNcell VM NSC+HTT exon 1 and ReNcell VM NSC+full-length HTT cell lines were 
expanded long-term and kept under cryopreservation at a maximum total passage 
number of twenty-one (section 2.1.1.4), or maintained in routine cell culture in the same 
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way as wild-type ReNcell VM NSCs (section 2.1.1.3). Transgenic lines were used in 
experiments as NSCs or differentiated into mature neuronal cultures at less than ten 
passages post-expansion or post-thawing (less than a total passage number of 31). 
Production of exon 1 or full-length HTT proteins with appropriate polyQ lengths was 
confirmed by a combination of Western blotting (sections 2.4.4 and 2.5.1), dot blotting 
(section 2.4.5), ICC (section 2.5.2), MSD assay (section 2.5.6.2) and TR-FRET assay 
(section 2.5.7). Stable expression of the transgenes was checked every 3-4 passages 
by monitoring continued eGFP reporter expression in HTT exon 1 lines, and antibiotic 
resistance in full-length HTT lines. 
2.4 Protein biochemistry 
2.4.1 Preparation of cell lysates 
2.4.1.1 Standard preparation of cell lysates for Western blotting or dot blotting 
Cells were harvested from the culture surface and pelleted out of culture medium using 
the same methods as were applied in routine cell culture (section 2.1.1). Differentiated 
ReNcell VM neuronal cultures were treated the same way as NSC cultures. Cells were 
washed in PBS and re-suspended in ice-cold Lysis Buffer (Appendix II-iv) by pipetting 
until achieving a homogenous solution. Suspended lysates were then incubated on ice, 
with agitation, for 15-20 min. Small samples of lysate were taken and protein 
concentration was quantified by Bradford protein assay [Bio-Rad] (section 2.4.2.1) or 
bicinchoninic acid (BCA) assay (section 2.4.2.2). For Western blot lysates, to 
precipitate proteins, reduce aggregation, and remove lipids, 100 µL lysate was added 
to 900 µL ice-cold methanol in a 1.5 mL Eppendorf tube, and incubated at −20 °C for at 
least 30 min. Samples were then centrifuged at 18,000 × g for 10 min at 4 °C, methanol 
was poured off, and the pellet was left to air dry. Dry pellets were re-suspended to 1 
mg/mL protein in 1× Sample buffer (Appendix II-v) and incubated on a shaking heater 
at 95 °C, 800 rpm for 10 min, until pellets had completely dissolved. 
2.4.1.2 Preparation of myeloid cell lysates 
Culture medium was removed and myeloid cells were lysed directly in the culture 
vessel with the addition of ice-cold RIPA buffer (Appendix II-ii). For BMD-macrophages 
and BMD-microglia, culture plates were then incubated at 4 °C for 15 min on a shaking 
platform set to 400 rpm to remove the cells from the culture surface. Cell lysates were 
homogenised by pipetting, collected into 0.5 mL Eppendorf tubes and stored at −80 °C 
until ready for use. When ready to prepare samples, cell pellets were thawed on ice 
and a quantification of total protein was made by BCA assay (section 2.4.2.2). Lysates 
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were mixed with 1× Sample buffer (Appendix II-v) to a final protein concentration of 1 
mg/mL, and incubated at 95 °C for 10 min. 
2.4.2 Quantification of total protein 
2.4.2.1 Bradford Assay (Bio-Rad) 
The Bio-Rad protein assay is a colorimetric assay based on the Bradford dye-binding 
method (Bradford 1976), and works on the principle that Coomassie brilliant blue G-
250 dye binds to amino acid residues and the resultant colour change, which can be 
measured by reading its absorbance, is linear in relation to the amount of protein within 
a solution. The assay was used to quantify total protein concentration of cell lysates 
prepared in buffers which did not contain high concentrations of detergents, which are 
known to interfere with this assay, as per the manufacturer’s instructions and Standard 
Procedure for Microtiter Plates protocol. Firstly, dye reagent was prepared by diluting 
one-part Dye Reagent Concentrate with four parts ddH2O, and syringe filtering the 
solution to remove particulates. Five dilutions of BSA were prepared as protein 
standards (0, 50, 100, 300 and 500 µg/mL), and samples were prepared as pure, 1:2, 
1:10 and 1:20 dilutions in PBS. Ten microlitres of each protein standard and sample 
dilution was pipetted into separate wells of a clear, flat-bottomed 96-well assay plate 
[Greiner], in duplicate. Then 200 µL diluted dye reagent was added to each well, and 
thoroughly mixed by pipetting. Samples were incubated for 5 min at RT before 
measuring the absorbance at 595 nanometres (nm) on a TECAN X-Fluor4 v4.51 plate 
reader [Sunrise]. The BSA protein standards were used to create a linear standard 
curve from which unknown protein concentrations were determined, using Microsoft 
Excel. 
2.4.2.2 Bicinchoninic acid (BCA) assay 
The BCA protein assay [Pierce, Thermo Fisher Scientific] is a colorimetric assay which 
works on the principle that peptide bonds in protein reduce Cu2+ ions from copper(II) 
sulfate to Cu+ ions, in a temperature-dependent reaction. The number of Cu2+ ions 
reduced is directly proportional to the amount of protein in a solution, and is measured 
by reading the absorbance of a purple-coloured complex which forms when BCA 
molecules chelate with Cu+ ions. The assay was used to quantify total protein in highly 
concentrated samples (BCA Assay has a broader dynamic range than Bradford Assay) 
prepared in buffers which contained high concentrations of detergents (known to 
interfere with the Bradford Assay), as per the manufacturer’s instructions. Firstly, BSA 
protein standards were prepared at the following concentrations: 0, 25, 125, 2500, 500, 
750, 1000, 1500 and 2000 µg/mL in appropriate buffer. Cell lysates were diluted 1:5 in 
PBS. Twenty-five microlitres of each protein standard and sample dilution was pipetted 
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into separate wells of a clear, flat-bottomed 96-well assay plate, in duplicate. Then 200 
µL prepared BCA Working Reagent was added to each well, and the plate was mixed 
thoroughly on a plate shaker for 30 s. The plate was then incubated in the dark for 30 
min at 37 °C. After allowing the plate to cool to RT, absorbance was measured at 562 
nm on a TECAN X-Fluor4 v4.51 plate reader. The BSA protein standards were used to 
create a linear standard curve from which unknown protein concentrations were 
determined, using Microsoft Excel. 
2.4.3 Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis 
(PAGE) 
Pre-cast Novex 8, 10, 12 or 4-20% Tris-Glycine 1.5 mm gels with 10 or 15 wells 
[Invitrogen] were assembled in an Invitrogen Novex Mini-Cell Gel tank and the 
chambers were filled with 1× Tris/Glycine/SDS Running buffer (Appendix II-vi). Cell 
lysates prepared in Sample Buffer (section 2.4.1) were loaded into separate gel wells 
at 20 µL (20 µg protein, as determined by Bradford Assay or BCA assay (sections 
2.4.2.1 and 2.4.2.2, respectively)) per lane, against 9 µL BioRad Precision Plus Protein 
Kaleidoscope, BioRad Precision Plus All Blue, HiMark Pre-Stained high molecular 
weight protein standard [Invitrogen] or Novex SeeBlue Plus2 Prestained standard [Life 
Technologies] molecular weight markers. Gels were run at 90 V constant voltage for 
approx. 10 min until samples had stacked at the stacking gel: resolving gel interface, 
then the voltage was increased to 150 V for approx. 1 h until samples had reached the 
end of the gel (or 3-4 h for full-length HTT protein to reach the middle of the gel). 
2.4.4 Electroblotting of proteins 
Following SDS-PAGE, proteins were transferred from the polyacrylamide gel to 
nitrocellulose membrane [Thermo Fisher Scientific] or Immobilon polyvinylidene 
fluoride (PVDF) membrane [Millipore]. The gel, membrane, Whatmann filter papers and 
sponges, which had been pre-soaked thoroughly in Electroblotting buffer [National 
Diagnostics] (Appendix II-vii) for at least 15 min, were assembled in a Novex blot 
module [Invitrogen] in an XCell Surelock Mini-Cell tank, according to the 
manufacturer’s instructions. The central chamber of the transfer tank was filled with 
Electroblotting buffer and the outer chambers with water to act as a coolant, and 
proteins were transferred from the gel to the membrane at 15 V overnight. For transfer 
of very large proteins, such as full-length HTT, the electroblotting process was 
conducted for 24 h at 15 V followed by a further 1 h at 35 V. As full-length HTT is also 
prone to aggregation, 0.1 % SDS was included in the Electroblotting buffer in these 
cases. Following transfer, the membrane was removed from the transfer apparatus and 
buffer was washed off by three 10 min washes in PBS on a gentle shake.  
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2.4.5 Dot-blotting 
Dot blotting apparatus was assembled with pre-soaked filters and a nitrocellulose 
membrane. Cell lysates prepared in Lysis Buffer (section 2.4.1.1) were dotted, in 
triplicate, onto the membrane at 20 µg per dot (as determined by BCA assay (section 
2.4.2.2)). All blank wells were blocked or filled with Lysis Buffer (Appendix II-iv) to 
ensure good draining. The vacuum was then applied to draw proteins into the 
membrane. 
2.5 Immunostaining and detection techniques 
2.5.1 Western blot or dot blot protein detection 
Following electroblotting of proteins separated by SDS-PAGE from polyacrylamide gel 
to a membrane (section 2.4.4; for Western blotting) or transfer of proteins from dotted 
cell lysates to a membrane by vacuum (section 2.4.5; for dot blotting), proteins were 
detected by different techniques depending on the optimal conditions for the specific 
protein or antibodies used for detection.  
2.5.1.1 Western blot or dot blot protein detection by infrared (IR) fluorescence 
The nitrocellulose membrane was incubated in Odyssey Blocking Buffer [LI-COR] for 1 
h at RT on a gentle shake. The membrane was then incubated in primary antibodies at 
the appropriate dilution (see Table 2.7 for details of primary antibodies used for 
immunoblotting) in Odyssey Blocking Buffer at RT for 2 h, or at 4 °C overnight, on a 
shaking platform. In some cases, two different primary antibodies were added at the 
same time, assuming the primary antibodies were raised in different species and the 
relevant secondary antibodies were conjugated to IR dyes of different wavelengths and 
there was no potential for cross-reactivity. Excess, unbound primary antibodies were 
then washed off the membrane by six 10 min washes in 0.1 % PBS Tween-20 (PBST), 
with gentle shaking throughout. The membrane was then incubated in IRDye 
secondary antibodies (see Table 2.8 for details of secondary antibodies used for 
immunoblotting) at 1:10,000 dilution in Odyssey blocking buffer, for 1 h at RT with 
gentle shaking, in the dark. Excess, unbound secondary antibodies were washed off 
the membrane with three 10 min washes in 0.1 % PBST, followed by three 10 min 
washes in PBS only, with gentle shaking in the dark throughout. IRDye secondary 
antibodies were visualised directly on the membrane by scanning using a LI-COR 
Odyssey Scanner. Protein levels were quantified by calculating relative fluorescence of 
background-subtracted integrated intensities (I.I.) on the digital images using Odyssey 
Software v2.1. Sample I.I.s were normalised to I.I.s generated from loading control 
probes. 
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2.5.1.2 Western blot protein detection by chemiluminescence 
Western blotting for the assessment of IκB degradation kinetics in stimulated myeloid 
cells was performed by Dr. Ulrike Träger (Prof. Sarah J. Tabrizi’s research group, UCL 
IoN, London, UK). Proteins were transferred to PVDF membrane, as described above 
(section 2.4.4). The washed membrane was incubated in 5 % non-fat dried milk in Tris-
buffered saline, pH 7.0, containing 0.1 % Tween-20 (TBST), for 2 h at RT on a gentle 
shake. The membrane was then incubated with anti-IκB primary antibodies (see Table 
2.7 for details of primary antibodies used for immunoblotting) in 5 % non-fat dried milk 
in PBST, at 4 °C overnight, on a shaking platform. Excess, unbound primary antibodies 
were then washed off the membrane by six 10 min washes in TBST, with gentle 
shaking throughout. The membrane was then incubated with alkaline phosphatase 
(AP)-conjugated secondary antibodies (see Table 2.8 for details of secondary 
antibodies used for immunoblotting) in 5 % non-fat dried milk in PBST, for 1 h at RT 
with gentle shaking. Excess, unbound secondary antibodies were washed off the 
membrane with six 10 min washes in TBST, with gentle shaking throughout. To 
develop the AP signal, the membrane was washed twice in Tropix assay buffer 
[Applied Biosystems] (Appendix II-viii), and then incubated with Tropix CDP-Star 
chemiluminescent AP-substrate [Applied Biosystems] for 5 min at RT. The signal was 
visualised by exposure to BioMax MR-1 film [Kodak], followed by development and 
fixation using a Xograph Imaging Machine [Xograph Imaging Systems]. The membrane 
was stripped by 10 min incubation in 1:10 diluted ReBlot Plus Strong solution [Millipore] 
on a gentle shake, and reprobed with anti-glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) primary antibodies (see Table 2.7 for details) and AP-conjugated secondary 
antibodies (see Table 2.8 for details) as a loading control. Developed blots were 
scanned using an HP Scanjet N6350 scanner and quantified by densitometry analysis 
of digital images at three different exposures using TotalLab TL100 image analysis 
software [Sigma Aldrich].  
2.5.1.3 Details of antibodies used for immunoblotting 
Table 2.7: Primary antibodies for immunoblotting 
Antibody/ 
antigen 
Host Dilution Cat No. Supplier 
4C9/  
aa65-84 HTT 
Mouse 
(IgG1) 
1:1000  
(1.38 mg/mL 
stock) 
NCA Kind gift from Dr. 
Andreas Weiss 
(Novartis, Switzerland) 
CD68 Mouse 
(IgG2b) 
1:200 MAB20401 R & D Systems 
CSF1R Rabbit 1:1000 LS-C167079 LifeSpan Biosciences 
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CX3CR1 Rabbit 1:500 NBP1-76872 Novus Biologicals 
ERK1/2 Rabbit 1:2000 M5670 Sigma 
GAPDH Rabbit 1:3000 G9545 Sigma 
GFP Rabbit 1:1000 A11122  Invitrogen 
Iba1 (isoforms 1 
and 3) 
Goat 1:500 NB100-1028 Novus Biologicals 
IκB Rabbit 1:500 sc-371 Santa Cruz 
Biotechnology 
mAB2166/ aa181-
810 HTT 
Mouse 
(IgG1) 
1:1000 MAB2166 
 
Millipore 
MW1/  
HTT polyQ 
Mouse 
(IgG2b)
1:2000  
(2.3 mg/mL 
stock) 
NCA Kind gift from Dr. 
Andreas Weiss 
(Novartis, Switzerland) 
P2Y12 Rabbit 1:400 ab183066 Abcam 
PU.1 Mouse 
(IgG1) 
1:500 ab88082 Abcam 
S830/  
mHTT polyQ  
Sheep 1:2000 NCA Kind gift from Prof. 
Gillian P. Bates (KCL, 
London, UK) 
β-actin Rabbit 1:10,000 SAB5500001 Sigma 
β-actin Mouse 
(IgG1) 
1:10,000 A5441 Sigma 
NCA, not commercially available 
Table 2.8: Secondary antibodies for immunoblotting 
Antibody Dilution Cat No. Supplier 
AP-conjugated anti-Rabbit IgG 1:10,000 A3687 Sigma 
IRDye 680LT Donkey anti-Mouse IgG 1:10,000 925-68022 LI-COR 
IRDye 680LT Donkey anti-Rabbit IgG 1:10,000 925-68023 LI-COR 
IRDye 680LT Goat anti-Rabbit IgG 1:10,000 925-68021 LI-COR 
IRDye 800CW Donkey anti-Goat IgG 1:10,000 925-32214 LI-COR 
IRDye 800CW Donkey anti-Mouse IgG 1:10,000 925-32212 LI-COR 
IRDye 800CW Goat anti-Mouse IgG 1:10,000 925-32210 LI-COR 
IRDye 800CW Goat anti-Rabbit IgG 1:10,000 925-32211 LI-COR 
 
Chapter 2 
116 
 
2.5.2 Immunocytochemistry (ICC) 
2.5.2.1 Preparation of coverslips for ICC 
Cells were seeded into 24-well culture plates at 1 × 105 cells per well on 13 mm 
diameter glass coverslips. For NSC cultures (and differentiated neuronal cultures), 
coverslips were sterilised by baking in an electric oven at 200 °C for 6 h, and laminin-
coated by incubating in 200 μL 20 μg/mL cold mouse laminin-1 PathClear in 20 mM 
cold Tris-HCl, pH 7, per coverslip, at 37 °C for 24 h. Before seeding NSCs, the laminin 
solution was removed and laminin-coated surfaces were washed in pre-warmed 
DMEM:F-12. For HeLa, N2a_R2 or primary MC cultures, coverslips were sterilised by 
soaking in 100 % ethanol for at least 10 min before allowing to air-dry in a tissue 
culture safety cabinet. Coverslips were then PDL-coated by incubating in 200 μL 0.1 
mg/mL PDL in sterile tissue culture grade distilled water, per coverslip, for 5 min at RT. 
Before seeding cells, PDL solution was removed and coverslips were thoroughly 
washed in sterile distilled water and allowed to air-dry for at least two hours. For BMD-
macrophage and BMD-microglia cultures, coverslips were sterilised in 100 % ethanol 
and allowed to air-dry before seeding. No cell attachment aids were required for these 
cells because they already adhere well to glass.  
2.5.2.2 Standard ICC 
When ready to perform ICC, cells were washed three times in PBS and fixed in 4 % 
paraformaldehyde (PFA) [Polysciences] in PBS for 15 min at RT. PFA was removed 
with five washes in PBS, then cells were permeabilised in 100 % ice-cold methanol for 
15 min at −20 °C. Methanol was removed with five washes in PBS. Cells were then 
incubated with 10 % BSA in PBS at 37 °C for 30 min, followed by a 1 h incubation with 
primary antibodies at the appropriate dilution (see Table 2.9 for details of primary 
antibodies used for ICC) in 1 % BSA in PBS at 37 °C. In some cases, two or more 
different primary antibodies were added at the same time, assuming the primary 
antibodies were raised in different species or were of different isotypes, and the 
relevant secondary antibodies were conjugated to different fluorophores and there was 
no potential for cross-reactivity. Excess, unbound primary antibodies were removed 
with five washes in PBS, then cells were incubated with 1:1000 dilution Alexa Fluor-
conjugated secondary antibodies (see Table 2.10 for details of secondary antibodies 
used for ICC) in 1 % BSA at 37 °C for 45 min. Excess, unbound secondary antibodies 
were removed with five washes in PBS. Coverslips were then mounted, cells down, on 
Superfrost glass microscope slides [Thermo Scientific] in Antifade Fluorescence 
Mounting Medium [Dako] containing 1 µg/mL 4',6-diamidino-2-phenylindole (DAPI). 
Immunofluorescent staining was visualised by confocal microscopy (section 2.7.3). 
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2.5.2.3 ICC with differentiated neuronal cultures 
Neuronal cultures were washed three times in PBS and fixed in 4 % PFA in PBS for 15 
min at RT. PFA was removed with five washes in PBS, then cells were permeabilised 
in 0.2 % Triton X-100 in PBS for 10 min at RT. Triton X-100 was removed with five 
washes in PBS. Cells were then incubated with 10 % goat serum (or donkey serum if 
primary antibodies were raised in sheep or goat e.g. S830); 1 % BSA in PBS for 1 h at 
RT, followed by an overnight incubation with primary antibodies at the appropriate 
dilution (see Table 2.9 for details of primary antibodies used for ICC) in 1 % BSA at 4 
°C. Excess, unbound primary antibodies were removed with five washes in 0.05 % 
PBST, then cells were incubated with 1:1000 dilution Alexa Fluor-conjugated 
secondary antibodies (see Table 2.10 for details of secondary antibodies used for ICC) 
in 1 % BSA at RT for 1 h. Excess, unbound secondary antibodies were removed with 
five washes in 0.05 % PBST. Coverslips were then mounted on Superfrost glass 
microscope slides in Antifade Fluorescence Mounting Medium [Dako] containing 1 
µg/mL DAPI or 1 µg/mL Hoechst 33342. Immunofluorescent staining was visualised by 
confocal microscopy (section 2.7.3). 
2.5.2.4 Details of antibodies used for ICC 
Table 2.9: Primary antibodies for ICC 
Antibody/ 
antigen 
Host Dilution Cat No. Supplier 
2B7/  
aa1-17 HTT 
Mouse 
(IgG1) 
1:500  
(4.854 mg/mL 
stock) 
NCA Kind gift from Dr. 
Andreas Weiss 
(Novartis, Switzerland) 
CD11b Mouse 
(IgG1)  
1:50 MCA551 Serotec 
CD14 Mouse 
(IgG1) 
1:50 MA5-14773 Thermo Scientific 
GAD67 Mouse 
(IgG2a) 
1:100 MAB5406 Millipore 
GFAP 
(conjugated to 
cy3) 
Mouse 
(IgG1) 
1:200 C9205 Sigma 
GFP Rabbit 1:1000 A11122  Invitrogen 
Iba1  
(isoforms 1 and 
3) 
Goat 1:20 NB100-1028 Novus Biologicals 
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mAB2166/  
aa181-810 HTT 
Mouse 
(IgG1) 
1:250 MAB2166 Millipore 
 
Mannose 
receptor 
(CD206) 
Rabbit 1:250 ab125028 Abcam 
MW1/  
HTT polyQ 
Mouse 
(IgG2b) 
1:1000  
(2.3 mg/mL 
stock) 
NCA Kind gift from Dr. 
Andreas Weiss 
(Novartis, Switzerland) 
S830/  
mHTT polyQ 
(aggregates) 
Sheep 1:500  NCA Kind gift from Prof. 
Gillian P. Bates (KCL, 
London, UK) 
TREM2 Goat 1:20 LS-C150090 LifeSpan Biosciences  
Tyrosine 
hydroxylase 
Mouse 
(IgG1) 
1:250 MAB318 Millipore 
βIII-tubulin Mouse 
(IgG2a) 
1:500 ab78078 Abcam 
NCA, not commercially available 
Table 2.10: Secondary antibodies for ICC 
Antibody Dilution Cat No. Supplier 
Alexa Fluor 488 Donkey anti-Goat IgG (H+L)  1:1000 A-11055 Invitrogen 
Alexa Fluor 488 Goat anti-Mouse IgG (H+L) 1:1000 A-11001 Invitrogen 
Alexa Fluor 488 Goat anti-Mouse IgG2a  1:1000 A-21131 Invitrogen 
Alexa Fluor 488 Goat anti-Mouse IgG2b  1:1000 A-21141 Invitrogen 
Alexa Fluor 488 Goat anti-Rabbit IgG (H+L)  1:1000 A-11034 Invitrogen 
Alexa Fluor 546 Donkey anti-Goat IgG (H+L) 1:1000 A-11056 Invitrogen 
Alexa Fluor 568 Goat anti-Mouse IgG1  1:1000 A-21124 Invitrogen 
Alexa Fluor 647 Donkey anti-Rabbit IgG (H+L) 1:1000 A-31573 Invitrogen 
 
2.5.3 Proximity ligation assay (PLA) 
Proximity ligation assay (PLA) allows for the detection, visualisation and quantification 
of proteins which directly interact, or are in close proximity, within cell samples 
prepared for microscopy. PLA was used to determine the level of interaction between 
HTT and IKKү in primary BMD-macrophages in various treatment paradigms, as per 
the manufacturer’s instructions [Duolink In Situ PLA, Olink Bioscience]. 
Monocytes were seeded on coverslips in 24-well culture plates at 1 × 106 cells per well 
and differentiated into BMD-macrophages as per the usual protocol (section 2.1.2.4). 
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Following treatments relevant to the specific experiment, cells were fixed in 4 % PFA 
and stained with 1 µg/mL fluorescent wheat germ agglutinin (WGA) [Life Technologies] 
for 5 min at 37 °C to label membranes. Excess WGA was removed with ten washes in 
PBS. Cells were then permeabilised in 100 % ice-cold methanol for 15 min at −20 °C, 
and then blocked with 10 % BSA in PBS for 30 min at 37 °C. Cells were probed with 
primary antibodies in 1 % BSA in PBS for 1 h at 37 °C (see Table 2.11 for details of 
primary antibodies and Table 2.12 for antibody pairs used for PLA). Excess, unbound 
primary antibodies were washed off with three 5 min washes in PBS with gentle 
agitation.  
To perform PLA, cells were then incubated with anti-mouse and anti-rabbit secondary 
antibodies conjugated with oligonucleotides (PLA probe MINUS and PLA probe PLUS). 
To do this, firstly the PLA probe was prepared by incubating 8 µL PLA PLUS with 8 µL 
PLA MINUS in 24 µL 1 % BSA in PBS, for 20 min at RT. Each coverslip was removed 
from the culture plate and sandwiched in parafilm with 40 µL pre-prepared PLA probe, 
and incubated for 1 h at 37 °C in a humidified chamber. Coverslips were then returned 
to culture plates and given two 5 min washes in Duolink In Situ Wash Buffer A 
(Appendix II-ix) with gentle agitation, before transferring back to parafilm. Two 
oligonucleotides were then hybridised to the two PLA probes by incubation in 1 × 
Duolink In Situ Ligation Solution (consisting of the two oligonucleotides and Ligase) for 
30 min at 37 °C in a humidified chamber. If the oligonucleotides were in close 
proximity, they would join to form a closed circle. Coverslips were then returned to 
culture plates and given two 5 min washes in Duolink In Situ Wash Buffer A with gentle 
agitation, before transferring back to parafilm. The DNA template was then amplified in 
a rolling-circle amplification (RCA) reaction. Coverslips were incubated in 1 × Duolink 
In Situ Red Amplification Solution (consisting of nucleotides and fluorescently labelled 
oligonucleotides) with Polymerase for 100 min at 37 °C in a humidified chamber. One 
of the oligonucleotides hybridised to one of the PLA probes acts as a primer for a RCA 
reaction using the ligated circle as a template, and the fluorescently labelled 
oligonucleotides hybridise to the RCA product. Coverslips were then returned to culture 
plates and given two 10 min washes in 1 % Duolink In Situ Wash Buffer B (Appendix II-
x) followed by one 2 min wash with 0.01 % Duolink In Situ Wash Buffer B, with gentle 
agitation, in the dark. Finally, coverslips were mounted on glass microscope slides in 7 
µL Duolink In Situ Mounting Medium with DAPI, and confocal fluorescence microscopy 
was used to detect and visualise fluorescently labelled oligonucleotides (section 2.7.3). 
Positive interactions, indicating two proteins which directly interact or are in close 
proximity, appear as distinct fluorescent red spots. Positive interactions were quantified 
as average number of spots per cell, from at least seven random fields of view per 
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experiment condition per subject. Cell perimeters were determined based on WGA 
staining and spot count quantification parameters were gated against positive and 
negative controls (see Table 2.12). Confocal images were processed, analysed and 
quantified using Volocity high performance 3D imaging software v6.1.1 [PerkinElmer], 
according to the protocol outlined in section 2.7.3.1. 
Table 2.11: Primary antibodies for PLA 
Antibody/ 
antigen 
Host Dilution Cat No. Supplier 
4C9/  
aa65-84 HTT 
Mouse 
(IgG1) 
1:300 
(1.38 mg/mL stock)
NCA Kind gift from Dr. Andreas 
Weiss, Novartis, 
Switzerland 
IKKү Rabbit 1:100 sc-8330 Santa Cruz Biotechnology 
IKKβ Mouse 1:50 sc-271782 Santa Cruz Biotechnology 
 
Table 2.12: Antibody pairs used in PLA 
Type of pair Primary antibodies PLA probes 
Assay pair 
4C9 (HTT) 
-and- 
IKKү 
PLA probe MINUS anti-mouse 
-and- 
PLA probe PLUS anti-rabbit 
Positive control 
IKKβ 
-and- 
IKKү 
PLA probe MINUS anti-mouse 
-and- 
PLA probe PLUS anti-rabbit 
Negative control 4C9 only 
PLA probe MINUS anti-mouse 
-and- 
PLA probe PLUS anti-rabbit 
Negative control IKKү only 
PLA probe MINUS anti-mouse 
-and- 
PLA probe PLUS anti-rabbit 
IKKү and IKKβ primary antibody pair was used as a positive control as these proteins are 
known to directly interact under the conditions tested. 
2.5.4 Fluorescence-activated cell sorting (FACS) 
FACS is a type of flow cytometry which can be used to physically separate cells into 
groups based on their light scattering and fluorescent properties. To select for ReNcell 
VM NSCs expressing HTT exon 1 transgenes following transduction (section 2.3.4.2), 
cells were sorted by detection of the co-expressed eGFP reporter. FACS was 
performed entirely by Dr. Eva C. Sirinathsingh (Prof. Gillian P. Bates’ research group, 
KCL, London, UK).  
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2.5.5 Imaging flow cytometry (IFC) 
IFC is an analytical technique which combines flow cytometry with fluorescent confocal 
microscopy, allowing for high-throughput fluorescent and morphological analysis of 
cellular events. IFC was used to detect, visualise and quantify NFκB nuclear 
translocation in various treatment paradigms, in monocytes. 
Monocytes were seeded into 6-well culture plates at 2 × 106 cells per well, as per the 
usual protocol (section 2.1.2.3). Following treatment relevant to the specific 
experiment, culture medium was removed and cells were harvested by scraping from 
the culture surface in ice-cold PBS and transferring into a clear V-bottom 96-well assay 
plate [Greiner]. Cells were fixed with intracellular fixation buffer [IC Fixation Buffer, 
eBioscience] for 15 min at 4 °C with gentle shaking. Fixation buffer was removed with 
three 5 min washes in PBS, and then cells were permeabilised in 1 × Permeabilization 
Buffer [eBioscience] for 10 min at 4 °C with gentle shaking. Cells were given one 5 min 
wash in PBS then incubated with NFκB p65 XP Rabbit antibodies [Cell Signaling 
Technology; Cat No. 8242] diluted 1:200 in 1 × Permeabilization Buffer for 60 min at 4 
°C with gentle shaking. Excess, unbound primary antibody was washed off with two 5 
min washes in PBS, and then cells were incubated with donkey anti-rabbit IgG (H+L) 
R-phycoerythrin (PE)-conjugated secondary antibodies [eBioscience; Cat No. 12-4739] 
diluted 1:100 in FACS buffer (Appendix II-xi) for 60 min at RT, with gentle shaking in 
the dark. Excess, unbound secondary antibody was washed off with two 5 min washes 
in FACS buffer. Cells were then re-suspended in FACS buffer and stained with 1 µg/mL 
DAPI immediately prior to analysis. 
Prepared samples were run on the ImageStream MkII [Amnis by EMD Millipore] IFC 
machine using INSPIRE for the ISX MkII software [EMD Millipore]. PE was excited by 
the 488 nm laser and DAPI by the 405 nm laser, and both were detected in different 
channels at 40× magnification. Full brightfield (BF) illumination images were also taken. 
A minimum of 10,000 images were acquired per experiment condition, per subject, and 
analysed using IDEAS software [Amnis]. Images were firstly gated for ‘single cells’ 
which were ‘in focus’ and ‘double-stained’. These gated cells provided a total cell 
number from which the percentage ‘translocated’ cells were calculated i.e. the 
percentage of cells which showed nuclear localisation of NFκB rather than cytoplasmic 
localisation. See Table 2.13 for details of gating parameters. 
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Table 2.13: Gating parameters for IFC analysis 
Name of 
gate 
X axis plot Y axis plot Meaning Gate position 
#1  
Single cells 
BF area BF aspect 
ratio 
Circularity Images with 50-
300 area and 0.5-
1.0 aspect ratio 
#2  
In focus 
BF RMS 
gradient 
Normalised 
frequency 
Contrast 50+ RMS 
gradient 
#3  
Double-
stained 
DAPI intensity PE intensity Nucleus and 
NFκB co-staining 
Cell population in 
upper right 
quadrant 
#4  
Translocated 
BF object 
mask defining 
cell boundary 
↓ 
Eroded by 2 
pixels to 
exclude cell 
membrane 
↓ 
DAPI/PE 
similarity 
feature 
Normalised 
frequency 
Degree to which 
DAPI and NFκB 
staining overlap 
2.5+ similarity 
feature within the 
defined mask 
Similarity feature is a log transformed Pearson’s correlation coefficient used to measure the 
degree to which two images are linearly correlated, relating in this case to a comparison of 
DAPI and PE intensity. RMS, root mean square. 
2.5.6 Solid-phase immunoassays 
2.5.6.1 Enzyme-linked immunosorbent assay (ELISA) 
MG-CM and BMD-microglia lysates were prepared, harvested and stored as previously 
described (section 2.1.5.1). When ready to perform the ELISA, MG-CM was removed 
from −80 °C storage and thawed slowly to RT. ELISAs were performed using the 
Human BDNF or Human beta-NGF ELISA Kits for serum, plasma, cell culture 
supernatant and urine [Sigma Aldrich] according to the manufacturer’s instructions and 
the protocol for Sandwich Assay Procedure. Samples and BDNF or beta-NGF protein 
standards were added, in duplicate, at 100 µL per well into a supplied 96-well assay 
plate pre-coated with capture antibodies, and incubated for 2.5 h at RT with gentle 
shaking. Solution was removed and plates were washed four times with 1× Wash 
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Buffer, patting out any remaining liquid by inverting the plate and blotting on clean 
paper towels. Biotinylated Human BDNF or Human beta-NGF Detection Antibody 
Solution was then added at 100 µL per well and the plate was incubated for 1 h at RT 
with gentle shaking. The solution was discarded and wash steps were repeated as 
above. Horseradish peroxidase (HRP)-Streptavidin solution was then added at 100 µL 
per well and the plate was incubated for 45 min at RT with gentle shaking. The solution 
was discarded and wash steps were repeated as above before adding 3,3’,5,5’-
Tetramethylbenzidine (TMB) One-Step Substrate Reagent at 100 µL per well. The 
plate was incubated for 30 min at RT with gentle shaking. Stop Solution was then 
added at 50 µL per well, and the absorbance was read immediately at 450 nm on a 
TECAN X-Fluor4 v4.51 plate reader. The BDNF or beta-NGF protein standards were 
used to create a standard curve from which unknown neurotrophin concentrations in 
MG-CM were determined, using GraphPad Prism v5.00 for Windows [GraphPad 
Software; La Jolla California, USA] and Microsoft Excel. 
BMD-microglia lysates were removed from −80 °C storage and thawed slowly to RT 
before performing BCA assay to determine protein concentrations of each lysate 
(section 2.4.2.2). MG-CM neurotrophin concentrations were normalised to total protein 
from the relevant cell lysates. 
2.5.6.2 MesoScale Discovery (MSD) assay 
MC-CM, Mφ-CM or MG-CM and monocyte, BMD-macrophage or BMD-microglia 
lysates, respectively, were prepared, harvested and stored as previously described 
(section 2.1.5.1). When ready to perform MSD, conditioned media was removed from 
−80 °C storage and thawed slowly to RT. Cytokine levels in MC-CM were measured 
using Human Th1/Th2 10-Plex Tissue Culture Kit [MSD] analysing ten different 
cytokines simultaneously (IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p70, IL-13 and 
TNFα), or Human IL-6 Singleplex Kit [MSD], according to the manufacturer’s 
instructions. Cytokine levels in Mφ-CM were measured using V-PLEX Human 
Proinflammatory Panel I (4-Plex) [MSD] analysing four different cytokines 
simultaneously (IFNү, IL-1β, IL-6 and TNFα), according to the manufacturer’s 
instructions. Cytokine levels in MG-CM were measured using V-PLEX Human 
Proinflammatory Panel I (10-Plex) [MSD] analysing ten different cytokines 
simultaneously (IFNγ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and TNFα), 
according to the manufacturer’s instructions.  
For the Human Th1/Th2 10-Plex Tissue Culture Kit, an initial blocking step was 
required. One percent MSD Blocker B (containing blocking and stabilising agents) in 
PBS was added to a provided 96-well assay plate, at 150 µL per well. The plate was 
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sealed with an adhesive plate cover and incubated for 1 h at RT with shaking at 1000 
rpm. Solution was discarded and plates were washed three times with 0.05 % PBST, 
patting out any remaining liquid by inverting the plate and blotting on clean paper 
towels. This blocking step was not required for other MSD assays. Pre-prepared 
standards and samples (diluted as appropriate in provided Diluent 2 (containing 
proteins, blockers and preservatives), as determined by calibration optimisation in pre-
testing) were added at 50 µL, in duplicate, to a provided 96-well assay plate pre-coated 
with capture antibodies immobilised on a working electrode surface. Analyte capture 
antibodies are organised in a single spot for singleplex plates, or in a patterned array of 
spots for multiplex plates. The plate was sealed with an adhesive plate cover and 
incubated for 2 h at RT with shaking at 1000 rpm. Solution was removed and wash 
steps were performed as above. Pre-prepared Detection Antibody Solution containing 
cytokine-specific Detection Antibodies conjugated with electrochemiluminescent labels 
(MSD SULFO-TAG), was then added at 25 µL per well and the plate was covered and 
incubated for 2 h at RT with shaking at 1000 rpm. Wash steps were repeated as above, 
and then 2 × Read Buffer T (with surfactant) was added at 150 µL per well, catalysing 
the electrochemiluminescent reaction. The plate was then loaded onto a Sector Imager 
6000 (Model 1200) MSD instrument, operated using MSD Discovery Workbench 
software. A voltage was applied to the plate electrodes causing the captured labels to 
emit light, for which the intensity was measured to provide a quantitative measure of 
analytes in the sample. Sample concentrations were calculated by the software, using 
the calibrator standards of known analyte concentrations.  
Cell lysates were removed from −80 °C storage and thawed slowly to RT before 
performing BCA assay to determine protein concentrations of each lysate (section 
2.4.2.2). Analyte concentrations were normalised to total protein from the relevant cell 
lysates. 
2.5.6.3 HTT quantitation using MSD 
Total HTT and expanded HTT levels were quantified in ReNcell VM+HTT exon 1 NSC 
and 10 DD neuronal cultures using the MSD platform and a proprietary, optimised 
protocol. Cell pellets were sent to Evotec-CHDI HTT Quantitation Service, Hamburg, 
Germany. Total human HTT was detected using 2B7/4C9 antibody pair (service HTT 
assay reference #39) and polyQ expanded (mutant) HTT was detected using 2B7/MW1 
antibody pair (service HTT assay reference #6). Both assays were quantified by 
standard recombinant HTT reference protein (Human HTT NF573Q23 spiked into 0.01 
mg/mL of a wild-type mouse whole brain lysate (C57BL/6)). Cell pellets were lysed in 
120-300 µL MSD lysis buffer (depending on pellet size) and protein concentration was 
determined by BCA assay (section 2.4.2.2). All lysates were run in parallel on the same 
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MSD plate and tested in technical triplicates at a final concentration of 0.01 mg/mL. 
Standard proteins were applied at a final concentration range between 0.001 and 1 
fmol/µL. Final buffer concentrations can be found in Appendix II-xii. Samples were 
analysed in a total of two assay runs. 
2.5.7 Time-resolved fluorescence resonance energy transfer (TR-FRET) 
Time-resolved fluorescence resonance energy transfer (TR-FRET) was used to 
quantify levels of total HTT and expanded HTT in ReNcell VM+full-length HTT NSC 
lines. Dry cell pellets were sent to Dr. Andreas Weiss (IRBM-Promidis, Italy) who 
performed TR-FRET as described in ‘Microtiter plate quantification of mutant and wild-
type huntingtin normalized to cell count’ (Weiss et al. 2011). Two antibody pairs, 
2B7/4C9 and 2B7/MW1, were used to simultaneously detect wild-type HTT and mHTT, 
respectively. 2B7 was labelled with the donor fluorophore terbium (Tb) cryptate Lumi4, 
which when excited transfers energy over non-overlapping emission spectra to excite 
two acceptor fluorophores, D2 (labelling MW1) and Alexa488 (labelling 4C9), 
simultaneously. After excitation of the Tb donor at 320 nm and a time delay of 100 μs, 
emission signals of Alexa488 and D2 were detected at 520 and 665 nm, respectively. 
The 2B7/4C9 antibody pair displays preferential detection of wild-type HTT because 
the epitopes are separated by the polyQ stretch, and polyQ elongation in mHTT 
increases the distance between the two labelled antibodies resulting in a reduced TR-
FRET signal. The 2B7/MW1 antibody pair displays preferential detection of mHTT due 
to the specificity of MW1 for elongated polyQ stretches. The HTT signals were 
normalised to PicoGreen signal, a highly sensitive fluorescent double-stranded specific 
DNA dye, whose signal intensity correlates with the amount of double-stranded DNA, 
and therefore the number of cells in a sample. PicoGreen was excited at 485 nm and 
detected at 535 nm. 
2.6 Cytotoxicity assays 
2.6.1 Lactate dehydrogenase (LDH) cytotoxicity assay 
CytoTox 96 Non-Radioactive Cytotoxicity Assay [Promega] is a colorimetric assay 
which was used to quantitatively measure lactate dehydrogenase (LDH) in cell culture 
supernatants as a broad indicator of total cell death by apoptosis and/or necrosis. LDH 
is a stable cytosolic enzyme which is released upon cell lysis. The assay was 
performed, according to the manufacturer’s instructions, to measure cytotoxicity in 
neuronal or myeloid cell cultures following media titration, in neuronal cultures treated 
with Mφ-CM or MG-CM in co-culture experiments, and in primary monocytes treated 
with a range of laquinimod concentrations. 
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Culture supernatants were added, at least in duplicate, to a 96-well clear flat-bottomed 
assay plate at 50 µL per well. A control culture well, or all cultures, were then lysed in 
0.9 % v/v Triton X-100 for 45 min on a shaking platform at 400 rpm, releasing all LDH 
from the cells into the culture supernatant (Total LDH). Total LDH supernatants were 
added to the assay plate. In order to measure background LDH, media only and/or Mφ-
CM or MG-CM from the same aliquot which had been used to treat the neurons were 
also included in the assay. Prepared Substrate Mix reconstituted in Assay Buffer was 
added at 50 µL per well, and the plate was incubated for 30 min at RT in the dark. In a 
coupled enzymatic reaction, LDH converts oxidised NAD+ and lactate to reduced 
nicotinamide adenine dinucleotide (NADH) and pyruvate. In turn, NADH and the 
tetrazolium salt 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium (INT) are 
converted into a red formazan product (and NAD+) by NADH dehydrogenase. The 
amount of colour formed is proportional to the number of lysed cells. Stop Solution (1 M 
acetic acid) was then added at 50 µL per well and absorbance of the red formazan 
product was measured at 490 nm on a TECAN X-Fluor4 v4.51 plate reader. Data was 
analysed using Microsoft Excel, and percentage cell death for each condition was 
calculated using the following formula: 
ṿⱡݎẚⱡⱶݐẘⱦⱡ	ẚⱡↄↄ	ẛⱡẘݐⱨ		 ൌ 		 ẋݑ݌ⱡݎⱶẘݐẘⱶݐ	ṷṧṯ	 െ 	ẙẘẚⱴⱦݎⱷݑⱶẛẍⱷݐẘↄ	ṷṧṯ	 െ 	ẙẘẚⱴⱦݎⱷݑⱶẛ 			ൈ 		100		
2.6.2 ATP cell viability assay 
CellTiter-Glo Luminescent Cell Viability Assay [Promega] was used to measure the 
number of viable cells in a culture by quantifying their levels of ATP, indicative of 
metabolic activity. The assay was performed, according to the manufacturer’s 
instructions, to measure cell viability in neuronal or myeloid cell cultures following 
media titration in pre-testing for co-culture. It is important to note that due to mHTT-
induced mitochondrial dysfunction, ATP levels may be affected in mHTT-expressing 
cells, and consequently results from this assay should be interpreted with caution. In all 
cases, an alternative measure of cytotoxicity/viability was used in conjunction with this 
assay. 
Cells were cultured in 96-well plates and treated as per the relevant experiment. When 
ready to perform the assay, culture medium was removed and replaced with 100 µL 
fresh RT culture medium. In order to measure background luminescence, media was 
also added to wells without any cells. Pre-prepared Cell-Titer Glo Reagent was added 
at 100 µL per well, and the mixture was pipetted up and down to detach cells from the 
culture surface. The culture plate was incubated for 2 min at RT with vigorous shaking 
to induce cell lysis, then cells were transferred into a 96-well white, flat-bottomed, 
chimney-well assay plate [Greiner] and incubated at RT without shaking for a further 10 
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min to stabilise the luminescent signal. A thermostable luciferase (Ultra-Glo 
Recombinant Luciferase) generates a stable “glow-type” luminescence when, along 
with magnesium ions, it catalyses the reaction of Beetle Luciferin, ATP and oxygen to 
Oxyluciferin, adenosine monophosphate (AMP), pyrophosphate and carbon dioxide. 
The luminescent signal is proportional to the amount of ATP present, which is 
proportional to the number of viable cells (Crouch et al. 1993). Luminescence was 
recorded using a TECAN Infinite plate reader and TECAN iControl software, and data 
was analysed using Microsoft Excel. Average background luminescence was 
subtracted from all sample readings. 
2.6.3 Propidium iodide (PI) viable cell exclusion 
PI is a red fluorescent stain which intercalates in DNA. As it is also membrane 
impermeant, PI stains only the nuclei of dead or compromised cells, and is generally 
excluded from viable cells. PI staining was used to quantify the number of non-viable 
cells in neuronal cultures following media titration in pre-testing for co-culture, and 
following treatment with Mφ-CM or MG-CM in co-culture. PI viable cell exclusion 
measures cellular demise at a snap shot in time and can be used simulatenously with a 
nuclear stain, such as Hoechst, to distinguish apoptotic cells from healthy or necrotic 
cells by assessment of nuclear shape and condensation.  
Neurons were cultured on coverslips and treated as per the relevant experiment. To 
measure cytotoxicity, PI was added directly to the culture medium at 1.25 µg/mL final 
concentration and cells were returned to the incubator for 20 min. Hoechst 33342 was 
then added directly to the culture medium at 0.8 µg/mL final concentration and cells 
were returned to the incubator for a further 10 min. Coverslips were then carefully 
removed from culture wells and floated face-down on 3 µL 37 °C DPBS on a glass 
microscope slide. Cells were imaged immediately using a Zeiss LSM 710 confocal 
microscope (section 2.7.3), and images were quantified using the methods described in 
section 2.7.3.1. 
2.6.4 Trypan Blue viable cell exclusion 
Trypan Blue is a dye which is impermeant to the intact cell membranes of viable cells. 
It can, however, traverse the compromised membranes of non-viable cells, staining 
them blue. Trypan Blue exclusion was used to count viable cells in routine cell culture 
and before cryopreservation of cell lines. A 0.4 % solution of Trypan Blue [Thermo 
Fisher Scientific] in DPBS was added 1:10 to a small volume of cells in suspension. 
Ten microlitres cell suspension was pipetted onto a haemocytometer, and cells were 
visualised using a light microscope to count total number of viable cells per millilitre of 
cell suspension. 
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2.7 Microscopy 
All images were visualised, analysed and quantified blinded to experiment condition 
and subject group to eliminate experimenter bias. 
2.7.1 Phase-contrast microscopy 
A Zeiss Axiovert 25 inverted microscope, equipped with 10×, 20× and 40× objectives, 
was used to view and monitor cells during routine cell culture. A NIKON Eclipse TS100 
inverted microscope equipped with 10×, 20× and 40× objectives and linked to photo 
viewing software was used to acquire phase-contrast images. 
2.7.2 Live-cell epifluorescence microscopy 
A NIKON Eclipse TS100 inverted microscope equipped with a FITC filter (465-495 nm) 
was used to detect native eGFP reporter expression in cells transduced with HTT exon 
1 by infection with A2UCOE lentiviruses. Images were acquired using linked photo 
viewing software. 
2.7.3 Confocal fluorescence microscopy 
A Zeiss LSM 710 confocal microscope was used to acquire confocal images of cells 
with immunofluorescent staining. DAPI and Hoechst 33342 were excited by the 405 nm 
laser. Alexa Fluor 488 and WGA were excited by the 488 nm laser. PI was excited by 
the 514 nm laser. Alexa Fluor 568 and the red fluorescent spots produced by PLA were 
excited by the 561 nm laser. Zeiss Immersol Immersion Oil 518F was dabbed onto 
each coverslip before viewing cells via Plan-Apochromat 40×/1.4 or 63×/1.4 oil 
differential interference contrast (DIC) M27 objectives. All images were taken with 
constant gain and pinhole settings at a resolution of 1024 × 1024 pixels. Operation of 
the microscope and processing of acquired images was performed using ZEN Imaging 
Software (Black edition) [Zeiss]. 
Confocal microscopy images of mHTT aggregates in ReNcell VM+HTT exon 1 
neuronal cultures were acquired using the Opera LX High Content Screening (HCS) 
system [PerkinElmer; Waltham, Massachusetts, USA]. The system was operated by 
Dr. Christin Luft (Dr. Robin Ketteler’s research group, Laboratory for Molecular Cell 
Biology (LMCB)-MRC, UCL, London, UK). 
2.7.3.1 Confocal image quantification methods 
All confocal images acquired for quantification of any form were taken from at least five 
random fields of view per coverslip from at least duplicate coverslips.  
To perform cell counts on acquired confocal images, ImageJ image analysis software 
(Schneider et al. 2012) was used to perform automated cell counts using the built-in 
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ImageJ Quantitation Tasks outlined in Figure 2.4. This method was used for 
quantification of: percentage eGFP reporter positive cells in NSCs transduced with HTT 
exon 1; percentage full-length mHTT expressing cells (by ICC with 2B7/MW1 co-stain 
(section 2.5.2) in NSCs transduced with full-length HTT (138 CAG); and percentage 
non-viable cells (by PI viable cell exclusion (section 2.6.3)) in wild-type neuronal 
cultures for co-culture media titration, or following treatment with Mφ-CM or MG-CM in 
co-culture. Total cell counts were acquired using the software and then the number of 
eGFP positive, 2B7/MW1 co-stained, and PI positive cells, respectively, were counted 
manually. Percentage positive cells was calculated from at least ten random fields of 
view, taken at a maximum magnification of 40×, from at least duplicate cultures. 
To identify expression of the transgene in a subclone of ReNcell VM+full-length mHTT 
(138 CAG) NSCs, levels of HTT and mHTT were detected by ICC with 2B7 and MW1 
respectively. Intensity of staining was quantified using Volocity v6.1.1 and the built-in 
Volocity Quantitation Tasks outlined in Figure 2.5, and compared to wild-type NSCs. 
Volocity software was also used to quantify the average number of red fluorescent 
spots per cell in BMD-macrophages following PLA (section 2.5.3), using the built-in 
Volocity Quantitation Tasks outlined in Figure 2.6. 
 
 
Figure 2.4: ImageJ Quantitation Tasks for automated cell counting 
Each image was quantified independently. Cell counts for each image were recorded in 
Microsoft Excel and used in further calculations. 
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Figure 2.5: Volocity signal intensity Quantitation Tasks 
HTT and mHTT levels quantified in cells by measuring intensity of 2B7 (red) and MW1 (green) 
staining, respectively, in confocal images following ICC. Total intensity and cell number (DAPI 
count) were measured. Data was extracted from Volocity and imported into Microsoft Excel for 
analysis. Total intensity per image was divided by total cell number per image to give average 
intensity per cell. 
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Figure 2.6: Volocity Quantitation Tasks for PLA image analysis 
Parameters (protocol) were set using positive control images before applying to all sample 
images and negative controls. Data was extracted from Volocity and imported into Microsoft 
Excel for analysis. Total number of red spots was divided by total DAPI count to give average 
number of spots per cell for each image. 
2.8 Small molecule drug testing (laquinimod) 
Pre-clinical drug testing of laquinimod in primary HD patient myeloid cells (monocytes 
and BMD-macrophages from healthy volunteers, pre-manifest HD gene carriers and 
manifest HD patients), was performed in collaboration with Teva Pharmaceutical 
Industries Ltd. Laquinimod, a quinolone-3-carboxamide, was received as a white 
powder, and was reconstituted in sterile tissue culture grade water. The lowest 
therapeutic dose tested in humans (for the treatment of MS) is 0.6 mg, which equates 
to a plasma level of 1 µM active drug (98 % albumin-bound; 1.8-2.0 % free active 
drug). Laquinimod has an 80 h half-life in humans and a 3.5 h half-life in mice. 
2.8.1 Testing drug cytotoxicity in vitro 
Monocyte cultures were treated with a range of laquinimod concentrations (0, 0.001, 
0.01, 0.1, 0.5, 1, 5, 10, 50 or 100 μM), in duplicate, for 24 or 48 h. Cell death levels 
post-treatment were assessed by LDH cytotoxicity assay, as described in section 
2.6.1., and compared to cell death levels in untreated monocyte cultures. 
2.8.2 Measuring cytokine release in laquinimod-treated myeloid cells 
Monocyte cultures were treated with 1 or 5 µM laquinimod for 2 or 24 h, or were 
untreated. Cells were then given a media change, and for cultures in the “stimulated” 
condition, 1 µg/mL LPS and 10 ng/mL IFNү was included. Cultures were returned to 
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the incubator for 24 h. Three drug treatment durations and two drug concentrations 
were tested: 2 h pre-treatment (2hPT) or 24 h pre-treatment (24hPT) with 1 or 5 µM 
laquinimod, and 24 h 5 µM pre-treatment with 24 h continued 5 µM laquinimod 
treatment during stimulation (24 h pre-treatment with 24 h continued treatment, 
24hPT+24hCT). MC-CM and cell lysates were collected, processed and stored as 
described in section 2.1.5.1, and cytokine levels were measured using MSD Human 
Th1/Th2 10-Plex Tissue Culture Kit or Human IL-6 Singleplex Kit, as described in 
section 2.5.6.2. Results for IFNү levels were not considered in the analysis due to 
presence of this cytokine in monocyte culture medium as a priming agent for stimulated 
conditions.  
2.8.3 Investigating NFκB pathway modulation as laquinimod mechanism of 
action 
The effects of laquinimod on dysfunctional NFκB signalling in HD myeloid cells was 
assessed by monitoring IκB degradation kinetics, p65 nuclear translocation, and 
interactions between mHTT and IKKү in laquinimod-treated cells.  
IκB degradation kinetics in response to LPS stimulation were assessed by Western 
blotting techniques. Monocytes received 24hPT with 5 µM laquinimod, or were 
untreated, then were stimulated with 1 µg/mL LPS over a time-course of 0-60 min. Cell 
lysates were prepared as described in section 2.4.1.2 and Western blots were 
performed as described in sections 2.4.3, 2.4.4 and 2.5.1.2. 
NFκB p65 nuclear translocation in response to LPS stimulation was assessed by IFC. 
Monocytes received 24hPT with 5 µM laquinimod, or were untreated, then were 
stimulated with 1 µg/mL LPS for 45 min. IFC was then performed as described in 
section 2.5.5. 
Interactions between mHTT and IKKү were assessed by PLA. BMD-macrophages 
were treated with 5 µM laquinimod for 24 h, or were untreated. Cells were then fixed 
and PLA was performed as described in section 2.5.3. 
2.9 Statistical analyses and data presentation 
Experiment results which were analysed statistically included at least three biological 
repeats i.e. parallel measurements of biologically distinct samples (e.g. the same 
experiment performed on different days using the same cell line at different passage 
numbers; or measuring responses in primary cells from several different subjects 
receiving the same treatments at the same time). Experiments were performed with at 
least two internal replicates per condition i.e. repeated measurements of the same 
condition (e.g. duplicate cell treatment wells) and/or sample (e.g. triplicate assay read-
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outs). Mean average results from experiment internal replicates were calculated using 
Microsoft Excel. 
Unless otherwise stated, statistical analysis of data was performed using GraphPad 
Prism v5.00 for Windows, and data were presented graphically using the same 
software. Data are presented as mean ± standard error of the mean (SEM), or in some 
cases as mean ± standard deviation (SD). Statistical p-values are graphically 
presented as follows: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
2.9.1 Student’s t-test 
To compare the mean differences between two groups (e.g. laquinimod-treated versus 
untreated), based on a single response variable (e.g. percentage p65 nuclear 
translocation), a two-tailed, Student’s t-test was used. If the two groups could be 
matched (e.g. comparing the effects of two different treatments in the same subjects), 
the t-test was paired. 
2.9.2 Analysis of variance (ANOVA) 
To compare the mean differences between three or more groups (e.g. healthy 
volunteer, pre-manifest HD and manifest HD subject groups), based on a continuous 
response variable (e.g. percentage neuronal culture death), an analysis of variance 
(ANOVA) was used. When groups of a single factor were compared based on a single 
response variable (e.g. comparing subject groups by percentage cell death), a one-way 
ANOVA was used. When groups of two or more factors were compared based on a 
single response variable (e.g. comparing percentage cell death in different subject 
groups over various time-points), a two-way ANOVA was used.  
If the groups could be matched (e.g. comparing IκB degradation kinetics over time in 
laquinimod-treated or untreated cells from the same subjects), and no data was 
missing for each condition, repeated measures (RM) were used in the ANOVA. If 
subject matching was found to be significant (p<0.05) by the ANOVA, this indicated 
that RM had successfully separated between-subject variability from within-subject 
variability, therefore controlling for factors that cause variability between subjects and 
resulting in a powerful statistic test. If subject matching was found to be non-significant 
(p>0.05), this indicated that the matching was not effective, and consequently repeated 
measures is a much less powerful statistical test due to having fewer degrees of 
freedom. In cases of ineffective subject matching, an ordinary ANOVA (without RM) 
was used. 
To compare each group mean with every other group mean, one-way ANOVAs were 
performed with Tukey post-hoc tests. If each group mean was compared to one control 
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mean, a Dunnett post-hoc test was performed. If two-way ANOVAs were performed, 
appropriate sets of means were compared by Bonferroni post-hoc multiple comparison 
tests. 
2.9.3 Linear mixed regression model 
Statistical analysis of cytokine levels in MC-CM from laquinimod-treated (and 
untreated) monocytes was performed by an independent statistician, Ruth Farmer 
(London School of Hygiene & Tropical Medicine, Department of Medical Statistics, 
London, UK). Her description of the statistical model she used to analyse the data set, 
taken from the publication of this collaborative work in Journal of Neurochemistry 
(‘Laquinimod dampens hyperactive cytokine production in Huntington’s disease patient 
myeloid cells’ (Dobson et al. 2016) (Appendix III-i)), is as follows: 
“The data set was split into two - stimulated and non-stimulated conditions - to perform 
statistical analysis. Not every subject had a measurement for every condition due to 
some samples failing quality control, leading to unbalanced data. Data were log 
transformed prior to analysis to improve normality assumptions. A linear mixed model 
was fitted to each of the subsets separately, assuming exchangeable correlation, with 
robust standard errors to allow for misspecification of the covariance structure. 
Comparisons of interest were calculated using linear contrasts. This approach allows 
for data from a subject to be used even if some of the conditions are missing, under a 
missing at random assumption. For the HD combined comparisons, a weighted 
combination of pre-manifest HD and manifest HD was used, based on the total number 
of patients in those subgroups. All analyses were additionally adjusted for age. Multiple 
comparison adjustments were not made due to the small sample size and lack of 
independency in cytokine activity, and this was taken into consideration when 
reviewing the findings from these analyses. All results of cytokine levels and statistical 
analysis of this data are graphically presented and reported on the logarithmic scale. It 
is important to note that natural differences in cytokine release from primary human 
monocytes leads to highly variable data, and the sample size limits the precision for 
which estimates of between condition and between group differences can be made. 
Therefore, in cases where there is absence of statistical evidence it is not possible to 
determine whether this is due to no effect or that the random variation in 
measurements masks any effect that may be present.” 
2.9.4 Power calculations 
In some cases, power calculations were performed to determine appropriate sample 
sizes using DSS Researcher’s Tool Kit Sample Size Calculator [online source at 
www.dssresearch.com, DSS Research, DC, USA]. Data from preliminary experiments 
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with a sample size of at least n=3 were used to provide test values, and sample 
averages and SDs for each sample. The confidence level (α-error level) i.e. the 
probability of incorrectly rejecting the null hypothesis that there is no difference in the 
average values, was set to 5 % (an alpha of 5 % to a 95 % confidence interval). 
Statistical power (β-error level) i.e. the probability of incorrectly failing to reject the null 
hypothesis, was set to 50 %. Sample sizes required to give the power to observe 
differences between sample groups were then automatically calculated. 
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3 Development and characterisation of 
human neuronal-myeloid cell co-culture 
models of HD 
3.1 Background 
To assess neuronal-myeloid cell interactions in the pathogenesis of HD, there is a 
requirement for the development of novel HD cell models and co-culture models. 
Current HD cell culture models include primary cells isolated from HD animal models or 
HD patients, immortalised human cell lines over-expressing N-terminal fragments of 
mHTT or the full-length gene and iPSC lines derived from HD patients. While all of 
these models have provided invaluable insight into pathological cellular mechanisms of 
HD, they are also limited in their usefulness for investigating pathogenic neuronal-
myeloid cell interactions in HD due to model-specific drawbacks. Primary neurons and 
microglia are either not of human origin or lack availability on a large scale, 
immortalised human neuronal and myeloid cell lines generally fail to represent their 
primary human cell counterparts, and the derivation of specific neuronal subtypes or 
microglia from iPSCs is not yet fully established. With the aim of assessing cellular 
interactions between neurons and myeloid cells in HD, there is a requirement for the 
development of novel neuronal and microglial HD cell models. 
Transgenic mice are the most commonly used animal models in HD research, and can 
be classified as fragment, full-length or knock-in models depending on how they were 
generated. Fragment models, such as R6/2 (Mangiarini et al. 1996), express N-
terminal fragments of human mHTT on a wild-type diploid murine Htt background; full-
length models, such as BACHD (Gray et al. 2008) or YAC128 (Hodgson et al. 1999; 
Slow et al. 2003; Van Raamsdonk et al. 2007), express full-length human mHTT on a 
wild-type diploid murine Htt background; and knock-in models, such as Hdh 
(Q150/Q150) (Shelbourne et al. 1999), express the endogenous murine Htt gene with 
CAG repeats added, or ‘knocked-in’, to create an expanded murine Htt gene. Various 
different primary cell types have been isolated from these HD mouse models and 
cultured ex vivo, and studying them has led to the discovery of several cellular and 
molecular mechanisms underlying key pathological processes caused by mHTT 
expression. Of particular importance, is the availability of primary neurons throughout 
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the disease course, which recapitulate many features of neurons in vivo (Ross and 
Tabrizi 2011), and cannot be isolated from humans until post-mortem.  
HD mouse models have been shown to mimic some of the pathological features and 
symptoms of HD, such as widespread aggregate deposition throughout the brain, 
neurodegeneration and late-onset behavioural phenotypes including motor 
abnormalities (Heng et al. 2008). However, a major issue confounding the study of 
cells from these models is that HD is an illness which only occurs in humans, and no 
individual animal model fully recapitulates the complex pathological phenotypes and 
progressive motor, cognitive and psychiatric impairments observed in HD, including the 
massive striatal neuronal degeneration seen in humans (Ross and Tabrizi 2011). 
Consequently, while animal models have been invaluable in improving our 
understanding of the human condition and provide means to screen potential 
therapeutic compounds in an in vivo setting, it is essential that HD is additionally 
studied on a human background alongside the use of animal models.  
With the aim of studying cellular neural-immune interactions in HD pathogenesis and 
discovering immunomodulatory agents to alter the course of disease, another 
significant issue is that immune systems are species specific. Key differences have 
been reported between human and murine primary microglia (Smith and Dragunow 
2014; Watkins and Hutchinson 2014) and many of the therapeutic immunomodulatory 
reagents recently developed are human specific (Shultz et al. 2012). HD mice and the 
primary cell cultures derived from them are therefore flawed for investigation of the 
immune system and neural-immune interactions in HD. 
Immortalised human cell lines have also been used to model HD in vitro. Human HD 
cell lines have been developed using transient transfection, stable transduction and 
inducible expression strategies with N-terminal fragments of mHTT or the full-length 
gene. Most commonly, cell models of HD utilise the exon 1 fragment of mHTT. Exon 1 
contains the expanded CAG repeat region leading to HD and has been shown to exist, 
independently of the full-length protein, in vivo in the neuronal nuclei of the Hdh 
(Q150/Q150) knock-in mouse model (Landles et al. 2010), in HD post-mortem brain 
(DiFiglia et al. 1997) and in HD patient peripheral immune cells (Weiss et al. 2012), 
following aberrant splicing of mHTT mRNA (Sathasivam et al. 2013) and/or proteolytic 
cleavage and fragmentation of the full-length protein (Landles et al. 2010; Weiss et al. 
2012). There is a large body of evidence which suggests the exon 1 protein fragment is 
the primary pathogenic species in HD, and is sufficient to cause neuronal dysfunction 
and death (Mangiarini et al. 1996; Ross and Tabrizi 2011). Indeed, the R6/2 model, 
expressing human mHTT exon 1, has the most severe and fast-progressing disease 
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phenotype of any HD mouse model (Heng et al. 2008) along with a distinct 
proinflammatory immune profile representative of the human condition (Björkqvist et al. 
2008). Cell lines expressing only exon 1 of mHTT therefore represent highly relevant 
cell models of HD, and due to its small size (exon 1 coding sequence; 269 bp (21 
CAG)), exon 1 can easily be packaged into virus particles and efficiently inserted into 
the genomic DNA of a cell line for stable, long-term expression over multiple passages.  
The full-length HTT gene is very large, spanning 180 Kb and consisting of 67 exons. 
HTT exon transcripts are expressed as two alternatively polyadenylated forms; a larger 
transcript of approximately 13.7 Kb which is expressed predominantly in brain, and a 
smaller transcript of approximately 10.3 Kb which is more widely expressed. 
Consequently, introduction of the full-length mutant transgene into the genomic DNA of 
a cell line is complex; viral delivery can be very inefficient and ultimately translation into 
the final 350 KDa protein is often unsuccessful. For this reason, very few HD cell lines 
exist with stable expression of full-length mHTT. While exon 1 models have led to novel 
insights into the pathophysiology of HD, it may also be important to study the HD 
mutation in the context of the whole HTT gene and protein. Native mHTT has been 
shown to exist in its full-length form in HD patient post-mortem brain, in the brains of 
BACHD mice, and in the brains and primary neurons from a Q140/Q140 knock-in 
mouse model of HD (Sapp et al. 2012). In vitro the expanded polyglutamine region 
within the monomeric full-length mHTT protein has been associated with increased 
cellular toxicity (Sapp et al. 2012), and in a HD Drosophila model and BACHD mice, 
neuropathology and behavioural phenotypes occur with expression of human full-
length mHTT in the absence of detectable N-terminal fragments (Gray et al. 2008; 
Romero et al. 2008). This is evidence to indicate a role of full-length mHTT in the 
pathogenesis of HD and thus there is a requirement for the development of better full-
length cellular models. 
Immortalised human HD cell lines have proved valuable for biochemical investigations 
(Ross and Tabrizi 2011), and being human cells they more closely recapitulate human-
specific biological processes (Shultz et al. 2012) than primary murine cells. However, 
immortalised cell lines have often been transformed with oncogenes, viruses and other 
inducible modifications which may alter their phenotype and affect the outcome of 
experiments. Additionally, for one of the main cell types of interest, microglia, none of 
the available immortalised human cell lines (for example CHME3, HMC3 and HMO6 
(Janabi et al. 1995; Nagai et al. 2001)) fully recapitulate the phenotypes of these cells 
in vivo, or even of their primary human microglia counterparts.  
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In order to combat the limitations of animal cells or immortalised cell lines, primary 
human cells can also be isolated from healthy volunteers or HD patients, cultured ex 
vivo and manipulated in an in vitro setting. Primary human HD cells can be obtained 
from blood samples, buccal smears or biopsies of skin, fat or muscle in the living 
patient. Experiments using such samples have proven very useful for studying general 
cellular pathophysiology caused by native mHTT expression, and for drug screening 
strategies, over the disease course in an ex vivo HD patient setting. More specifically, 
protocols have been highly optimised for the isolation and differentiation of specific 
peripheral immune cell subtypes from whole blood samples, including the isolation of 
monocytes and in vitro differentiation into BMD-macrophages (Björkqvist et al. 2008; 
Träger et al. 2014a), allowing for the study of immune cell dysfunction in primary HD 
patient cells directly. Primary human neuronal and microglial cultures, however, are 
much more difficult to obtain. Isolation protocols are highly invasive, involving surgical 
brain biopsies, which are seldom performed for therapeutic or diagnostic purposes in 
HD patients, or cultures taken immediately post-mortem. Such samples are therefore 
not ideal for large-scale experiments due to their lack of availability, and generally only 
provide a window into end-stage disease on post-mortem. The development and 
screening of therapeutics in cells, with the aim of slowing or preventing HD 
progression, requires the use of models which can recapitulate pre-manifest and early 
stages of manifest disease, as this is the optimal window for intervention before large-
scale neuronal loss. 
While the culture of primary HD microglia is not feasible on a large-scale due to 
difficulties in obtaining samples and lack of availability, it has also been reported that 
despite having different developmental origins (Ginhoux et al. 2010; Saijo and Glass 
2011; Goldmann et al. 2016) and unique molecular signatures (Greter et al. 2015; 
Michell-Robinson et al. 2015), microglia and BMD-macrophages are highly dynamic 
and become almost phenotypically indistinguishable when exposed to the same 
microenvironment (Enose et al. 2005; Greter et al. 2015). Under neuroinflammatory 
conditions there is a large phenotypic overlap between microglia and recruited BMD-
macrophages, and it is thought this may be because BMD-macrophages adopt a 
functional and morphological state similar to resident microglia in an equal response to 
the same environmental stimuli (O’Koren et al. 2016). Indeed, when cultured ex vivo 
under identical conditions, primary microglia and BMD-macrophages display structural 
and functional similarities (Gordon et al. 1988; Schmid et al. 2009; Butovsky et al. 
2014). Therefore, in the interest of developing a microglial cell model which better 
represents the phenotypes of human microglia than current immortalised cell lines, it 
may be feasible to differentiate ex vivo HD patient monocytes into microglia-like cells 
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by exposing differentiating cultures to stimuli representative of the CNS environment. 
Ohgidani and colleagues recently reported direct induction of ramified microglia-like 
cells from human monocytes by treatment with GM-CSF and IL-34 (Ohgidani et al. 
2014). 
Recently established iPSCs derived from HD patients (Park et al. 2008) offer many of 
the positive aspects of both primary human cell culture and immortalised cell lines, and 
may be especially useful for the culture of HD patient neurons in vitro. Fibroblasts can 
be isolated from HD patients and re-programmed as pluripotent stem cells via the 
introduction of genes for specific transcription factors (Takahashi and Yamanaka 2006; 
Park et al. 2008). Following this, pluripotent stem cells can be differentiated in vitro into 
cell types of interest, including specific neuronal subtypes, some of which have been 
shown to exhibit some disease-relevant phenotypes (Lu and Palacino 2013). However, 
they have limitations including genetic heterogeneity and phenotypic variability 
between cell lines, a lack of isogenic genetic controls, absence of mHTT aggregates, 
lack of a robust neurodegenerative phenotype, and long differentiation protocols of 
greater than ninety days. Also, protocols for differentiation of iPSCs into authentic 
MSNs (the main neuronal subtype of interest for the study of HD) or microglia, are not 
yet fully established.  
A human NSC-derived neuronal model, ReNcell VM, addresses many of the 
deficiencies outlined above for iPSC-derived neuronal models. ReNcell VM was 
derived from human foetal ventral mesencephalon and immortalised by retroviral 
transduction with a v-myc oncogene (Donato et al. 2007). NSCs were expanded long-
term and can be differentiated into mature neuronal cultures which have been well 
reported as a valid model of human neurons in culture (Hoffrogge et al. 2006; Donato 
et al. 2007; Wood-Kaczmar et al. 2008; Gandhi et al. 2009; Morgan et al. 2009; Choi et 
al. 2014). ReNcell VM has also been demonstrated to successfully model 
neurodegenerative diseases in vitro, including AD (Choi et al. 2014) and PD (Wood-
Kaczmar et al. 2008; Gandhi et al. 2009), following disease-relevant genetic 
manipulation of the cell line. ReNcell VM therefore shows potential for modelling 
human HD neurons by stable transduction with human mHTT exon 1 or the full-length 
mHTT gene. Wild-type and HD lines may be derived from NSCs from a renewable 
source with an isogenic background, which maintain genotype over at least 80 
passages and can be robustly and consistently differentiated into cultures with high 
neuronal yields and minimal phenotypic variability over a period of only 5-14 days 
(Hoffrogge et al. 2006; Donato et al. 2007; Wood-Kaczmar et al. 2008; Gandhi et al. 
2009; Morgan et al. 2009; Choi et al. 2014). 
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Overall, it is clear that there is requirement for new neuronal and microglial cell models 
of HD which more accurately represent the human disease while being easily 
obtainable and useable on a large scale. Here, ReNcell VM neuronal lines with stable 
expression of human mHTT exon 1 or full-length mHTT were generated and a novel 
differentiation protocol for induction of microglia-like cells from ex vivo HD patient 
monocyte cultures was discovered. These cell models have the potential to meet 
necessary requirements while avoiding many of the deficiencies of the aforementioned 
HD cell models. Once established, these novel neuronal and microglial models of HD 
were placed in various co-culture paradigms, along with BMD-macrophages which can 
be differentiated in vitro from ex vivo primary monocyte cultures using a previously 
established protocol (Träger et al. 2014a), in order to investigate neuronal-myeloid cell 
interactions in the pathogenesis of HD. Various novel neuronal-myeloid cell HD co-
culture models were developed and characterised here and their usefulness for 
investigation of HD pathophysiology was assessed.  
3.2 Aims 
1) Characterise wild-type ReNcell VM NSCs and differentiated neuronal cultures. 
2) Generate novel human ReNcell VM NSC-derived neuronal cell lines with stable 
expression of human HTT exon 1 with CAG repeats in the pathogenic and non-
pathogenic range. 
3) Generate novel human ReNcell VM NSC-derived neuronal cell lines with stable 
expression of full-length human HTT with CAG repeats in the pathogenic and non-
pathogenic range. 
4) Develop a novel differentiation protocol for induction of microglia-like cells from ex 
vivo monocyte cultures isolated from healthy volunteers and HD patients, and 
characterise BMD-microglia as a model of human microglia in culture. 
5) Develop HD and control co-culture models using HTT exon 1 and full-length HTT 
cell lines in combination with BMD-macrophages and BMD-microglia.  
3.3 Methods 
A summary of methods used in this Chapter is outlined below. Full details of 
experimental protocols can be found in Chapter 2: Materials and Methods. 
ReNcell VM NSCs were cultured as described in section 2.1.1.3 and differentiated into 
mature neuronal cultures by spontaneous differentiation (section 2.1.4.1) or induced 
differentiation (section 2.1.4.2). Wild-type ReNcell VM NSCs and neuronal cultures 
were characterised using phase-contrast microscopy (section 2.7.1) and ICC (section 
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2.5.2) with confocal fluorescence microscopy (section 2.7.3), and genotyped using 
CAG repeat-sizing (section 2.2.4) and sequencing of native HTT exon 1 (section 2.2.3).  
ReNcell VM+HTT exon 1 and ReNcell VM+full-length HTT neuronal cell lines were 
generated by transduction with retroviruses carrying A2UCOE (section 2.2.1.1) or 
MSCV (section 2.2.1.2) viral vectors, respectively, containing human HTT transgenic 
inserts. A2UCOE+HTT exon 1 and MSCV+full-length HTT plasmid DNA was amplified 
and purified as described in section 2.2.2, and presence of the correct plasmids and 
HTT transgenes was confirmed by restriction enzyme digests (sections 2.2.5 and 2.2.6) 
and sequencing (section 2.2.3). Concentration and purity of plasmid DNA was 
determined by NanoDrop (section 2.2.7). A2UCOE+HTT exon 1 and MSCV+full-length 
HTT plasmids were packaged into retroviruses using HEK293T and Phoenix-AMPHO 
(section 2.1.1.1) packaging cell lines, respectively, as described in section 2.3.1. 
Retroviruses were subsequently concentrated by ultracentrifugation (section 2.3.2). 
A2UCOE+HTT exon 1 lentivirus and MSCV+full-length HTT retrovirus viability and 
transduction efficiency was tested in HEK293T and HeLa cells (section 2.1.1.1), 
respectively, as described in section 2.3.3. Expression of eGFP reporter was monitored 
by live-cell fluorescence imaging with a FITC filter (section 2.7.2) in HEK293T cells 
transduced with A2UCOE+HTT exon 1 lentiviruses, and HeLa cells transduced with 
MSCV+full-length HTT retroviruses were subjected to antibiotic selection (using 
antibiotic concentrations determined by kill curves, which were performed in HeLa cells 
and ReNcell VM NSCs as described in section 2.3.4.1). Expression of HTT or mHTT 
trans-protein was monitored in selected HeLa cells using Western blotting (sections 
2.4.1.1, 2.4.2.1, 2.4.3, 2.4.4 and 2.5.1) and ICC techniques with confocal fluorescence 
microscopy. Viruses were used to infect ReNcell VM NSCs (section 2.3.4.2). 
Successfully transduced NSCs, ReNcell VM+HTT exon 1 or ReNcell VM+full-length 
HTT, were selected for by expression of eGFP reporter or antibiotic resistance, 
respectively, (as described in section 2.3.4.3), using FACS (section 2.5.4) or antibiotic 
treatment (sections 2.3.4.1 and 2.3.4.3), respectively.  
ReNcell VM transgenic cell lines were confirmed and maintained as described in 
section 2.3.4.4. ReNcell VM+HTT exon 1 NSCs and differentiated neuronal cultures 
were characterised by phase-contrast microscopy to assess cell morphology; Western 
blotting to detect exon 1 trans-protein expression; MSD assay (section 2.5.6.2) to 
quantify levels of HTT trans-protein expression; ICC with confocal fluorescence 
microscopy to determine cellular composition of the cultures and confirm eGFP 
reporter and HTT trans-protein expression; ICC with Opera LX HCS system (section 
2.7.3) to detect mHTT aggregates; and LDH cytotoxicity assay (section 2.6.1) to 
assess mHTT-induced neurotoxicity. ReNcell VM+full-length HTT NSCs and 
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differentiated neuronal cultures were characterised by ICC with confocal fluorescence 
microscopy to detect HTT over-expression and mature neurons. Clonal cell lines were 
generated by expansion from single-cell seeding, and clonal lines were characterised 
by dot-blot (sections 2.4.1.1, 2.4.2.2, 2.4.5 and 2.5.1) and TR-FRET assay (section 
2.5.7) to assess HTT and/or mHTT expression levels; Western blot to confirm HTT 
over-expression was full-length; ICC with confocal fluorescence microscopy to confirm 
HTT over-expression and content of mature neuronal cultures in the selected final 
clone; and LDH cytotoxicity assay to assess mHTT-induced neurotoxicity. 
Primary human samples were classified as described in section 2.1.2.1. Primary 
human monocytes were isolated from whole blood (section 2.1.2.2) and cultured ex 
vivo (section 2.1.2.3) or were differentiated into BMD-macrophages (section 2.1.2.4) or 
BMD-microglia (section 2.1.2.5). Mutant HTT expression in HD patient myeloid cell 
cultures was detected by ICC with confocal fluorescence microscopy. BMD-microglia 
cultures were characterised by phase-contrast microscopy to assess morphological 
phenotypes; and expression of specific microglial cell markers was confirmed by 
Western blotting and ICC with confocal fluorescence microscopy. N2a_R2 cells 
(section 2.1.1.2) were used as a negative control for detection of microglia cell markers 
by ICC. In some cases, myeloid cell cultures were stimulated, as described in section 
2.1.3.2. 
Neuronal-BMD-macrophage and neuronal-BMD-microglia co-culture models were 
developed as described in sections 2.1.5.1 and 2.1.5.2 (co-culture by conditioned 
medium transfer), 2.1.5.3 (co-culture by medium shared concurrently) and 2.1.5.4 (co-
culture by direct physical contact). Media titrations were also performed and various 
stimulation paradigms were trialled. Co-culture models were analysed by phase-
contrast microscopy, ATP cell viability assay (section 2.6.2), PI viable cell exclusion 
(section 2.6.3), Bio-Rad Protein Assay (section 2.4.2.1) and LDH cytotoxicity assay. 
Statistical analyses were performed as described in section 2.9.  
3.4 Contributions 
 Dr. Jennifer Parker (Prof. Sarah J. Tabrizi’s research group, UCL IoN, London, 
UK) optimised the protocol for induced differentiation of ReNcell VM NSCs into 
neuronal cultures to promote development of specific neuronal subtypes. Dr. 
Parker also provided the original ICC confocal microscopy images for 
characterisation of neuronal subtypes within ReNcell VM differentiated neuronal 
cultures, which are presented in Figure 3.2; panels C, F and G. 
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 Andrea Hawarth (Neurogenetics, NHNN, London, UK) genotyped ReNcell VM 
NSC HTT alleles by CAG repeat-sizing. 
 Dr. Ralph André (Prof. Sarah J. Tabrizi’s research group, UCL IoN, London, 
UK) sequenced ReNcell VM NSC genomic HTT exon 1 and provided the 
original ICC confocal images of ReNcell VM+full-length HTT differentiated 
neuronal cultures (Figure 3.16; B).  
 Gary Adamson (Genetics and Diagnostics, MRC Prion Unit, IoN, London, UK) 
operated the automated DNA sequencing machine for analysis of HTT exon 1 
and full-length HTT transgenes in A2UCOE and MSCV plasmid vectors, 
respectively. 
 Dr. Eva C. Sirinathsingh (Prof. Gillian P. Bates’ research group, KCL, London, 
UK) selected for eGFP-expressing ReNcell VM NSCs by FACS.  
 Total HTT and expanded HTT levels were quantified in ReNcell VM+HTT exon 
1 NSC and neuronal cultures by MSD assay, performed by Evotec-CHDI HTT 
Quantitation Service, Hamburg, Germany. 
 Dr. Rhia Ghosh (Prof. Sarah J. Tabrizi’s research group, UCL IoN, London, UK) 
provided the original ICC images showing mHTT aggregation in ReNcell 
VM+HTT exon 1 neuronal cultures (Figure 3.10). The Opera LX HCS system 
which was used to acquire the images was operated by Dr. Christin Luft (Dr. 
Robin Ketteler’s research group, LMCB-MRC, UCL, London, UK). 
 Dr. Alison Wood-Kaczmar (Prof. Sarah J. Tabrizi’s research group, UCL IoN, 
London, UK) carried out the single-cell cloning of ReNcell VM+full-length HTT 
cell lines and provided the original ICC images showing HTT over-expression in 
ReNcell VM+full-length HTT (138 CAG) clone 8 (Figure 3.18). 
 Dr. Rob Goold (Prof. Sarah J. Tabrizi’s research group, UCL IoN, London, UK) 
performed dot blots and Western blots for HTT quantification in ReNcell 
VM+full-length HTT clonal lines, and provided the original images of these 
which are presented in Figure 3.17; A-C. 
 Dr. Andreas Weiss (IRBM-Promidis, Italy) analysed HTT and mHTT expression 
levels in ReNcell VM+full-length mHTT (138 CAG) clonal NSC lines by TR-
FRET assay. 
3.5 Results 
3.5.1 Characterisation of ReNcell VM NSCs and differentiated neuronal cultures 
ReNcell VM NSCs were differentiated by either spontaneous differentiation or induced 
differentiation techniques and cell morphology was assessed throughout the 
differentiation process by phase-contrast microscopy. NSCs in culture displayed a 
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classic paving-stone like morphology. Following initiation of spontaneous 
differentiation, cells proliferated for a further 2-3 days, and by 5-7 DD cell bodies had 
shrunk and begun to develop processes. Over the following two weeks, processes 
grew longer and thinner, arborizing and connecting in a web-like network. Cultures 
thinned out as undifferentiated cells died off and were washed away by media 
changes. ReNcell VM morphology throughout the differentiation process can be seen 
in Figure 3.1. Differentiated neuronal cultures have been maintained for up to 7 weeks 
with no obvious changes in morphology from 21 DD onwards. 
Successful spontaneous differentiation of NSCs into mature neuronal cultures was 
determined by ICC with confocal fluorescence microscopy. Antibodies directed at βIII-
tubulin identified a high yield of mature neurons in cultures post-10 DD, and GFAP 
stained a sub-population of NSC-derived astrocytes, all of which also expressed native 
HTT as detected by anti-HTT 2B7 antibody (Figure 3.2; A-E). Differentiation by 
induction promoted the development of neuronal subtypes expressing tyrosine 
hydroxylase (TH) and glutamic acid decarboxylase (GAD)67, indicative of 
dopaminergic and GABAergic neurons, respectively (Figure 3.2; F and G).  
 
Figure 3.1: Morphological analysis of ReNcell VM differentiation 
ReNcell VM NSCs were differentiated by spontaneous differentiation. Phase-contrast images 
were taken of the cultures at 0 (NSC), 7, 14 and 21 DD using 10×, 20× and 40× objectives. 
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Figure 3.2: Characterisation of ReNcell VM neuronal culture composition 
Confocal fluorescence microscopy images of 10 DD ReNcell VM neuronal cultures following 
ICC for neuronal and astrocytic expression markers. Spontaneous differentiation resulted in a 
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high yield of cells with βIII-tubulin expression indicative of a pan-neuronal phenotype (A) and a 
smaller GFAP+ astrocytic sub-population (B-D), all of which express native HTT, as determined 
by staining with 2B7 anti-HTT antibody (E). Induced differentiation resulted in development of 
very small populations of GAD67+ GABAergic (F) and TH+ dopaminergic (G) neuronal 
subtypes. Scale bars, where indicated = 50 µm; Image C = 63×; Panels F and G = 40×. 
To ensure ReNcell VM had native HTT CAG repeats within the normal range, genomic 
DNA was extracted from the cells and genotyped by CAG repeat-sizing. ReNcell VM 
genomic HTT exon 1 was also sequenced. CAG repeat-sizing confirmed that ReNcell 
VM was diploid for HTT with CAG repeat sizes of 16 and 20 (± 2), in the non-
pathogenic range, and sequencing results revealed no genetic mutations within exon 1. 
This NSC-derived neuronal model was therefore taken forward for the development of 
HTT exon 1 and full-length HTT HD transgenic cell lines.  
3.5.2 Generation of human HD neuronal cell lines with stable expression of 
human mHTT exon 1 
A2UCOE lentiviral vectors containing human HTT exon 1 with 29, 71 or 129 CAG 
repeats, and an eGFP alone control vector, were a kind gift from Prof. Gillian P. Bates 
(KCL, London, UK), and made by Dr. Eva C. Sirinathsingh of the same laboratory 
research group. Full details of the expression systems, including plasmid maps, can be 
found in section 2.2.1.1.  
A2UCOE+HTT exon1 (29, 71 or 129 CAG) and A2UCOE+eGFP alone plasmid vector 
DNA was amplified and purified, then restriction digests were performed to confirm 
correctness of the plasmids and check for DNA contamination. Firstly, plasmid DNA 
was digested with BamHI and resulting DNA fragments were separated by agarose gel 
electrophoresis and sized against HyperLadder I DNA ladder which was run in parallel. 
BamHI recognises two sites within A2UCOE; one site 2225 bp 5’ to the HTT exon 1 
transgene, and one site 21 bp 3’ to the transgene. Therefore, BamHI was expected to 
cut out the whole transgenic insert (entire coding sequence of HTT exon 1 + first 21 bp 
of HTT intron 2), which had a predicted size of 616 bp (129 CAG), along with 2250 bp 
flanking plasmid DNA. Figure 3.3 shows that digestion of each vector with BamHI 
produced DNA fragments at sizes appropriate to represent HTT exon 1 transgenes + 
flanking plasmid; in the region of 2500-3000 bp with increasing size in correlation with 
expanding CAG repeat length. 
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Figure 3.3: Restriction digest of A2UCOE+HTT exon 1 plasmid vectors 
A2UCOE+HTT exon 1 (29, 71 or 129 CAG) plasmid vectors were digested with restriction 
enzyme BamHI and resulting DNA fragments were separated by agarose gel electrophoresis 
alongside DNA ladder HyperLadder I. Each digested (BamHI) plasmid sample was run 
alongside an undigested (uncut) control sample. DNA was visualised by exposure of 
intercalated ethidium bromide to UV light and an image of the gel is presented above. Smaller 
fragments in digested samples (transgene + flanking plasmid) appear between 2500 and 3000 
bp, and increase in size in correlation with expanding CAG repeat length; expected sizes were 
2566 (29 CAG), 2692 (71 CAG) and 2866 (129 CAG). Expected size of remaining plasmid was 
10126 bp, and a band of this approximate size can be seen in all digested samples.  
HTT exon 1 transgenes were then sequenced in order to confirm their presence within 
the lentiviral vectors, and to check their CAG repeat lengths and any mutations. 
Analysis confirmed that each of the vectors contained a human HTT exon 1 transgene, 
other than the eGFP alone control construct which did not contain any HTT exon 1 
sequence, as expected. All HTT sequences were in frame, with no mutations, and 
shared 100 % homology with the published NCBI; nucleotide; RefSeqGene reference 
sequence NG_009378.1 for Homo sapiens HTT cDNA (IT15), chromosome 4. 
However, there were some variations from the predicted sequences in the CAG repeat 
regions: A2UCOE+HTT exon 1 (29 CAG) actually had 30 CAG repeats and 
A2UCOE+HTT exon 1 (129 CAG) had 122 CAG repeats. A2UCOE+HTT exon 1 (71 
CAG) had 71 CAG repeats as expected. For reasons of clarity, the plasmids (and 
lentiviruses and cell lines created using them) will still be referred to as A2UCOE+HTT 
exon 1 (29, 71 or 129 CAG) throughout this Thesis. In addition, all three HTT exon 1 
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transgene CAG repeat regions had a CAA interruption in place of the ninth penultimate 
CAG codon. While individuals with 29 or 30 CAG repeats in HTT are unaffected by HD, 
this is considered to be an intermediate genotype because the CAG repeat is unstable 
and there is potential risk of expansion into the disease range (Ha et al. 2012), 
especially in cells with high replication rates (Snell et al. 1993; Walker 2007). It is 
possible that presence of the CAA interruption may reduce the propensity for 
expansion within the CAG tract. The BAC in BACHD mice, for example, was 
engineered to include a mixed CAG/CAA repeat in human mHTT exon 1, and unlike 
R6/2 mice which have a purely CAG repeat tract, the repeat length remains stable in 
the germline over many generations (Yang and Gray 2011). As both CAA and CAG 
encode glutamine, an uninterrupted polyQ stretch should still be translated in the final 
HTT exon 1 protein. Figure 3.4 shows an annotated electropherogram from HTT exon 
1 transgene sequencing. 
 
Figure 3.4: Annotated electropherogram from automatic DNA sequencing of 
A2UCOE+HTT exon 1 (29 CAG) 
HTT exon 1 transgenes were sequenced in A2UCOE lentiviral plasmid vectors, with flanking 
primers (Table 2.1), using an automated DNA analyser. Electropherograms for each sample 
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were analysed in the forward and reverse directions using Geneious Pro. An example 
electropherogram (HTT exon 1 (29 CAG)) is shown above, with regions of interest labelled. 
The concentration and purity of A2UCOE+HTT exon1 (29, 71 or 129 CAG) and 
A2UCOE+eGFP reporter only plasmid DNA was determined by NanoDrop, and results 
are reported in Table 3.1. A260/A280 ratios were approximately 1.9 for all plasmids, 
indicating no protein or RNA contamination within the samples (protein and RNA 
contaminants are expected to produce ratios of less than 1.8 or more than 2.0, 
respectively). A260/A230 ratios were above 2.0 for all plasmids, indicating no other 
contaminants within the DNA samples. All plasmid DNA was therefore considered to be 
sufficiently pure and of high quality for use in transfection procedures. 
Table 3.1: A2UCOE+HTT exon 1 plasmid DNA concentration and purity 
 
Plasmid 
DNA 
concentration/
ng/µL 
 
A260/A280 
 
A260/A230 
A2UCOE+HTT exon 1 (29 CAG) 2637.6 1.89 2.22 
A2UCOE+HTT exon 1 (71 CAG) 1866.4 1.91 2.25 
A2UCOE+HTT exon 1 (129 CAG) 2482.9 1.89 2.13 
A2UCOE+eGFP reporter only 1602.6 1.91 2.26 
 
A2UCOE+HTT exon 1 (29, 71 or 129 CAG) and A2UCOE+eGFP reporter only plasmid 
vectors were packaged into VSV-G coated lentiviruses by PEI-mediated transfection 
into the HEK293T packaging cell line along with VSV-G-expressing envelope plasmid 
MD.G2 and GAG/pol-expressing packaging plasmid CMVRd8.74. Lentiviral 
supernatants were collected and tested for viability and transduction efficiency by 
infection of fresh HEK293T cell cultures and monitoring of eGFP reporter expression. 
Figure 3.5 shows eGFP reporter expression in HEK293T cells 3 days post-infection 
with A2UCOE+HTT exon 1 lentiviral supernatants. 
Positive eGFP reporter expression was detected in all HEK293T cultures following 
infection with each lentiviral supernatant, and no eGFP signal was detected in the 
polybrene only negative control treatment condition. This confirmed the viability of all 
A2UCOE+HTT exon 1 lentiviral supernatants. Viral titre appeared to be very low on 
account of a MOI of ~1 % in HEK293T cells. Lentiviral supernatants were therefore 
subsequently concentrated by ultracentrifugation through a sucrose gradient with the 
aim of increasing titre. Concentrated lentiviruses were tested and titrated in fresh 
HEK293T cell cultures in the same way as described above for lentiviral supernatants 
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(and in more detail in section 2.3.3.1), and 1:100 was determined to be the optimum 
dilution for all concentrated lentiviruses, resulting in a MOI of ~50 % in HEK293T cells.  
 
Figure 3.5: eGFP reporter expression in HEK293T cell cultures infected with 
A2UCOE+HTT exon 1 lentiviral supernatants 
HEK293T cells were infected with A2UCOE+HTT exon 1 (29, 71 or 129 CAG) or 
A2UCOE+eGFP reporter only lentiviral supernatants for 24 h. Cells were then given a fresh 
culture medium change and returned to the incubator for a further 48 h. Successful transduction 
with HTT exon 1 transgenes was determined by detection of eGFP reporter expression using 
live-cell fluorescence microscopy with a FITC filter. Three random fields of view per condition 
were imaged, and one example image for each condition is presented above. As polybrene was 
used to aid infection, a polybrene only treatment condition (without lentiviral supernatant) was 
added as a negative control for eGFP detection. 
Concentrated A2UCOE+HTT exon 1 (29, 71 or 129 CAG) and A2UCOE+eGFP 
reporter only lentiviruses were then used to infect ReNcell VM NSCs, at 1:100 dilution, 
as described in detail in section 2.3.4.2. Successful transduction was initially confirmed 
by detection of eGFP reporter expression, using live-cell fluorescence microscopy with 
a FITC filter, 3 days post-infection. NSC cultures were then expanded, and expression 
of the transgenes was confirmed by ICC techniques using antibodies directed at eGFP 
and mHTT, as shown in Figure 3.6. Five random fields of view were taken for each 
infected NSC culture using confocal fluorescence microscopy, and the average number 
of eGFP-expressing cells in each culture was calculated using these images and the 
quantification methods outlined in section 2.7.3.1, in order to determine transduction 
efficiency. The results of this analysis can be found in Table 3.2. 
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ReNcell VM NSC+HTT exon 1 cultures were then selected for eGFP-expressing cells 
by FACS. Cells of similar eGFP expression levels across the different NSC lines were 
expanded for characterisation and use in experiments.  
 
Figure 3.6: Confirmation of HTT transgene and eGFP reporter expression in 
transduced ReNcell VM NSCs  
ReNcell VM NSCs were infected with A2UCOE+HTT exon 1 (29, 71 or 129 CAG), or 
A2UCOE+eGFP reporter only lentiviruses, and expanded. ICC with antibodies directed at eGFP 
revealed expression of the eGFP reporter (green) in all cultures. MW1 antibody binds to the 
polyQ region of HTT and displays preferential binding to elongated polyQ stretches, resulting in 
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increased binding in correlation with expanding polyQ length and a preference for mHTT over 
normal HTT. ICC with MW1 resulted in a signal (mHTT; red) which can be seen to increase with 
expanding HTT CAG repeat length in the images above, indicating successful expression of 
HTT exon 1 transgenes in NSCs. Images were taken with a confocal fluorescence microscope 
and are examples from 5 random fields of view taken per infected NSC culture. Secondary 
antibodies only were directed at eGFP reporter only-expressing NSCs as a negative control and 
to determine background fluorescence detection levels (top panel). Scale bars = 50 µm. 
Table 3.2: Transduction efficiency of A2UCOE+HTT exon 1 lentiviruses in 
ReNcell VM NSCs 
A2UCOE+eGFP only lentivirus-infected ReNcell VM NSCs 
Field  Total cell count No. eGFP-
expressing NSCs 
% transduced NSCs 
1 34 5 14.71 
2 53 19 35.85 
3 56 16 28.57 
4 24 3 12.50 
5 51 26 50.98 
Mean average transduction efficiency: 28.52 
A2UCOE+HTT exon 1 (29 CAG) lentivirus-infected ReNcell VM NSCs 
Field  Total cell count No. eGFP-
expressing NSCs 
% transduced NSCs 
1 20 15 75.00 
2 25 22 88.00 
3 22 18 81.82 
4 21 16 76.19 
5 26 14 53.85 
Mean average transduction efficiency: 74.97 
A2UCOE+HTT exon 1 (71 CAG) lentivirus-infected ReNcell VM NSCs 
Field  Total cell count No. eGFP-
expressing NSCs 
% transduced NSCs 
1 20 15 75.00 
2 29 27 93.10 
3 18 9 50.00 
4 20 13 65.00 
5 18 12 66.67 
Mean average transduction efficiency: 69.95 
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A2UCOE+HTT exon 1 (129 CAG) lentivirus-infected ReNcell VM NSCs 
Field  Total cell count No. eGFP-
expressing NSCs 
% transduced NSCs
1 36 16 44.44 
2 33 14 42.42 
3 21 12 57.14 
4 26 8 30.77 
5 18 11 61.11 
Mean average transduction efficiency: 47.18 
 
3.5.2.1 Characterisation of ReNcell VM+HTT exon 1 neuronal cell lines 
All ReNcell VM NSC+HTT exon 1 NSC cultures grew well in culture and expanded at 
comparative rates to wild-type, non-transduced NSCs. NSC cultures were all of similar 
morphology, although HTT exon 1 (71 CAG) NSCs appeared spindlier. This could be 
an indication of a mHTT-induced morphological phenotype in these cells. Upon 
differentiation, using the induced differentiation protocol, all NSC cultures adopted 
neuronal-like morphology with changes occurring in line with wild-type NSC 
differentiation and over a similar time-course. By 25 DD, some minor differences could 
be observed between the neuronal cultures: HTT exon 1 (71 CAG) and HTT exon 1 
(129 CAG) neuronal cultures had thinned out more than HTT exon 1 (29 CAG), eGFP 
reporter only and wild-type neuronal cultures, leaving larger and more numerous gaps 
between surviving cells. This could be due to a toxic phenotype of the expanded CAG 
repeats in these mHTT-expressing neurons. Interestingly, HTT exon 1 (29 CAG) 
neuronal cultures appeared to be denser than eGFP reporter only and wild-type 
neuronal cultures, and cells bunched into patches. This could indicate a higher survival 
rate of differentiated cells or a prolonged turnover of NSCs prior to differentiation. 
Images of ReNcell VM NSC+HTT exon 1 NSC cultures and 25 DD neuronal cultures 
can be seen in Figure 3.7.  
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Figure 3.7: Morphology of ReNcell VM+HTT exon 1 NSC lines and 
differentiated neuronal cultures  
Phase-contrast images of ReNcell VM+HTT exon 1 NSCs and 25 DD neuronal cultures 
(induced differentiation). Wild-type (WT; non-transduced) ReNcell VM cultures presented for 
comparison (top panel). All images taken with 10× objective. 
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Expression of HTT exon 1 trans-protein with 29Q, 71Q or 129Q was confirmed by 
Western blotting in ReNcell VM+HTT exon 1 (29, 71 or 129 CAG), ReNcell VM+eGFP 
reporter only and wild-type ReNcell VM NSCs and 25 DD (induced differentiation) 
neuronal cultures. Proteins which co-stained with 4C9 and S830 were detected in 
ReNcell VM+HTT exon 1 (29 CAG), ReNcell VM+HTT exon 1 (71 CAG) and ReNcell 
VM+HTT exon 1 (129 CAG) NSC and DD25 neuronal cultures (Figure 3.8). The sizes 
of these proteins were consistent with those expected for HTT exon 1 with 
approximately 29, 71 or 129 polyQ, respectively, with larger glutamine repeats 
becoming more retarded in the gel during SDS-PAGE (Landles et al. 2010). 4C9 alone 
detected several bands in all samples which could be associated with fragments of 
native HTT (Weiss et al. 2012). S830 is directed at mHTT polyQ and has preference for 
expanded polyQ regions, however it will still bind to polyQ stretches within the normal 
range. Over-expression of HTT exon 1 within the normal polyQ range (29Q) was 
detected in ReNcell VM+HTT exon 1 (29 CAG) NSCs and DD25 neuronal cultures by 
increased S830 signal, in co-stain with 4C9, compared with wild-type and ReNcell 
VM+eGFP reporter only cultures. It was therefore confirmed that ReNcell VM NSCs 
which had been transduced with HTT exon 1 (29, 71 or 129 CAG) were successfully 
expressing HTT exon 1 trans-protein of the correct size, and that this was also the case 
following differentiation into mature neuronal cultures. 
Interestingly, N-terminal fragments smaller than exon 1 were detected in ReNcell 
VM+HTT exon 1 (129 CAG) NSC and DD25 neuronal cultures, which may be a result 
of post-translational proteolytic cleavage of the highly-expanded exon 1 fragment. Also, 
protein co-staining for 4C9 and S830 was detected in the region transferred directly 
from the polyacrylamide gel wells in both of the mHTT-expressing DD25 neuronal 
cultures (ReNcell VM+HTT exon 1 (71 CAG) and ReNcell VM+HTT exon 1 (129 
CAG)). This may indicate presence of mHTT aggregates in the mature HD neuronal 
cultures, which were more resistant to denaturation processes during preparation of the 
cell lysates and were therefore too large to enter the gel during electrophoresis (Figure 
3.8).  
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Figure 3.8: Confirmation of HTT exon 1 protein expression in ReNcell VM+HTT 
exon 1 neuronal cell lines 
Wild-type (WT) ReNcell VM, ReNcell VM+HTT exon 1 (29, 71 or 129 CAG) and ReNcell 
VM+eGFP reporter only (eGFP) NSC and DD25 (induced differentiation) neuronal cultures were 
harvested and cell lysates prepared. Proteins were separated according to their electrophoretic 
mobility by SDS-PAGE and transferred into a membrane by electroblotting. The membrane was 
then probed with 4C9 and S830 primary antibodies, directed against HTT and mHTT, 
respectively, and IRDye-conjugated secondary antibodies. IR signals were visualised directly on 
the membrane using a LI-COR Odyssey Scanner (HTT, red; mHTT, green). Presented here is a 
representative example of two repeat Western blots. The blot is pictured as an annotated image 
with merged 4C9/S830 signals (top left panel), and as 4C9 only and S830 only images (right). 
The Western blot was also probed for β-actin (red; 42 KDa) as a loading control (bottom left 
panel). Detected proteins were sized against BioRad Precision Plus All Blue protein standard. 
Dotted yellow boxes highlight HTT exon 1 proteins expressed from the transgenes. Dotted red 
boxes highlight shorter N-terminal fragments of mHTT which may occur due to proteolytic 
cleavage of mHTT exon 1 produced by mHTT transgenes. The dotted blue box highlights 
possible aggregates of mHTT which have remained in the gel wells during SDS-PAGE.  
Total HTT and expanded HTT in the NSCs and 25 DD neuronal cultures was then 
quantified using the MSD platform and a proprietary, optimised protocol. Total HTT was 
measured using 2B7/4C9 antibody pair and expanded HTT was measured using 
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2B7/MW1 antibody pair, in wild-type ReNcell VM, ReNcell VM+HTT exon 1 (29, 71 or 
129 CAG) and ReNcell VM+eGFP reporter only NSC and 10 DD neuronal cultures 
(induced differentiation). Results of the MSD analysis are presented in Figure 3.9.  
Total HTT levels were found to be higher in all cells expressing HTT exon 1 transgenes 
(ReNcell VM+HTT exon 1 (29, 71 or 129 CAG) NSCs and neurons) compared with 
cells which did not (wild-type ReNcell VM and ReNcell VM+eGFP reporter only NSCs 
and neurons). This occurs due to induction by the A2UCOE promoter as well as 
expression of the transgenes on a diploid native HTT background, and provided further 
confirmation of successful trans-protein production in the cell lines. Expanded HTT was 
also only detected in cells expressing the mHTT exon 1 transgenes (ReNcell VM+HTT 
exon 1 (71 or 129 CAG) NSCs and neurons). Total HTT was of similar levels in 
ReNcell VM+HTT exon 1 (71 CAG) and ReNcell VM+HTT exon 1 (129 CAG) NSCs; 
51.67 and 58.33 fmol/mg, respectively. However, total HTT levels were approximately 
three-fold higher, 169.33 fmol/mg, in ReNcell VM+HTT exon 1 (29 CAG) NSCs, which 
may indicate higher expression of the HTT exon 1 (29 CAG) transgene. Ideally, all 
ReNcell VM+HTT exon 1 lines would express the transgene to equal levels, however 
as it was the control line with CAG repeats in the normal range which had higher total 
HTT levels, this was considered to be acceptable. Expanded HTT levels were higher in 
neuronal cultures than NSCs, suggesting a potential build-up of mHTT exon 1 protein 
in the post-mitotic cells. This could be an indication of mHTT aggregation in these 
neurons. Expanded HTT levels were also higher in ReNcell VM+HTT exon 1 (129 
CAG) than ReNcell VM+HTT exon 1 (71 CAG), potentially indicating that mHTT with 
more expanded polyQ has a higher propensity for build-up and/or aggregation. 
However, as the MW1 antibody (used for detection of expanded HTT in this assay) has 
more affinity for expanded polyQ, the detection of higher MW1 signal in ReNcell 
VM+HTT exon 1 (129 CAG) may just be due to more antibodies binding to each 
individual exon 1 protein. 
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Figure 3.9: Levels of total and expanded HTT in ReNcell VM+HTT exon 1 
NSCs and neuronal cultures 
Total HTT and expanded HTT levels were measured by MSD assay in wild-type ReNcell VM, 
ReNcell VM+HTT exon 1 (29, 71 or 129 CAG) and ReNcell VM+eGFP reporter only (eGFP) 
NSC and DD10 (induced differentiation) neuronal cultures. Total HTT levels (A) were measured 
using 2B7/4C9 antibody pair and expanded HTT levels (B) were measured using 2B7/MW1 
antibody pair. All measurements were normalised to total protein concentration per culture. It is 
important to note that the assay for measurement of total HTT was performed independently 
from the assay for measurement of expanded HTT, and due to differential kinetics of the two 
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assays, comparisons should not be made across the two data sets. Bars = mean average of 
three independent assay measurments from the same culture; error bars = SD; Below LOD, 
below limit of detection. 
 
 
Figure 3.10: Detection of mHTT aggregates in ReNcell VM+mHTT exon 1 (71 
or 129 CAG) NSCs and differentiated neuronal cultures 
Wild-type (WT) ReNcell VM, ReNcell VM+HTT exon 1 (29, 71 or 129 CAG) and ReNcell 
VM+eGFP only NSCs (A) and 14 DD neuronal cultures (B; induced differentiation) were probed 
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with antibodies directed at mHTT polyQ (S830; white), eGFP (green) and βIII-tubulin (red) using 
ICC techniques. Nuclei were stained with Hoechst 33342 (blue). Cultures were then imaged 
using the Opera LX HCS system. Cells containing aggregates of mHTT exon 1 are indicated 
with yellow arrows, and some examples are magnified below the images for closer inspection. 
Scale bars = 50 µm. 
MSD assay analysis of expanded HTT levels had shown potential build-up of mHTT in 
neurons expressing HTT exon 1 with 71 or 129 CAG (Figure 3.9), and Western blot 
results had provided some evidence for the presence of mHTT aggregates in these 
neurons (Figure 3.8). ICC techniques utilising S830 anti-mHTT polyQ antibodies were 
therefore applied to NSC and 14 DD neuronal cultures (induced differentiation) with the 
aim of detecting mHTT aggregates. Cultures were then imaged using the Opera LX 
HCS system, and some examples are presented in Figure 3.10. 
A punctate S830 signal was detected in some cells in ReNcell VM+HTT exon 1 (71 
CAG) and ReNcell VM+HTT exon 1 (129 CAG) NSC and neuronal cultures, confirming 
the presence of mHTT aggregates. This was not detected in wild-type ReNcell VM, 
ReNcell VM+eGFP reporter only or ReNcell VM+HTT exon 1 (29 CAG) cultures. In 
NSCs, the aggregates were cytoplasmic or perinuclear and appeared small and 
diffuse. In 14 DD neuronal cultures, the aggregates were much larger and had formed 
intranuclear inclusions. Intranuclear inclusions were found in cells which stained 
positively for βIII-tubulin, confirming them as neurons. Additionally, all cells in 
transduced ReNcell VM NSC and neuronal cultures stained positively for eGFP, 
showing that 100 % cells were expressing the transgenes. 
In order to determine whether there was any mHTT-induced toxicity in ReNcell 
VM+HTT exon 1 (71 CAG) and ReNcell VM+HTT exon 1 (129 CAG) neurons, LDH 
cytotoxicity assays were performed on neuronal cultures. ReNcell VM+eGFP reporter 
only and ReNcell VM+HTT exon 1 (29, 71 or 129 CAG) NSCs were differentiated until 
10 DD by spontaneous differentiation. Cells were given a fresh culture medium change 
and returned to the incubator for a further 24 h. LDH cytotoxicity assays were then 
performed and results are displayed in Figure 3.11. 
Neuronal culture type was a significant source of variation in neuronal culture death 
(p=0.010). Expression of mHTT exon 1 (71 CAG) resulted in significantly more 
neuronal death than expression of HTT exon 1 (29 CAG), p<0.05, suggesting that 
mHTT exon 1 71Q is more toxic than HTT exon 1 29Q and an indication of mHTT-
induced neurotoxicity in this HD neuronal cell model. Interestingly, expression of mHTT 
exon 1 with a more expanded CAG tract (129 CAG) resulted in similar levels of death 
as HTT exon 1 (29 CAG), and significantly less death than HTT exon 1 (71 CAG), 
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p<0.01. This suggests that mHTT exon 1 71Q is more neurotoxic than mHTT exon 1 
129Q in this model. 
 
Figure 3.11: mHTT exon 1-induced cytotoxicity in ReNcell VM neuronal 
cultures 
LDH cytotoxicity assays were performed on ReNcell VM+HTT exon 1 (29 CAG), ReNcell 
VM+mHTT exon 1 (71 CAG), ReNcell VM+mHTT exon 1 (129 CAG) and ReNcell VM+eGFP 
reporter only neuronal cultures (11 DD, spontaneous differentiation) after 24 h incubation in 
standard NM culture medium. Results are presented as mean average neuronal culture death 
(calculated as described in section 2.6.1) relative to untreated eGFP reporter only neuronal 
culture death (baseline death levels), from three independent cultures per cell line, each with 
three internal experimental replicates, ± SEM. Data were statistically analysed using one-way 
ANOVA with Tukey post-hoc analyses; *p<0.05, **p<0.01. 
3.5.3 Generation of human HD neuronal cell lines with stable expression of 
human full-length mHTT 
MSCVpuro+full-length HTT (15 CAG) and MSCVhyg+full-length mHTT (138 CAG) 
retroviral vectors were a kind gift from Prof. Michael R. Hayden (University of British 
Columbia, Canada). Full details of the expression systems, including plasmid maps, 
can be found in section 2.2.1.2.  
MSCVpuro+full-length HTT (15 CAG) and MSCVhyg+full-length mHTT (138 CAG) 
plasmid DNA was amplified and purified, then restriction digests were performed to 
confirm correctness of the plasmids and check for DNA contamination. Firstly, plasmid 
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DNA was digested with XhoI and resulting DNA fragments were separated by agarose 
gel electrophoresis and sized against HyperLadder I and HyperLadder IV DNA ladders 
which were run in parallel. XhoI recognises two sites within each plasmid; one site in 
MSCV MCS located 12 bp 5’ to the HTT transgene, and one naturally occurring 
sequence within HTT cDNA located 387 bp 3’ to the CAG repeat tract. Therefore, XhoI 
was expected to cut out an N-terminal HTT fragment containing the CAG repeat + 12 
bp flanking plasmid DNA, which had predicted sizes of 494 bp for MSCVpuro+full-
length HTT (15 CAG) and 863 bp for MSCVhyg+full-length mHTT (138 CAG).  
 
Figure 3.12: Restriction digest of MSCV+full-length HTT plasmid vectors 
MSCVpuro+full-length HTT (15 CAG) and MSCVhyg+full-length mHTT (138 CAG) plasmid 
vectors were digested with restriction enzyme XhoI (A) or EcoRI and HpaI (B) and resulting 
DNA fragments were separated by agarose gel electrophoresis alongside DNA ladders 
HyperLadder I and HyperLadder IV. Each digested (XhoI, HpaI, EcoRI or HpaI+EcoRI) plasmid 
sample was run alongside an undigested (uncut) control sample. DNA was visualised by 
exposing intercalated ethidium bromide to UV light and images of the gels are presented above. 
XhoI digestion DNA gel results (A) are presented at two different exposures to more clearly 
demonstrate DNA bands representing N-terminal HTT fragments containing the CAG repeat 
(top) and remaining plasmid (bottom). Clear bands can be seen at ~500 bp in MSCVpuro+full-
length HTT (15 CAG) and ~850 bp in MSCVhyg+full-length mHTT (138 CAG) samples following 
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digestion with XhoI (A), confirming CAG repeat tracts of the correct approximate size. Digestion 
with EcoRI and HpaI also produced DNA bands at the estimated sizes (B), confirming 
correctness of both plasmids. 
Figure 3.12; A shows that digestion of each vector with XhoI produced DNA fragments 
at sizes appropriate to represent N-terminal HTT fragments with 15 or 138 CAG 
repeats, as predicted. The plasmid vectors were then digested with EcoRI and HpaI. 
EcoRI recognises two sites within the HTT cDNA sequence (bp 4698 and bp 5175) and 
a site in MSCV MCS located directly 3’ to the HTT transgene. In MSCVhyg+full-length 
mHTT (138 CAG), EcoRI also recognises a site within hygr. Therefore, digestion of 
MSCVpuro+full-length HTT (15 CAG) with EcoRI alone was predicted to produce three 
DNA fragments of 477 bp (HTT cDNA bp 4535-5012 (15 CAG)), 4405 bp (HTT cDNA 
bp 5012 (15 CAG)-MCS) and ~11 Kb (the remainder of the plasmid). Digestion of 
MSCVhyg+full-length mHTT (138 CAG) was expected to produce four DNA fragments 
of 477 bp, 4405 bp, ~11 Kb, and an additional fragment of unknown size due to the 
restriction site within hygr (full Clontech plasmid sequence is proprietary). HpaI 
recognises only one site in each vector, which is located in MSCV MCS directly 5’ to 
the HTT transgene. Digestion with HpaI alone was consequently expected to linearize 
each plasmid, producing single DNA fragments of 15.7 Kb for MSCVpuro+full-length 
HTT (15 CAG) (6.3 Kb MSCVpuro + 9.4 Kb full-length HTT cDNA with 15 CAG) or 16.8 
Kb for MSCVhyg+full-length mHTT (138 CAG) (7.0 Kb MSCVhyg + 9.8 Kb full-length 
mHTT cDNA with 138 CAG). Following digestion of each plasmid with EcoRI and HpaI, 
alone or in combination, resulting DNA fragments were separated by agarose gel 
electrophoresis and sized against HyperLadder I and HyperLadder IV DNA ladders 
which were run in parallel. DNA bands of the predicted sizes were detected in each 
digested sample, as shown in Figure 3.12; B, which confirmed that each of the 
plasmids was correct and contained full-length HTT transgenes with CAG repeats in 
the correct range. No additional bands were detected, other than a faint band at ~2000 
bp in EcoRI digestions which was attributed to star activity of this enzyme, confirming 
no contamination of plasmid DNA.  
Full-length HTT transgenes were then sequenced in order to confirm their presence 
within the retroviral vectors, and to check their CAG repeat lengths and any mutations. 
Analysis confirmed that each of the vectors contained a full-length human HTT cDNA 
transgene with 15 CAG repeats for MSCVpuro+full-length HTT (15 CAG) and 136 CAG 
repeats for MSCVhyg+full-length mHTT (138 CAG). For reasons of clarity, the latter 
plasmid (and retroviruses and cell lines created using it) will still be referred to as 
MSCV+full-length mHTT (138 CAG) throughout this Thesis. The expanded HTT 
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transcript also contained 13 CAA interruptions in the CAG repeat tract. The transgenic 
inserts included the full coding DNA transcript followed by 600 bp non-coding DNA and 
a polyadenylated tail. Sequences were in frame, had no mutations in exon 1, and 
shared exact homology with the published NCBI; nucleotide; RefSeqGene reference 
sequence NG_009378.1 for Homo sapiens HTT cDNA (IT15) 10.3 Kb transcript, 
chromosome 4, other than the exceptions outlined in Table 3.3. Variations from the 
reference sequence were mostly synonymous substitutions or located in the non-
coding sequence, so would not lead to changes in the final HTT protein. There were, 
however, three nonsynonymous nucleotide substitutions leading to amino acid coding 
changes: two of which were identified in both transgenes (codons for arginine instead 
of lysine and histidine instead of tyrosine), and one which was identified only in the full-
length mHTT (138 CAG) transgene (codon for asparagine instead of threonine). 
Threonine → asparagine (bp 5165) and tyrosine → histidine (bp 6933) are known 
natural variants (SNPs) in HTT, which correspond to variants rs363125 and rs362331, 
respectively, in the Database of Single Nucleotide Polymorphism (dbSNP) 
(https://www-ncbi-nlm-nih-gov.libproxy.ucl.ac.uk/SNP/). Lysine → arginine (bp 3721) is 
not recorded as a known natural variant in HTT (UniProtKB – P42856; 
http://www.uniprot.org/uniprot/P42858), however polymorphisms in the HTT gene have 
not yet been fully established. Lysine and arginine are similar amino acids (both have 
electrically charged, basic side chains and are of similar size), therefore this variation 
should make little difference to the tertiary structure of the final HTT protein. Also, as 
the same variation occurs in both the HTT (15 CAG) and mHTT (138 CAG) transgenes, 
it was not considered to be problematic. 
Table 3.3: Description of sequencing results for full-length HTT cDNA 
transgenes 
HTT transgene 
Full-length human HTT cDNA  
(15 CAG) 
Full-length human mHTT cDNA  
(138 CAG) 
Size 
Full transgene = 10030 bp 
Coding sequence = 9417 bp 
Full transgene = 10358 bp 
Coding sequence = 9780 bp 
CAG repeat size 
15 136 (including 13 CAA interruptions) 
Variations from reference sequence 
 bp 281: GAA → GAG 
Synonymous substitution (glutamic acid) 
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bp 1196: ACC → ACT 
 Synonymous substitution (threonine) 
bp 3721: AAA → AGA 
Nonsynonymous substitution (lysine → arginine) 
 bp 5165: ACT → AAT 
Nonsynonymous substitution (threonine 
→ asparagine) 
bp 6933: TAC → CAC 
Nonsynonymous substitution (tyrosine → histidine) 
bp 7184: CTA → CTC 
Synonymous substitution (leucine) 
 
bp 9811: C → G 
Non-coding sequence 
 
bp 9923: C → A 
Non-coding sequence 
bp 9958: C → T 
Non-coding sequence 
Reference sequence = NCBI; nucleotide; RefSeqGene; NG_009378.1 for Homo sapiens HTT 
cDNA (IT15) 10.3 Kb transcript, chromosome 4. bp numbers refer to locations in the cDNA 
reference sequence. A, adenine; C, cytosine; G, guanine; T, tyrosine. 
The concentration and purity of MSCVpuro+full-length HTT (15 CAG) and 
MSCVhyg+full-length mHTT (138 CAG) plasmid DNA was determined by NanoDrop, 
and results are reported in Table 3.4. A260/A280 ratios were 1.9 for both plasmids, 
indicating no protein or RNA contamination within the samples, and A260/A230 ratios 
were above 2.0, indicating no other contaminants within the DNA samples. Plasmid 
DNA was therefore considered to be sufficiently pure and of high quality for use in 
transfection procedures. 
Table 3.4: MSCV+full-length HTT plasmid DNA concentration and purity 
Plasmid 
DNA concentration/ 
ng/µL 
A260/A280 A260/A230 
MSCVpuro+full-length HTT  
(15 CAG) 
2814.2 1.90 2.21 
MSCVhyg+full-length mHTT  
(138 CAG) 
2507.9 1.90 2.22 
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MSCVpuro+full-length HTT (15 CAG) and MSCVhyg+full-length mHTT (138 CAG) 
plasmids have wild-type genomes of 6.3 and 7.0 Kb, respectively, and HTT transgene 
inserts of 10.0 Kb and 10.3 Kb, respectively. For a retroviral expression system, which 
usually have insert size capacities in the range of 2.5-5.0 Kb, these plasmids are very 
large, and therefore viral titre was expected to be very low. MSCV retroviral expression 
systems are, however, optimised for introducing and expressing target genes in 
pluripotent cell lines, including human stem cells such as ReNcell VM NSCs, and viral 
expression systems with larger insert size capacities, such as adenovirus gene delivery 
systems, do not facilitate transgene integration into the genome of the target cell. 
Adeno-associated virus (AAV) expression systems have a much larger typical titre, but 
again, do not generally facilitate genome integration. The MSCV retroviral expression 
system was therefore selected for introducing and expressing the full-length HTT 
transgenes in ReNcell VM NSCs. As viral titre was predicted to be very low, it was 
expected that retroviral supernatants would require concentration. For this reason, 
pseudotyped viruses were created with VSV-G foreign viral envelope protein, to 
increase stability of the viral particles and maintain their structural integrity during 
ultracentrifugation. MSCVpuro+full-length HTT (15 CAG) and MSCVhyg+full-length 
mHTT (138 CAG) plasmid vectors were packaged into dual 4070A (amphotropic)/VSV-
G coated retroviruses by transfection into the Phoenix-AMPHO retrovirus producer cell 
line, along with VSV-G-expressing envelope plasmid MD.G2, using FuGene HD 
Transfection Reagent. The 4070A envelope and GAG/pol packaging proteins were 
encoded from constructs carried by Phoenix-AMPHO.  
Retroviral supernatants were collected and tested for viability by infection of HeLa cell 
cultures and monitoring survival rates under antibiotic selection. Firstly, puromycin and 
hygromycin antibiotic kill curves were performed in HeLa cells, as described in detail in 
section 2.3.4.1. Cells were treated with a range of puromycin (0-15 µg/mL) or 
Hygromycin B (0-500 µg/mL) concentrations and approximate percentage cell survival 
was interpreted daily by visualisation of HeLa cultures using phase-contrast 
microscopy. The optimum antibiotic selection concentration was considered to be the 
minimum concentration required to give 100 % HeLa cell death after 3-4 days for 
puromycin, which was 0.2 µg/mL, and 7-8 days for Hygromycin B, which was 300 
µg/mL (Figure 3.13). Four days post-infection with MSCVpuro+full-length HTT (15 
CAG) or MSCVhyg+full-length mHTT (138 CAG) retrovirus supernatants, 0.2 µg/mL 
puromycin or 300 µg/mL Hygromycin B, respectively, was added to the HeLa cell 
culture medium, and medium changes with the addition of fresh antibiotics were 
performed every two days. Retrovirus viability was assessed by monitoring cell survival 
under antibiotic selection. Infections with retroviral supernatants which resulted in at 
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least 5 % surviving cells after four days puromycin selection or seven days Hygromycin 
B selection, followed by an exponential growth phase under continued selection, were 
considered to contain viable retrovirus, and were subsequently taken forward for 
concentration by ultracentrifugation. 
Concentrated MSCVpuro+full-length HTT (15 CAG) and MSCVhyg+full-length mHTT 
(138 CAG) retroviruses were tested for viability and transduction efficiency in HeLa 
cells, as described in detail in section 2.3.3.2. HeLa cells were infected with 
concentrated retrovirus at 1:100, 1:1000 and 1:10,000 dilutions, or received no 
infection, and were subjected to antibiotic selection. After four days puromycin 
selection or 7 days Hygromycin B selection, non-infected cells were completely dead, 
cells which received no antibiotic treatment had reached 100 % confluence, and 
infected cultures had ~15-20 % surviving cell populations. The exception was HeLa 
cells infected with MSCVpuro+full-length HTT (15 CAG) concentrated retrovirus at 
1:10,000 dilution, which did not survive under antibiotic selection, indicating low viability 
or poor transduction efficiency. All other infections were deemed to contain viable 
retroviruses with reasonable transduction efficiency. 
 
Figure 3.13: Antibiotic kill curves in HeLa cell cultures 
HeLa cells were treated, in triplicate, with puromycin (A) or Hygromycin B (B) at a range of 
concentrations. Average percentage surviving cells compared to untreated cells was monitored 
daily, and determined by visualisation of cell cultures using a light microscope. Cells were given 
a media change with the addition of fresh antibiotics every 2 days. The optimum antibiotic 
selection concentration was considered to be the minimum concentration required to give 100 
% cell death after 3-4 days for puromycin, and 7-8 days for Hygromycin B (purple dashed lines 
indicate optimum day range; purple line graphs indicate optimum antibiotic concentrations). Kill 
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curves were performed firstly with a broad concentration range (top graphs) and again with a 
narrower concentration range (bottom graphs).  
While MSCV retroviral expression systems are optimised for the delivery and 
expression of target genes in pluripotent cell lines, there was still a possibility that 
transgene silencing may occur in transduced NSCs due to the highly dynamic 
epigenetic regulation taking place in these cells. Therefore, in order to ensure that the 
retroviruses were functional, successful expression of the transgenes was firstly tested 
in the transduced HeLa cells. Cultures which had survived antibiotic selection were 
grown to confluence and expanded, and expression of full-length HTT trans-protein 
was detected by Western blotting and ICC techniques with confocal fluorescence 
microscopy. 
Full-length HTT protein runs at ~350 KDa by SDS-PAGE, and anti-HTT antibody 
mAB2166 detected proteins of this size in Western blots of transduced HeLa cell 
lysates. Cells transduced with full-length HTT had stronger expression of this protein 
than non-transduced (wild-type) cells (Figure 3.14; A, mAB2166), indicating expression 
of the trans-proteins. When Western blots were probed with anti-mHTT polyQ antibody 
MW1, protein bands were detected in HeLa cell cultures transduced with full-length 
mHTT (138 CAG), but not in wild-type cultures or cultures transduced with full-length 
HTT (15 CAG) (Figure 3.14; A, MW1), indicating presence of mHTT with expanded 
polyQ in these cells. MW1 labelled very faint bands at ~350 KDa (full-length mHTT), 
and stronger bands ranging between 150 and 250 KDa, indicating possible 
fragmentation of the full-length protein. Cultures which had received the most 
concentrated infections (1:100 concentrated retrovirus) were taken forward for testing 
by ICC, as described in sections 2.3.3.2 and 2.5.2. Fixed cells were probed with 2B7 
(anti-HTT) and MW1 (anti-mHTT polyQ) antibodies, which detected over-expression of 
HTT in both transduced cultures compared with wild-type HeLa cells, and mHTT 
expression in cultures transduced with full-length mHTT (138 CAG) (Figure 3.14; B). 
This provided further evidence for expression of the HTT trans-proteins and confirmed 
that the retroviruses were viable.  
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Figure 3.14: Full-length HTT trans-protein expression in HeLa cell cultures 
infected with MSCV+full-length HTT concentrated retroviruses 
A) Western blots of lysates from wild-type (WT) HeLa cell cultures, and HeLa cell cultures 
infected with concentrated MSCVpuro+full-length HTT (15 CAG) or MSCVhyg+full-length mHTT 
(138 CAG) retroviruses at 1:100, 1:1000 or 1:10,000 dilutions. Membranes were probed with 
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mAB2166 (anti-HTT) (left) and MW1 (anti-mHTT polyQ) (right) primary antibodies which were 
detected by IRDye-conjugated secondary antibodies and visualised using a LI-COR Odyssey 
Scanner. Protein weight was determined by two high molecular weight protein standards which 
were run alongside. B) ICC showed increased expression of HTT in transduced HeLa cells 
compared with wild-type HeLa cells (2B7; red), and mHTT expression in cells transduced with 
full-length mHTT (138 CAG) (MW1; green). DAPI (blue) was used to stain nuclei. Cell cultures 
were imaged using confocal fluorescence microscopy. Example images presented from six 
random fields of view per culture. Scale bar = 50 µm. 
As expected, viral titre was very low, and therefore the highest concentration of 
retrovirus was used for subsequent infections of ReNcell VM NSCs, as described in 
detail in section 2.3.4.2. Additionally, a double infection method was used to improve 
transduction efficiency. ReNcell VM NSCs were infected with concentrated 
MSCVpuro+full-length HTT (15 CAG) or MSCVhyg+full-length mHTT (138 CAG) 
retroviruses at 1:100 dilution for 24 h, followed by another consecutive 24 h infection to 
increase MOI. Cells were then expanded over one passage before undergoing 
antibiotic selection. NSC cultures transduced with full-length HTT (15 CAG) were 
selected with 0.125 µg/mL puromycin and NSC cultures transduced with full-length 
mHTT (138 CAG) were selected with 40 µg/mL Hygromycin B. These optimum 
antibiotic concentrations had been determined previously by performing kill curves in 
ReNcell VM NSCs (Figure 3.15). Cultures were maintained under antibiotic selection 
for 1 week (puromycin) or 2 weeks (Hygromycin B), at which point small colonies of 
surviving cells had begun to expand. Cultures were then grown to confluence and 
expanded over two passages.  
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Figure 3.15: Antibiotic kill curves in ReNcell VM NSC cultures 
ReNcell VM NSCs were treated, in triplicate, with puromycin (A) or Hygromycin B (B) at a range 
of concentrations. Average percentage surviving cells compared to untreated cells was 
monitored daily, and determined by visualisation of cell cultures using a light microscope. Cells 
were given a media change with the addition of fresh antibiotics every 2 days. The optimum 
antibiotic selection concentration was considered to be the minimum concentration required to 
give 100 % cell death after 3-4 days for puromycin, and 7-8 days for Hygromycin B (purple 
dashed lines indicate optimum day range; purple line graphs indicate optimum antibiotic 
concentrations). Kill curves were performed firstly with a broad concentration range (top graphs) 
and again with narrower concentration ranges (bottom graphs).  
3.5.3.1 Characterisation of ReNcell VM+full-length HTT neuronal cell lines 
Stable expression of the trans-proteins in ReNcell VM+full-length HTT (15 CAG) and 
ReNcell VM+full-length mHTT (138 CAG) NSCs was determined by ICC (as described 
for HeLa+full-length HTT cell lines above, and in detail in section 2.5.2) (Figure 3.16; 
A). Like wild-type ReNcell VM, these transduced NSCs could be differentiated into 
mature neuronal cultures by spontaneous differentiation (Figure 3.16; B).  
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Figure 3.16: Characterisation of selected ReNcell VM+full-length HTT cell lines 
Confocal fluorescence microscopy images of wild-type ReNcell VM and ReNcell VM+full-length 
mHTT (138 CAG) NSC cultures (A) show expression of mHTT trans-protein in the transgenic 
cell line following ICC with antibodies directed at mHTT polyQ (MW1; green). ReNcell VM+full-
length HTT (15 CAG) and ReNcell VM+full-length mHTT (138 CAG) can be differentiated into 
mature neuronal cultures (spontaneous differentiation) (B) which express HTT (mAB2166; 
green) and βIII-tubulin (red). All images are representative examples from at least five random 
fields of view from two cultures. Nuclei stained with DAPI (blue). Scale bars = 50 µm. 
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Figure 3.17: HTT quantification in ReNcell VM+full-length HTT clonal lines 
Wild-type ReNcell VM NSC and ReNcell VM+full-length HTT (15 CAG) and ReNcell VM+full-
length mHTT (138 CAG) NSC clone lysates were dot blotted (A) or Western blotted (C) and 
probed for HTT (mAB2166) and GAPDH (loading control). IRDye-labelled secondary antibodies 
bound to HTT (green) and GAPDH (red) were visualised by LI-COR Odyssey scanner. Relative 
HTT levels were calculated by normalising HTT levels to GAPDH levels (B), as detected by dot 
blot. HTT levels in ReNcell VM+full-length mHTT (138 CAG) NSC clones relative to wild-type 
NSCs were confirmed by TR-FRET assay (F) utilising results from 2B7-4C9 antibody pair 
analysis (D). 2B7-MW1 antibody pair analysis (E) confirmed expression of mHTT in ReNcell 
VM+full-length mHTT (138 CAG) C8 NSCs. All panels presented in this figure are examples 
taken from several different clone screening batches. 
It was observed that there was large cell-to-cell variability in HTT expression levels 
within each culture (Figure 3.16; A), indicating variable transgene expression, and 
consequently there was a requirement for generation of clonal transgenic cell lines. 
ReNcell VM+full-length HTT (15 CAG) or ReNcell VM+full-length mHTT (138 CAG) 
NSCs were seeded into a 96-well culture plate at 1 cell per well and cultures which 
grew to confluence were expanded as individual clonal cell lines. From single-cell 
seeding, approximately 40 clonal cell lines of each original ReNcell VM+full-length HTT 
line survived and were expanded. Of these clones, approximately 20 of each line were 
screened for presence and expression level of the trans-proteins by dot blotting, 
Western blotting and TR-FRET assay. Wild-type ReNcell VM NSC and ReNcell VM 
clone lysate samples were dot blotted, in triplicate, and probed with antibodies directed 
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at HTT (mAB2166) and GAPDH (Figure 3.17; A). Clone HTT levels, relative to wild-
type NSCs, were determined by normalising HTT levels to GAPDH levels in each 
sample (Figure 3.17; B), and clones with HTT levels at least two-fold higher than wild-
type NSCs were confirmed as expressing the trans-protein. Cell lysates were then run 
on Western blots and again probed for HTT (mAB2166) to check the sizes of the HTT 
fragments against a protein ladder (Figure 3.17; C). TR-FRET assay was performed on 
selected ReNcell VM+mHTT (138 CAG) NSC clones which had been shown to over-
express HTT by dot blotting and Western blotting techniques. 2B7-4C9 antibody pair 
was used to quantify HTT levels in each of the clones, and in wild-type ReNcell VM 
NSCs, (Figure 3.17; D) and 2B7-MW1 antibody pair was used to simultaneously 
quantify mHTT levels (expanded polyQ) (Figure 3.17; E). HTT levels in each clone 
were then calculated relative to wild-type ReNcell VM NSC HTT levels, using results 
from the 2B7-4C9 TR-FRET assay (Figure 3.17; F).  
ReNcell VM+mHTT (138 CAG) Clone 8 (C8) was determined, by dot blot and TR-FRET 
assay, to have approximately four-fold HTT over-expression compared to wild-type 
ReNcell VM NSCs. Over-expression of HTT protein within the full-length size range 
was also detected by Western blot, along with smaller over-expressing fragments, and 
C8 was the only full-length mHTT (138 CAG) clone for which mHTT with expanded 
polyQ was detected by TR-FRET (2B7-MW1 antibody pair). HTT over-expression in C8 
was also observed by ICC, as can be seen in Figure 3.18. ReNcell VM+mHTT (138 
CAG) C8 was therefore confirmed to be expressing the full-length mHTT trans-protein.  
Due to the large volume of work required to generate, expand and screen each clonal 
line, this process was carried out in batches and ReNcell VM+mHTT (138 CAG) clones 
were completed first. At the time of writing this Thesis, no final ReNcell VM+HTT (15 
CAG) clones had been fully verified.  
To assess mHTT-induced neurotoxicity in the full-length line, wild-type and ReNcell 
VM+full-length mHTT (138 CAG) C8 ReNcell VM were differentiated (spontaneous 
differentiation) to 10 DD. Neuronal cultures were then given a fresh medium change 
and returned to the incubator for 24 h before performing LDH cytotoxicity assays. 
Percentage cell death over this 24 h window was not found to be affected by 
expression of full-length mHTT (Figure 3.19). 
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Figure 3.18: HTT over-expression in ReNcell VM+full-length mHTT (138 CAG) 
C8 
Confocal fluorescence microscopy images following ICC of wild-type ReNcell VM and ReNcell 
VM+full-length mHTT (138 CAG) C8 NSC cultures (A) and 5 DD neuronal cultures 
(spontaneous differentiation) (B) with antibodies directed at HTT (mAB2166; green) show over-
expression of HTT in C8 of the transgenic line. Mature neurons stained positively for βIII-tubulin 
(red) indicating successful differentiation. Interestingly, mHTT-expressing cultures appeared to 
differentiate more slowly than wild-type cultures, as can be seen by the higher number of NSCs 
and lower number of mature neurons at 5 DD. Nuclei were stained with DAPI (blue).  
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Figure 3.19: Full-length mHTT-induced neurotoxicity in ReNcell VM neuronal 
cultures 
Ten DD (spontaneous differentiation) wild-type ReNcell VM and ReNcell VM+full-length mHTT 
(138 CAG) C8 neuronal cultures were cultured in fresh medium for 24 h before performing LDH 
cytotoxicity assays, in triplicate cultures, to assess neurotoxicity. Results presented as mean 
average percentage cell death (calculated as described in section 2.6.1) of two independent 
biological repeats ± SEM. Data were statistically analysed using two-tailed, paired t-test and the 
difference in the means was found to be not significant (p=0.639). 
3.5.4 Differentiation of primary human monocytes into macrophages and 
microglia-like cells in culture 
3.5.4.1 HD patient myeloid cells express mHTT 
Primary human monocytes were isolated from whole blood samples collected from 
healthy volunteers and manifest HD patients and cultured ex vivo. Monocytes were 
then differentiated into BMD-macrophages using a previously published and well-
establish protocol (Akagawa et al. 2006; Kwan et al. 2012b; Träger et al. 2014a), which 
is described in section 2.1.2.4. Differentiation was induced by GM-CSF, which 
promotes the development of macrophages with a proinflammatory M1-type 
phenotype. HD patient BMD-macrophages were shown to express mHTT by ICC and 
confocal fluorescence microscopy (Figure 3.20).  
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Figure 3.20: mHTT expression in HD patient BMD-macrophages 
Confocal fluorescence microscope images of BMD-macrophages differentiated from monocytes 
isolated from a healthy volunteer (HV; top panel) or HD patient (bottom panel) following ICC 
with antibodies directed at HTT (2B7; red) and mHTT polyQ (MW1; green). Nuclei were stained 
with DAPI (blue). MW1 has preference for expanded HTT polyQ and can be seen above to 
produce higher signal in HD patient BMD-macrophages than healthy volunteer BMD-
macrophages, indicating expression of mHTT in these cells. Images presented here are 
representative examples from three healthy volunteer cultures and five manifest HD patient 
cultures, with at least five fields of view per culture. Images taken at 40× objective. 
3.5.4.2 In vitro differentiation of primary human monocytes into microglia-like cells 
Most co-culture set-ups require both cell types to be cultured in the same medium, and 
therefore a compatible culture medium must be used. For the development of 
neuronal-myeloid cell co-culture models of HD, media titrations were performed, as 
described in detail below (section 3.5.5), in both ReNcell VM neuronal cultures and 
BMD-macrophage cultures using standard neuronal culture medium (NM) and standard 
BMD-macrophage medium (RPMI/FBS). Surprisingly, while observing BMD-
macrophages during culture in increasing titrations of NM, these cells became 
microglia-like in their morphology and behaviour. BMD-macrophages initially exhibited 
a classic round, ‘fried egg’ morphology and were transformed into ramified cells with 
dendritic-like, arborizing processes which appeared to actively and physically survey 
the local micro-environment. This transformation occurred over a period of four days 
and was more pronounced with higher NM titrations. On account of this interesting 
morphological transformation, these cells were investigated further as a potential model 
of human microglia in culture.  
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Figure 3.21: Morphological analysis of in vitro differentiation of primary human 
monocytes 
Phase-contrast microscope images showing morphology of healthy volunteer (HV) and manifest 
HD patient myeloid cells as they are differentiated from primary monocytes to BMD-
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macrophages (induced by GM-CSF) to microglia-like cells (by media change into NM). BMD-
macrophages and microglia-like cells are shown in non-stimulated and stimulated (2 µg/mL LPS 
and 10 ng/mL IFNү for 24 h) conditions. Cultures were imaged using 10× objective (A) and 40× 
objective (B). Images are representative examples from at least five fields of view per culture, 
and represent similar observations made when differentiating cultures isolated from several 
independent healthy volunteers and HD patients.  
Monocytes were isolated from one healthy volunteer and one manifest HD patient and 
differentiated into BMD-macrophages. BMD-macrophages were then stimulated with 2 
µg/mL LPS and 10 ng/mL IFNγ for 24 h, or were given a fresh culture medium change, 
and returned to the incubator for a further 4 days. Microglia-like cultures were then 
stimulated with 2 µg/mL LPS and 10 ng/mL IFNγ for 24 h. Cell cultures underwent 
morphological analysis using live-cell phase-contrast microscopy throughout the 
different differentiation stages and in non-stimulated and stimulated conditions as 
monocytes, BMD-macrophages, stimulated BMD-macrophages, microglia-like cells and 
stimulated microglia-like cells (Figure 3.21).  
Monocytes were small round cells which grew larger and ‘fried egg’ like and 
proliferated during differentiation into BMD-macrophages. When stimulated, BMD-
macrophages proliferated further and rounded up. Some cells became rod-like and 
polarised, indicative of migratory behaviour. No obvious morphological differences 
were observed between healthy volunteer and HD patient cells in these conditions. 
After four days culture in NM, BMD-macrophages grew larger and some cells had 
become ramified and microglia-like in their morphology, as had been observed 
previously in media titration experiments. This was the same in both healthy volunteer 
and HD patient cultures. Interestingly, when these microglia-like cells were stimulated, 
apparent differences were observed between healthy volunteer and HD patient 
cultures. In healthy volunteer cultures, approximately 10 % of the cells displayed some 
ramification, while the rest of the cells had rounded up and appeared activated. In HD 
patient cultures, around half of the cells appeared small, round and activated but the 
other half had become extremely ramified, sending out several long processes.  
3.5.4.3 Characterisation of BMD-microglia-like cell cultures 
In order to characterise stimulated HD patient microglia-like cells further, these cultures 
were observed in much closer detail, and comparisons were made with morphological 
analyses performed on primary microglia in the literature. It was found that these cell 
cultures shared several characteristics with primary microglia (Figure 3.22). 
Morphological phenotypes were similar to primary microglia isolated from human or 
murine brain tissue (Figure 3.22; A), and examples of various activation states were 
Chapter 3 
184 
 
observed, including small, round and activated forms; amoeboid forms; and ramified 
forms with several short processes or fewer long processes (Figure 3.22; B). This 
suggests that HD patient microglia-like cells are highly dynamic and can exist in a 
continuum of activation states, with morphologies more closely modelling microglia 
than peripheral macrophages. More specific morphological phenotypes were also 
observed, including vacuole and granular formations (Figure 3.22; C), indicative of 
phagocytic activities.  
Microglia undergo pronounced morphological changes when they seed CNS tissue 
during early embryogenesis and differentiate from embryonic myeloid precursors into 
functionally specialised microglia. The cells change from amoeboid immature cells on 
CNS entry; to polarised, migrating cells; to proliferating, ramified cells with several short 
processes; and finally, to the typical ramified microglia with long processes which are 
observed throughout the adult brain parenchyma. Cells exhibiting each of these 
morphological transformations were present in HD patient microglia-like cell cultures 
(Figure 3.22; D). 
When observing ramified cell populations within HD patient microglia-like cell cultures, 
long processes could be seen to actively survey the local micro-environment. They 
extended out into the extracellular space and appeared to sense neighbouring cell 
processes before retracting slightly and moving into free spaces. This was a dynamic 
process which could be observed in real time under the light microscope (Figure 3.22; 
E; top, left). Interestingly, in some cases processes were observed to make direct 
physical contact with several neighbouring cells (Figure 3.22; E; top, right), and one 
event was observed in real time where a microglia-like cell appeared to send out a 
tubule structure from its cell body, which subsequently joined with the cell body of a 
neighbouring cell (Figure 3.22; E; bottom, right). The tubule was of different 
composition than a normal process, with a narrower diameter and cytoplasmic density.  
A cluster of activated microglia is commonly termed a ‘microglial nodule’, without a 
strict definition of the cell number. This phenomenon was observed in stimulated HD 
patient microglia-like cell cultures (Figure 3.22; F), but not in non-stimulated cultures, 
BMD-macrophage cultures, or in any cultures differentiated from healthy volunteer 
monocytes. Surrounding microglial nodules was an inner ring of small, round, activated 
cells, and an outer ring of migrating cells, polarised in the direction of the nodule. 
Ramified cells were found distant from the nodule. This showed that not only did these 
microglia-like cell cultures contain cells of varying microglial morphologies, but that 
these morphologies were representative of reactive phenotypes, and the cells were 
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responding dynamically and appropriately to their local micro-environment. Microglial 
nodule formation may also be a mHTT-induced phenomenon. 
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Figure 3.22: In-depth morphological analysis of HD patient microglia-like cell 
cultures 
HD patient monocytes were differentiated into BMD-macrophages before changing culture 
medium into NM for 4 days. Cells were then stimulated with 2 µg/mL LPS and 10 ng/mL IFNү 
for 24 h. Cultures were studied using phase-contrast microscopy and photomicrographs are 
presented above. Observations indicated that these cells were morphologically and 
phenotypically similar to primary microglia. Comparisons were made between these HD patient 
microglia-like cells and primary microglia cultures presented in the literature. Images presented 
above are representative of observations made from at least ten independent HD patient cell 
cultures. A) HD patient microglia-like cells display similar morphology to primary human 
microglia (top) and primary mouse microglia (bottom). Yellow arrows highlight cells which 
specifically exemplify similar morphologies. Images taken with 10× (top, right) and 40× (bottom, 
right) objectives. Literature source: ScienCell Research Laboratories 
(http://www.sciencellonline.com/products-services/primary-cells/human-microglia.html (top, left) 
and http://www.sciencellonline.com/mouse-microglia-364.html (bottom, left)). B) A 
morphological comparison of rat microglia before and after stimulation with IFNү (left). Non-
stimulated microglia: both amoeboid and ramified forms could be observed, and some cells 
showed a long, single process or several short processes (ramified). Stimulated microglia: 
changed their morphology and were smaller and rounder (activated). The same morphological 
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phenotypes could be observed in HD patient microglia-like cells (right), and examples are 
indicated with yellow arrows and labelled. Images were taken with 40× (top, right) and 20× 
(bottom, right) objectives. Literature source: Investigative Ophthalmology & Visual Science, 
Volume 40, Issue 13, Pages 3186-3193, ‘Retinal microglia differentially express phenotypic 
markers of antigen-presenting cells in vitro’ (Matsubara et al. 1999). C) A morphological 
comparison of human microglia following treatment with Aβ or vehicle (left). Vehicle-treated: 
ramified cells. Aβ-treated: change in morphology, white arrows highlight microglia 
demonstrating amoeboid and vacuole formation responses. The same morphological 
phenotypes could be observed in HD patient microglia-like cells (right), as well as granular 
formations, and examples are indicated with yellow arrows and labelled. Images were taken 
with a 40× objective. Literature source: Journal of Leukocyte Biology, Volume 79, Issue 3, 
Pages 596-610, ‘Gene expression changes by amyloid beta peptide-stimulated human post-
mortem brain microglia identify activation of multiple inflammatory processes’ (Walker et al. 
2006). D) When microglia populate the CNS during development, they undergo pronounced 
morphological changes, from amoeboid immature cells to the typical ramified microglia 
observed throughout the brain parenchyma. These changes are depicted as illustrations (top). 
Similar morphological phenotypes could be observed in HD patient microglia-like cells (bottom), 
and examples are indicated with yellow arrows. Images were taken with 40× (top, left; top, right; 
bottom, right) and 20× (bottom, left) objectives. Literature source: Philosophical Transactions of 
the Royal Society of London. Series B, Biological Sciences, Volume 369, Issue 1654, Page 
20130593, ‘Fine-tuning the central nervous system: microglial modelling of cells and synapses’ 
(Xavier et al. 2014). E) HD patient microglia-like cells were observed to send out long, mobile 
processes which appeared to actively and physically survey their local environment (top, left), 
and in many cases made direct physical contact with cell bodies and processes of neighbouring 
cells (top, right). Such cell-to-cell physical interaction has been reported in the literature 
between microglia and neurons, where activated microglial cells have been observed to kill 
dying neurons by direct contact (bottom, left). A similar example was observed between two HD 
patient microglia-like cells where direct contact appeared to exist via a tubule (bottom, right). 
Images were taken with 40× (top, left; bottom, right) and 20× (top, right) objectives. Bottom, left 
fluorescence microscope image of stimulated (1 µg/mL LPS) BV2 microglial cell killing a dying 
MN9D dopaminergic neuron in co-culture by direct contact is an unpublished image owned by, 
and printed with permission from, Hajji Nabil, Lecturer in cancer and epigenetics, Imperial 
College London Hammersmith Campus. The image relates to sources in the literature from 
Nature, Volume 472, Issue 7343, Pages 319-324, ‘Caspase signalling controls microglia 
activation and neurotoxicity’ (Burguillos et al. 2011a) and Neurobiology of Disease, Volume 41, 
Issue 1, Pages 177-188,, ‘Apoptosis-inducing factor mediates dopaminergic cell death in 
response to LPS-induced inflammatory stimulus: evidence in Parkinson's disease patients’ 
(Burguillos et al. 2011b). F) Active phenomenon similar to development of microglial nodules 
observed in HD patient microglia-like cell cultures. Nodule regions labelled on top micrograph, 
and cell morphological phenotypes within each region are indicated in bottom micrographs. 
Images were taken with 4× (top) and 10× (bottom) objectives. 
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BMD-microglia-like cell cultures were then characterised as a model of microglia by 
their expression of specific markers. Monocytes were isolated from healthy volunteers 
and manifest HD patients and differentiated into microglia-like cells. Microglia-like cells 
were then stimulated with 2 µg/mL LPS and 10 ng/mL IFNү for 24 h. ICC was 
performed on healthy volunteer monocytes, microglia-like cells and stimulated 
microglia-like cells with antibodies directed at CD11b, CD14, ionized calcium-binding 
adapter molecule 1 (Iba1), mannose receptor (CD206) or TREM2. N2a_R2 cells were 
also used as a negative control for these microglial characterisation markers. N2a_R2 
had been genomically screened by Dr. Peter C. Klöhn (MRC Prion Unit, IoN, London, 
UK) and were found to not express the tested markers (CD11b, CD14, Iba1 and 
CD206), or to express them at very low levels (TREM2). Western blotting was 
performed on non-stimulated and stimulated healthy volunteer and manifest HD patient 
microglia-like cell culture lysates with antibodies directed at CD68, CSF1R, CX3CR1, 
Iba1, P2Y12 or PU.1. 
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Figure 3.23: Expression of microglial markers in microglia-like cell cultures  
A) Confocal fluorescence microscope images of monocytes isolated from healthy volunteers 
(HV), microglia-like cells differentiated from healthy volunteer monocytes in culture, microglia-
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like cells stimulated with 2 µg/mL LPS and 10 ng/mL IFNү for 24 h and N2a_R2 (negative 
control) cells. ICC was performed with antibodies directed at CD11b, CD14, Iba1, mannose 
receptor (CD206) or TREM2 (green). Nuclei were stained with DAPI (blue). Some microglia-like 
cells were probed with fluorophore-conjugated secondary antibodies only (top panels) to control 
for background signal. Images are representative examples from at least five fields of view from 
at least two independent cultures from at least two different individual donors. Images in each 
column are of myeloid cells from the same donor. Scale bars = 50 µm. B) Western blot 
membrane scans of non-stimulated and stimulated (2 µg/mL LPS and 10 ng/mL IFNү for 24 h) 
BMD-microglia-like cell lysates from three independent healthy volunteer (HV) and three 
independent manifest HD patient blood donors per blot. Blots were probed with antibodies 
directed at CD68, CSF1R, CX3CR1, Iba1, P2Y12 or PU.1, and β-actin (loading control), and 
secondary IRDye-conjugated secondary antibodies were detected by scanning with a LI-COR 
Odyssey scanner. Proteins were sized against BioRad Precision Plus All Blue protein 
standards. 
ICC with confocal fluorescence microscopy (Figure 3.23; A) showed that monocytes 
expressed the markers CD11b, CD14 and Iba1. Upon differentiation into microglia-like 
cells, expression of CD14 was decreased while CD11b and Iba1 expression was 
increased, marking differentiation into mature macrophages/microglia. CD11b and Iba1 
expression was further increased in response to stimulation, which represents 
microglial activation. Monocytes did not express mannose receptor or TREM2, and 
expression of these markers was induced upon differentiation into microglia-like cells. 
In the microglial-like cells, mannose receptor expression was strong in both non-
stimulated and stimulated conditions, confirming that these cells were both mature and 
polarised towards an M2 phenotype. TREM2 expression was high in non-stimulated 
microglia-like cells and decreased after stimulation, in accordance with its role (along 
with DAP12) in regulating microglial activation state. Western blots of BMD-microglia-
like cell lysates (Figure 3.23; B) showed expression of microglial markers CD68, 
CSF1R, CX3CR1, Iba1, P2Y12 and PU.1 in both healthy volunteer and manifest HD 
patient cultures and in both stimulated and non-stimulated conditions.  
Taking into account both the expression of key microglial markers (CD11b, CD68, 
CSF1R, CX3CR1, Iba1, mannose receptor, P2Y12, PU.1 and TREM2; Figure 3.23), 
and the microglia-specific morphological phenotypes exhibited by these cells (presence 
of all microglial morphological forms: small, round and activated, amoeboid, polarised, 
ramified with several short processes, highly ramified with very long processes; sub-
cellular granule and vacuole formations indicative of phagocytic functions; process 
motility and cell-to-cell contact via processes and tubules; microglial nodule formations; 
polarised migration towards sites of activity; Figure 3.22), it was determined that the 
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microglia-like cultures were more similar to human microglia than to human peripheral 
tissue macrophages, and were henceforth referred to as BMD-microglia. 
3.5.5 Development of human HD neuronal-myeloid cell co-culture models 
With the aim of investigating neuronal-myeloid cell interactions in the pathogenesis of 
HD, co-culture models were developed. ReNcell VM+HTT exon 1 or ReNcell VM+full-
length HTT neuronal cell cultures were co-cultured with BMD-macrophages or BMD-
microglia differentiated from monocytes isolated from healthy volunteers, pre-manifest 
HD gene carriers or manifest HD patients, as outlined in Table 3.5.  
Table 3.5: Neurons and myeloid cells to be used in co-culture 
Neurons Myeloid cells 
ReNcell VM+HTT exon 1 neuronal cultures 
BMD-macrophages 
Neuronal cell line HTT exon 1 genotype 
ReNcell VM 
+HTT exon 1 (29 CAG) 
Normal, over-expressing Healthy volunteers 
ReNcell VM 
+mHTT exon 1 (71 CAG) 
Expanded, HD, over-
expressing 
Pre-manifest HD 
gene carriers 
ReNcell VM 
+mHTT exon 1 (129 CAG) 
Highly expanded, HD, over-
expressing 
Manifest HD patients
ReNcell VM 
+eGFP reporter only 
Normal, control BMD-microglia 
ReNcell VM+full-length HTT neuronal cultures 
Healthy volunteers 
Neuronal cell line Full-length HTT genotype 
Wild-type ReNcell VM Normal 
Pre-manifest HD 
gene carriers  
ReNcell VM+full-length 
mHTT (138 CAG) C8 
Highly expanded, HD, over-
expressing 
Manifest HD patients
Details on the classification of primary human myeloid cells can be found in section 2.1.2.1. 
Three different co-culture paradigms were trialled, with the aim of assessing relevant 
aspects of neuronal-myeloid cell communication: co-culture by conditioned medium 
transfer, to assess the effects of factors released from one cell-type on the phenotype 
of the other; co-culture by medium shared concurrently, for examination of cross-
communication between both cell-types; and co-culture by direct physical contact, to 
determine the effects of direct cell-to-cell interactions.  
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3.5.5.1 Co-culture media titrations 
In all three co-culture paradigms to be trialled, it was necessary for both cell-types to be 
cultured in the same medium, and therefore an optimised culture medium which was 
compatible for both cell-types was required. To achieve this, culture medium titrations 
were performed using standard neuronal culture medium (NM; Appendix I-v) and 
standard BMD-macrophage culture medium (RPMI/FBS; Appendix I-iv; without GM-
CSF differentiation induction factor) in 10 DD wild-type ReNcell VM neuronal cultures 
(spontaneous differentiation) and healthy volunteer BMD-macrophages. Neurons and 
BMD-macrophages were given a medium change into a range of combination media 
titrations from 100 % NM to 100 % RPMI/FBS and maintained in culture for up to 7 
days. To determine any confounding effects of combination culture media, cytotoxicity 
was assessed by ATP cell viability assay, PI viable cell exclusion and LDH cytotoxicity 
assay. Cultures were also monitored daily by live-cell phase-contrast microscopy. 
ATP cell viability assay showed neuronal and BMD-macrophage viability to be variable 
across media titration conditions, but these changes were not consistent with a dose-
response effect (Figure 3.24; A). Viability measurements were also higher for media 
combination conditions than for control standard culture medium for both cell-types, 
suggesting that neither neurons or BMD-macrophages were adversely affected by 
culture in combination media. PI viable cell exclusion and LDH cytotoxicity assay 
showed that neurons cultured in 100 % RPMI/FBS culture medium for 4 days did not 
have significantly different death levels compared with neurons cultured in 100 % NM 
(Figure 3.24; B and C). All cell cultures were observed to appear healthy in all 
conditions for up to 7 days culture in combination medium. Neuronal culture 
morphology was not observed to be particularly affected by any of the media titrations, 
however BMD-macrophage morphology was significantly altered by increasing 
titrations of NM (Figure 3.24; D). Surprisingly, BMD-macrophages appeared to 
transform into microglia-like cells. These cultures were later characterised as a model 
of microglia with further in-depth morphological and phenotypic analysis (section 
3.5.4.2; above), and subsequently referred to as BMD-microglia. As none of the media 
titrations were found to reduce neuronal or BMD-macrophage viability, co-culture 
paradigms were developed using 100 % RPMI/FBS culture medium for neuronal-BMD-
macrophage co-cultures and 100 % NM for neuronal-BMD-microglia co-cultures. 
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Figure 3.24: Co-culture media titrations  
Co-culture NM-RPMI/FBS combination media titrations in healthy volunteer BMD-macrophages 
and 10 DD wild-type ReNcell VM neuronal cultures (spontaneous differentiation). A) ATP cell 
viability assay at day 4 culture in combination media. Combination medium cell culture viability 
expressed relative to standard culture medium cell viability (100 % NM for neurons and 0 % NM 
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(100 % RPMI/FBS) for BMD-macrophages; marked with dashed, purple line). B) Percentage 
dead cells measured by PI viable cell exclusion in neurons following 4 days culture in 100 % 
NM or 100 % RPMI/FBS. Bars = mean average percentage PI-stained cells from three 
independent neuronal cultures per condition; error bars = ± SEM. Statistically analysed using 
two-tailed, unpaired t test: p=0.454 (not significant). C) LDH cytotoxicity assay of neurons 
cultured in 100 % NM or 100 % RPMI/FBS for 4 days. Neuronal death levels presented as 
absorbance (ABS) at 490 nm, a direct measurement of red formazan product of the LDH assay 
(3 internal assay replicates; media background subtracted). Bars = mean average ABS from 
three independent neuronal cultures per condition; error bars = ± SEM. Statistically analysed 
using two-tailed, unpaired t test: p=0.479 (not significant). D) Live-cell phase-contrast 
micrographs of neurons and BMD-macrophages following 3 days culture in combination media. 
A-D analyses were performed on different cell cultures in separate, independent media titration 
experiments. Each experiment included 3 replicate cell cultures per condition.  
3.5.5.2 Co-culture by conditioned medium transfer and stimulation paradigms 
Procedures for co-culture by conditioned medium transfer are described in detail in 
sections 2.1.5.1 and 2.1.5.2.  
Fourteen DD wild-type ReNcell VM neuronal cultures were treated, in duplicate, at 1:1 
with Mφ-CM from non-stimulated healthy volunteer, pre-manifest HD or manifest HD 
BMD-macrophages and RPMI/FBS culture medium, for 4 days. BMD-macrophages 
were at 7 DIV and had been allowed to condition the culture medium for 4 days. 
Neuronal survival and morphology was observed daily by phase-contrast microscopy 
and at day 4 cultures were assessed by PI viable cell exclusion and LDH cytotoxicity 
assay to measure neurotoxicity. Final protein concentration was determined by BioRad 
Bradford Assay as a crude measure of overall survival and cell number. 
No obvious differences were observed in neuronal cell density or morphology in any of 
the conditions over the 4-day treatment with conditioned medium. PI viable cell 
exclusion and LDH cytotoxicity assay did not reveal any significant differences in 
neuronal cell death following any Mφ-CM treatments compared with RPMI/FBS culture 
medium alone, or between healthy volunteer and HD patient Mφ-CM treatments 
(Figure 3.25; A). Overall, there was an observed trend for a decrease in neuronal death 
and an increase in total protein concentrations (Figure 3.25; B) following treatment with 
healthy volunteer or HD patient Mφ-CM, compared with RPMI/FBS culture medium 
alone. It is therefore possible that Mφ-CM from non-stimulated BMD-macrophages is 
neuroprotective. 
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Figure 3.25: Neuronal-BMD-macrophage co-culture by conditioned medium 
transfer  
A) Cell death levels in 14 DD (spontaneous differentiation) wild-type ReNcell VM neuronal 
cultures treated for 4 days, in duplicate, with Mφ-CM from non-stimulated healthy volunteer (HV; 
n=3), pre-manifest HD (preHD; n=1) or manifest HD (manHD; n=4) BMD-macrophages, or 
RPMI/FBS culture medium only. Mφ-CM treatments were 1:1 with fresh RPMI/FBS culture 
medium. Cell death was measured by PI viable cell exclusion (left) and LDH cytotoxicity assay 
(right). Cell death levels are presented as mean average percentage PI-stained cells from six 
random fields of view or mean average absorbance (ABS) at 490 nm of red formazan product 
from LDH assay (3 internal assay replicates per condition; media background subtracted), ± 
SEM. Data were statistically analysed using one-way ANOVA (excluding pre-manifest HD which 
had an n of 1) which returned a p value of 0.451 (not significant) for PI viable cell exclusion and 
0.377 (not significant) for LDH cytotoxicity assay. B) Protein levels in 14 DD wild-type ReNcell 
VM neuronal cultures treated for 4 days, in duplicate, with Mφ-CM from non-stimulated healthy 
volunteer (HV; n=2) or manifest HD (manHD; n=2) at 1:1 with fresh RPMI/FBS culture medium, 
or RPMI/FBS culture medium only. Protein levels were measured by Bio-Rad Protein Assay in 
neuronal cell lysates and presented as mean average protein concentration ± SEM. 
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The same paradigm was then tested for neuronal-BMD-microglia co-culture. Ten DD 
wild-type ReNcell VM neuronal cultures were treated directly, in duplicate, with MG-CM 
from non-stimulated healthy volunteer or manifest HD BMD-microglia, for 4 days. BMD-
microglia were at 11 DIV and had been allowed to condition the culture medium for 4 
days. As Mφ-CM treatment had shown a trend for decreased neuronal death in 
neuronal-BMD-macrophage co-cultures, an additional conditioned medium treatment 
was added to control for conditioned medium in general i.e. non-myeloid cell-specific 
neuroprotective factors. This control treatment was neuronal conditioned medium (N-
CM): NM which had been transferred from wild-type 14 DD ReNcell VM neuronal 
cultures after 4 days of conditioning. Following 4 days treatment with MG-CM or N-CM, 
neuronal death was assessed by PI viable cell exclusion and LDH cytotoxicity assay 
(Figure 3.26).  
 
Figure 3.26: Neuronal-BMD-microglia co-culture by conditioned medium 
transfer  
Ten DD (spontaneous differentiation) wild-type ReNcell VM neuronal cultures were treated 
directly for 4 days, in duplicate, with MG-CM from non-stimulated healthy volunteer (HV; n=3) or 
manifest HD (manHD; n=3) BMD-microglia, or in triplicate with N-CM or NM only. Neuronal 
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death was assessed by PI viable cell exclusion (A) and LDH cytotoxicity assay (B). Neuronal 
death levels are presented as mean average percentage PI-stained cells from 10 random fields 
of view per culture (method representative example image shown in panel A, right (manifest HD 
MG-CM-treated neuronal culture); arrows highlight PI-stained nuclei; scale bars = 50 µm) or 
mean average percentage neuronal death (calculated as described in section 2.6.1 with total 
LDH calculated from 3 untreated neuronal cultures), ± SEM. Data were statistically analysed 
using one-way ANOVA which returned a p value of 0.385 (not significant) for PI viable cell 
exclusion and 0.002 (significant) for LDH cytotoxicity assay. Tukey post-hoc analysis results are 
presented as *p<0.05, **p<0.01. 
PI viable cell exclusion showed cell death levels to be very low in all conditions, and 
there were no significant differences in cell death levels detected in neuronal cultures 
treated with healthy volunteer or HD patient MG-CM compared with neurons cultured in 
NM alone (Figure 3.26; A). This method of measuring cytotoxicity does not account for 
cells which have already undergone complete lysis, apoptosis or necrosis, which may 
explain the extremely low cell death levels measured. PI viable cell exclusion may 
therefore be more appropriate for measuring cell death under acute conditions 
(minutes to hours) rather than over days as was tested in this case. LDH cytotoxicity 
assay revealed a significant effect of healthy volunteer (p<0.05) or manifest HD 
(p<0.01) MG-CM treatment on reducing neuronal death, compared with culture in NM 
alone (Figure 3.26; B). N-CM treatment did not affect percentage neuronal death, 
indicating that MG-CM-induced reduction in neuronal death was a BMD-microglia-
specific effect, and not due to the medium being conditioned in general. There were no 
significant differences between healthy volunteer and HD patient MG-CM treatments. 
Overall, these results suggest that in non-stimulated conditions, both healthy 
volunteers and manifest HD patients BMD-microglia release factors which are 
neuroprotective in co-culture with wild-type neurons. 
LPS/IFNү co-stimulation paradigms were then developed to induce acute or chronic 
inflammatory phenotypes in healthy volunteer and HD patient BMD-macrophages or 
BMD-microglia. To assess the effects of HD myeloid cell hyper-reactivity on 
neurotoxicity, these acute and chronic co-stimulation paradigms were applied to 
neuronal-myeloid cell co-cultures. The procedures for acute or chronic stimulation of 
myeloid cells with LPS and IFNү are described in detail in section 2.1.3.2. Briefly, the 
acute stimulation paradigm involved a pulse stimulation of healthy volunteer and HD 
patient myeloid cells with LPS and IFNү for 1 h, followed by a fresh culture medium 
change. Conditioned medium was then collected at various time-points after the 
medium change and used to treat neurons in co-culture. Chronic stimulation was 
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continuous stimulation of the myeloid cells with LPS and IFNү with collection of 
conditioned medium over a range of time-points from 1 to 48 h.  
A range of LPS stimulation concentrations (10 -1000 ng/mL) were tested in healthy 
volunteer, pre-manifest HD and manifest HD BMD-macrophages. BMD-macrophages 
were stimulated with LPS at each of the concentrations, in duplicate, for 24 h. 
Conditioned medium was then collected (chronic stimulation Mφ-CM) and cells were 
given a fresh culture medium change (no LPS) and returned to the incubator for a 
further 24 h. Conditioned medium was collected again after this 24 h rest period 
(chronic stimulation + rest Mφ-CM). Healthy volunteer, pre-manifest HD and manifest 
HD Mφ-CM was then used to treat 21 DD wild-type ReNcell VM neuronal cultures, in 
duplicate, for 4 days, and neurotoxicity was measured by LDH cytotoxicity assay. 
All Mφ-CM treatment conditions resulted in decreased neuronal death levels compared 
with untreated (neurons cultured in RPMI/FBS alone) (Figure 3.27), suggesting that 
healthy volunteer, pre-manifest HD and manifest HD Mφ-CM is neuroprotective in 
chronically-stimulated conditions as well as non-stimulated conditions (0 ng/mL LPS-
stimulation). Following treatment with chronic stimulation Mφ-CM, LPS concentration 
was a significant source of variation in percentage neuronal death (p<0.001) (Figure 
3.27; top). LPS concentration was not a significant source of variation in chronic 
stimulation + rest Mφ-CM conditions (p>0.05) (Figure 3.27; bottom), and this was most 
likely due to alterations in the activation state of BMD-macrophages back to a baseline, 
resting state during the 24 h rest period. As this was preliminary data, with a biological 
n of 1 per subject group, no conclusions could be drawn relating to subject group 
comparisons. It was noted, however, that the highest LPS concentration tested, 1 
µg/mL, showed potential for detecting differences between healthy volunteer and HD 
patient Mφ-CM-effects on neuronal death. 
Human neuronal-myeloid cell co-culture models of HD 
203 
 
 
Figure 3.27: Neuronal death levels after treatment with Mφ-CM from BMD-
macrophages stimulated with a range of LPS concentrations  
Twenty-one DD (spontaneous differentiation) wild-type ReNcell VM neuronal cultures were 
treated, in duplicate, for 4 days with Mφ-CM from healthy volunteers (HV; n=1), pre-manifest 
HD (preHD; n=1) or manifest HD (manHD; n=1) BMD-macrophages stimulated with 0, 10, 100, 
500 or 1000 ng/mL LPS, in duplicate. BMD-macrophages were stimulated for 24 h (chronic 
stimulation Mφ-CM; top) or were stimulated for 24 h followed by 24 h rest (chronic stimulation + 
rest Mφ-CM; bottom). Neurotoxicity was measured by LDH cytotoxicity assay and results are 
presented as mean average percentage neuronal death (calculated as described in section 
2.6.1 with total LDH calculated from 3 neuronal cultures in RPMI/FBS culture medium only 
(untreated)) ± SEM. Percentage cell death of untreated neuronal cultures is marked with purple, 
dashed lines. Data were statistically analysed using two-way ANOVA which found the variation 
in LPS concentration to be a significant source of variation for chronic stimulation Mφ-CM 
(p<0.001) but not in chronic stimulation + rest Mφ-CM (p=0.167).  
In chronic LPS/IFNү stimulation paradigms (without rest), it was possible that LPS may 
still be present as an active stimulus in myeloid cell conditioned medium post-
processing, and consequently may have direct effects on neuronal cultures. ReNcell 
VM neuronal cultures contain a sub-population of astrocytes which are likely to express 
TLR4, the LPS receptor (Trudler et al. 2010). Neurons have also been reported to 
express TLR4 (Leow-Dyke et al. 2012). IFNү concentration in conditioned medium may 
also be higher due to presence of the original stimulus. In order to determine the direct 
effects of LPS and IFNү on cell death in neuronal cultures, 10 DD wild-type ReNcell 
VM and ReNcell VM+full-length mHTT (138 CAG) neuronal cultures were treated 
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directly with the highest stimulus concentrations of LPS (2 µg/mL) and IFNү (10 
ng/mL), alone or in combination, for 24 h. Percentage cell death in neuronal cultures 
was then determined by LDH cytotoxicity assay. 
 
 Figure 3.28: Direct treatment of wild-type and HD neurons with LPS and IFNү 
Ten DD (spontaneous differentiation) wild-type ReNcell VM or ReNcell VM+full-length mHTT 
(138 CAG) C8 neuronal cultures were treated directly, in duplicate, with 2 µg/mL LPS and 10 
ng/mL IFNү, alone or in combination, or received no treatment, for 24 h. Percentage cell death 
in neuronal cultures was determined by LDH cytotoxicity assay and is presented as mean 
average percentage cell death (calculated as described in section 2.6.1) of three independent 
biological repeats ± SEM. Data were statistically analysed using two-way ANOVA and neither 
treatment condition (p=0.997) or neuronal cell line (p= 0.869) were found to be significant 
sources of variation. 
None of the stimulation treatments were found to have a significant effect on cell death 
compared with untreated in either wild-type or HD (full-length mHTT (138 CAG)) 
ReNcell VM neuronal cultures (Figure 3.28). There were also no significant differences 
in cell death between wild-type and HD neuronal cultures in untreated or treated 
conditions. This indicates that any differences in neuronal cell death detected following 
treatment with myeloid cell conditioned media are due to factors released by the 
myeloid cells and not due to direct effects of LPS and IFNү. LPS and IFNү are not 
directly toxic to wild-type or HD neurons in culture. 
Finally, an alternative stimulation paradigm was trialled as a crude model of CNS injury. 
Wild-type mature neuronal cultures (21 DD by spontaneous differentiation) were 
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subjected to physical damage by rapid shaking (400 rpm on a shaking platform for 10 
min). Supernatants, containing visible floating cell debris, were then collected from the 
neuronal cultures. Healthy volunteer and pre-manifest HD BMD-macrophages were 
stimulated, in duplicate, with these supernatants at 1:1 with fresh RPMI/FBS, for 24 h. 
Non-stimulated conditions were RPMI/FBS only or 1:1 NM:RPMI/FBS to control for the 
media composition of the stimulated condition. Mφ-CM (stimulation Mφ-CM) was then 
collected, processed and stored as per the usual protocol (section 2.1.5.1), including a 
centrifugation step to spin-out cell debris from the conditioned medium. BMD-
macrophages were changed into fresh culture medium and cultured for a further 24 h 
before collecting Mφ-CM again (stimulation + rest Mφ-CM). Mφ-CM was then used to 
treat wild-type neuronal cultures for 4 days, and LDH cytotoxicity assays were 
performed to assess percentage cell death in neuronal cultures. 
 
Figure 3.29: Neuronal death levels after treatment with Mφ-CM from BMD-
macrophages stimulated with damaged neurons 
Twenty-one DD (spontaneous differentiation) wild-type ReNcell VM neuronal cultures were 
treated, at least in triplicate, for 4 days with Mφ-CM from healthy volunteer (HV; n=1) or pre-
manifest HD (preHD; n=1) BMD-macrophages, or were cultured in RPMI/FBS only (untreated). 
Mφ-CM was prepared from BMD-macrophages which had been stimulated with damaged 
neurons (stimulated), or cultured in R10/FBS medium or NM:RPMI/FBS culture medium (non-
stimulated), for 24 h (stimulation Mφ-CM; left) or had received the same treatment followed by a 
24 h rest period (stimulation + rest Mφ-CM; right). Neurotoxicity was measured by LDH 
cytotoxicity assay and results are presented as mean average percentage neuronal death 
(calculated as described in section 2.6.1 with total LDH calculated from 3 untreated neuronal 
cultures) ± SEM. Percentage cell death of untreated neuronal cultures is marked by purple, 
dashed lines.  
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Preliminary data showed that treatment of neuronal cultures with Mφ-CM prepared 
from BMD-macrophages stimulated with damaged neurons did not alter percentage 
cell death compared with non-stimulated Mφ-CM in the same media composition 
(NM:RPMI/FBS) (Figure 3.29). There were, however, differences detected between the 
effects of healthy volunteer and pre-manifest HD Mφ-CM on neuronal death. When 
BMD-macrophages had been cultured in NM:RPMI/FBS media (stimulated or non-
stimulated), pre-manifest HD Mφ-CM treatment resulted in increased neuronal death 
compared with healthy volunteer Mφ-CM treatment in both stimulation Mφ-CM and 
stimulation + rest Mφ-CM conditions. Additionally, in the stimulation + rest condition, 
healthy volunteer Mφ-CM reduced neuronal death below baseline levels (untreated 
neurons) and pre-manifest HD Mφ-CM increased neuronal death above baseline 
levels. This suggests that in this model healthy volunteer Mφ-CM was neuroprotective 
and pre-manifest HD Mφ-CM was neurotoxic. With a biological n of 1, however, no final 
conclusions were drawn from these results involving subject group comparisons.  
3.5.5.3 Co-culture by medium shared concurrently 
Procedures for co-culture by medium shared concurrently are described in detail in 
section 2.1.5.3.  
Wild-type ReNcell VM NSCs and healthy volunteer or manifest HD monocytes were 
seeded on coverslips and differentiated into 11 DD neurons (spontaneous 
differentiation) or BMD-macrophages, respectively. One coverslip of each cell-type 
(one neuronal culture and one healthy volunteer or manifest HD BMD-macrophage 
culture) was then transferred into one well of a 6-well plate and cultured simultaneously 
in RPMI/FBS culture medium for 3 days. Co-cultures were monitored daily by live-cell 
phase-contrast microscopy, and at day 3 coverslips were removed from co-culture and 
analysed independently by ATP cell viability assay. 
Phase-contrast microscopy at 3 days in co-culture revealed that manifest HD BMD-
macrophages appeared much healthier than healthy volunteer BMD-macrophages 
(Figure 3.30; A). Manifest HD BMD-macrophages had proliferated and fried-egg like 
morphology was maintained, while healthy volunteer BMD-macrophages had become 
small, round and activated and the majority of cells had subsequently died. Neuronal 
cultures appeared to be unaffected in co-culture with manifest HD BMD-macrophages, 
however in co-culture with healthy volunteer BMD-macrophages one of the neuronal 
cultures was adversely affected as can be seen in Figure 3.30; A, HV #2 co-culture. 
ATP cell viability assay of neuronal and BMD-macrophage cultures showed that 
neuronal viability was not affected by co-culture with healthy volunteer or manifest HD 
BMD-macrophages in this model (Figure 3.30; B, left). Manifest HD BMD-macrophage 
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viability was slightly higher than healthy volunteer BMD-macrophage viability following 
co-culture with neurons (Figure 3.30; B, right), however BMD-macrophage viability was 
highly variable overall resulting in a large SEM. 
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Figure 3.30: Analysis of neuronal-BMD-macrophage co-culture by medium 
shared concurrently 
Eleven DD (spontaneous differentiation) wild-type ReNcell VM neurons and healthy volunteer 
(HV; n=2) or manifest HD (manHD; n=2) BMD-macrophages were cultured on coverslips and 
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combined in co-culture with shared culture medium (RPMI/FBS). Each co-culture combination 
was tested in duplicate. A) Phase-contrast micrographs of neurons (left) and BMD-
macrophages (right) after 3 days in co-culture. Representative images of each individual co-
culture are presented, including 2 healthy volunteer and 2 manifest HD co-cultures with BMD-
macrophages differentiated from monocytes isolated from 2 independent healthy volunteers 
(HV #1 and HV #2) and 2 independent manifest HD patients (manHD #1 and manHD #2) 
donors. B) Neuronal (left) and BMD-macrophage (right) viability after 3 days in co-culture as 
determined by ATP cell viability assay, presented as mean average luminescence in relative 
light units (RLU) per healthy volunteer or manifest HD co-culture ± SEM (luminescence is 
directly proportional to cell viability as a function of this assay). 
3.5.5.4 Co-culture by direct physical contact 
Procedures for co-culture by direct physical contact are described in detail in section 
2.1.5.4.  
Healthy volunteer (n=3) or manifest HD (n=3) BMD-microglia were added directly on 
top of 18 DD (induced differentiation) wild-type ReNcell VM neuronal cultures. The co-
cultures were then stimulated with 2 µg/mL LPS and 10 ng/mL IFNү, or received no 
treatment (non-stimulated), and were monitored by phase-contrast microscopy. In all 
conditions, the following observations were made with immediate effect: all BMD-
microglia transformed into small, round, activated cells and spread amongst the 
neurons, then large amounts of floating cell debris appeared and the neuronal cell 
layers lifted completely from the culture surface. It was concluded that this model of co-
culture by direct physical contact was not viable for assessment of neuronal-myeloid 
cell interactions due to the rapid destruction of the neuronal cell layer by BMD-
microglia.  
3.6 Discussion 
In order to investigate interactions between the CNS and innate immune system in the 
pathogenesis of HD, neuronal-myeloid cell co-culture models of HD were developed. 
Due to a lack of high-quality HD neuronal cell models which fully recapitulate relative 
aspects of the human condition, novel HD neuronal cell lines were generated. 
Additionally, a novel technique was discovered for the differentiation of primary human 
monocytes into microglia-like cells. 
3.6.1 Human neuronal cell models of HD 
3.6.1.1 ReNcell VM neuronal cultures 
NSC-derived ReNcell VM neuronal cultures have been well characterised in the 
literature as a good model of human neurons in vitro (Hoffrogge et al. 2006; Donato et 
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al. 2007; Wood-Kaczmar et al. 2008; Gandhi et al. 2009; Morgan et al. 2009; Choi et al. 
2014). In the first 7 DD using spontaneous differentiation or similar methods, ReNcell 
VM have been shown to display a large rearrangement of the proteome in a pattern 
consistent with differentiation into mature neuronal cultures (Hoffrogge et al. 2006). At 
14-29 DD, it has been reported that some neurons express functional Na+-channels 
and are electrophysiologically active, a phenomenon which occurs in a higher number 
of neurons if differentiation is induced rather than spontaneous (Donato et al. 2007).  
Here, morphological and expression analyses confirmed that using the spontaneous 
differentiation technique, ReNcell VM NSCs can be robustly differentiated into mature 
neuronal cultures with a high neuronal yield and a small astroglial sub-population. The 
neuronal cultures were also shown to express native HTT and display similar 
morphology and characteristics as reported by others (Donato et al. 2007; Wood-
Kaczmar et al. 2008; Gandhi et al. 2009; Choi et al. 2014). Induced differentiation 
increased the yield of specific neuronal sub-types within the mature cultures, including 
GABAergic and dopaminergic neurons, as was also reported by Wood-Kaczmar et al. 
(2008) and Gandhi et al. (2009). When considering the effects of inflammation on 
neurodegeneration, it is important to note that cell-to-cell interactions involving 
neurons, myeloid cells and astrocytes are necessary for the generation of 
neuropathogenesis in HD (Gu et al. 2005; Gu et al. 2007; Bradford et al. 2009; 
Bradford et al. 2010; Möller 2010; Crotti and Glass 2015). Astrocytes play important 
roles in the maintenance of a chronic feed-forward loop of chronic neuroinflammation 
as well as providing neurotrophic support to degenerating neurons (Saijo and Glass 
2011; Crotti and Glass 2015; Doty et al. 2015). Therefore, neuronal cultures containing 
a small population of astrocytes were considered to be optimum for modelling neural-
immune interactions in co-culture models of HD.  
As ReNcell VM neuronal cultures are a well-established model of human neurons in 
culture, and reported morphological and phenotypic characteristics had been 
confirmed, this cell line was taken forward for the development of HD neuronal cell 
lines to study neuronal-myeloid cell interactions in HD pathogenesis. With the aim of 
achieving mature cultures with a pan-neuronal phenotype, the spontaneous 
differentiation technique was generally preferred and was used in most experiments. 
Spontaneous differentiation to 21-49 days was also used by Choi and colleagues, who 
recently published the first human neuronal culture AD model to recapitulate Aβ and 
tau pathology (Choi et al. 2014). 
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3.6.1.2 HD neuronal cell lines expressing HTT exon 1 
Human neuronal cell models of HD were generated by lentiviral transduction of ReNcell 
VM NSCs with human HTT exon 1. Four different neuronal cell lines were developed: 
three expressing human HTT exon 1 with CAG repeats in the non-pathogenic range 
(ReNcell VM+HTT exon 1 (29 CAG)) or pathogenic range (ReNcell VM+mHTT exon 1 
(71 CAG) and ReNcell VM+mHTT exon 1 (129 CAG)) in addition to an eGFP reporter, 
and one control line expressing the eGFP reporter only. All transgenic neuronal cell 
lines could be differentiated into mature neuronal cultures with a high yield of βIII-
tubulin-positive neurons and some GFAP-positive astrocytes, and expression of normal 
or mHTT exon 1 trans-protein was confirmed in both NSC and mature neuronal 
cultures.  
The mHTT exon 1-expressing neuronal cultures presented with characteristics similar 
to human HD neurons in vivo; including fragmentation of mHTT, inclusions composed 
of mHTT aggregates and neurotoxicity caused by mHTT expression. N-terminal 
fragments smaller than exon 1 were detected only in ReNcell VM+mHTT exon 1 (129 
CAG) NSCs and neuronal cultures, which may be a result of post-translational 
proteolytic cleavage of the highly-expanded exon 1 fragment. N-terminal HTT 
fragments of this size have previously been detected in HD patient cells and not in 
healthy volunteer cells (Weiss et al. 2012). The shortest N-terminal fragments of 
mHTT, including an exon 1 only HTT protein, have also been demonstrated to 
accumulate into detergent-insoluble complexes which form cytoplasmic nuclear 
inclusion bodies, representing one of the neuropathological hallmarks of HD (Davies et 
al. 1997; DiFiglia et al. 1997; Landles et al. 2010). Intranuclear inclusions of mHTT 
were also detected in the HD neuronal cell lines (ReNcell VM+mHTT exon 1 (71 CAG) 
and ReNcell VM+mHTT exon 1 (129 CAG)) but not in non-HD neuronal cell lines (wild-
type ReNcell VM, ReNcell VM+HTT exon 1 (29 CAG) and ReNcell VM+eGFP reporter 
only). Mutant HTT aggregates were present in both NSCs and mature neuronal 
cultures, and interestingly were perinuclear or cytoplasmic in NSCs and intranuclear in 
mature neurons. It has previously been shown that expression of mHTT exon 1 protein 
fragment is sufficient to cause neuronal dysfunction and death (Mangiarini et al. 1996; 
Ross and Tabrizi 2011). The same was demonstrated here, where expression of mHTT 
exon 1 (71 CAG) in ReNcell VM resulted in higher neuronal culture death levels 
compared with expression of HTT exon 1 (29 CAG), indicating mHTT-induced 
neurotoxicity in this neuronal cell culture model of HD.  
Overall, it was demonstrated that these human NSC-derived HD neuronal cell lines 
over-expressing mHTT exon 1 recapitulate several features of neurons in the HD 
patient brain. They are an improvement on many currently available HD cell models 
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because they are human and neuronal, and they accurately represent the human 
disease like their primary human neuron counterparts whilst also being easily 
obtainable and useable on a large scale. Unlike iPSC-derived neurons, these neuronal 
cell lines can be robustly and reproducibly differentiated from NSCs into a high yield of 
mature HD neurons with isogenic controls. This can be conducted in a short time-frame 
and with minimal genetic heterogeneity and phenotypic variability between cell lines. 
Consequently, it is considered that ReNcell VM+mHTT exon 1 neuronal cell lines are a 
high-quality neuronal cell model of HD. 
3.6.1.3 HD neuronal cell lines expressing full-length HTT 
Human neuronal cell models of HD were generated by retroviral transduction of 
ReNcell VM NSCs with full-length human HTT cDNA. Two different neuronal cell lines 
were developed: one expressing full-length human HTT with 15 CAG repeats (non-
pathogenic range) and one expressing full-length human mHTT with 138 CAG repeats 
(pathogenic range). Both cell lines could be differentiated from NSCs into mature 
neuronal cultures expressing the full-length HTT trans-proteins. This model therefore 
provides evidence for successful introduction of full-length human HTT cDNA into the 
genomic DNA of a NSC line by means of retroviral delivery, as well as subsequent 
expression of the full-length HTT protein in differentiated neuronal cultures.  
Initial assessments of the HD neuronal cell line showed that expression of full-length 
mHTT (138 CAG) did not cause increased baseline cell death in neuronal cultures 
compared with wild-type neurons. However, due to time limitations, this cell model was 
not fully characterised; especially ReNcell VM+full-length HTT (15 CAG) which did not 
reach the final stages of verification after generation of clonal cell populations. In the 
interest of moving forward with the development of neuronal-myeloid cell co-culture 
models of HD, wild-type ReNcell VM were used in place of ReNcell VM+full-length HTT 
(15 CAG) as a non-HD neuronal culture alongside ReNcell VM+full-length mHTT (138 
CAG) HD neuronal cultures.  
Further work is required to complete the development and characterisation of this full-
length HTT neuronal cell model of HD. 
3.6.2 Primary human HD myeloid cells 
3.6.2.1 BMD-macrophages 
Differentiation of primary human monocytes into macrophages in vitro by GM-CSF 
induction promotes the development of macrophages with a proinflammatory M1-type 
phenotype. These BMD-macrophages have previously been shown to express several 
key macrophage markers including CD11b, CD11c, MHC class II human leukocyte 
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antigen (HLA)-DR and HLA-DQ, Fc (Fragment, crystallisable antibody region)ү 
receptors I and II and Scavenger Receptor type A; express important genes associated 
with the NFκB pathway; produce major macrophage-derived cytokines including IL-1β, 
IL-6, IL-8 and TNFα; and exhibit phagocytic and migratory activities (Akagawa et al. 
2006; Kwan et al. 2012b; Träger et al. 2014a). Monocytes differentiated in vitro into 
BMD-macrophages in this way are therefore considered to be a highly representative 
model of tissue macrophages in vivo.  
HD patient peripheral myeloid cells have previously been shown to express mHTT 
(Björkqvist et al. 2008; Weiss et al. 2012; Träger et al. 2014a), and likewise, HD patient 
BMD-macrophages were shown here to express mHTT. This has been demonstrated 
to lead to dysfunctional behaviours in these macrophages including aberrant NFκB 
signalling, increased release of proinflammatory cytokines and impaired migration 
(Kwan et al. 2012b; Träger et al. 2014a). HD patient BMD-macrophages have also 
been shown to be hyper-reactive in response to stimulation with LPS and IFNү (Träger 
et al. 2014a). As combined stimuli, LPS and IFNү recapitulate in vitro the 
neuroinflammatory milieu present in the degenerating HD brain, or the proinflammatory 
peripheral environment, and promote classical activation of BMD-macrophages. This 
leads to production of proinflammatory cytokines, iNOS and ROS; increased 
expression of MHC class II molecules and CD68; increased antigen presentation; and 
increased microbicidal activity (Gordon and Taylor 2005). 
Whilst mHTT-induced dysfunction of HD patient BMD-macrophages has already been 
well described, in both non-stimulated and stimulated (LPS and IFNү) conditions, the 
effects this has on neurodegeneration in the HD brain is not yet known. Therefore, HD 
patient BMD-macrophages were used in the development of various experimental co-
culture paradigms, with the HD neuronal cell models which had been generated, in 
order to examine these effects. 
3.6.2.2 BMD-microglia 
When performing media titrations for the development of neuronal-myeloid cell co-
culture models, it was discovered that the culture of BMD-macrophages in NM culture 
medium caused the morphological and phenotypic transformation of these 
macrophages into microglia-like cells (BMD-microglia). 
Microglia are derived by primitive haematopoiesis in the foetal yolk sac and seed CNS 
tissue during early embryogenesis (Ginhoux et al. 2010; Saijo and Glass 2011; 
Goldmann et al. 2016). The embryonic myeloid precursors are exposed to factors in 
CNS tissue which drive the expression of specific genes for differentiation into 
functionally specialised microglia (Saijo and Glass 2011; Lavin et al. 2015), and 
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throughout this process they undergo pronounced morphological changes; from 
amoeboid immature cells on CNS entry; to polarised, migrating cells; to proliferating, 
ramified cells with several short processes; and finally to the typical ramified microglia 
with long processes which are observed throughout the adult brain parenchyma (Xavier 
et al. 2014). Cells exhibiting each of these morphological transformations were present 
in HD BMD-microglia cultures, and this could be due to differentiation of these cells 
from peripheral BMD-macrophages into microglia-like cells following a switch to a CNS-
like environment by the change in culture medium. It is possible that the change in 
culture medium to NM triggered the induction of genes which drive differentiation into 
microglia. NM, for which the complete formulation can be found in Appendices I-v and 
I-vii, was developed by ReNeuron for the differentiation and maintenance of ReNcell 
VM prior to therapeutic surgical transplantation into the human brain, and is therefore 
optimised to replicate the environment of their destination. 
When peripheral macrophages are recruited to the brain following injury, they adopt a 
functional and morphological state similar to resident microglia due to an equal 
response to the same environmental stimuli (O’Koren et al. 2016). CNS-resident 
microglia and CNS-infiltrating macrophages have even been deemed morphologically 
and phenotypically indistinguishable (Enose et al. 2005; Schmid et al. 2009; Greter et 
al. 2015). Any heterogeneity in vivo is therefore likely to be dependent on cellular 
differentiation, tissue distribution and responses to endogenous and exogenous stimuli, 
rather than intrinsic differences (Schmid et al. 2009), in which case modelling of a pro-
neuronal micro-environment in vitro may promote a microglial phenotype in 
peripherally-derived myeloid cells. It is therefore possible that such microglial 
developmental transformation, or BMD-macrophage CNS-infiltration, has been 
modelled in these BMD-microglia cultures by maintaining them in NM. 
Other microglial morphological phenotypes observed in HD patient BMD-microglia 
cultures included active and dynamic surveying of the local environment via motile 
processes, direct physical contact between neighbouring cells via processes and 
tubules, formation of microglial nodules and polarised migration. A search of the 
literature did not reveal any reports of direct contact occurring between two microglia 
cells via their processes or tubule-like structures, however similar events have been 
reported to occur between microglia and neurons in the context of modulating neuronal 
activity (Wake et al. 2009; Tremblay et al. 2010; Li et al. 2012) or direct killing of 
damaged neurons (unpublished work presented by Hajji Nabil, Lecturer in cancer and 
epigenetics, Imperial College London Hammersmith Campus; Figure 3.22, E). 
Microglial nodules can exhibit both pro- and anti-inflammatory phenotypes, and their 
development is a phenomenon in viral encephalitis, traumatic brain injury, brain infarct, 
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and MS, where microglial nodules are associated with degenerating white matter 
(Singh et al. 2013). Microglial nodules are not found in the healthy CNS (Singh et al. 
2013). It was shown here that microglial nodules developed in BMD-microglia cultures 
differentiated from HD patient but not healthy volunteer monocytes, possibly occurring 
in response to cell-autonomous mHTT expression.  
Subcellular morphological phenotypes of microglia were also observed, including 
vacuole and granular formations. Such phenotypes have previously been shown to 
occur in microglial cells in response to neurodegenerative disease or CNS injury. 
Exposure of human post-mortem brain-derived microglia cultures to aggregated Aβ can 
induce a transformation into amoeboid, reactive cells which form vacuoles (Walker et 
al. 2006). In vivo, microglia in the human basal ganglia have been observed to 
transform into compound granular corpuscles which develop into large, round, 
amoeboid cells heavily loaded with lipoid, in response to CNS injury leading to general 
paralysis (Fleming 1930). These transformations are indicative of phagocytic activities 
and were found in the HD BMD-microglia cultures, possibly occurring as a result of cell-
autonomous mHTT expression.  
BMD-microglia also expressed several key microglial markers. Upon differentiation of 
monocytes into BMD-microglia, expression of CD14 was decreased while CD11b and 
Iba1 expression was increased, marking differentiation into mature 
macrophages/microglia. CD14 expression has previously been shown to be much 
higher in blood monocytes in brain vessels than in plaque-associated microglia in AD 
brains (Walker and Lue 2015). CD11b and Iba1 expression further increased in 
response to stimulation with LPS and IFNү. This has been shown previously to occur in 
microglia during neurodegenerative inflammation and nerve injury (Ito et al. 1998; Roy 
et al. 2006). Iba1 interacts with actin bundles and is involved with membrane ruffling 
and phagocytosis (Ito et al. 1998). Monocytes did not express mannose receptor or 
TREM2, and expression of these markers was induced upon differentiation into BMD-
microglia. Mannose receptor is a marker of alternatively activated (M2) macrophages 
and is expressed by mature brain-resident microglia (Gordon and Taylor 2005; 
Peferoen et al. 2015), while monocytes have no, or very low, expression of this marker. 
In BMD-microglia, mannose receptor expression was strong in both non-stimulated and 
stimulated conditions, confirming that these cells were both mature and polarised 
towards an M2 phenotype. Within the CNS, TREM2 is a PRR exclusively expressed by 
microglia (Lucin and Wyss-Coray 2009) and, along with its core molecular complex 
partner DAP12, is involved in the regulation of phagocytosis and the modulation of anti-
inflammatory responses through inhibition of TLR signalling (Doty et al. 2015; Lue et al. 
2015). TREM2/DAP12 is also involved in the maintenance of microglia in a quiescent, 
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unactivated state (Saijo and Glass 2011). In BMD-microglia cultures, TREM2 
expression was high in non-stimulated cells and decreased after stimulation, in 
accordance with its role in regulating microglial activation state. As a marker, TREM2 is 
also functionally similar to M2 anti-inflammatory receptors (Walker and Lue 2015), 
providing further support for the BMD-microglia being of M2 phenotype. 
BMD-microglia were also demonstrated to express the microglial markers CD68, 
CSF1R, CX3CR1, P2Y12 and PU.1 in both healthy volunteer and manifest HD cultures 
and in both stimulated and non-stimulated conditions. CD68 is a lysosomal protein 
which can be used to stain microglia (Graeber et al. 1990; Slepko and Levi 1996), and 
is indicative of phagocytic activity (Zotova et al. 2013). High levels of CD68 expression 
are associated with activated microglia, whilst low levels of expression are associated 
with quiescent, ramified microglia (Graeber et al. 1990; Slepko and Levi 1996; Kingham 
et al. 1999). Microglia differentiation and proliferation is initiated by CSF1 and its 
receptor CSF1R, CD34 and transcription factors PU.1, C/EBPs and AP1 (Saijo and 
Glass 2011). Microglial-like cells were shown here to express both CSF1R and PU.1, 
and PU.1 expression may be higher in HD patient BMD-microglia than healthy 
volunteer BMD-microglia. The expression of mHTT has previously been shown to 
confer a cell-autonomous increase in proinflammatory gene expression associated with 
increased expression and transcriptional activities of PU.1 in a rat microglial cell line 
(Crotti et al. 2014). Microglia in the striatum and cortex of HD patient brains were also 
shown to express elevated levels of PU.1 (Crotti et al. 2014). Expression of CSF1R has 
been shown to be upregulated in microglia in the brains of patients with AD and ALS 
(Akiyama et al. 1994), and several studies have classified CSF1R signalling as similar 
to M2 activation (Walker and Lue 2015). The chemokine fractalkine (CX3CL1) is 
expressed on the surface of neurons in the CNS, and is a unique ligand for its receptor 
CX3CR1, which is expressed by microglia in the CNS parenchyma. When CX3CL1 
activates CX3CR1 in models of inflammation, microglia are maintained in a non-
neurotoxic, quiescent state and basal microglial process dynamism, motility and 
surveillance activities are promoted (Eyo and Wu 2013). Finally, the membrane-bound 
purinergic receptor P2Y12 is a microglia-specific marker in the CNS which is selectively 
expressed on human ramified and amoeboid microglia and elevated under 
neuropathologic conditions which promote alternative activation (Moore et al. 2015; 
Satoh et al. 2016). Expression of this marker is absent, or much reduced, in 
perivascular BMD-macrophages and monocytes in the human brain (Moore et al. 2015; 
Satoh et al. 2016). P2Y12 maintains microglia in a highly ramified state (Haynes et al. 
2006) and mediates microglial process motility, polarisation, chemotaxis and migration 
(Honda et al. 2001; Moore et al. 2015; Satoh et al. 2016; Sipe et al. 2016).  
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Overall, characterisation of the BMD-microglia cultures by antigenic criteria revealed 
that the cells expressed several key microglial markers and were polarised towards an 
M2 alternatively activated phenotype with promotion of a ramified, surveying and 
quiescent phenotype. As the cells were originally differentiated from primary monocytes 
into macrophages by GM-CSF induction, which promotes the development of 
classically activated M1-type macrophages, this is evidence that the activation state of 
macrophages is highly dynamic and fully differentiated mature macrophages can 
switch from one polarisation to another. While several studies have reported certain 
expression markers to be microglia-specific (e.g. P2Y12), many others conclude that 
there is little evidence that such markers can distinguish between microglia and 
infiltrating peripherally-derived macrophages (Walker and Lue 2015). However, taking 
into account both the expression of key microglial markers (CD11b, CD68, CSF1R, 
CX3CR1, Iba1, mannose receptor, P2Y12, PU.1 and TREM2), and the microglia-
specific morphological phenotypes exhibited by these cells (presence of all microglial 
morphological forms: small, round and activated, amoeboid, polarised, ramified with 
several short processes, highly ramified with very long processes; sub-cellular granule 
and vacuole formations indicative of phagocytic functions; process motility and cell-to-
cell contact via processes and tubules; microglial nodule formations; and polarised 
migration towards sites of activity), it was determined that the BMD-microglia cultures 
were more similar to human microglia than to human peripheral tissue macrophages.  
BMD-microglia therefore represent a novel model of human microglia in culture. They 
are more similar to human microglia in vivo or ex vivo by morphological and antigenic 
criteria than currently available immortalised human microglial cell lines (Janabi et al. 
1995; Nagai et al. 2001), and unlike primary human microglia, they can be 
differentiated from an easily accessible and more available source. As HD patient 
peripheral myeloid cells express mHTT, this also represents a useful model for the 
study of microglial cell dysfunction and neuronal-microglial cell interactions, over the 
disease course, in primary HD patient cells. 
3.6.3 Neuronal-myeloid cell co-culture models of HD 
Three different neuronal-myeloid cell co-culture paradigms were trialled: co-culture by 
conditioned medium transfer, co-culture by medium shared concurrently, and co-
culture by direct physical contact. This was with the aim of developing co-culture 
models to analyse interactions between BMD-macrophages or BMD-microglia 
differentiated from monocytes isolated from healthy volunteers, pre-manifest HD gene 
carriers or manifest HD patients with wild-type, HTT exon 1 or full-length HTT ReNcell 
VM neuronal cultures. 
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The conditioned medium transfer co-culture model was developed with the aim of 
determining the effects of factors secreted by myeloid cells, in various stimulated and 
non-stimulated conditions, on neuronal phenotypes. This will allow for comparisons to 
be made between the effects of healthy volunteer and HD patient myeloid cells on 
normal and HD neuronal cultures. Preliminary results showed that wild-type neuronal 
cultures treated with conditioned medium from non-stimulated healthy volunteer or HD 
patient BMD-microglia had decreased cell death levels compared with untreated. Cell 
death levels were not reduced by treatment with medium conditioned by other neurons. 
This suggests that both healthy volunteer and HD patient BMD-microglia, specifically, 
release neuroprotective factors. There were no differences between the effects of 
healthy volunteer and HD patient BMD-microglia on neuronal death. 
To assess bi-directional communication between myeloid cells and neurons in HD, co-
culture models were developed where both cell types could share the same medium. 
This allows neuronal-myeloid cell interactions by secreted, soluble factors such as 
cytokines, chemokines, ROS and RNS. In this model, morphological assessment 
showed HD BMD-macrophages to survive better than healthy volunteer BMD-
macrophages in co-culture. Unlike the HD patient cultures, healthy volunteer BMD-
macrophages transformed into small, round, activated cells and subsequently died off. 
However, viability analysis of both neurons and BMD-macrophages in co-culture 
revealed large variability between cultures and no differences were found between 
healthy volunteer and HD patient neuronal or BMD-macrophage viability overall. 
In the CNS, microglia are dynamic cells which are free to migrate towards sites of 
neuronal injury. Microglia also make transient direct physical contact with neurons, 
functioning to support neuro-modulation during normal physiology (Eyo and Wu 2013; 
Heneka et al. 2014). Additionally, neurons suppress the activation of microglia through 
cell-to-cell contact (Saijo and Glass 2011). Following CNS injury or infection, ramified 
microglia may destroy damaged neurons by direct contact and phagocytic microglia 
clear neuronal debris and pathogens (Saijo and Glass 2011). Similar behaviours had 
also been observed here in HD patient BMD-microglia cultures. Therefore, in order to 
assess how these cell-to-cell interactions may be altered in HD, neuronal-BMD-
microglia co-culture models were trialled where both cell-types were able to come in 
direct contact with each other. However, when allowed to make direct physical contact, 
BMD-microglia damaged the neuronal cell layer so rapidly that little analysis could be 
performed in this model. This could possibly have occurred due to phagocytosis and 
digestion of the laminin-coating used to aid neuronal adherence to the culture surface. 
It was concluded that this co-culture model was not viable for assessment of neuronal-
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myeloid cell interactions due to the rapid destruction of the neuronal cell layer by BMD-
microglia.  
Co-stimulation with LPS and IFNү is a well-established method of inducing general 
activation in primary human myeloid cells (Ziegler et al. 1988; Cramer and Klemsz 
1997; Träger et al. 2014a; Björkqvist et al. 2008; Kelly and O’Neill 2015), and can also 
be used to model neuroinflammatory activation of microglia in neurodegenerative 
diseases: LPS is a PAMP, but activates TLR4 like several DAMPs associated with 
neurodegeneration and neurodegenerative disease (Saijo and Glass 2011; Amor et al. 
2014; Heneka et al. 2014; Doty et al. 2015); and IFNү is a proinflammatory cytokine 
which is upregulated in the brain and/or plasma of patients with ALS, HD and PD and is 
involved in the maintenance of chronic neuroinflammation (Nagatsu et al. 2000a; 
Björkqvist et al. 2008; Reale et al. 2009a; Wild et al. 2011; Ellrichmann et al. 2013; 
Doty et al. 2015). LPS/IFNү co-stimulation paradigms were therefore developed to 
induce acute or chronic inflammatory phenotypes in healthy volunteer and HD patient 
BMD-macrophages or BMD-microglia. HD myeloid cells have previously been 
demonstrated to be hyper-reactive in response to LPS and IFNү co-stimulation, and 
release elevated levels of proinflammatory cytokines compared with healthy volunteer 
myeloid cells (Björkqvist et al. 2008; Träger et al. 2014a). To assess the effects of HD 
myeloid cell hyper-reactivity on neurotoxicity, these acute and chronic co-stimulation 
paradigms were applied here to neuronal-myeloid cell co-cultures. BMD-macrophages 
stimulated with a range of LPS concentrations had differential effects on wild-type 
neuronal survival following conditioned medium transfer, as detected by LDH 
cytotoxicity assay, and the highest LPS concentration tested, 1 µg/mL, showed 
potential for detecting differences between the effects of healthy volunteer and HD 
patient Mφ-CM treatments on neuronal death. 
An alternative stimulation paradigm was trialled as a crude model of CNS injury, 
whereby wild-type mature neuronal cultures were subjected to physical damage by 
shaking, and were used to directly stimulate BMD-macrophages. Mφ-CM was then 
used to treat wild-type neurons. As observed in other co-culture paradigms, there was 
a general trend for decreased neuronal death following treatment with Mφ-CM, 
however, unlike LPS stimulation, stimulation with damaged neurons did not lead to an 
effect on neuronal survival compared with non-stimulated Mφ-CM. Interestingly though, 
there were differences detected between the effects of healthy volunteer and pre-
manifest HD Mφ-CM on neuronal survival. There was a trend for pre-manifest HD Mφ-
CM treatment resulting in increased neuronal death compared with healthy volunteer 
Mφ-CM treatment in stimulated and non-stimulated conditions. When stimulation was 
followed by a rest period, healthy volunteer Mφ-CM reduced neuronal death below 
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baseline levels (untreated neurons) and pre-manifest HD Mφ-CM increased neuronal 
death above baseline levels. This suggests that in this case healthy volunteer Mφ-CM 
was neuroprotective and pre-manifest HD Mφ-CM was neurotoxic.  
Overall, it was confirmed that co-culture by conditioned medium transfer was a suitable 
and viable model for assessing the effects of factors released by myeloid cells on 
neurotoxicity in co-culture models of HD. LDH cytotoxicity assay was the most sensitive 
measure of neuronal cell death and was capable of detecting differential effects of 
conditioned media treatments on neurotoxicity. Using this co-culture paradigm, there 
was some preliminary evidence that healthy volunteer and HD patient BMD-microglia 
are neuroprotective in co-culture with wild-type neurons, and there are potentially 
different effects of healthy volunteer and HD patient myeloid cell conditioned medium 
on neuronal survival following stimulation with the highest LPS concentration tested, 1 
µg/mL. Stimulation conditions of 2 µg/mL LPS with 10 ng/mL IFNү (peak maximal 
response) have previously been used to detect differences in healthy volunteer and HD 
myeloid cell proinflammatory cytokine release (Träger et al. 2014a), and these same 
concentrations, applied in acute or chronic paradigms, should be used in future 
experiments utilising this co-culture model. It was confirmed here that these stimulation 
conditions do not directly cause neurotoxicity. 
3.7 Summary 
Novel neuronal-myeloid cell co-culture models of HD were developed with the aim of 
studying interactions between these cell types in the pathogenesis of HD. Novel human 
HD and control NSC-derived neuronal cell lines expressing human HTT exon 1 or full-
length human HTT were developed and characterised. Mature neuronal cultures 
expressing mHTT exon 1 exhibited several characteristics of pathologically affected 
neurons in the HD patient brain, including sub-fragmentation of mHTT protein, 
intranuclear inclusions composed of mHTT aggregates, and mHTT-induced neuronal 
death. A novel technique was discovered for the differentiation of primary human 
monocytes into microglia-like cells, and these BMD-microglia are similar to primary 
human microglia by morphological and antigenic criteria. BMD-macrophages and BMD-
microglia were differentiated in vitro from primary human monocytes isolated from 
healthy volunteers, pre-manifest HD gene carriers and manifest HD patients and 
placed in various co-culture paradigms with HD or non-HD neuronal cultures. 
Preliminary data showed that conditioned medium transferred from healthy volunteer or 
HD patient BMD-microglia to neuronal cultures is neuroprotective. Co-culture by 
conditioned medium transfer with subsequent cell death analysis by LDH cytotoxicity 
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assay was determined to be a viable model for the assessment of the effects of factors 
released by myeloid cells, under various controlled conditions, on neurotoxicity. 
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4 Investigation into neuronal-myeloid 
cell interactions in co-culture models of 
HD 
4.1 Background 
The innate immune system is known to play a significant role in the pathogenesis of 
HD. Neuroinflammation, involving microglial activation, astrogliosis and elevated levels 
of proinflammatory factors, is an early and active component of the disease course 
(Singhrao et al. 1999; Sapp et al. 2001; Pavese et al. 2006; Tai et al. 2007a; Tai et al. 
2007b; Björkqvist et al. 2008; Silvestroni et al. 2009; Politis et al. 2011; Tabrizi et al. 
2013), and is accompanied by parallel inflammatory events in the periphery mediated 
by monocytes and macrophages (Dalrymple et al. 2007; Björkqvist et al. 2008; Wild et 
al. 2011; Ellrichmann et al. 2013; Heneka et al. 2014; Chang et al. 2015). These 
inflammatory events correlate with neurodegenerative processes and disease 
progression (Sapp et al. 2001; Pavese et al. 2006; Dalrymple et al. 2007; Tai et al. 
2007a; Tai et al. 2007b; Björkqvist et al. 2008; Politis et al. 2011; Wild et al. 2011; 
Ellrichmann et al. 2013; Heneka et al. 2014). However, whether myeloid cell activation 
and inflammation associated with neurodegeneration in HD is protective, damaging or 
has no effect remains to be clearly defined.  
Myeloid cells are the likely source of elevated levels of proinflammatory factors in the 
brain and plasma of HD patients. Microglia, monocytes and macrophages isolated from 
HD patients or HD mouse models are hyper-reactive when stimulated and release 
increased levels of cytokines, including IL-1β, IL-6, IL-8 and TNFα (Björkqvist et al. 
2008; Träger et al. 2014a). This dysfunction of the innate immune system could be a 
reactive process to neurodegeneration and peripheral pathologies, or may be caused 
by cell-autonomous expression of mHTT (Crotti et al. 2014; Träger et al. 2014a). It is 
likely that both cell-to-cell interactions between neurons and microglia and cell-
autonomous myeloid cell dysfunction are involved in generation of a feed-forward cycle 
of chronic inflammation in HD (Gu et al. 2005; Gu et al. 2007; Bradford et al. 2009; 
Bradford et al. 2010; Möller 2010; Crotti and Glass 2015). However, the effects this has 
on neurodegenerative processes is not clear. 
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Cytokines are important mediators of communication between the immune system and 
the CNS (Eskandari and Sternberg 2002; Wrona 2006). Microglia release cytokines 
which interact directly with neuronal receptors, and cytokines produced by peripheral 
myeloid cells regulate CNS activity directly by crossing the BBB and interacting with 
neuronal receptors, or indirectly by triggering the production of CNS-derived mediators 
via a relay involving cells at the BBB, or stimulating afferent neurons (Eskandari and 
Sternberg 2002; Wrona 2006). The proinflammatory cytokines IL-1β, IL-6 and TNFα, 
which are known to be released at elevated levels by myeloid cells in HD, have been 
shown to have neuromodulatory properties by impacting synaptic transmission and 
neuronal excitability (Vezzani and Viviani 2015). IL-2 and the Th1-type cytokines G-
CSF, IFNγ IL-1α, IL-1β, IL-6, IL-12 and TNFα regulate numerous pathways in neurons, 
including cytokine–receptor interactions, MAPKs, TLRs, apoptosis, PPAR signalling, 
cell adhesion molecules, antigen processing and Jak-STAT signalling (Benjamins 
2013). These cytokines also upregulate production of certain neurotransmitters and 
their receptors, elements of the ubiquitin-proteasome pathway, iNOS, SOD2 and genes 
involved in the Wnt and Notch signalling pathways (Benjamins 2013). The Th2-type 
cytokines IL-4, IL-5, IL-10 and TGF-β regulate genes related to neuroactive ligand-
receptors, calcium and long-term potentiation, upregulate arginase 1 expression 
leading to decreased NO generation and enhanced neurite outgrowth, and 
downregulate the gene for NCOR2 which could potentially lead to inhibition of histone 
demethylases and promotion of neuronal differentiation (Benjamins 2013). It is 
therefore likely that dysfunctional cytokine release by HD myeloid cells has an impact 
on neuronal function, and potentially on neurotoxicity or neuroprotection of 
degenerating neurons. Excessive proinflammatory cytokine release by microglia and 
peripheral myeloid cells has previously been demonstrated to contribute to 
neurotoxicity, and inhibition of IL-6 or TNFα, centrally or peripherally, has been shown 
to have beneficial therapeutic effects in HD (Bouchard et al. 2012; Hsiao et al. 2014). 
The polarisation of myeloid cells towards an M1 phenotype, which produce Th1-type 
cytokines, or M2 phenotype, which produce Th2-type cytokines, may also yield 
differential effects on neurotoxicity or neuroprotection in HD.  
Neurotrophins are another major class of soluble factors involved in neuronal-myeloid 
cell communication, and like cytokines, levels of neurotrophins are also altered in HD. 
During homeostasis, microglia and peripheral myeloid cells secrete the neurotrophins 
NGF and BDNF which interact with their neuronal receptors to regulate neuronal 
survival, function, maintenance and repair (Nakajima et al. 2001; Saijo and Glass 
2011). In response to acute striatal injury, activation of microglia and macrophages has 
been shown to induce expression of BDNF and stimulate dopaminergic sprouting and 
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repair (Batchelor et al. 1999). However, in HD it has been reported that there is 
reduced transcription and expression of BDNF and its main receptor, TrkB, in HD 
patient brain and HD mouse models (Zuccato et al. 2001; Ginés et al. 2006). This has 
been implicated as a possible contributor to striatal degeneration, and increasing BDNF 
levels was shown to reduce neurotoxicity and ameliorate neurological signs in animal 
models of HD (Puerta et al. 2010; Xie et al. 2010). Alternatively, striatal NGF 
expression has been shown to be increased in animal models of HD, while expression 
of its main receptor, TrkA, may be increased or decreased (Alberch et al. 2004). 
Microglia could be a source of these increased NGF levels, as inflammatory mediators 
such as cytokines, complement factors and DAMPs are potent stimulators of microglial 
NGF synthesis (Schindowski et al. 2008). It may be considered that dysregulated 
neuronal-myeloid cell interactions and cell-autonomous mHTT-induced toxicity in 
myeloid cells could result in aberrant expression and release of neurotrophins, and 
alterations in signalling via these essential neuroprotectants in HD could be critical for 
the survival or death of damaged and degenerating neurons.  
Here, novel co-culture models of HD were utilised to dissect some of the complex 
interactions underlying neuronal-myeloid cell communication in the pathogenesis of 
HD. Preliminary data had shown that transfer of conditioned medium from healthy 
volunteer or HD patient BMD-microglia to wild-type neuronal cultures reduced neuronal 
cell death levels, indicating that both healthy volunteer and HD myeloid cells release 
neuroprotective factors. The aims of this current study were firstly to investigate further 
the effects of factors released by myeloid cells on neuronal death or survival in HD. 
Secondly, aims were to analyse the production of Th1- and Th2-type cytokines (and IL-
2) and the neurotrophins NGF and BDNF in healthy volunteer and HD patient myeloid 
cells, to identify factors contributing to neurotoxicity or neuroprotection in HD. This will 
determine whether myeloid cells are neuroprotective or neurotoxic in HD, and 
potentially reveal altered release of specific cytokines or neurotrophins by cell-
autonomous mechanisms in HD patient myeloid cells.  
4.2 Aims 
1) Determine the effects of healthy volunteer and HD patient Mφ-CM and MG-CM on 
the survival of wild-type and HD neurons in non-stimulated and stimulated 
conditions. 
2) Analyse levels of release of Th1-type cytokines, Th2-type cytokines and IL-2 in 
healthy volunteer and HD patient BMD-macrophages and BMD-microglia in non-
stimulated and stimulated conditions. 
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3) Analyse levels of release of the neurotrophins NGF and BDNF in healthy volunteer 
and HD patient BMD-microglia in non-stimulated and stimulated conditions. 
4) Determine which factors released by healthy volunteer and HD patient BMD-
macrophages and BMD-microglia contribute to neuroprotection or neurotoxicity of 
HD neurons in co-culture. 
4.3 Methods 
A summary of methods used in this Chapter is outlined below. Full details of 
experimental protocols can be found in Chapter 2: Materials and Methods. 
BMD-macrophages and BMD-microglia were differentiated in vitro (as described in 
sections 2.1.2.4 and 2.1.2.5, respectively) from primary human monocyte cultures 
(isolated from whole blood samples and cultured ex vivo as described in sections 
2.1.2.2 and 2.1.2.3). Human samples were classified as described in section 2.1.2.1. 
BMD-macrophages and BMD-microglia were stimulated (acute or chronic) with 2 
µg/mL LPS and 10 ng/mL IFNү, as described in section 2.1.2.6, or were non-
stimulated. Neuronal cultures were differentiated by spontaneous differentiation 
(section 2.1.3.1) from wild-type ReNcell VM (section 2.1.1.3), ReNcell VM+HTT exon 1 
(29/71/129 CAG or eGFP reporter only; sections 3.5.2 and 3.5.2.1) or ReNcell VM+full-
length mHTT (138 CAG C8; sections 3.5.3 and 3.5.3.1) NSCs. Co-culture was 
performed by transfer of conditioned medium from myeloid cell cultures to neuronal 
cultures (section 2.1.4.2), and conditioned medium was collected and prepared as 
described in section 2.1.4.1. In some experiments, neuronal cultures were treated 
directly with cytokines; Recombinant Human IL-6 Protein [R&D Systems] and 
Recombinant Human TNF-alpha Protein [R&D Systems]. Following treatment with 
myeloid cell-conditioned medium or cytokines, neuronal death was analysed by LDH 
cytotoxicity assay (section 2.6.1). Conditioned medium content analysis was performed 
by MSD assay (section 2.5.6.2) for cytokines and ELISA (section 2.5.6.1) for 
neurotrophins. Where cytokine or neurotrophin levels are normalised to total protein, 
total protein levels were measured using BCA assay (section 2.4.2.2) in myeloid cell 
lysates which were prepared as described in section 2.1.4.1. Statistical analyses were 
performed as described in section 2.9.  
4.4 Contributions 
I, Lucianne Dobson performed all the work described in this chapter. No contributions 
were made by others.  
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4.5 Results 
4.5.1 Effects of BMD-macrophage released factors on neuronal death in a co-
culture model of HD 
LPS-stimulation of myeloid cells in vitro triggers a range of intracellular processes 
leading to the release of soluble factors into the culture media. Some factors may be 
released immediately e.g. ROS and RNS, whilst proteins requiring modification or 
assembly may take longer e.g. cytokine pro-proteins, and expression and release of 
new proteins can take even longer still. Following the activation phase comes 
resolution of the immune response and any potential long-term phenotypic changes, or 
death. In order to capture released factors at each of these response phases, BMD-
macrophages were subjected to acute stimulation, or were non-stimulated, and 
conditioned medium was collected over a time-course. Healthy volunteer, pre-manifest 
HD and manifest HD BMD-macrophages were stimulated with 2 µg/mL LPS and 10 
ng/mL IFNү, or were not stimulated, for 1 h then given a fresh medium change. Mφ-CM 
was collected at 2, 4, 8 and 24 h post-acute stimulation (or post-medium change for 
non-stimulated conditions) and was used to treat wild-type ReNcell VM neuronal 
cultures for 4 days. Neuronal culture death levels were then analysed by LDH 
cytotoxicity assay, and results are presented in Figure 4.1.  
 
Figure 4.1: Effects of healthy volunteer and HD patient BMD-macrophage acute 
stimulation over time on wild-type neuronal survival 
Healthy volunteer (HV; n=6), pre-manifest HD (preHD; n=5) and manifest HD (manHD; n=9) 
BMD-macrophage cultures were stimulated with 2 µg/mL LPS and 10 ng/mL IFNү, or were not 
stimulated, for 1 h. Cultures were then given a fresh culture medium change into standard BMD-
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macrophage culture medium (RPMI/FBS) and Mφ-CM was collected at 2, 4, 8 and 24 h post-
acute stimulation (stimulated conditions) or post-medium change (non-stimulated conditions). 
Wild-type ReNcell VM neuronal cultures (6 DD) were treated with Mφ-CM, in triplicate, for 4 
days, or were untreated. Neuronal culture death was then analysed by LDH cytotoxicity assay 
and results are presented as mean average percentage neuronal culture death (calculated as 
described in section 2.6.1 with total LDH calculated from 3 neuronal cultures in RPMI/FBS 
culture medium only (untreated)) from biological repeats, each with three internal experimental 
replicates, ± SEM. Percentage cell death of untreated neuronal cultures is marked with purple, 
dashed lines. Data were statistically analysed using two-way ANOVA: for non-stimulated 
conditions neither Mφ-CM subject group (p=0.921) or time post-medium change (p=0.994) were 
found to be significant sources of variation in percentage neuronal culture death (p>0.05); in 
stimulated conditions Mφ-CM subject group was not a significant source of variation (p=0.544) 
but time post-acute stimulation was a significant source of variation (p<0.001) in percentage 
neuronal culture death. Bonferroni post-tests did not reveal any significant differences (p>0.05) 
between any of the Mφ-CM subject groups at any of the time-points in either non-stimulated or 
stimulated conditions. 
Results showed an increase in wild-type neuronal culture death following all non-
stimulated and stimulated (acute) Mφ-CM treatment conditions compared with 
untreated. This indicates that Mφ-CM treatments were neurotoxic. Treatment of wild-
type neurons with Mφ-CM from BMD-macrophages which had been subjected to acute 
stimulation resulted in significant variation in percentage neuronal culture death, and 
this was not found in the non-stimulated condition. Neuronal death at 2 h post-acute 
stimulation was similar to non-stimulated (approximately 20-25 %), but then neuronal 
death increased over two-fold at 4-8 h post-acute stimulation (approximately 50-70 %) 
before declining again at 24 h (to approximately 40-45 %). This suggests that in 
response to acute stimulation with LPS and IFNү, BMD-macrophages release factors 
which increase in neurotoxicity over time, followed by a phase of resolution and 
decrease in neurotoxicity. Mφ-CM collected at 4 and 8 h post-acute stimulation was the 
most neurotoxic. There were no significant differences between healthy volunteer and 
HD Mφ-CM subject groups at any of the time-points. 
To determine the effects of healthy volunteer or HD patient BMD-macrophage released 
factors on HD neurons, wild-type ReNcell VM and ReNcell VM+full-length mHTT (138 
CAG) HD neuronal cultures were treated, in parallel, with Mφ-CM for 24 h. Mφ-CM had 
been collected from healthy volunteer, pre-manifest HD and manifest HD BMD-
macrophages which had been subjected to acute stimulation, or were non-stimulated, 
at 2, 4, 8 and 24 h post-acute stimulation or post-medium change. Neuronal culture 
death levels were analysed by LDH cytotoxicity assay and results are displayed in 
Figure 4.2. 
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Figure 4.2: Wild-type versus HD neuronal culture death following treatment 
with Mφ-CM  
Healthy volunteer (HV; n=5), pre-manifest HD (preHD; n=4) and manifest HD (manHD; n=8) 
BMD-macrophage cultures were stimulated with 2 µg/mL LPS and 10 ng/mL IFNү, or were not 
stimulated, for 1 h. Cultures were then given a fresh culture medium change into standard BMD-
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macrophage culture medium (RPMI/FBS) and Mφ-CM was collected at 2, 4, 8 and 24 h post-
acute stimulation (stimulated conditions) or post-medium change (non-stimulated conditions). 
Wild-type ReNcell VM and ReNcell VM+full-length mHTT (138 CAG) HD neuronal cultures (10 
DD) were treated with Mφ-CM, in triplicate, for 24 h, or were untreated. Neuronal culture death 
was then analysed by LDH cytotoxicity assay and results are presented as mean average 
percentage wild-type or HD neuronal culture death (calculated as described in section 2.6.1) 
relative to untreated wild-type or HD neuronal culture death, respectively, from biological 
repeats, each with three internal experimental replicates, ± SEM. Data were statistically 
analysed using two-way ANOVA with Bonferroni post-tests; *p<0.05, **p<0.01. 
Neuronal culture type (wild-type versus HD) was found to be a significant source of 
variation in neuronal culture death relative to untreated, independent of time-point, 
following all Mφ-CM treatments over the time-course: non-stimulated healthy volunteer 
(p<0.0001), pre-manifest HD (p=0.022) and manifest HD (p<0.0001) Mφ-CM 
treatments; and stimulated (acute) healthy volunteer (p<0.0001), pre-manifest HD 
(p=0.0073) and manifest HD (p<0.0001) Mφ-CM treatments. HD neuronal culture death 
relative to untreated was significantly higher than wild-type neuronal culture death 
relative to untreated following 24 h treatment with Mφ-CM from healthy volunteer BMD-
macrophages at 2, 4 and 8 h time-points and manifest HD BMD-macrophages at 4, 8, 
and 24 h time-points, in non-stimulated conditions; and healthy volunteer BMD-
macrophages at 8 and 24 h time-points and manifest HD BMD-macrophages at 2, 4, 8 
and 24 h time-points, in acute stimulation conditions. Pre-manifest HD Mφ-CM 
treatments did not significantly affect HD neuronal culture death compared with wild-
type neuronal culture death at any individual time-point in non-stimulated or stimulated 
(acute) conditions. HD neuronal culture death levels were generally higher following 
Mφ-CM treatments compared with untreated, whereas wild-type neuronal culture death 
levels were generally lower than untreated after Mφ-CM treatments. Taken together, 
these results indicate that Mφ-CM treatments have a neurotoxic effect in HD neurons 
which leads to significantly more neuronal culture death in HD neuronal cultures 
compared with wild-type neuronal cultures. Overall, there were no significant 
differences found between healthy volunteer and pre-manifest HD or manifest HD Mφ-
CM treatments on wild-type or HD neuronal culture death, in non-stimulated or 
stimulated (acute) conditions, over the time-course. 
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4.5.2 Effects of BMD-microglia released factors on neuronal death in a co-
culture model of HD 
4.5.2.1 Acute stimulation of BMD-microglia in co-culture 
The acute stimulation time-course co-culture paradigm described above for BMD-
macrophages was repeated with BMD-microglia and wild-type neurons. Healthy 
volunteer and manifest HD BMD-microglia were stimulated with 2 µg/mL LPS and 10 
ng/mL IFNү, or were not stimulated, for 1 h then given a fresh medium change. MG-CM 
was collected at 2, 4, 8, 24 and 48 h post-acute stimulation (or post-medium change for 
non-stimulated conditions) and was used to treat wild-type ReNcell VM neuronal 
cultures for 24 h. Neuronal culture death levels were then analysed by LDH cytotoxicity 
assay, and results are presented in Figure 4.3. Neither MG-CM subject group or time 
post-medium change/post-acute stimulation were significant sources of variation in 
non-stimulated or stimulated conditions (p>0.05). There were no significant differences 
between any of the MG-CM subject groups at any of the time-points in either non-
stimulated or stimulated conditions (p>0.05). 
 
Figure 4.3: Effects of healthy volunteer and HD patient BMD-microglia acute 
stimulation over time on wild-type neuronal survival 
Healthy volunteer (HV; n=3) and manifest HD (manHD; n=4) BMD-microglia cultures were 
stimulated with 2 µg/mL LPS and 10 ng/mL IFNү, or were not stimulated, for 1 h. Cultures were 
then given a fresh culture medium change into standard BMD-microglia culture medium (NM) 
and MG-CM was collected at 2, 4, 8, 24 and 48 h post-acute stimulation (stimulated conditions) 
or post-medium change (non-stimulated conditions). Wild-type ReNcell VM neuronal cultures 
(18 DD) were treated with MG-CM, in triplicate, for 24 h, or were untreated. Neuronal culture 
death was then analysed by LDH cytotoxicity assay and results are presented as mean average 
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percentage neuronal culture death (calculated as described in section 2.6.1) from biological 
repeats, each with three internal experimental replicates, ± SEM. Percentage cell death of 
untreated neuronal cultures is marked with purple, dashed lines. Data were statistically 
analysed using two-way ANOVA with Bonferroni post-tests.  
4.5.2.2 Chronic stimulation of BMD-microglia in co-culture  
A chronic stimulation paradigm, more closely modelling the neuroinflammatory 
environment in the degenerating HD brain, was then assessed in BMD-microglia in co-
culture with wild-type or HD neurons. Healthy volunteer, pre-manifest HD and manifest 
HD BMD-microglia were stimulated continuously with 2 µg/mL LPS and 10 ng/mL IFNү, 
or were not stimulated. MG-CM was collected after 2, 4, 8, 24 and 48 h chronic 
stimulation (stimulated conditions) or post-medium change (non-stimulated conditions). 
MG-CM was then used to treat wild-type ReNcell VM and ReNcell VM+full-length 
mHTT (138 CAG) HD neuronal cultures, in parallel, for 24 h. Neuronal culture death 
after treatments was analysed by LDH cytotoxicity assay, and results are displayed in 
Figure 4.4. 
MG-CM subject group was found to be a significant source of variation in wild-type 
neuronal culture death in non-stimulated conditions (p=0.040). Manifest HD MG-CM 
treatment resulted in significantly reduced neuronal culture death, below untreated 
levels, compared to healthy volunteer MG-CM at the 24 h time-point (p<0.05), and 
compared to pre-manifest HD MG-CM at the 48 h time-point (p<0.05). This suggests 
that MG-CM from non-stimulated manifest HD BMD-microglia is neuroprotective in co-
culture with wild-type neurons. MG-CM subject group was not a significant source of 
variation (p>0.05) in wild-type neuronal culture death in stimulated (chronic) conditions, 
nor in HD neuronal culture death in non-stimulated or stimulated (chronic) conditions.  
Duration of chronic stimulation was a significant source of variation in wild-type 
(p=0.007) and HD (p=0.001) neuronal culture death, and time post-medium change 
was not a significant source of variation in non-stimulated conditions (p>0.05). Chronic 
stimulation conditions showed trends for increased neuronal culture death over time, 
above untreated levels, indicating that chronic stimulation of BMD-microglia may lead 
to release of factors which increase in neurotoxicity over time.  
Neuronal culture type (wild-type versus HD) was a significant source of variation in 
neuronal culture death following treatment with non-stimulated manifest HD MG-CM 
(p=0.003) or stimulated (chronic) healthy volunteer MG-CM (p=0.020). Both conditions 
resulted in a trend for lower death levels in wild-type neuronal cultures compared with 
HD neuronal cultures, indicating that these MG-CM treatments were more protective to 
wild-type neurons and/or more toxic to HD neurons.  
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Figure 4.4: Effects of healthy volunteer, pre-manifest HD and manifest HD 
BMD-microglia chronic stimulation over time on wild-type and HD neuronal 
survival 
Healthy volunteer (HV; n=3), pre-manifest HD (preHD; n=3) and manifest HD (manHD; n=3) 
BMD-microglia cultures were stimulated continuously with 2 µg/mL LPS and 10 ng/mL IFNү, or 
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were not stimulated, and MG-CM was collected at 2, 4, 8, 24 and 48 h chronic stimulation 
(stimulated conditions) or post-medium change (non-stimulated conditions). Wild-type ReNcell 
VM and ReNcell VM+full-length mHTT (138 CAG) HD neuronal cultures (10 DD) were treated 
with MG-CM, in duplicate, for 24 h, or were untreated. Neuronal culture death was then 
analysed by LDH cytotoxicity assay and results are presented as mean average percentage 
neuronal culture death (A) (calculated as described in section 2.6.1) or mean average 
percentage neuronal culture death relative to untreated (B) from biological repeats, each with 
three internal experimental replicates, ± SEM. Results are presented as comparisons of the 
effects of healthy volunteer, pre-manifest HD and manifest HD MG-CM treatments on neuronal 
culture death (A) and comparisons of wild-type and HD neuronal culture death in response to 
MG-CM treatments (B). Percentage cell death of untreated neuronal cultures is marked with 
purple, dashed lines. Data were statistically analysed using two-way ANOVA with Bonferroni 
post-tests.  
Differences between the effects of MG-CM treatments on wild-type neuronal culture 
death had begun to appear at 24 and 48 h time-points in non-stimulated and stimulated 
(chronic) conditions, and there was some evidence that the effects of MG-CM 
treatments on neuronal culture death could be different in wild-type and HD neurons at 
24 and 48 h time-points in non-stimulated and stimulated (chronic) conditions (Figure 
4.4). It is possible that significance was not reached in some cases due to the high 
level of variability in the data, and this was most likely introduced by use of human 
samples. To ensure that the null hypotheses (that there is no difference in the average 
values at 24 or 48 h time-points) were not incorrectly accepted, or rejected, power 
calculations were performed (as described in detail in section 2.9.4) to determine 
appropriate sample sizes. Test values were taken from 24 and 48 h time-point data 
comparing the effects of healthy volunteer, pre-manifest HD and manifest HD MG-CM 
on wild-type neuronal death in non-stimulated and stimulated (chronic) conditions 
(Figure 4.4; A) and used to calculate minimum sample sizes required to detect effect 
differences, or accept the null hypothesis. Results of these analyses are presented in 
Table 4.1. 
Table 4.1: Sample size calculations for wild-type neuron-BMD-microglia co-
culture experiments 
Test 
condition 
Test 
value 
Sample 
condition 
Sample 
mean 
SD for 
sample 
α-error 
level 
β-error 
level 
Sample 
size (n) 
Wild-type neurons treated with non-stimulated MG-CM 
untreated 9.26 HV; 24 h 11.13 4.35 5 % 50 % 15 
untreated 9.26 preHD; 24 h 8.44 2.44 5 % 50 % 24 
untreated 9.26 manHD; 24 h 3.30 1.38 5 % 50 % 0 
untreated 9.26 HV; 48 h 9.00 2.32 5 % 50 % 215 
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untreated 9.26 preHD; 48 h 14.52 7.28 5 % 50 % 5 
untreated 9.26 manHD; 48 h 6.48 2.08 5 % 50 % 2 
HV; 24 h 11.13 preHD; 24 h 8.44 2.44 5 % 50 % 2 
HV; 24 h 11.13 manHD; 24 h 3.3 1.38 5 % 50 % 0 
preHD; 24 h 8.44 HV; 24 h 11.13 4.35 5 % 50 % 7 
preHD; 24 h 8.44 manHD; 24 h 3.30 1.38 5 % 50 % 0 
manHD; 24 h 3.30 HV; 24 h 11.13 4.35 5 % 50 % 1 
manHD; 24 h 3.30 preHD; 24 h 8.44 2.44 5 % 50 % 1 
HV; 48 h 9.00 preHD; 48 h 14.52 7.28 5 % 50 % 5 
HV; 48 h 9.00 manHD; 48 h 6.48 2.08 5 % 50 % 2 
preHD; 48 h 14.52 HV; 48 h 9.00 2.32 5 % 50 % 0 
preHD; 48 h 14.52 manHD; 48 h 6.48 2.08 5 % 50 % 0 
manHD; 48 h 6.48 HV; 48 h 9.00 2.32 5 % 50 % 2 
manHD; 48 h 6.48 preHD; 48 h 14.52 7.28 5 % 50 % 2 
Wild-type neurons treated with stimulated (chronic) MG-CM 
untreated 9.26 HV; 24 h 14.17 3.87 5 % 50 % 2 
untreated 9.26 preHD; 24 h 19.40 7.44 5 % 50 % 1 
untreated 9.26 manHD; 24 h 13.69 3.59 5 % 50 % 2 
untreated 9.26 HV; 48 h 15.10 3.99 5 % 50 % 1 
untreated 9.26 preHD; 48 h 22.51 14.56 5 % 50 % 3 
untreated 9.26 manHD; 48 h 20.28 11.75 5 % 50 % 3 
HV; 24 h 14.17 preHD; 24 h 19.40 7.44 5 % 50 % 5 
HV; 24 h 14.17 manHD; 24 h 13.69 3.59 5 % 50 % 151 
preHD; 24 h 19.40 HV; 24 h 14.17 3.87 5 % 50 % 1 
preHD; 24 h 19.40 manHD; 24 h 13.69 3.59 5 % 50 % 1 
manHD; 24 h 13.69 HV; 24 h 14.17 3.87 5 % 50 % 176 
manHD; 24 h 13.69 preHD; 24 h 19.40 7.44 5 % 50 % 5 
HV; 48 h 15.10 preHD; 48 h 22.51 14.56 5 % 50 % 10 
HV; 48 h 15.10 manHD; 48 h 20.28 11.75 5 % 50 % 14 
preHD; 48 h 22.51 HV; 48 h 15.10 3.99 5 % 50 % 1 
preHD; 48 h 22.51 manHD; 48 h 20.28 11.75 5 % 50 % 75 
manHD; 48 h 20.28 HV; 48 h 15.10 3.99 5 % 50 % 2 
manHD; 48 h 20.28 preHD; 48 h 22.51 14.56 5 % 50 % 115 
Healthy volunteer, HV, pre-manifest HD gene carrier, preHD; manifest HD patient, manHD 
The pre-manifest HD group was the most variable, having a higher SD than healthy 
volunteer and manifest HD groups in all conditions (non-stimulated and stimulated at 
24 and 48 h). Comparisons between pre-manifest HD and healthy volunteer or 
manifest HD MG-CM treatments therefore require a larger sample size than other MG-
CM treatment comparisons. For non-stimulated conditions, the sample size 
requirements had already been met (n=3) for most comparisons of MG-CM treatments. 
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Exceptions were healthy volunteer versus pre-manifest HD MG-CM at 24 and 48 h. In 
stimulated (chronic) conditions, several comparisons required a larger sample size than 
n=3 for appropriate statistical power. As a result, sample size was increased to 
compare healthy volunteer versus manifest HD MG-CM in stimulated (chronic) 
conditions at 24 and 48 h time-points (Figure 4.5; A). Non-stimulated conditions were 
run alongside to assess the effects of chronic stimulation of BMD-microglia on neuronal 
death (Figure 4.5; B). 
 
Figure 4.5: Effects of chronic stimulation of healthy volunteer versus manifest 
HD MG-CM on wild-type neuronal survival, at 24 and 48 h stimulation 
Healthy volunteer (HV; n=12) and manifest HD (manHD; n=16) BMD-microglia cultures were 
stimulated continuously with 2 µg/mL LPS and 10 ng/mL IFNү, or were not stimulated, and MG-
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CM was collected at 24 and 48 h chronic stimulation (stimulated conditions) or post-medium 
change (non-stimulated conditions). Wild-type ReNcell VM neuronal cultures (10 DD) were 
treated with MG-CM, in duplicate, for 24 h, or were untreated. Neuronal culture death was then 
analysed by LDH cytotoxicity assay and results are presented as mean average percentage 
neuronal culture death (calculated as described in section 2.6.1) from biological repeats, each 
with three internal experimental replicates, ± SEM. Results are presented as comparisons of the 
effects of healthy volunteer and manifest HD MG-CM treatments on neuronal culture death (A) 
and comparisons of the effects of non-stimulated and stimulated MG-CM treatments on 
neuronal culture death (B). Percentage cell death of untreated neuronal cultures is marked with 
purple, dashed lines. Data were statistically analysed using two-way ANOVA with Bonferroni 
post-tests: *p<0.05, **p<0.01.  
There were no significant differences (p>0.05) between the effects of healthy volunteer 
and manifest HD MG-CM treatments on wild-type neuronal culture death in non-
stimulated or stimulated conditions at 24 or 48 h post-medium change or chronic 
stimulation. However, stimulation was a significant source of variation at both 24 h 
(p=0.0003) and 48 h (p=0.001) time-points, and treatment of wild-type neuronal 
cultures with stimulated MG-CM resulted in significantly higher death than treatment 
with non-stimulated MG-CM for both healthy volunteer (p<0.05 at 24 and 48 h) and 
manifest HD (p<0.01 at 24 h and p<0.05 at 48 h) subject groups. Non-stimulated 
healthy volunteer and manifest HD MG-CM treatments resulted in average death levels 
below untreated, and stimulated healthy volunteer and manifest HD MG-CM treatments 
resulted in average death levels above untreated. This suggests that chronic 
stimulation of BMD-microglia for 24 or 48 h leads to the release of neurotoxic factors, 
but the effects this has on wild-type neuronal culture death does not differ between 
healthy volunteer and manifest HD BMD-microglia.  
4.5.2.3 BMD-microglia in co-culture with ReNcell VM+HTT exon 1 neurons 
To further investigate the effects of microglia-released factors on HD neuronal death, 
co-culture was performed with BMD-microglia and ReNcell VM+HTT exon 1 neuronal 
cultures. Healthy volunteer and manifest HD BMD-microglia were stimulated 
continuously with 2 µg/mL LPS and 10 ng/mL IFNү (chronic stimulation), or were not 
stimulated, for 24 h or 48 h. MG-CM was used to treat ReNcell VM+HTT exon 1 (29 
CAG), ReNcell VM+mHTT exon 1 (71 CAG), ReNcell VM+mHTT exon 1 (129 CAG) 
and ReNcell VM+eGFP reporter only neuronal cultures, in parallel, for 24 h. Neuronal 
culture death was then analysed by LDH cytotoxicity assay and results are presented 
in Figure 4.6.  
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Figure 4.6: Effects of healthy volunteer and HD patient MG-CM treatments on 
ReNcell VM+HTT exon 1 non-HD and HD neuronal culture death 
Healthy volunteer (HV; n=4) and manifest HD (manHD; n=4) BMD-microglia cultures were 
stimulated continuously with 2 µg/mL LPS and 10 ng/mL IFNү, or were not stimulated, and MG-
CM was collected at 24 and 48 h chronic stimulation (stimulated conditions) or post-medium 
change (non-stimulated conditions). ReNcell VM+HTT exon 1 (29 CAG), ReNcell VM+mHTT 
exon 1 (71 CAG), ReNcell VM+mHTT exon 1 (129 CAG) and ReNcell VM+eGFP reporter only 
neuronal cultures (28 DD) were treated with MG-CM, in duplicate, for 24 h, or were untreated. 
Neuronal culture death was then analysed by LDH cytotoxicity assay and results are presented 
as mean average neuronal culture death (calculated as described in section 2.6.1) relative to 
untreated eGFP reporter only control neuronal culture death (baseline neuronal culture death 
levels), from biological repeats, each with three internal experimental replicates, ± SEM. Data 
were statistically analysed using two-way ANOVA with Bonferroni post-tests; *p<0.05, **p<0.01. 
Neuronal culture type (ReNcell VM+HTT exon 1 with 29 CAG, 71 CAG or 129 CAG) 
was a significant source of variation in neuronal culture death levels in non-stimulated 
MG-CM conditions (p=0.007 at 24 h time-point and p<0.0001 at 48 h time-point) or 
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stimulated MG-CM conditions (p=0.0005 at 24 h time-point and p<0.0001 at 48 h time-
point). This indicates that expression of HTT exon 1 with 29 CAG, 71 CAG or 129 CAG 
in ReNcell VM neuronal cultures leads to differential effects on neuronal culture death 
levels, independent of MG-CM treatment conditions, and HTT exon 1 71 CAG had 
higher neuronal death than HTT exon 1 29 CAG or 129 CAG. MG-CM treatment 
(untreated, healthy volunteer MG-CM or manifest HD MG-CM) was also a significant 
source of variation in neuronal culture death levels in the 48 h stimulated condition 
(p=0.021), indicating that untreated neuronal cultures or neuronal cultures treated with 
48 h stimulated MG-CM from healthy volunteers or HD patients had differential effects 
on neuronal culture death levels, independent of neuronal culture type. The interaction 
between MG-CM treatments and neuronal culture type was a significant source of 
variation in neuronal culture death levels in the 48 h non-stimulated condition 
(p=0.003), indicating that different MG-CM treatments had differential effects on 
different neuronal culture types in this condition.  
There were no significant differences between the effects of healthy volunteer and HD 
patient MG-CM treatments on neuronal culture death levels in ReNcell VM+HTT exon 
1 with 29 CAG, 71 CAG or 129 CAG, in non-stimulated or stimulated conditions. 
Neither healthy volunteer or HD patient MG-CM treatments altered neuronal culture 
death levels from untreated levels in ReNcell VM+HTT exon 1 (29 CAG) or ReNcell 
VM+HTT exon 1 (129 CAG) neuronal cultures. In ReNcell VM+HTT exon 1 (71 CAG) 
neuronal cultures, however, MG-CM treatments had variable effects, depending on the 
condition, on reducing neuronal culture death levels compared with untreated. At the 
24 h time-point, in non-stimulated conditions healthy volunteer MG-CM treatment 
reduced ReNcell VM+HTT exon 1 (71 CAG) neuronal culture death levels (p<0.05) and 
manifest HD MG-CM treatment did not (p>0.05), suggesting that in non-stimulated 
conditions MG-CM from healthy volunteer BMD-microglia is neuroprotective and MG-
CM from HD patient BMD-microglia is not. In stimulated conditions, neither healthy 
volunteer or manifest HD MG-CM treatments reduced ReNcell VM+HTT exon 1 (71 
CAG) neuronal culture death levels (p>0.05), suggesting that MG-CM from stimulated 
healthy volunteer or HD patient BMD-microglia is not neuroprotective. At the 48 h time-
point, both healthy volunteer and manifest HD MG-CM treatments significantly reduced 
ReNcell VM+HTT exon 1 (71 CAG) neuronal culture death levels in both non-
stimulated (p<0.01 and p<0.05, respectively) and stimulated (p<0.05 for both 
comparisons with untreated) conditions, suggesting that MG-CM from non-stimulated 
or stimulated healthy volunteer or HD patient BMD-microglia is neuroprotective at this 
time-point. 
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4.5.3 Direct treatment of neurons with proinflammatory cytokines 
Stimulation of myeloid cells with LPS and IFNү triggers the production and release of 
cytokines, and HD patient myeloid cells release elevated levels of the proinflammatory 
cytokines IL-6 and TNFα in response to stimulation. To determine whether IL-6 and 
TNFα could contribute towards the observed neurotoxicity of BMD-macrophages and 
BMD-microglia following stimulation, wild-type neuronal cultures were treated directly 
with a range of IL-6 and TNFα concentrations, alone or in combination, for 24 h. 
Neuronal culture death was then analysed by LDH cytotoxicity assay and results are 
presented in Figure 4.7.  
 
Figure 4.7: Effects of proinflammatory cytokine (IL-6 and TNFα) treatments on 
wild-type neuronal culture death 
Wild-type ReNcell VM neuronal cultures (10 DD) were treated, in triplicate, with 0.1, 1, 5, 100 or 
500 ng/mL IL-6 or TNFα or IL-6+TNFα, for 24 h, or were untreated. Neuronal culture death was 
then analysed by LDH cytotoxicity assay and results are presented as mean average 
percentage neuronal culture death (calculated as described in section 2.6.1) from 3/4 biological 
repeats per treatment condition, each with three internal experimental replicates, ± SEM. Data 
were analysed using one-way ANOVA with Dunnett’s multiple comparisons tests, comparing all 
treatment conditions to untreated.  
IL-6, TNFα or IL-6+TNFα treatments were not significant sources of variation in wild-
type neuronal culture death, and no individual treatment condition resulted in 
significantly increased neuronal culture death compared with untreated. This suggests 
that the proinflammatory cytokines IL-6 and TNFα do not directly cause wild-type 
neuronal death, although the data was highly variable. 
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4.5.4 Investigation into factors released by healthy volunteer and HD patient 
myeloid cells 
4.5.4.1 Proinflammatory cytokine release in healthy volunteer and HD patient BMD-
macrophages  
In section 4.5.1, treatment of neuronal cultures with Mφ-CM from non-stimulated or 
stimulated (acute) healthy volunteer or manifest HD BMD-macrophages was shown to 
result in significantly higher death levels in HD neuronal cultures compared with wild-
type neuronal cultures, at several time-points post-medium change or post-acute 
stimulation (Figure 4.2). To assess factors which may have contributed to neurotoxicity 
in HD neuronal cultures in this co-culture experiment, Mφ-CM which had been 
collected from the same sources was analysed for proinflammatory cytokine content. 
Proinflammatory cytokine release in healthy volunteer, pre-manifest HD and manifest 
HD BMD-macrophages was compared.  
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Figure 4.8: Levels of proinflammatory cytokine release in healthy volunteer, 
pre-manifest HD and manifest HD BMD-macrophages 
Healthy volunteer (HV; n=5), pre-manifest HD (preHD; n=4) and manifest HD (manHD; n=8) 
BMD-macrophage cultures were stimulated with 2 µg/mL LPS and 10 ng/mL IFNү, or were not 
stimulated, for 1 h. Cultures were then given a fresh culture medium change into standard BMD-
macrophage culture medium (RPMI/FBS) and Mφ-CM was collected at 2, 4, 8 and 24 h post-
acute stimulation (stimulated conditions) or post-medium change (non-stimulated conditions). 
Cytokine levels in Mφ-CM were measured by MSD assay and normalised to total protein. 
Results are presented as mean average cytokine level from biological repeats, each with three 
internal experimental replicates, ± SEM. Data were statistically analysed using two-way ANOVA 
with Bonferroni post-tests; *p<0.05, ***p<0.001. 
Levels of the proinflammatory cytokines IFNү, IL-1β, IL-6 and TNFα were measured in 
non-stimulated and stimulated (acute) healthy volunteer, pre-manifest HD and manifest 
HD Mφ-CM, over several time-points post-medium change or post-acute stimulation, 
using MSD assay. Results are presented in Figure 4.8. In both non-stimulated and 
stimulated conditions, Mφ-CM subject group was not a significant source of variation in 
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IFNү, IL-1β, IL-6 or TNFα levels, indicating that healthy volunteer, pre-manifest HD and 
manifest HD BMD-macrophages do not release different levels of these cytokines, 
independent of time-point. In stimulated conditions, time post-acute stimulation was a 
significant source of variation in IL-1β (p=0.001), IL-6 (p<0.0001) and TNFα (p<0.0001) 
levels, independent of Mφ-CM subject group, and levels of these proinflammatory 
cytokines increased over time. At the 24 h time-point, manifest HD Mφ-CM had higher 
levels of IL-1β and TNFα (p<0.05 and p<0.001, respectively) compared with pre-
manifest HD Mφ-CM post-acute stimulation, indicating that manifest HD BMD-
macrophages release elevated levels of IL-1β and TNFα compared with pre-manifest 
HD BMD-macrophages, over 24 h following acute stimulation. There were no 
differences between healthy volunteer and pre-manifest HD or manifest HD Mφ-CM 
IFNү, IL-1β, IL-6 or TNFα levels in non-stimulated or stimulated conditions.  
4.5.4.2 Th1- and Th2-type (and IL-2) cytokine release in healthy volunteer and HD 
patient BMD-microglia  
In section 4.5.2.3, non-stimulated MG-CM from healthy volunteers was shown to 
reduce mHTT-induced neurotoxicity in ReNcell VM+mHTT exon 1 (71 CAG) neuronal 
cultures at 24 and 48 h time-points, and non-stimulated MG-CM from manifest HD 
patients reduced mHTT-induced neurotoxicity in this neuronal culture at the 48 h time-
point, but not at the 24 h time-point. In stimulated (chronic) conditions, both healthy 
volunteer and manifest HD MG-CM treatments reduced mHTT-induced neurotoxicity in 
ReNcell VM+mHTT exon 1 (71 CAG) neuronal cultures at 48 h post-stimulation, but not 
at 24 h post-stimulation (Figure 4.6). To assess which factors may contribute to 
protection from mHTT-induced neurotoxicity in this co-culture model, and whether this 
involved polarisation of BMD-microglia towards an M1 or M2 phenotype, levels of Th1- 
and Th2-type cytokines, and IL-2, were measured in MG-CM.  
BMD-microglia from healthy volunteers and manifest HD patients were stimulated 
continuously with 2 µg/mL LPS and 10 ng/mL IFNү (chronic stimulation), or were not 
stimulated, for 24 h or 48 h. MG-CM was then collected and levels of Th1-type 
cytokines (IFNү, IL-1β, IL-6, IL-8, IL-12 and TNFα), Th2-type cytokines (IL-4, IL-10 and 
IL-13) and IL-2 were measured by MSD assay. Results are presented in Figure 4.9. 
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Figure 4.9: Levels of Th1- and Th2-type (and IL-2) cytokine release in healthy 
volunteer and manifest HD BMD-microglia 
Healthy volunteer (HV; n=17) and manifest HD (manHD; n=15) BMD-microglia cultures were 
stimulated continuously with 2 µg/mL LPS and 10 ng/mL IFNү, or were not stimulated, for 24 or 
48 h. Cytokine levels in MG-CM were then measured by MSD assay and normalised to total 
protein. Results are presented as mean average cytokine level from biological repeats, each 
with three internal experimental replicates, ± SEM, in MG-CM from non-stimulated BMD-
microglia (A) and stimulated (chronic) MG-CM (B). Data were statistically analysed using two-
way ANOVA with Bonferroni post-tests; *p<0.05, **p<0.01. 
In non-stimulated conditions, MG-CM subject group (healthy volunteer or manifest HD) 
was a significant source of variation in levels of IFNү (p=0.022) and IL-2 (p=0.010), 
where manifest HD BMD-microglia released elevated levels of these cytokines 
compared with healthy volunteer BMD-microglia, independent of time-point. At the 24 h 
time-point, manifest HD BMD-microglia released higher levels of IFNү (p<0.01) and IL-
2 (p<0.01) than healthy volunteer BMD-microglia, but this effect was lost at 48 h. In 
stimulated (chronic) conditions, MG-CM subject group was a significant source of 
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variation in levels of IL-12 (p=0.044), where manifest HD BMD-microglia released 
elevated levels of this cytokine compared with healthy volunteer BMD-microglia, 
independent of time-point. At 24 h chronic stimulation, manifest HD BMD-microglia 
released elevated levels of IL-10 compared with healthy volunteer BMD-microglia 
(p<0.05), and at 48 h chronic stimulation manifest HD BMD-microglia released reduced 
levels of TNFα compared with healthy volunteer BMD-microglia (p<0.05). Duration of 
chronic stimulation (24 or 48 h) was a significant source of variation, independent of 
MG-CM subject group, in levels of IFNү (p<0.0001), IL-4 (p=0.009) and IL-13 (p=0001), 
where levels of IFNү were higher at 48 h post-stimulation than 24 h post-stimulation, 
and levels of IL-4 and IL-13 were lower at 48 h post-stimulation than 24 h post-
stimulation. There were no significant differences detected between healthy volunteer 
MG-CM and manifest HD MG-CM for any of the other cytokines analysed.  
4.5.4.3 Neurotrophin release in healthy volunteer and HD patient BMD-microglia  
In addition to cytokine release, the release of neurotrophins by healthy volunteer and 
manifest HD BMD-microglia was also analysed to assess potential neuroprotective 
factors in MG-CM. BMD-microglia from healthy volunteers and manifest HD patients 
were stimulated continuously with 2 µg/mL LPS and 10 ng/mL IFNү (chronic 
stimulation), or were not stimulated, for 24 h or 48 h. MG-CM was then collected and 
levels of the neurotrophins NGF and BDNF were measured by ELISA. Results are 
presented in Figure 4.10. 
There was no difference between healthy volunteer and manifest HD MG-CM NGF 
levels in stimulated or non-stimulated conditions at 24 or 48 h time-points (p<0.05 for 
all comparisons). Levels of NGF release by BMD-microglia were also not affected by 
chronic stimulation. In non-stimulated conditions, time was a significant source of 
variation in BDNF levels (p=0.0006), with levels being higher at the 48 h time-point 
compared with the 24 h time-point, independent of MG-CM subject group (healthy 
volunteer or manifest HD BMD-microglia). MG-CM subject group was not a significant 
source of variation in BDNF levels in non-stimulated conditions. In stimulated (chronic) 
conditions, however, MG-CM subject group was a significant source of variation in 
BDNF levels (p=0.0001), and at 48 h chronic stimulation, levels of BDNF release were 
significantly higher in manifest HD BMD-microglia compared with healthy volunteer 
BMD-microglia (p<0.001). Duration of chronic stimulation was also a significant source 
of variation in BDNF levels in stimulated conditions (p<0.0001), with BDNF levels being 
higher at the 48 h time-point compared with the 24 h time-point, independent of MG-
CM subject group. 
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Figure 4.10: Levels of neurotrophin release in healthy volunteer and manifest 
HD BMD-microglia 
Healthy volunteer (HV; n=10) and manifest HD (manHD; n=10) BMD-microglia cultures were 
stimulated continuously with 2 µg/mL LPS and 10 ng/mL IFNү, or were not stimulated, for 24 or 
48 h. Neurotrophin levels in MG-CM were then measured by ELISA and normalised to total 
protein. Results are presented as mean average neurotrophin level from biological repeats, 
each with three internal experimental replicates, ± SEM. Data were statistically analysed using 
two-way ANOVA with Bonferroni post-tests; ***p<0.001. 
Chapter 4 
250 
 
4.6 Discussion 
4.6.1 BMD-macrophage-neuronal co-culture 
4.6.1.1 Wild-type and HD (ReNcell VM+full-length mHTT (138 CAG)) neuronal culture 
death in co-culture with BMD-macrophages 
Treatment of wild-type neuronal cultures with Mφ-CM from non-stimulated healthy 
volunteer, pre-manifest HD or manifest HD BMD-macrophages resulted in higher 
neuronal culture death levels compared with untreated, and acute stimulation of BMD-
macrophages increased wild-type neuronal culture death levels over time, peaking at 
4-8 h post-stimulation over a 24 h time-course. This suggests that factors released by 
BMD-macrophages are neurotoxic at baseline and acute stimulation increases this 
toxicity. The same Mφ-CM treatments also resulted in higher death levels in HD 
neuronal cultures compared with wild-type neuronal cultures, indicating that factors 
released by BMD-macrophages are less neuroprotective and/or more neurotoxic in HD 
neurons compared with wild-type neurons. This is in support of multiple studies which 
report a neurotoxic role for immune cell activation and inflammation in HD (Andre et al. 
2016). There were no differences detected between the effects of healthy volunteer, 
pre-manifest HD and manifest HD BMD-macrophages on wild-type or HD neuronal 
culture death in co-culture.  
4.6.1.2 Proinflammatory cytokine release in BMD-macrophages 
To examine potential neurotoxic factors released by BMD-macrophages, levels of the 
proinflammatory cytokines IFNү, IL-1β, IL-6 and TNFα were measured in the Mφ-CM 
used to treat wild-type and HD neurons in co-culture. In stimulated conditions, levels of 
IL-1β, IL-6 and TNFα were found to increase over time, over the 24 h time-course, and 
these increases mostly correlated with increasing neuronal culture death levels. It is 
possible, therefore, that BMD-macrophages are neurotoxic due to release of the 
proinflammatory cytokines IL-1β, IL-6 and TNFα. However, direct treatment of wild-type 
neuronal cultures with IL-6 and TNFα, alone or in combination, was not found to cause 
neurotoxicity, suggesting that these proinflammatory cytokines are not directly 
neurotoxic when taken in isolation.  
There were no differences in proinflammatory cytokine release detected between 
healthy volunteer, pre-manifest HD and manifest HD BMD-macrophages in non-
stimulated or stimulated (acute) conditions, other than at 24 h post-acute stimulation 
where manifest HD BMD macrophages released elevated levels of IL-1β and TNFα 
compared with pre-manifest HD BMD-macrophages. This may explain why there were 
no differences between the effects of healthy volunteer, pre-manifest HD and manifest 
HD Mφ-CM treatments on neuronal culture death levels. Träger et al. (2014a) also 
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reported that there was no difference in levels of release of IL-1β or IL-6 in pre-manifest 
HD or manifest HD BMD-macrophages compared with healthy volunteer BMD-
macrophages, but they did report an increase in release of TNFα in pre-manifest HD 
and manifest HD BMD-macrophages compared with healthy volunteer BMD-
macrophages after 24 h chronic stimulation.  
4.6.2 BMD-microglia-neuronal co-culture 
4.6.2.1 Wild-type and HD (ReNcell VM+full-length mHTT (138 CAG)) neuronal culture 
death in co-culture with BMD-microglia 
Unlike Mφ-CM treatments, MG-CM treatments did not increase death levels in wild-
type neuronal cultures compared with untreated, and acute stimulation of BMD-
microglia did not increase neurotoxicity of MG-CM treatments over time, over a 48 h 
time-course. Chronic stimulation of BMD-microglia, however, did increase wild-type 
and HD neuronal culture death levels above untreated, over time, and stimulated MG-
CM treatments resulted in significantly more wild-type neuronal culture death than non-
stimulated MG-CM treatments at 24 and 48 h chronic stimulation. This suggests that 
acute stimulation of healthy volunteer, pre-manifest HD and manifest HD BMD-
microglia does not affect neuronal death, but chronic stimulation is neurotoxic in wild-
type and HD neuronal cultures. These findings are consistent with multiple studies 
which report that chronic microglial activation and inflammation is neurotoxic in HD 
(Cicchetti et al. 2009; Crotti et al. 2014; Heneka et al. 2014). 
In non-stimulated conditions, treatment of wild-type neuronal cultures with MG-CM from 
manifest HD BMD-microglia reduced death levels below untreated levels, and these 
levels were lower than healthy volunteer MG-CM treatment at 24 h and pre-manifest 
HD MG-CM treatment at 48 h, suggesting that manifest HD BMD-microglia are more 
neuroprotective than healthy volunteer or pre-manifest HD BMD-microglia. Non-
stimulated manifest HD MG-CM treatments also reduced wild-type neuronal culture 
death below HD neuronal culture death levels, overall, while non-stimulated healthy 
volunteer or pre-manifest HD MG-CM treatments did not; and stimulated (chronic) 
healthy volunteer MG-CM treatments increased HD neuronal culture death levels 
above wild-type neuronal culture death levels, overall, while stimulated (chronic) 
manifest HD MG-CM treatments did not.  
4.6.2.2 ReNcell VM+HTT exon 1 (29, 71 or 129 CAG) neuronal culture death in co-
culture with BMD-microglia 
ReNcell VM+HTT exon 1 HD neurons were shown previously in this Thesis to exhibit 
several features similar to neurons in the HD patient brain (section 3.5.2.1). Baseline 
neuronal culture death levels were shown to be higher in ReNcell VM+mHTT exon 1 
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(71 CAG) neuronal cultures compared with ReNcell VM+HTT exon 1 (29 CAG) or 
ReNcell VM+mHTT exon 1 (129 CAG) neuronal cultures (Figure 3.11), and it was 
determined that this was most likely due to mHTT exon 1-induced neurotoxicity. Here, 
ReNcell VM+HTT exon 1 (29, 71 or 129 CAG) neuronal cultures were treated with MG-
CM from non-stimulated and stimulated (chronic) healthy volunteer and manifest HD 
BMD-microglia, to assess the effects of BMD-microglia released factors on neuronal 
culture death.  
None of the MG-CM treatments altered death levels in ReNcell VM+HTT exon 1 (29 
CAG) or ReNcell VM+mHTT exon 1 (129 CAG) neuronal cultures from untreated, 
however, several MG-CM treatments reduced levels of death in ReNcell VM+mHTT 
exon 1 (71 CAG) neuronal cultures compared with untreated. In non-stimulated 
conditions, healthy volunteer MG-CM reduced neuronal death at 24 h whilst manifest 
HD MG-CM did not, suggesting that non-stimulated healthy volunteer BMD-microglia 
were neuroprotective and non-stimulated manifest HD BMD-microglia were not. By 48 
h non-stimulated, however, both healthy volunteer and manifest HD MG-CM reduced 
neuronal death. After 24 h chronic stimulation, neither healthy volunteer nor manifest 
HD MG-CM reduced neuronal death, but after 48 h chronic stimulation both healthy 
volunteer and manifest HD MG-CM reduced neuronal death.  
Overall, these results suggest that both healthy volunteer and manifest HD BMD-
microglia protect HD neurons from mHTT-induced neurotoxicity leading to neuronal 
death. Others have also reported that microglia may be neuroprotective in HD via 
provision of trophic support to degenerating neurons (Andre et al. 2016), and Kraft et 
al. (2012) showed that wild-type microglia increased neuronal survival in mHTT-
expressing neurons in co-culture. It has been considered that cell-autonomous 
dysfunction caused by mHTT expression in HD patient immune cells may reduce these 
protective functions (Heneka et al. 2014), however it was shown here that this is not 
the case under most conditions. It has also been proposed that microglial activation 
and neuroinflammation are neurotoxic in HD (Cicchetti et al. 2009; Crotti et al. 2014; 
Heneka et al. 2014), or are simply reactive processes; responding to 
neurodegeneration but not contributing to it in either a beneficial or harmful capacity 
(Wang et al. 2014a). The findings presented here, however, provide evidence for a 
neuroprotective role of microglia in HD.  
4.6.2.3 Th1- and Th2-type (and IL-2) cytokine release in BMD-microglia 
To examine potential neuroprotective factors released by BMD-microglia which may 
contribute to protection from mHTT-induced neurotoxicity, and to assess M1 versus M2 
microglial phenotypes in co-culture, levels of Th1-type cytokines (IFNү, IL-1β, IL-6, IL-
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8, IL-12 and TNFα), Th2-type cytokines (IL-4, IL-10 and IL-13) and IL-2 were measured 
in non-stimulated and stimulated (chronic) MG-CM from healthy volunteer and manifest 
HD BMD-microglia.  
In non-stimulated conditions, manifest HD BMD-microglia released elevated levels of 
IFNү and IL-2 compared with healthy volunteer BMD-microglia, at the 24 h time-point. 
In this same condition, healthy volunteer MG-CM reduced ReNcell VM+mHTT exon1 
(71 CAG) HD neuronal culture death and manifest HD MG-CM did not. At the 48 h 
time-point, these cytokine increases did not occur in manifest HD BMD-microglia, and 
both healthy volunteer and manifest HD MG-CM reduced ReNcell VM+mHTT exon1 
(71 CAG) HD neuronal culture death in this condition in co-culture. This suggests that 
elevated release of IFNү and IL-2 by BMD-microglia may prevent protection from 
mHTT-induced neurotoxicity in co-culture. 
In stimulated (chronic) conditions, manifest HD BMD-microglia released elevated levels 
of IL-12 compared with healthy volunteer BMD-microglia, independent of time-point. 
Manifest HD BMD-microglia also released elevated levels of IL-10 after 24 h chronic 
stimulation and reduced levels of TNFα after 48 h chronic stimulation, compared with 
healthy volunteer BMD-microglia. Increased release of anti-inflammatory Th2-type 
cytokine IL-10 followed by decreased release of proinflammatory Th1-type cytokine 
TNFα may indicate that manifest HD BMD-microglia had become more M2-polarised 
than healthy volunteer BMD-microglia. Elevated release of IL-10 after 24 h chronic 
stimulation did not correlate with protection from mHTT-induced neurotoxicity, as both 
healthy volunteer and manifest HD MG-CM treatments did not decrease ReNcell 
VM+mHTT exon1 (71 CAG) HD neuronal culture death in this condition. Reduced 
release of TNFα may have contributed to protection from mHTT-induced neurotoxicity, 
as manifest HD MG-CM treatment decreased ReNcell VM+mHTT exon1 (71 CAG) HD 
neuronal culture death in this condition, however, healthy volunteer MG-CM treatment 
also decreased neuronal culture death. 
There were no differences between healthy volunteer and manifest HD BMD-microglia 
in levels of cytokine release for any of the other cytokines analysed. When taken 
together, levels of release of Th1-type cytokine IFNү were decreased, and levels of 
release of Th2-type cytokines IL-4 and IL-13 were increased in both healthy volunteer 
and manifest HD BMD-microglia after 48 h chronic stimulation compared with 24 h 
chronic stimulation. This may be indicative of polarisation of BMD-microglia towards an 
M2 phenotype during chronic stimulation. Altered levels of release of these cytokines 
also correlated with protection from mHTT-induced neurotoxicity, as both healthy 
volunteer and manifest HD MG-CM treatments reduced ReNcell VM+mHTT exon1 (71 
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CAG) HD neuronal culture death after 48 h chronic stimulation, but not after 24 h 
chronic stimulation. 
4.6.2.4 Neurotrophin release in BMD-microglia 
Neurotrophins are a major class of neuroprotectants in the CNS. To examine potential 
neuroprotective factors released by BMD-microglia which may contribute to protection 
from mHTT-induced neurotoxicity, levels of release of two key neurotrophins, NGF and 
BDNF, were analysed in non-stimulated and stimulated (chronic) healthy volunteer and 
manifest HD BMD-microglia. There was no difference between healthy volunteer BMD-
microglia and manifest HD BMD-microglia in levels of NGF release, and levels of NGF 
release were not affected by chronic stimulation. Levels of BDNF release, however, 
were approximately 3-fold higher in manifest HD BMD-microglia compared with healthy 
volunteer BMD-microglia after 48 h chronic stimulation. Levels of BDNF release were 
also higher in both healthy volunteer and manifest HD BMD-microglia at the 48 h time-
point compared with the 24 h time-point in both non-stimulated and stimulated 
conditions. Increased levels of BDNF release in healthy volunteer BMD-microglia 
correlated with reduced ReNcell VM+mHTT exon1 (71 CAG) HD neuronal culture 
death in stimulated (chronic) conditions, and increased levels of BDNF release in 
manifest HD BMD-microglia correlated with reduced neuronal culture death in both 
non-stimulated and stimulated (chronic) conditions. Taken together, these results 
highlight BMD-microglia BDNF release as a contributor to protection of HD neurons 
from mHTT-induced neurotoxicity in co-culture. 
4.6.3 Protective and deleterious neuronal-myeloid cell interactions in HD  
In BMD-macrophage-neuronal co-culture, increases in the release of the 
proinflammatory cytokines IL-1β, IL-6 and TNFα in stimulated (acute) BMD-
macrophages correlated with neurotoxicity, or reduced neuroprotection, in HD neuronal 
cultures. Pathological roles of these proinflammatory cytokines have previously been 
reported in HD and they are considered to be key mediators of disease progression. 
Plasma levels of IL-6 and TNFα increase in correlation with disease progression and 
severity in HD patients (Dalrymple et al. 2007; Björkqvist et al. 2008; Heneka et al. 
2014); and in R6/2 mice, inhibition of IL-6 diminished weight loss and reduced motor 
deficits (Bouchard et al. 2012) and inhibition of TNFα decreased neuroinflammation 
and neurodegeneration and improved motor function (Hsiao et al. 2014). IL-1β 
augments inflammatory signals in the CNS and is involved in neuronal death (Ona et 
al. 1999). 
Peripheral inflammatory events could directly contribute to neuroinflammation and 
neurodegenerative processes in the CNS (Eskandari and Sternberg 2002; Wrona 
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2006), and multiple studies have shown peripheral immune dysfunction as a key 
modifier of neuroinflammation and central pathogenesis in HD (Zwilling et al. 2011; 
Bouchard et al. 2012; Franciosi et al. 2012; Kwan et al. 2012a). The BBB is 
compromised in HD (Drouin-Ouellet et al. 2015), and while CNS influx of peripherally-
derived immune cells has not been reported (Silvestroni et al. 2009; Möller 2010), there 
may be uncontrolled passage of blood-borne factors, such as cytokines, between the 
periphery and the brain (Drouin-Ouellet et al. 2015). Peripherally-derived cytokines can 
also enter the CNS in non-pathological conditions by directly crossing the BBB 
(Eskandari and Sternberg 2002; Wrona 2006). Here, BMD-macrophages, but not BMD-
microglia, released elevated levels of IL-1β, IL-6 and TNFα in response to stimulation. 
It is therefore possible that peripheral macrophages, and not microglia, are the source 
of elevated levels of IL-1β, IL-6 and TNFα which have been reported in the brain and 
CSF of HD patients and HD animal models (Ona et al. 1999; Björkqvist et al. 2008; 
Silvestroni et al. 2009; Bouchard et al. 2012; Ellrichmann et al. 2013; Alto et al. 2014). 
In BMD-microglia-neuronal co-culture, manifest HD BMD-microglia released elevated 
levels of IFNү and IL-2 compared with healthy volunteer BMD-microglia in non-
stimulated conditions, and this correlated with a loss of neuroprotection in HD neuronal 
cultures. IFNү has previously been shown to be elevated in the serum of HD patients 
(Kwan et al. 2012a) and levels of microglial IL-2 release have previously been shown to 
be elevated in association with brain injury (Girard et al. 2008). It has been reported 
that IFNү can cause neurotoxicity via activation of astrocytes (Hashioka et al. 2015). 
Long-term central administration of IL-2 in rats has been shown to promote 
neuroinflammation, myelin damage and neuronal loss (Hanisch et al. 1997). 
Although not released at different levels in HD BMD-microglia compared with healthy 
volunteer BMD-microglia, increased release of the Th2-type cytokines IL-4 and IL-13 
correlated with neuroprotection of HD neurons in co-culture in stimulated (chronic) 
conditions. Plasma levels of IL-4 have previously been shown to increase with HD 
progression (Björkqvist et al. 2008). Th2-type cytokines are released by alternatively 
activated (M2) microglia, and IL-4 and IL-13 promote alternative activation (Martinez 
and Gordon 2014). Th1-type cytokines are released by classically activated (M1) 
microglia. Levels of release of anti-inflammatory Th2-type cytokine IL-10 were elevated 
in stimulated (chronic) manifest HD BMD-microglia compared with healthy volunteer 
BMD-microglia, and this was followed by a decrease in the release of Th1-type 
cytokine TNFα in manifest HD BMD-microglia compared with healthy volunteer BMD-
microglia, which may be associated with neuroprotection of HD neurons in co-culture. 
This suggests that M2-polarised microglia are neuroprotective in HD whilst microglia 
polarised more towards M1 phenotype are not, and in conditions of chronic 
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inflammation, manifest HD microglia become more polarised towards an M2 phenotype 
than healthy volunteer microglia. M1 microglia have increased proinflammatory 
cytokine, iNOS and ROS production and can contribute to chronic inflammation-related 
neurotoxicity, while M2 microglia promote tissue repair and suppress inflammation 
(Berger 2000; Gordon and Taylor 2005). Analysis of striatal tissue gene expression in 
symptomatic R6/2 mice previously revealed Th1-type cytokines as potential regulators 
of disease (Crocker et al. 2006), and it has been reported that HD patient macrophages 
shift from a proinflammatory M1 phenotype to an anti-inflammatory M2 phenotype over 
the disease course in HD, along with an increase in IL-10-expressing macrophages in 
progressing symptomatic disease (Di Pardo et al. 2013). 
Increased release of BDNF in non-stimulated and stimulated (chronic) healthy 
volunteer and manifest HD BMD-microglia correlated with neuroprotection of HD 
neurons in co-culture, and after chronic stimulation, BDNF release was highly elevated 
in manifest HD BMD-microglia compared with healthy volunteer BMD-microglia. 
Microglia constitutively secrete low levels of BDNF during homeostasis, but during CNS 
inflammation or following injury, BDNF production is chronically upregulated (Nakajima 
et al. 2001; Kleij and Bienenstock 2007; Venkatesan et al. 2010; Gomes et al. 2013). 
HTT is involved in the production and transport of BDNF (Cattaneo et al. 2005), so it is 
possible that mHTT is dysregulated in these functions, leading to elevated release in 
response to chronic stimulation. BDNF supports neuronal survival, function and tissue 
repair and maintains CNS homeostasis (Saijo and Glass 2011), and it has been shown 
to have neuroprotective effects in several CNS injury and neurodegenerative disease 
models (Linker et al. 2010; Lee et al. 2012). Pharmacological approaches for the 
treatment of HD have included administration of BDNF to preserve remaining neural 
activity (Giampà et al. 2013), and increasing BDNF levels was shown to reduce 
neurotoxicity and ameliorate neurological signs in animal models of HD (Puerta et al. 
2010; Xie et al. 2010). 
4.7 Summary 
Healthy volunteer, pre-manifest HD and manifest HD BMD-macrophages are 
neurotoxic in co-culture with wild-type and HD (ReNcell VM+full-length mHTT (138 
CAG)) neurons. Levels of neuronal death were higher in HD neurons than wild-type 
neurons, and neurotoxicity increased following acute stimulation with LPS and IFNү. 
Increases in neuronal death were associated with elevated release of proinflammatory 
cytokines IL-1β, IL-6 and TNFα by BMD-macrophages.  
In non-stimulated conditions, manifest HD BMD-microglia were more neuroprotective in 
co-culture with wild-type neurons than healthy volunteer or pre-manifest HD BMD-
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microglia, and following chronic stimulation with LPS and IFNү, HD (ReNcell VM+full-
length mHTT (138 CAG)) neuronal culture death levels were higher than wild-type 
levels in co-culture with healthy volunteer BMD-microglia, but not in co-culture with 
manifest HD BMD-microglia. Acute stimulation of BMD-microglia with LPS and IFNү did 
not affect wild-type neuronal death in co-culture. 
Healthy volunteer and manifest HD BMD-microglia rescued HD neurons (ReNcell 
VM+mHTT exon 1 (71 CAG)) from mHTT-induced neurotoxicity leading to neuronal 
death in co-culture. Neuroprotective microglia phenotypes were associated with 
elevated levels of BDNF release, reduced levels of IFNү and IL-2 release in non-
stimulated conditions, and polarisation towards an M2-phenotype (decreased release 
of Th1-type cytokine TNFα and increased release of Th2-type cytokines IL-4, IL-10 and 
IL-13) during chronic stimulation with LPS and IFNү. In conditions of chronic 
stimulation, manifest HD BMD-microglia were considered to be more M2-polarised than 
healthy volunteer BMD-microglia, and levels of BDNF release were approximately 
three-fold higher in manifest HD BMD-microglia than healthy volunteer BMD-microglia.  
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5 Investigation into the effects of 
laquinimod on rescuing hyper-reactive 
immune cell dysfunction in HD patient 
myeloid cells  
5.1 Background 
Neurodegeneration and disease progression are accompanied by central and 
peripheral inflammation in HD, including activation of myeloid cells and elevated levels 
of proinflammatory factors in the brain, CSF and plasma (Singhrao et al. 1999; Sapp et 
al. 2001; Pavese et al. 2006; Dalrymple et al. 2007; Tai et al. 2007a; Tai et al. 2007b; 
Björkqvist et al. 2008; Silvestroni et al. 2009; Politis et al. 2011; Wild et al. 2011; Tabrizi 
et al. 2013; Chang et al. 2015). Blood plasma levels of proinflammatory cytokines are 
elevated early in HD pathogenesis, before the onset of clinical symptoms, and increase 
in correlation with disease progression and severity (Dalrymple et al. 2007; Björkqvist et 
al. 2008; Heneka et al. 2014), indicating that peripheral inflammatory events may 
contribute to neurodegenerative processes and disease progression in HD. Myeloid 
cells are the prime candidates for the source of these elevated cytokine levels. 
Microglia, monocytes and macrophages isolated from HD patients or HD mouse 
models are hyper-reactive in response to stimulation, and release elevated levels of 
proinflammatory cytokines (Björkqvist et al. 2008; Träger et al. 2014a). This may be 
due to dysfunctional cell-autonomous mechanisms caused by mHTT expression in 
myeloid cells (Crotti et al. 2014; Träger et al. 2014a). 
Laquinimod is a novel orally-active immunomodulatory drug which has been 
demonstrated to downregulate immune cell activation and inflammation in the 
periphery (Yang et al. 2004; Schulze-Topphoff et al. 2012) and in the CNS (Brück et al. 
2012; Mishra et al. 2014). In two Phase III clinical trials, laquinimod was shown to have 
beneficial effects on inflammation, brain atrophy and disease progression in MS 
patients, and was also demonstrated to be safe and well-tolerated in humans (Comi et 
al. 2012; Filippi et al. 2014; Vollmer et al. 2014). MS and HD share some similar 
pathological features, including inflammation in association with myelin, axonal and 
neuronal loss (Ellrichmann et al. 2013). Therefore, laquinimod may have potential to 
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slow brain atrophy rate and disease progression in HD patients through central and 
peripheral immunomodulatory mechanisms, as it has been shown to do in MS. 
HD myeloid cells have been demonstrated to release elevated levels of 
proinflammatory Th1-type cytokines, including IL-1β, IL-6, IL-8 and TNFα, in response 
to stimulation with LPS and IFNү (Björkqvist et al. 2008; Träger et al. 2014a), and 
multiple studies report a neurotoxic role for immune cell activation and elevated 
proinflammatory Th1-type cytokines in HD (Ona et al. 1999; Crocker et al. 2006; 
Cicchetti et al. 2009; Bouchard et al. 2012; Crotti et al. 2014; Heneka et al. 2014; Hsiao 
et al. 2014; Andre et al. 2016). In Chapter 4 of this Thesis, BMD-macrophages were 
shown to increase wild-type and HD (ReNcell VM+full-length mHTT (138 CAG)) 
neuronal death in co-culture, and this was associated with elevated release of 
proinflammatory Th1-type cytokines IL-1β, IL-6 and TNFα following acute stimulation 
with LPS and IFNү (section 4.6.1). BMD-microglia were demonstrated to rescue HD 
neurons (ReNcell VM+mHTT exon 1 (71 CAG)) from mHTT-induced neurotoxicity 
leading to neuronal death in co-culture, and this was associated with reduced levels of 
IL-2 and proinflammatory Th1-type cytokine IFNү release in non-stimulated conditions, 
and polarisation towards an M2-phenotype (decreased release of Th1-type cytokine 
TNFα and increased release of Th2-type cytokines IL-4, IL-10 and IL-13) during chronic 
stimulation with LPS and IFNү (sections 4.5.2.3 and 4.5.4.2). Therefore, promoting the 
polarisation of myeloid cells towards an M2 phenotype may be beneficial in HD. 
Laquinimod has been shown to drive an immunomodulatory shift in immune cell 
phenotypes away from M1 and Th1-type cytokine production and towards M2 and Th2-
type cytokine production in vivo in animal models of MS and in vitro in primary human 
microglia and PBMCs (Zou et al. 2002; Yang et al. 2004; Brück and Wegner 2011; 
Schulze-Topphoff et al. 2012; Mishra et al. 2014). Laquinimod may therefore have the 
potential to promote reparative and neuroprotective M2 and Th2-type inflammatory 
phenotypes whilst suppressing M1 and Th1-type proinflammatory and neurotoxic 
phenotypes in HD. 
Hyper-reactivity of the innate immune response in HD is due partly to NFκB pathway 
dysregulation (Khoshnan et al. 2004; Hsiao et al. 2013; Träger et al. 2014a). Aberrant 
NFκB signalling has been demonstrated in peripheral myeloid cells isolated from HD 
patients, where mHTT was shown to interact with the ү subunit of IKK, leading to a 
more rapid degradation of IκB following LPS stimulation in HD myeloid cells compared 
with healthy volunteer myeloid cells (Träger et al. 2014a). This resulted in increased 
and prolonged NFκB activity and increased NFκB-dependent gene expression, leading 
to the elevated production and release of proinflammatory Th1-type cytokines in 
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response to stimulation (Khoshnan et al. 2004; Björkqvist et al. 2008; Träger et al. 
2014a). Also, mHTT-induced transcriptional dysregulation affects key inflammatory 
signalling pathways in HD patient myeloid cells, including elements of the NFκB 
pathway (Träger et al. 2014a). Laquinimod mechanism of action may involve alteration 
of NFκB signalling. In a mouse model of MS, laquinimod administration reduced the 
proportion of astrocytes with nuclear NFκB (p65/RelA) immune-reactivity (Brück et al. 
2012), and in human PBMC cultures laquinimod treatment increased IκB expression 
and decreased expression of downstream NFκB genes (Gurevich et al. 2010). 
Laquinimod-induced reduction of p65 translocation has also been demonstrated in 
primary murine astrocytes (Brück et al. 2012). Laquinimod may therefore have the 
potential to reverse NFκB pathway dysfunction in HD patient myeloid cells and dampen 
the elevated production of proinflammatory Th1-type cytokines in these cells. 
When orally-administered, laquinimod is quickly absorbed into the blood stream from 
where only a small percentage (7-8 %) crosses the BBB and penetrates the CNS. It is 
therefore likely that laquinimod acts primarily in the periphery, although the drug has 
been shown to have both central and peripheral affects. Multiple studies have shown 
peripheral immune dysfunction as a key modifier of neuroinflammation and central 
pathogenesis in HD, and intervention of peripheral inflammatory events has previously 
been shown to modulate central neuropathology and disease progression (Zwilling et 
al. 2011; Bouchard et al. 2012; Franciosi et al. 2012; Kwan et al. 2012a). Changes in 
peripheral cytokine profile has the potential to affect neuroinflammatory processes by 
CNS-entry of peripherally-derived cytokines (Eskandari and Sternberg 2002; Wrona 
2006; Drouin-Ouellet et al. 2015). 
The effects of laquinimod treatment on Th1- and Th2-type cytokine release (and IL-2) 
in primary monocytes isolated from HD patients was investigated, to determine whether 
laquinimod can reduce hyper-reactive proinflammatory cytokine release in these cells, 
and promote a switch from M1 and Th1-type proinflammatory and neurotoxic 
phenotypes to M2 and Th2-type reparative and neuroprotective phenotypes. The 
effects of laquinimod treatment on mHTT-IKKү protein interactions, IκB degradation 
kinetics and nuclear translocation of NFκB p65 was also investigated in HD patient 
peripheral myeloid cells, to determine if laquinimod can reverse NFκB pathway 
dysfunction in these cells. This was the first demonstration of the effects of laquinimod 
in HD patient myeloid cells. 
5.2 Aims 
1) Determine if laquinimod treatments are toxic in primary human monocytes. 
Effects of laquinimod on hyper-reactivity in HD patient myeloid cells 
 
261 
 
2) Determine if laquinimod treatment alters Th1- and Th2-type (and IL-2) cytokine 
release away from M1 and in favour of an M2 functional signature in primary 
human monocytes isolated from HD patients, in non-stimulated and stimulated 
conditions. 
3) Determine if laquinimod treatment can reverse NFκB pathway dysfunction in HD 
patient myeloid cells by examining mHTT-IKKү protein interactions, IκB 
degradation kinetics and nuclear translocation of NFκB p65 in laquinimod-treated 
HD patient monocytes and BMD-macrophages. 
5.3 Methods 
A summary of methods used in this Chapter is outlined below. Full details of 
experimental protocols can be found in Chapter 2: Materials and Methods. 
Human samples were classified as described in section 2.1.2.1. Primary human 
monocytes were isolated from healthy volunteers, pre-manifest HD gene carriers and 
manifest HD patients (section 2.1.2.2) and cultured ex vivo (section 2.1.2.3), and BMD-
macrophages were differentiated in vitro from primary human monocyte cultures 
(section 2.1.2.4). In cases where myeloid cells are referred to as “stimulated”, cells 
were stimulated as described in section 2.1.2.6. Details for laquinimod, including 
pharmacokinetic information on the compound, can be found in section 2.8. 
Laquinimod toxicity was tested in primary human monocyte cultures as described in 
section 2.8.1, using LDH cytotoxicity assay (section 2.6.1). Laquinimod treatment 
conditions were as described in section 2.8.2, and levels of cytokine release were 
measured in non-stimulated and stimulated conditions using MSD Human Th1/Th2 10-
Plex Tissue Culture Kit or Human IL-6 Singleplex Kit (section 2.5.6.2). Investigations 
into laquinimod-induced NFκB pathway modulation were performed as described in 
section 2.8.3. Interactions between mHTT and IKKү were assessed by PLA (section 
2.5.3), IκB degradation kinetics were assessed by Western blotting techniques 
(sections 2.4.1.2, 2.4.3, 2.4.4 and 2.5.1.2; antibody details in section 2.5.1.3) and NFκB 
p65 nuclear translocation was assessed by IFC (section 2.5.5). Statistical analyses 
were performed as described in section 2.9.  
5.4 Contributions 
 Pre-clinical drug testing of laquinimod in HD patient myeloid cells was 
performed in collaboration with Teva Pharmaceutical Industries Ltd, who 
provided the compound. 
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 All laboratory work described in this Chapter was performed in equal parts by 
Dr. Ulrike Träger (Prof. Sarah J. Tabrizi’s research group, UCL IoN, London, 
UK) and myself, Lucianne Dobson.  
 Statistical analysis of levels of cytokine release in laquinimod-treated (and 
untreated) monocytes was performed by an independent statistician, Ruth 
Farmer (London School of Hygiene & Tropical Medicine, Department of Medical 
Statistics, London, UK).  
Findings presented in this chapter were published in Journal of Neurochemistry 
(Appendix III-i):  
Dobson L., Träger U., Farmer R., Hayardeny L., Loupe P., Hayden M. R., Tabrizi S. J. 
(2016) Laquinimod dampens hyperactive cytokine production in Huntington's disease 
patient myeloid cells. J. Neurochem. 137, 782-794. 
5.5 Results 
5.5.1 Testing laquinimod toxicity in ex vivo human monocyte cultures 
Before investigating the effects of laquinimod on reversing hyper-reactivity in HD 
patient myeloid cells, it was important to determine whether laquinimod treatments 
were toxic in these cells. Healthy volunteer and HD patient monocytes were treated for 
24 h or 48 h with a range of laquinimod concentrations from 0.001 to 100 µM, including 
previously published concentrations (1 µM and 5 µM) which had been used to treat 
human PBMCs in culture (Brück and Wegner 2011). Cell death was then assessed by 
LDH cytotoxicity assay and compared with levels of death in untreated monocyte 
cultures. Results are presented in Figure 5.1. 
Laquinimod concentration was not a significant source of variation in percentage 
monocyte survival after 48 h laquinimod treatment (p>0.05), but it was after 24 h 
laquinimod treatment (p=0.016). However, none of the individual laquinimod treatment 
conditions, after 24 h or 48 h treatment, showed a statistically significant difference in 
percentage monocyte survival compared with untreated (p>0.05), and confidence 
intervals (calculated at the 95 % confidence level) around the mean percentage 
survival relative to untreated cells spanned 100 % survival in all laquinimod-treated 
conditions, and were generally narrow. After 24 h laquinimod treatment, 1 μM and 5 μM 
laquinimod resulted in a mean average of 95.39 % and 101.01 % monocyte survival 
relative to untreated cells, respectively, and the lower limits of the confidence intervals 
for these results were 79.17 % for 1 μM laquinimod and 82.91 % for 5 μM laquinimod. 
After 48 h laquinimod treatment, 1 μM and 5 μM laquinimod resulted in a mean 
average of 99.84 % and 97.54 % monocyte survival relative to untreated cells, 
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respectively, and the lower limits of the confidence intervals for these results were 
88.01 % for 1 μM laquinimod and 86.84 % for 5 μM laquinimod. These results 
confirmed that at concentrations of 1 µM and 5 µM, one can be confident that the true 
cell survival relative to untreated is above 79 % after 24 h treatment and above 86 % 
after 48 h treatment, which was taken to be acceptable in terms of establishing a lack 
of laquinimod toxicity. Therefore, previously published concentrations of 1 µM and 5 
µM laquinimod (Brück and Wegner 2011) were used for subsequent experiments, 
which are relevant concentrations based on physiological in vivo data for plasma levels 
of laquinimod in humans (Preiningerova 2009; Sennbro et al. 2006) and mice 
(Brunmark et al. 2002). 
 
Figure 5.1: Primary human monocyte survival following laquinimod treatment 
Healthy volunteer and manifest HD monocyte cultures (n=6) were treated, in duplicate, with 0, 
0.001, 0.01, 0.1, 0.5, 1, 5, 10, 50 or 100 μM laquinimod for 24 or 48 h. Toxicity was then 
analysed by LDH cytotoxicity assay and results are presented as mean average laquinimod-
treated monocyte survival from biological repeats, expressed as a percentage of untreated 
monocyte survival, each with three internal experimental replicates, ± SEM. Laquinimod 
treatment concentrations of 1 µM and 5 µM laquinimod (boxed) were used in subsequent 
experiments. Data were statistically analysed using one-way ANOVA with Dunnett’s multiple 
comparison tests comparing all laquinimod treatment conditions to untreated.  
5.5.2 Investigation into the effects of laquinimod on elevated cytokine release 
in HD patient monocytes 
To determine whether laquinimod can reduce elevated proinflammatory cytokine 
release in HD patient myeloid cells, and promote an M1 to M2 phenotype switch in 
these cells, Th1- and Th2-type (and IL-2) cytokine release was measured in untreated 
and laquinimod-treated healthy volunteer, pre-manifest HD and manifest HD 
monocytes, in non-stimulated and stimulated conditions. Monocyte cultures were pre-
treated with 1 µM or 5 µM laquinimod for 2 or 24 h, or were untreated. Cells were then 
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stimulated with 1 µg/mL LPS and 10 ng/mL IFNү, or were non-stimulated, for 24 h (with 
or without continued laquinimod treatment). See Table 5.1 for details of the laquinimod 
treatment conditions tested. Levels of the following cytokines were then measured in 
monocyte culture supernatants (MC-CM), by MSD assay: Th1-type cytokines: IL-1β, IL-
6, IL-8, IL-12 and TNFα; Th2-type cytokines: IL-4, IL-5, IL-10 and IL-13; and IL-2. 
Table 5.1: Laquinimod treatment conditions 
Laquinimod treatment  
duration 
Laquinimod treatment 
concentration 
Stimulation 
conditions 
2 h pre-treatment (2hPT) 1 µM or 5 µM 
Stimulated or  
non-stimulated 
24 h pre-treatment (24hPT) 1 µM or 5 µM 
Stimulated or  
non-stimulated 
24 h pre-treatment with 24 h 
continued treatment (24hPT+24hCT) 
5 µM 
Stimulated or  
non-stimulated 
 
5.5.2.1 Cytokine release in non-laquinimod-treated monocytes 
In non-stimulated conditions, levels of all cytokines, other than IL-6, were significantly 
higher (p<0.05), or borderline (p=0.05-0.06), in manifest HD MC-CM compared with 
healthy volunteer MC-CM. Levels of IL-5, IL-8 and IL-13 (p<0.05) were also higher in 
pre-manifest HD MC-CM compared with healthy volunteer MC-CM. While the other 
cytokines tested were not elevated in pre-manifest HD MC-CM, both pre-manifest HD 
and manifest HD subject groups showed similar trends, and combining the HD subjects 
increased the power sufficiently to detect a statistically significant (p<0.05), or 
borderline significant (p=0.05-0.06), increase in all cytokines tested in HD MC-CM 
compared with healthy volunteer MC-CM. This suggests that in non-stimulated 
conditions, HD monocytes release elevated levels of both Th1-type cytokines (IL-1β, 
IL-6, IL-8, IL-12 and TNFα) and Th2-type cytokines (IL-4, IL-5, IL-10 and IL-13), as well 
as IL-2. 
In stimulated conditions, there was evidence of an increase in levels of IL-1β, IL-5 and 
IL-13 in manifest HD MC-CM compared with healthy volunteer MC-CM, with log levels 
of these cytokines being approximately 0.4 higher in manifest HD MC-CM and 
differences being of at least borderline statistical significance (p<0.06). Levels of IL-4, 
IL-6 and IL-10 had increases of similar magnitude in manifest HD MC-CM compared 
with healthy volunteer MC-CM, but these differences did not reach borderline 
significance (p>0.07). IL-8 levels were lower in pre-manifest HD MC-CM compared with 
healthy volunteer MC-CM, with borderline statistical significance (p=0.05). All other 
Effects of laquinimod on hyper-reactivity in HD patient myeloid cells 
 
265 
 
comparisons of cytokine levels in pre-manifest HD or manifest HD MC-CM compared 
with healthy volunteer MC-CM were not significant or borderline significant. Overall, in 
stimulated conditions there was little statistical evidence of differences in cytokine 
release between pre-manifest HD or manifest HD monocytes and healthy volunteer 
monocytes.  
5.5.2.2 Cytokine release in laquinimod-treated non-stimulated monocytes 
In non-stimulated healthy volunteer MC-CM, levels of IL-4 (p=0.009) and IL-5 (p=0.002) 
were increased after 2hPT with 1 µM laquinimod, compared with untreated, and there 
was a borderline increase in levels of IL-12 (p=0.062). After 24hPT with 1 µM 
laquinimod, levels of IL-4 and IL-5 were still estimated to be higher, but to a lesser 
degree which was not statistically significant. When treated with 5 μM laquinimod, 
levels of IL-5 (p=0.025) and IL-12 (p=0.036) were increased after 2hPT, compared with 
untreated; levels of IL-4 (p=0.014), IL-5 (p=0.002) and TNFα (p=0.022) were increased 
after 24hPT, compared with untreated; and levels of IL-2 (p=0.030), IL-5 (p=0.007), IL-
10 (p=0.004), IL-12 (p=0.026), IL-13 (p=0.005) and TNFα (p=0.006) were increased 
after 24hPT+24hCT, compared with untreated, in non-stimulated healthy volunteer MC-
CM. None of the laquinimod treatments had a statistically significant effect on cytokine 
levels compared with untreated in non-stimulated pre-manifest HD or manifest HD MC-
CM (Figure 5.2). This suggests that in non-stimulated conditions, laquinimod elevates 
release of Th1-type cytokines, Th2-type cytokines and IL-2 in healthy volunteer 
monocytes, but does not affect cytokine release in pre-manifest HD or manifest HD 
monocytes. 
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Figure 5.2: Cytokine release in non-stimulated monocytes treated with 
laquinimod 
Healthy volunteer (HV; n=6-15), pre-manifest HD (preHD; n=4-9) and manifest HD (manHD; 
n=8-18) monocyte cultures were pre-treated with 1 µM or 5 µM laquinimod, or were untreated, 
for 2 h or 24 h followed by 24 h rest, or were pre-treated with 5 µM laquinimod followed by 24 h 
continued treatment with 5 µM laquinimod. All conditions were tested in duplicate in monocyte 
cultures from each subject. Levels of Th1-type cytokines (A) and Th2-type cytokines (and IL-2) 
(B) were then measured in MC-CM by MSD assay, with two internal MSD assay experimental 
replicates per condition per subject culture. Results are presented as mean average loge 
cytokine level normalised to total protein per culture, from biological repeats, ± SD. Data were 
statistically analysed using a linear mixed regression model (as described in detail in section 
2.9.3); *p<0.05, **p<0.01. 
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5.5.2.3 Cytokine release in stimulated monocytes pre-treated with 1 µM laquinimod 
In stimulated healthy volunteer monocytes, 2hPT with 1 µM laquinimod did not have a 
significant effect on levels of any of the cytokines measured, compared with untreated 
(p>0.05). After 24hPT with 1 µM laquinimod, there was a significant increase in levels 
of IL-5 (p=0.035) and a borderline significant increase in levels of IL-8 (p=0.064), 
compared with untreated.  
In stimulated pre-manifest HD monocytes, 2hPT with 1 µM laquinimod resulted in a 
significant decrease in levels of IL-8 (p=0.004) and a borderline significant decrease in 
levels of IL-6 (p=0.069), compared with untreated. After 24hPT with 1 µM laquinimod, 
levels of IL-6 were significantly decreased compared with untreated (p=0.028). 
In stimulated manifest HD monocytes, 2hPT with 1 µM laquinimod also resulted in a 
significant decrease in levels of IL-8 (p=0.005), compared with untreated. After 24hPT, 
however, there were no statistically significant effects of 1 µM laquinimod treatment, 
compared with untreated, on levels of any of the cytokines measured (p>0.05).  
Results for cytokine release in stimulated monocytes pre-treated with 1 µM laquinimod 
are presented in Figure 5.3. 
5.5.2.4 Cytokine release in stimulated monocytes pre-treated with 5 µM laquinimod 
In stimulated healthy volunteer monocytes, 2hPT or 24hPT with 5 µM laquinimod did 
not have a significant effect on levels of any of the cytokines measured, compared with 
untreated (p>0.05). After 24hPT+24hCT with 5 µM laquinimod there was a significant 
decrease in levels of IL-6 (p=0.004) and a significant increase in levels of IL-5 
(p=0.047) and IL-13 (p=0.041), compared with untreated. 
In stimulated pre-manifest HD monocytes, although not always statistically significant, 
levels of cytokines following treatment with 5 µM laquinimod were generally lower than 
untreated. IL-2 and IL-5 were the only exceptions, which showed trends for increased 
levels compared with untreated. These increases, however, were small in magnitude 
and not statistically significant. After 2hPT with 5 µM laquinimod, there were significant 
decreases in levels of IL-6 (p=0.015) and IL-10 (p=0.037), compared with untreated, in 
stimulated pre-manifest HD MC-CM. After 24hPT, there were significant decreases in 
levels of IL-8 (p=0.015), IL-10 (p=0.015) and IL-13 (p=0.033) compared with untreated. 
After 24hPT+24hCT, there were significant decreases in levels of IL-6 (p=0.016) and 
IL-10 (p=0.004) compared with untreated. 
In stimulated manifest HD monocytes, 2hPT with 5 µM laquinimod did not have a 
significant effect on levels of any of the cytokines measured, compared with untreated 
(p>0.05). However, after 24hPT with 5 µM laquinimod, there were at least borderline 
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significant decreases in levels of several cytokines compared with untreated. There 
were decreases in the Th1-type cytokines IL-1β (p=0.022), IL-6 (p=0.056), IL-8 
(p=0.052) and TNFα (p=0.007), and the Th2-type cytokines IL-5 (p=0.053), IL-10 
(p=0.044) and IL-13 (p=0.052). In addition, 24hPT with 5 μM laquinimod resulted in a 
statistically significant decrease in levels of the cytokines IL-1β, IL-10 and TNFα in 
manifest HD monocytes, which did not occur in healthy volunteer monocytes. While not 
statistically significant, many of the other cytokines were also decreased in manifest 
HD MC-CM and not in healthy volunteer MC-CM. This may suggest that 24hPT with 5 
μM laquinimod has more of an effect on reducing cytokine release in manifest HD 
monocytes than in healthy volunteer monocytes. After 24hPT+24hCT with 5 µM 
laquinimod, there were significant decreases in levels of IL-12 (p=0.028) and TNFα 
(p=0.009), and a borderline significant decrease in levels of IL-6 (p=0.053), compared 
with untreated, in stimulated manifest HD monocytes. Although not statistically 
significant, levels of IL-2, IL-4, IL-5 and IL-13 were increased, going against the trend 
for a decrease in cytokine levels occurring after 2hPT and 24hPT with 5 µM 
laquinimod. 
A secondary analysis was performed, with HD subject groups (pre-manifest HD and 
manifest HD) combined, to increase statistical power and assess differences in 
cytokine release between healthy volunteer and HD monocytes overall. In stimulated 
HD monocytes, 24hPT with 5 µM laquinimod resulted in at least borderline significant 
decreases in levels of the Th1-type cytokines IL-1β (p=0.006), IL-6 (p=0.059), IL-8 
(p=0.005) and TNFα (p=0.003), and the Th2-type cytokines IL-10 (p=0.003) and IL-13 
(p=0.009), compared with untreated. Additionally, the difference in change from the 
untreated condition between grouped HD subjects and healthy volunteers was of at 
least borderline significance for IL-1β (p=0.062), IL-5 (p=0.045), IL-10 (p=0.008), IL-13 
(p=0.005) and TNFα (p=0.045), suggesting that 24hPT with 5 µM laquinimod has a 
larger effect on reducing cytokine release in HD monocytes than in healthy volunteer 
monocytes. 
Results for cytokine release in stimulated monocytes pre-treated with 5 µM laquinimod 
are presented in Figure 5.3. 
Chapter 5 
270 
 
 
Effects of laquinimod on hyper-reactivity in HD patient myeloid cells 
 
271 
 
 
Figure 5.3: Cytokine release in stimulated monocytes pre-treated with 
laquinimod 
Healthy volunteer (HV; n=8-15), pre-manifest HD (preHD; n=5-9) and manifest HD (manHD; 
n=8-19) monocyte cultures were pre-treated with 1 µM or 5 µM laquinimod, or were untreated, 
for 2 h or 24 h followed by 24 h stimulation with 1 µg/mL LPS and 10 ng/mL IFNү, or were pre-
treated with 5 µM laquinimod followed by 24 h stimulation with continued treatment with 5 µM 
laquinimod. All conditions were tested in duplicate in monocyte cultures from each subject. 
Levels of Th1-type cytokines (A) and Th2-type cytokines (and IL-2) (B) were then measured in 
MC-CM by MSD assay, with two internal MSD assay experimental replicates per condition per 
subject culture. Results are presented as mean average loge cytokine level normalised to total 
protein per culture, from biological repeats, ± SD. Data were statistically analysed using a linear 
mixed regression model (as described in detail in section 2.9.3); *p<0.05, **p<0.01. 
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5.5.3 Investigation into the effects of laquinimod on NFκB pathway modulation 
in HD patient myeloid cells 
In section 5.5.2.4, 24hPT with 5 µM laquinimod was demonstrated to reduce cytokine 
release in response to stimulation in HD patient monocytes. To determine if laquinimod 
reduced cytokine release by reversing NFκB pathway dysfunction, the effects of 
laquinimod treatment on mHTT-IKKү protein interactions, IκB degradation kinetics and 
nuclear translocation of NFκB p65 were assessed in HD patient myeloid cells. 
5.5.3.1 Mutant HTT-IKKү protein interactions in laquinimod-treated HD patient BMD-
macrophages 
It has previously been shown that in HD patient myeloid cells, mHTT directly interacts 
with the ү subunit of IKK, and it is this dysfunctional interaction which may lead to 
elevated IκB degradation in HD patient myeloid cells compared with healthy volunteer 
myeloid cells (Träger et al. 2014a). To determine if laquinimod can reduce, or prevent, 
these dysfunctional protein interactions, pre-manifest HD and manifest HD BMD-
macrophages were treated with 5 µM laquinimod for 24 h, or were untreated, and PLA 
was performed to assess HTT-IKKү interactions in these cells. As demonstrated by 
Träger et al. (2014a), interactions between HTT and IKKү were detected in HD patient 
BMD-macrophages, however there was no significant difference between the number 
of HTT-IKKү interactions (PLA spots per cell) in laquinimod-treated BMD-macrophages 
compared with untreated BMD-macrophages (p=0.552) (Figure 5.4). This suggests that 
laquinimod does not affect the interaction between mHTT and IKKү in HD patient BMD-
macrophages. 
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Figure 5.4: Interactions between mHTT and IKKү in laquinimod-treated HD 
patient BMD-macrophages 
Pre-manifest HD and manifest HD BMD-macrophage cultures (n=5-6) were treated with 5 μM 
laquinimod, or were untreated, for 24 h. Interactions between HTT and IKKү were then detected 
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by PLA, using primary antibodies directed at HTT (4C9) and IKKү. Cells were imaged using 
confocal fluorescence microscopy, and a direct interaction between the two proteins is 
presented as a fluorescent red spot. Results are presented as mean average number of PLA 
spots per cell, from biological repeats, ± SEM (A). The positive control (primary antibodies 
directed at IKKү and IKKβ; two proteins known to directly interact) and negative controls 
(primary antibodies directed at HTT only (4C9) or IKKү only, with both secondary antibodies) 
indicate success of the assay. Representative example confocal fluorescence microscopy 
images following PLA in BMD-macrophages from the same HD patient are also presented (B). 
Nuclei were stained with DAPI (blue), membranes were stained with WGA (green), and red 
spots indicate direct interactions between HTT and IKKү. Scale bars = 50 µm. Data were 
statistically analysed using a paired, two-tailed, Student’s t-test to compare the mean 
differences in PLA spots per cell between laquinimod-treated and untreated HD patient BMD-
macrophages (5 matched pairs). 
5.5.3.2 IκB degradation kinetics in laquinimod-treated HD patient monocytes 
Träger et al. (2014a) had previously shown that degradation of IκB is more rapid in 
response to LPS stimulation in HD patient myeloid cells compared with healthy 
volunteer myeloid cells, leading to elevated nuclear translocation of NFκB p65. To 
determine if laquinimod can reduce this increased IκB degradation, IκB levels were 
measured by Western botting in HD patient monocyte cultures over a 60 min time-
course post-LPS stimulation, in untreated cells or cells which had received 24hPT with 
5 µM laquinimod. LPS stimulation resulted in the usual IκB degradation pattern for HD 
patient monocytes (Träger et al. 2014a), and laquinimod pre-treatment did not 
significantly alter IκB levels, compared with untreated, over time post-LPS stimulation 
(p=0.566) (Figure 5.5). There were also no significant differences in IκB levels between 
laquinimod-treated and untreated monocyte cultures at each time-point post-stimulation 
(p>0.05). This suggests that laquinimod does not affect IκB degradation kinetics in HD 
patient myeloid cells. 
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Figure 5.5: IκB degradation kinetics post-LPS stimulation in laquinimod-treated 
HD patient monocytes  
Manifest HD patient monocyte cultures (n=4) were pre-treated with 5 μM laquinimod, or were 
untreated, for 24 h, then were stimulated with 1 μg/ml LPS. Cell lysates were harvested at 0, 5, 
15, 30 and 60 min post-LPS stimulation and IκB levels were measured using Western blot. All 
IκB readings were normalised to the house-keeping protein GAPDH, and quantified by 
densitometry analysis giving a procedure defined unit (p.d.u.) for comparison of conditions. 
Results are presented as mean average IκB level from biological repeats, ± SEM. Data were 
statistically analysed using two-way RM ANOVA with Bonferroni post-tests. 
5.5.3.3 NFκB p65 nuclear translocation in laquinimod-treated HD patient monocytes 
It has previously been shown that in response to LPS stimulation, nuclear translocation 
of NFκB p65 is enhanced in HD patient myeloid cells compared with healthy volunteer 
myeloid cells (Träger et al. 2014a). Increased NFκB activity may be the cause for 
elevated proinflammatory cytokine release in these cells. Laquinimod treatment has 
been demonstrated to reduce p65 nuclear translocation in primary murine astrocytes 
(Brück et al. 2012). To determine if laquinimod can reduce increased nuclear 
translocation of p65 in HD patient myeloid cells, p65 nuclear translocation was 
assessed by IFC in manifest HD patient monocytes 45 min post-LPS stimulation, in 
untreated cells or cells which had received 24hPT with 5 µM laquinimod. There was no 
significant difference in the extent of p65 translocation in laquinimod-treated monocytes 
compared with untreated monocytes (p=0.466) (Figure 5.6). This suggests that 
laquinimod does not reduce increased nuclear translocation of p65 in HD patient 
monocytes. 
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Figure 5.6: Nuclear translocation of p65 in laquinimod-treated HD patient 
monocytes 
Manifest HD monocyte cultures (n=7) were treated with 5 μM laquinimod, or were untreated, for 
24 h, then were stimulated with 1 μg/ml LPS for 45 min. Nuclear translocation of p65 post-
stimulation was assessed by IFC and results are presented as mean average percentage 
translocated cells, from biological repeats, ± SEM (A). Representative example IFC images of 
monocytes from the same HD patient are also presented (B). Monocytes were probed for p65 
(green) and nuclei were stained with DAPI (pink) to determine extra- or intra-nuclear localisation 
of p65, and cells were considered to be “untranslocated” (top) or “translocated” (bottom), 
respectively. Data were statistically analysed using a paired, two-tailed, Student’s t-test to 
compare the mean differences in percentage translocated cells between laquinimod-treated and 
untreated HD patient monocytes (7 matched pairs). 
5.6 Discussion 
5.6.1 Cytokine release in healthy volunteer, pre-manifest HD and manifest HD 
monocytes 
It has previously been shown that HD patient monocytes release elevated levels of the 
proinflammatory cytokines IL-1β, IL-6 and TNFα, compared with healthy volunteer 
monocytes, in response to stimulation with LPS and IFNү (Björkqvist et al. 2008; 
Träger et al. 2014a). It was shown here that HD monocytes also release elevated 
levels of cytokines in non-stimulated conditions, including both Th1-type cytokines (IL-
1β, IL-6, IL-8, IL-12 and TNFα) and Th2-type cytokines (IL-4, IL-5, IL-10 and IL-13), as 
well as IL-2. This suggests that HD monocytes have an inherent dysfunctional 
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upregulation of cytokine release, and this does not only apply to proinflammatory Th1-
type cytokines, but also to Th2-type cytokines and IL-2.  
In stimulated conditions, manifest HD monocytes were shown here to release 
increased levels of IL-1β, IL-5 and IL-13, and pre-manifest HD monocytes released 
reduced levels of IL-8, compared with healthy volunteer monocytes. Levels of IL-6 and 
TNFα release were not increased in HD monocytes, unlike findings reported by 
Björkqvist et al. (2008) and Träger et al. (2014a). Reasons for these differences could 
be the lower LPS stimulation concentration used here (1 µg/mL rather than 2 µg/mL as 
was used by Björkqvist et al. and Träger et al.), and also the way cytokine levels were 
normalised. Here, cytokine levels were normalised to total protein levels per monocyte 
culture to account for cell number. Björkqvist et al. reported an increase in IL-6 levels in 
pre-manifest HD monocytes, but this was not normalised, and Träger et al. reported 
increases in IL-6 and TNFα levels in pre-manifest HD and manifest HD monocytes 
relative to the non-stimulated condition i.e. cytokine release was increased more in HD 
monocytes compared with increases in healthy volunteer monocytes. 
5.6.2 Effects of laquinimod treatments on cytokine release in healthy volunteer, 
pre-manifest HD and manifest HD monocytes 
Laquinimod did not reduce the dysfunctional upregulation of proinflammatory cytokine 
release in non-stimulated HD patient monocytes, and did not promote a Th2-type 
cytokine profile in these cells. In non-stimulated healthy volunteer monocytes, 
laquinimod treatment resulted in increases in Th1- and Th2-type cytokine release. In 
stimulated conditions, however, 24hPT with 5 µM laquinimod reduced the release of 
several cytokines in HD patient monocytes compared with untreated, including the Th1-
type cytokines IL-1β, IL-6, IL-8 and TNFα, and the Th2-type cytokines IL-5, IL-10 and 
IL-13, suggesting that laquinimod has an overall dampening effect on cytokine release 
in HD monocytes. The same laquinimod treatment also had an effect of larger 
magnitude in HD monocytes than in healthy volunteer monocytes for levels of IL-1β, IL-
5, IL-8, IL-10, IL-13 and TNFα release, suggesting that laquinimod has more of an 
effect on dampening cytokine release in HD patient monocytes than in healthy 
volunteer monocytes. 24hPT with 5 µM laquinimod had very little effect, if any, on 
levels of cytokine release in stimulated healthy volunteer monocytes.  
Trends in cytokine levels were generally consistent across laquinimod-treatment 
conditions in terms of laquinimod-induced changes being greater in magnitude at the 
higher drug concentration (5 µM) and with a longer pre-treatment duration (24 h). 
However, this did not usually extend to the 24hPT+24hCT condition, where in many 
cases a much smaller change from the untreated condition occurred than would have 
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been predicted, or there was even a change in the opposite direction. With the 
exception of IL-10, there were small increases in levels of release of the Th2-type 
cytokines after 24hPT+24hCT with 5 µM laquinimod. Interestingly, in stimulated healthy 
volunteer monocytes, levels of Th1-type cytokine IL-6 were decreased and levels of 
Th2-type cytokines IL-5 and IL-13 were increased, compared with untreated, indicating 
a potential laquinimod-induced M1 to M2 phenotype switch in these cells. In stimulated 
manifest HD patients, the same laquinimod treatment resulted in decreases in levels of 
Th1-type cytokines IL-12, TNFα and IL-6, and although not statistically significant, 
levels of IL-2 and the Th2-type cytokines IL-4, IL-5 and IL-13 were increased (levels of 
these cytokines were decreased in 2hPT and 24hPT conditions). It is possible that the 
24hPT+24hCT treatment condition may need to be considered independently from the 
pre-treatment only conditions due to laquinimod being present during stimulation. An 
alternative mechanism of action may be occurring under these conditions, such as 
competitive binding or confounding cross talk between intracellular signalling pathways.  
2hPT and 24hPT conditions did not show a laquinimod-induced shift from Th1- to Th2-
type cytokine balance, unlike what has been reported to occur in MS (Zou et al. 2002; 
Yang et al. 2004; Brück and Wegner 2011; Schulze-Topphoff et al. 2012). However, in 
MS, this laquinimod-induced cytokine shift was demonstrated in different systems than 
used here. Zou et al. (2002), Yang et al. (2004), Schulze-Topphoff et al. (2012) and 
Brück and Wegner (2011) all showed decreases in proinflammatory Th1-type cytokines 
and increases in anti-inflammatory and Th2-type cytokines in vivo in animal models of 
MS, following daily laquinimod treatment. Th1- to Th2-type cytokine switches were 
shown in sciatic nerve sections (Zou et al. 2002) or spleen mononuclear cells (Yang et 
al. 2004; Schulze-Topphoff et al. 2012) isolated from laquinimod-treated animals. 
However, in lymph node mononuclear cells and PBMCs isolated from laquinimod-
treated animals (Zou et al. 2002; Yang et al. 2004), or PBMCs isolated from healthy 
volunteers (Brück and Wegner 2011), the authors only report decreases in Th1-type 
cytokines. Also, in stimulated human microglia cultures, laquinimod pre-treatment was 
shown to reduce the release of both Th1-type cytokines TNFα, IL-1β, IL-12p70 and IL-
6 and Th2-type/regulatory cytokines IL-4, IL-10 and IL-1 receptor antagonist (IL-1RA) 
(Mishra et al. 2014). Therefore, the evidence presented here for a laquinimod-induced 
decrease in cytokine release overall from HD patient monocytes, and lack of a Th1- to 
Th2-type shift in cytokine balance in pre-treatment only conditions, is supported by the 
current literature on laquinimod effects in MS models and primary human myeloid cells. 
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5.6.3 Effects of laquinimod treatments on reversing NFκB pathway dysfunction 
in HD patient myeloid cells 
Modulation of NFκB signalling has previously been presented as a potential 
mechanism of action for laquinimod. Laquinimod reduced NFκB activation in a mouse 
model of MS and in primary human astrocyte cultures (Brück et al. 2012); and in 
laquinimod-treated PBMCs isolated from MS patients, genes downstream of NFκB 
signalling were downregulated (Gurevich et al. 2010). NFκB signalling has been shown 
to be pathologically enhanced in myeloid cells isolated from HD patients. This is due to 
a dysfunctional interaction between mHTT and IKKү which leads to a more rapid 
degradation of IκB, enhanced and prolonged nuclear translocation of NFκB p65 and 
elevated production and release of proinflammatory cytokines in response to LPS 
stimulation (Träger et al. 2014a). While a role for NFκB modulation in laquinimod 
mechanism of action has been proposed, here laquinimod did not reverse NFκB 
pathway dysfunction in HD patient myeloid cells. Laquinimod did not affect mHTT-IKKү 
protein interactions, IκB degradation kinetics or nuclear translocation of NFκB p65 in 
HD patient myeloid cells, compared with untreated. Similarly, whilst Brück et al. (2002) 
found NFκB activation to be markedly reduced in laquinimod-treated primary mouse 
astrocytes, they did not observe a reduction in NFκB activation in laquinimod-treated 
primary mouse microglia, in response to stimulation. This suggests that laquinimod-
induced reduction in cytokine release is not via modulation of NFκB signalling in 
myeloid cells. It has been suggested by others that laquinimod may suppress 
proinflammatory signalling in myeloid cells by reducing phosphorylation and activation 
of the MAPKs p38 and JNK (Mishra et al. 2012). 
5.6.4 Laquinimod as a potential therapeutic for the treatment of HD 
There is evidence that systemic inflammation leads to microglial activation in the CNS 
and exacerbation of neurodegeneration pathology (Palin et al. 2008; Perry 2007; Perry 
et al. 2007; Cunningham et al. 2007), and peripheral immune challenges accelerate 
disease progression in mouse models of HD (Hsiao et al. 2013). This indicates that 
peripheral immune events directly influence neuroinflammation and neuropathology in 
HD. Also, modulation of the peripheral immune system has previously been shown to 
have therapeutic benefit in HD. Transplantation of wild-type bone marrow into YAC128 
and BACHD mice reduced circulating proinflammatory cytokine levels, increased 
synaptic connections in the cortex, suppressed neuropathological defects and 
improved behavioural outcomes (Kwan et al. 2012a). Treatment of BACHD mice with a 
peripherally acting CB2 agonist ameliorated motor deficits, synapse loss and CNS 
inflammation, and prolonged survival by dampening peripheral immune activation 
(Bouchard et al. 2012). There is therefore evidence that peripheral immunomodulation 
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is a viable therapeutic target for the treatment of HD, and as laquinimod reduced 
elevated cytokine release in peripheral myeloid cells isolated from HD patients, this 
immunomodulator is a potential candidate. 
Björkqvist et al. (2008) reported elevated levels of Th1-type cytokines IL-6, IL-8 and 
TNFα as well as Th2-type cytokines IL-4 and IL-10 in plasma of HD patients compared 
with healthy volunteers, and a combination of IL-6, IL-8 and IL-10 cytokine increases 
was positively correlated with disease progression from pre-manifest HD through to 
manifest HD. Also, in Chapter 4 of this Thesis, elevated release of the proinflammatory 
Th1-type cytokines IL-1β, IL-6 and TNFα in BMD-macrophages was shown to cause 
neurotoxicity in co-culture. Laquinimod was shown here to reduce the release of all of 
these cytokines in HD patient monocytes. Laquinimod may therefore have the potential 
to reduce elevated plasma cytokine levels in HD patients and prevent the increasing 
levels associated with advancing disease, both peripherally and in the brain.  
Several anti-inflammatory strategies for the treatment of HD have shown potential at 
pre-clinical stages of research, however few have led to meaningful benefits in patients 
(Soulet and Cicchetti 2011). Laquinimod, however, has already been demonstrated to 
have beneficial effects on inflammation, brain atrophy and disease progression in MS, 
as well as being safe and well-tolerated in humans, in two Phase III clinical trials (Comi 
et al. 2012; Filippi et al. 2014; Vollmer et al. 2014). In MS, laquinimod was shown to 
downregulate immune cell activation and inflammation in the periphery (Yang et al. 
2004; Schulze-Topphoff et al. 2012) and in the CNS (Brück et al. 2012; Mishra et al. 
2014), and here, for the first time, this was also demonstrated to be the case in 
peripheral myeloid cells isolated from HD patients. Laquinimod therefore has the 
potential to slow neurodegeneration and disease progression in HD by downregulating 
inflammatory processes, as it has been shown to do in MS. Currently, laquinimod is 
under investigation for its potential effects in HD and a Phase II clinical trial (LEGATO-
HD) aimed at evaluating the efficacy, safety and tolerability of laquinimod as a 
treatment in patients with HD is in progress (Teva Pharmaceutical Industries 2016). 
5.7 Summary 
HD patient monocytes were shown to release elevated levels of both Th1-type 
cytokines (IL-1β, IL-6, IL-8, IL-12 and TNFα) and Th2-type cytokines (IL-4, IL-5, IL-10 
and IL-13), as well as IL-2, compared with healthy volunteer monocytes, in non-
stimulated conditions. This suggests that HD monocytes have an inherent 
dysfunctional upregulation of cytokine release. In stimulated conditions (LPS and 
IFNү), 24hPT with 5 µM laquinimod reduced Th1- and Th2-type cytokine release in HD 
patient monocytes, and did not affect cytokine release in healthy volunteer monocytes. 
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When laquinimod treatment was continued during stimulation (24hPT+24hCT), there 
was evidence of a laquinimod-induced Th1- to Th2-type shift in cytokine profile in 
healthy volunteer monocytes. Laquinimod did not affect mHTT-IKKү protein 
interactions, IκB degradation kinetics or nuclear translocation of NFκB p65 in HD 
patient myeloid cells, suggesting that the mechanism for laquinimod-induced 
modulation of cytokine release does not involve reversal of NFκB signalling dysfunction 
in these cells. Modulation of peripheral immune responses has been demonstrated to 
impact on central pathology and disease progression in HD, and therefore laquinimod 
may be a promising candidate for dampening the harmful effects of a dysfunctional 
innate immune system in HD. 
 
Chapter 6 
282 
 
6 Conclusions and future work 
The innate immune system, both centrally and peripherally, is known to play a 
significant role in the pathogenesis of HD. However, whether the myeloid cell activation 
and inflammation associated with neurodegeneration and disease progression in HD is 
protective, damaging or has no effect remains to be clearly defined. Here, neuronal-
myeloid cell interactions were examined in HD co-culture models, with the aim of 
investigating the contribution of myeloid cells to neurotoxicity or neuroprotection in the 
pathogenesis of HD. The effects of novel immunomodulatory drug laquinimod on 
reversing hyper-reactive immune responses in HD were also assessed. 
6.1 Novel human neuronal and microglial cell models of HD 
Firstly, there was a requirement for development of novel human neuronal and 
microglial cell models of HD which improve on the limitations of currently available cell 
models. Here, novel HD and non-HD human NSC-derived neuronal cell lines 
expressing full-length human HTT or human HTT exon 1 were developed and 
characterised. These cell lines can be differentiated into mature HD and non-HD 
neuronal cultures, and HD neuronal cultures expressing mHTT exon 1 exhibit several 
characteristics of pathologically affected neurons in the HD patient brain; including sub-
fragmentation of mHTT protein, intranuclear inclusions composed of mHTT 
aggregates, and mHTT-induced neuronal death. Additionally, a novel technique was 
discovered here for the differentiation of ex vivo human monocyte cultures, isolated 
from healthy volunteers or HD patients, into microglia-like cells (BMD-microglia). BMD-
microglia are similar to primary human microglia and human brain-resident microglia in 
vivo by both morphological and antigenic criteria: they exhibit microglia-specific 
morphological phenotypes (presence of all microglial morphological forms (small, round 
and activated; amoeboid; polarised; ramified with several short processes; highly 
ramified with very long processes); sub-cellular granule and vacuole formations 
indicative of phagocytic functions; process motility and cell-to-cell contact via 
processes and tubules; microglial nodule formations; and polarised migration towards 
sites of activity) and express key microglial markers (CD11b, CD68, CSF1R, CX3CR1, 
Iba1, mannose receptor, P2Y12, PU.1 and TREM2). BMD-microglia are polarised 
towards an M2 alternatively activated phenotype with promotion of a ramified, 
surveying and quiescent phenotype.  
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6.1.1 Usefulness of human HD neuronal cell models 
Unlike other available cell models of HD, the novel HTT exon 1-expressing HD 
neuronal cell lines presented in this Thesis are human and stably express human 
mHTT, have an isogenic control expressing normal human HTT, are easily obtainable 
and useable on a large scale, and over a short time-frame can be robustly and 
reproducibly differentiated from NSCs into high yield mature neuronal cultures which 
display several characteristics similar to pathologically affected neurons in the HD 
patient brain. This neuronal cell mode of HD will be useful for studying several cellular 
aspects of HD in a human setting in vitro, including mHTT fragmentation, mHTT 
aggregation, mHTT exon 1 toxicity and mHTT-induced neuronal death. The full-length 
HTT-expressing neuronal cell models may also be useful for investigating the effects of 
the full-length mHTT protein in cellular pathology in HD, however, further development 
and characterisation of this model is required.  
6.1.2 Usefulness of BMD-microglia as a model of human microglia in vitro 
Microglia are known to play important roles in CNS injury and disease, and 
dysregulated microglial activity is involved in the pathogenesis of multiple 
neurodegenerative diseases, including AD, ALS, HD and PD (Amor et al. 2014; 
Heneka et al. 2014; Doty et al. 2015). Modulation of microglial responses is therefore 
an attractive therapeutic target. The technique presented in this Thesis for the 
differentiation of primary human monocytes into microglia-like cells could be highly 
valuable for biological, pathophysiological and therapeutic studies in patient-specific 
BMD-microglia. Microglia isolated from animal models of CNS injury or disease are 
limited in their usefulness, and primary human microglia are difficult to obtain and 
unavailable on a large scale. BMD-microglia, however, are similar to primary human 
microglia or human microglia in vivo by both morphological and antigenic criteria, 
monocytes can be easily obtained using much less invasive procedures than would be 
required for isolation of microglia, and the protocol for induction of microglia-like cells is 
simple and can be completed in ten days. 
Recent coverage of the Keystone Symposium on “Microglia in the Brain” (Keystone, 
Colorado, USA 12-16 June 2016) (Fagan 2016) reported that three research groups 
independently announced that they had generated iPSC-derived microglia. Florent 
Ginhoux and colleagues (Agency for Science, Technology and Research, Singapore) 
reported their yet unpublished work demonstrating that they had recapitulated primitive 
haematopoiesis in vitro and generated primitive-like macrophages, that are genetically 
and phenotypically similar to in vivo yolk sac macrophages and microglia progenitors, 
from iPSCs. When placed in co-culture with neurons, these macrophages developed 
microglia-like processes that reached out and interacted with the neurons by direct 
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contact. These findings are similar to the observations made during the differentiation 
of BMD-macrophages into BMD-microglia described in this Thesis. Also, similarly to the 
technique described in this Thesis for the induction of microglia-like cells from BMD-
macrophages, Julien Muffat and colleagues (Whitehead Institute for Biomedical 
Research, Cambridge, Massachusetts, USA) reported that they had generated 
microglia-like cells from iPSC-derived primitive macrophages using a fully defined 
culture medium which they have developed. Muffat et al. showed that these microglia 
became ramified and sprouted processes, and when placed in co-culture with neurons 
and astrocytes, their transcriptional signature shifted more towards that of brain 
microglia than BMD-macrophages (Muffat et al. 2016). Edsel Abud and colleagues 
(University of California, Irvine, California, USA) also presented their yet unpublished 
work demonstrating that they had generated microglia-like cells from iPSC-derived 
primitive hematopoietic progenitors by exposing these cells to a mixture of 
different factors. These microglia-like cells were shown to express typical microglia 
markers, including P2Y12R, TREM2, and CX3CR1, which are also expressed by the 
BMD-microglia presented in this Thesis, and had whole-genome transcriptional profiles 
which closely matched those of primary microglia. Jennifer Pocock and colleagues had 
previously reported their development of microglia-like cells from iPSCs at the 4th 
Venusberg Meeting on Neuroinflammation in May 2015 (Pocock 2015). 
IPSC-derived microglia are therefore in the pipeline, and due to their differentiation via 
yolk sac macrophages and microglia progenitors they more closely model in vivo 
microglial developmental lineage. Also, due to their iPSC origin they are available on a 
much larger scale than primary human monocytes and BMD-microglia, which is 
necessary for high-throughput drug screening strategies. However, based on the 
characterisation completed to date, BMD-microglia are morphologically and 
phenotypically similar to primary human microglia and exhibit the same behaviours and 
marker expression profile as reported to be demonstrated in iPSC-derived microglia. 
Also, unlike iPSC-derived microglia, differentiation of BMD-microglia does not require 
extensive manipulation of the cells in vitro or complex co-culture systems, and patient-
specific microglia-like cells can be generated in a much shorter time-frame.  
Future directions should include further characterisation of BMD-microglia phenotypes 
and behaviours alongside primary human microglia cultures isolated from the same 
subjects for comparison; including migration, phagocytosis, cell signalling, 
transcriptional profiles and epigenetics. This will determine the authenticity and value of 
these BMD-microglia for use in translational research. An empirical approach should 
also be taken to analysing the factors in NM which contribute to differentiation of 
monocytes into microglia-like cells. 
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6.2 Neuroprotective and neurotoxic phenotypes of myeloid 
cells in HD 
In co-culture, healthy volunteer and HD patient BMD-microglia rescued HD neurons 
(expressing mHTT exon 1) from mHTT-induced neurotoxicity and reduced neuronal 
death. In non-stimulated conditions, neuroprotective BMD-microglial phenotypes were 
associated with elevated levels of BDNF release and reduced levels of IFNү and IL-2 
release. Under conditions of chronic inflammation (chronic stimulation with LPS and 
IFNү), BMD-microglia shifted more towards an M2 polarisation, indicated by decreased 
release of Th1-type cytokine TNFα and increased release of Th2-type cytokines IL-4, 
IL-10 and IL-13, and this was associated with neuroprotection. Manifest HD BMD-
microglia became more M2-polarised than healthy volunteer BMD-microglia during 
chronic stimulation, and released BDNF at approximately three-fold higher levels. Also, 
neuronal death levels were lower in HD neurons expressing full-length mHTT when in 
co-culture with manifest HD patient BMD-microglia than when in co-culture with healthy 
volunteer BMD-microglia. This suggests that in HD, microglia are neuroprotective and 
reduce mHTT-induced neurotoxicity and neuronal death via release of BDNF and Th2-
type cytokines. 
In contrast, BMD-macrophages, differentiated from ex vivo monocyte cultures isolated 
from healthy volunteers, pre-manifest HD gene carriers or manifest HD patients, were 
neurotoxic in co-culture with HD or non-HD neurons. Elevated release of the 
proinflammatory Th1-type cytokines IL-1β, IL-6 and TNFα from BMD-macrophages 
was associated with neuronal death. This suggests that in HD, peripheral macrophages 
release proinflammatory cytokines which are neurotoxic. It is possible that microglia are 
neuroprotective in HD, whilst peripheral macrophages release neurotoxic factors which 
may contribute to central pathogenesis. An alternative explanation is that the 
neuroprotective or neurotoxic phenotypes of myeloid cells in HD, whether derived 
centrally or peripherally, are dependent on M1/M2 polarisation. Monocytes were 
differentiated into BMD-macrophages by induction with GM-CSF, which promotes the 
development of classically activated M1 macrophages, and they were demonstrated 
here to be neurotoxic. BMD-microglia, however, were shown to express markers 
indicative of M2-polarisation (CSF1R, mannose receptor, TREM2), and were 
demonstrated here to be neuroprotective. As M2-polarised BMD-microglia were 
differentiated from monocytes via M1-polarised BMD-macrophages, this is also 
evidence that M1/M2 polarisation is highly dynamic and changeable, even in mature 
myeloid cells. 
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6.2.1 Cell signalling pathway analysis in HD co-culture models 
Going forward, it would be of use to interrogate intracellular signalling pathways and 
specific cell-to-cell interaction mechanisms in neuronal-myeloid cell co-culture models 
of HD. There should be a particular focus on investigations into mHTT-induced 
promotion of M1 to M2 polarisation and elevated BDNF release in response to 
stimulation in HD patient microglia-like cells; the specific effects of proinflammatory 
Th1-type cytokines IL-1β, IL-6 and TNFα on neurotoxicity; and the specific roles of IL-4, 
IL-13 and BDNF in rescuing HD neurons from mHTT-induced neurotoxicity. 
Understanding the cell signalling pathways involved in neuroprotective and neurotoxic 
myeloid cell phenotypes and the neuronal responses to factors released by myeloid 
cells is important. An improved knowledge may reveal specific therapeutic targets for 
promoting neuroprotective myeloid cell phenotypes while inhibiting neurotoxic 
phenotypes and/or protecting neurons from mHTT-induced neurotoxicity while reducing 
the impact of neurotoxic factors directly in neurons. 
6.2.2 Assessment of neuronal compromise  
In this Thesis, neurotoxicity of neurons in co-culture was measured by LDH cytotoxicity 
assay in the majority of experiments, and in some cases by PI viable dye exclusion as 
well. According to guidelines for the use and interpretation of assays for monitoring cell 
death in higher eukaryotes presented by Galluzzi et al. (2009), including 
recommendations provided by the Nomenclature Committee on Cell Death (NCCD), 
these methods are appropriate as a first-line approach for measuring end-stage cellular 
demise in the experimental settings used. However, to determine by which subroute 
cell death occurred, and to characterise cell death in mechanistic terms, additional 
techniques should be employed. It may be of interest to determine which mechanisms 
caused neurotoxicity of BMD-macrophages in co-culture e.g. whether neuronal death 
occurred by apoptotic or necrotic mechanisms; conversely, to assess whether the 
neuroprotective phenotypes of BMD-microglia in co-culture are due to rescue of 
neurons from apoptotic or necrotic cell death, and by which mechanisms this occurs. 
Additionally, more specific measures of neurotoxicity could be employed, including 
mitochondrial dysfunction, axonal degeneration and loss of synaptic integrity. These 
measurements can be used for assessment of subtle indications of neuronal 
compromise in co-culture models of HD, and also to further characterise mHTT-
induced neurotoxicity in HD neuronal cell models. 
6.2.3 Improvements on neuronal-myeloid cell co-culture models of HD 
Recently there has been progress made in protocols for the differentiation of iPSCs into 
specific neuronal sub-types (Kim et al. 2014; Ho et al. 2015; Shum et al. 2015; Mertens 
et al. 2016). MSNs are the main neuronal sub-type affected in HD, and currently the 
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protocols for development of authentic MSNs are improving; time-frames required for 
differentiation of iPSCs into MSNs are decreasing while yields of these neurons in the 
finally differentiated cultures are increasing (Delli Carri et al. 2013; Victor et al. 2014; 
Fjodorova et al. 2015; Noakes et al. 2015; Straccia et al. 2015; Stanslowsky et al. 
2016). Procedures have not yet been fully optimised, but HD iPSC-derived MSNs are 
in the pipeline and have the potential to improve on the neuronal cell lines presented in 
this Thesis for modelling HD neurons in vitro. Therefore, a novel improved neuronal-
myeloid cell co-culture model of HD may incorporate HD iPSC-derived MSNs and 
BMD-microglia differentiated from monocytes isolated from the same HD patient. 
Alternatively, iPSC-derived MSNs could be co-cultured with iPSC-derived microglia 
from the same HD patient source. To maximise bi-directional interaction and 
communication between MSNs and microglia in co-culture, and to more closely 
recapitulate the in vivo setting, a 3-dimensional co-culture model could be utilised. 
Such models have previously been developed using polycaprolactone fibre scaffolds 
(Daud et al. 2012), cross-linked polystyrene scaffolds (Amsbio 2016) and collagen-filled 
microfluidic platforms (Kim et al. 2011) for neuronal-glial co-culture. A patient-specific 
neuronal-microglia co-culture model of HD which is highly relevant to the human 
disease will be valuable for the screening of potential therapeutic compounds and for 
pre-clinical investigations relating to the effects of microglial phenotype modulation in 
HD. 
6.3 Inherent dysfunctional upregulation of cytokine 
production in HD patient monocytes 
Monocytes isolated from HD patients have previously been demonstrated to be hyper-
reactive in response to stimulation with LPS and IFNү, leading to elevated release of 
proinflammatory Th1-type cytokines compared with monocytes isolated from healthy 
volunteers (Björkqvist et al. 2008; Träger et al. 2014a). Here, it was shown that HD 
patient monocytes also release elevated levels of cytokines in non-stimulated 
conditions, and this includes Th1-type cytokines (IL-1β, IL-6, IL-8, IL-12 and TNFα) and 
Th2-type cytokines (IL-4, IL-5, IL-10 and IL-13), as well as IL-2. This suggests that HD 
monocytes have an inherent dysfunctional upregulation of cytokine production overall, 
which does not require an external stimulus to become manifest and does not only 
apply to proinflammatory Th1-type cytokines. Circulating monocytes may therefore be 
the primary contributors to elevated cytokine levels in HD patient plasma (Dalrymple et 
al. 2007; Björkqvist et al. 2008; Heneka et al. 2014), and of particular significance, to 
increasing levels of IL-6, IL-8 and IL-10 which have been shown to correlate with 
disease progression (Björkqvist et al. 2008). Interestingly, levels of cytokine release are 
not altered in T lymphocytes in HD patients (Miller et al. 2015), suggesting that the 
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dysfunctional upregulation of cytokine release demonstrated here involves a 
mechanism in myeloid cells which does not occur in cells of the adaptive immune 
system. It may therefore be worthwhile to investigate mechanisms of cytokine 
production and release in monocytes which differ from those in T lymphocytes and may 
be uniquely affected by mHTT expression. Such investigations could yield novel 
therapeutic targets for specific modulation of a dysfunctional innate immune system in 
HD. 
6.4 Laquinimod dampens hyper-reactive cytokine production 
in HD patient myeloid cells 
Investigations into neuronal-myeloid cell interactions in the pathogenesis of HD 
revealed myeloid cell M1/M2 polarisation as a potential modifier of neurotoxicity. 
Promotion of neuroprotective M2 phenotypes over neurotoxic M1 phenotypes in HD 
patient myeloid cells may therefore be a therapeutic target. Laquinimod has previously 
been shown to drive an immunomodulatory shift in immune cell phenotypes away from 
M1 and Th1-type cytokine production and towards M2 and Th2-type cytokine 
production in vivo in animal models of MS and in vitro in primary human microglia and 
PBMCs (Zou et al. 2002; Yang et al. 2004; Brück and Wegner 2011; Schulze-Topphoff 
et al. 2012; Mishra et al. 2014). Laquinimod was also shown to have beneficial effects 
on inflammation, brain atrophy and disease progression in MS patients, and was 
demonstrated to be safe and well-tolerated, in two Phase III clinical trials for the 
treatment of MS (Comi et al. 2012; Filippi et al. 2014; Vollmer et al. 2014). 
Here, 24 h pre-treatment with 5 µM laquinimod reduced the release of both Th1-type 
cytokines (IL-1β, IL-6, IL-8 and TNFα) and Th2-type cytokines (IL-5, IL-10 and IL-13) in 
HD patient myeloid cells in response to stimulation with LPS and IFNү. The same 
laquinimod treatment had no effects on cytokine release in healthy volunteer 
monocytes. When laquinimod treatment was continued during stimulation, Th2-type 
cytokine release (IL-5 and IL-13) was increased along with a decrease in Th1-type 
cytokine release (IL-6) in healthy volunteer monocytes, indicating an M1 to M2 
phenotype shift. However, this was not demonstrated in HD patient monocytes. It is 
possible that in response to stimulation with LPS and IFNү, HD patient monocytes 
become more M1-polarised than healthy volunteer monocytes, resulting in the higher 
levels of release of proinflammatory cytokines which has been reported by others 
(Björkqvist et al. 2008; Träger et al. 2014a). As a result, when laquinimod promotes an 
M1 to M2 shift in these cells, healthy volunteer monocytes reach M2 polarisation whilst 
the phenotype of HD patient monocytes lies somewhere on the continuum between M1 
and M2 activation states. Nevertheless, laquinimod did reverse hyper-reactive cytokine 
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production in HD patient monocytes, including IL-6, IL-8 and IL-10 for which increasing 
plasma levels correlate with disease progression (Björkqvist et al. 2008). Therefore, 
laquinimod is a promising candidate for dampening the harmful effects of a 
dysfunctional innate immune system in HD. 
6.4.1 Investigating laquinimod mechanism of action 
Modulation of NFκB signalling has previously been presented as a potential 
mechanism of action for laquinimod (Gurevich et al. 2010; Brück et al. 2012), and it had 
been demonstrated that hyper-reactive cytokine release in HD patient myeloid cells 
occurs, at least in part, as a result of dysfunctional NFκB signalling (Träger et al. 
2014a). The work presented in this Thesis, however, does not support a role for 
laquinimod reversing NFκB pathway dysfunction in HD patient myeloid cells, and 
further work is required to establish the mechanisms by which laquinimod dampens 
hyper-reactive cytokine release in these cells. It has been proposed that laquinimod 
may also suppress another proinflammatory signalling pathway by reducing 
phosphorylation and activation of the MAPKs p38 and JNK (Mishra et al. 2012). Other 
mechanisms which may be worth pursuing include those that influence myeloid cell 
M1/M2 polarisation balance, such as PPAR, Krueppel-like factor, IRF, STAT and 
hypoxia-inducible factor signalling, as well as microRNAs (Wang et al. 2014b). It would 
also be of interest to assess the effects of laquinimod on promoting neuroprotective 
over neurotoxic myeloid cell phenotypes in the neuronal-myeloid cell co-culture models 
of HD presented in this Thesis. 
6.5 Modulation of myeloid cell phenotypes as a therapeutic 
target in HD 
Overall, the findings presented in this Thesis highlight myeloid cell phenotypes as an 
important modulator of neurotoxicity in HD. M2-type HD myeloid cells which produce 
Th2-type cytokines and BDNF protect neurons from mHTT-induced neurotoxicity, 
whilst M1-type HD myeloid cells which produce proinflammatory Th1-type cytokines 
increase neuronal death. Therefore, harnessing the innate immune system in order to 
promote neuroprotective myeloid cell phenotypes whilst inhibiting neurotoxic 
phenotypes is an attractive therapeutic target. 
Laquinimod was demonstrated in this Thesis to be a promising candidate for 
dampening the harmful effects of a dysfunctional innate immune system in HD. 
Following on from these pre-clinical results in HD patient cells, laquinimod is currently 
in a Phase II clinical trial aimed at evaluating its efficacy, safety and tolerability as a 
treatment in patients with HD (LEGATO-HD; Teva Pharmaceutical Industries 2016). 
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Appendices 
Appendix I: Cell culture media 
I - i  DMEM/FBS culture medium 
DMEM  [Life 
Technologies] 
Foetal bovine serum (FBS) 10 % [Life 
Technologies] 
Penicillin;Streptomycin 5 U/mL; 5 μg/mL [Life 
Technologies] 
I - i i  OptiMEM/FBS culture medium 
OptiMEM  [Life 
Technologies] 
FBS 10 %  
Penicillin;Streptomycin 5 U/mL; 5 μg/mL  
I - i i i  ReN/NSC culture medium 
DMEM:F-12 (for complete formulation see Appendix I-vii) [Life 
Technologies] 
Human albumin solution  0.03%  
Transferrin (human recombinant)  5 µg/mL  
Putrescine dihydrochloride  16.2 μg/mL  
Insulin (human recombinant)  5 μg/mL  
T4 400 ng/mL  
T3 337 ng/mL  
Progesterone  60 ng/mL  
L-glutamine  2 mM [Life 
Technologies] 
Sodium selenite  40 ng/mL  
Heparin sodium  10 U/mL  
Corticosterone  10 ng/mL  
bFGF 10 ng/mL [PeproTech] 
EGF 20 ng/mL [PeproTech] 
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I - iv RPMI/FBS culture medium 
Roswell Park Memorial Institute 
(RPMI) medium 1640 
 [Life 
Technologies] 
FBS 10 %  
L-glutamine 2 mM  
Penicillin;Streptomycin 5 U/mL; 5 μg/mL  
I -v Neuronal medium (NM) 
DMEM:F-12 (for complete formulation see Appendix I-vii)   
Human albumin solution  0.03%  
Transferrin (human recombinant)  5 µg/mL  
Putrescine dihydrochloride  16.2 μg/mL  
Insulin (human recombinant)  5 μg/mL  
L-thyroxine (T4)  400 ng/mL  
Tri-iodo-thyronine (T3)  337 ng/mL  
Progesterone  60 ng/mL  
L-glutamine  2 mM  
Sodium selenite  40 ng/mL  
Heparin sodium  10 U/mL  
Corticosterone  10 ng/mL  
I -vi  NM/cAMP/GDNF 
DMEM:F-12 (for complete formulation see Appendix I-vii)  
Human albumin solution  0.03%  
Transferrin (human recombinant)  5 µg/mL  
Putrescine dihydrochloride  16.2 μg/mL  
Insulin (human recombinant)  5 μg/mL  
T4 400 ng/mL  
T3 337 ng/mL  
Progesterone  60 ng/mL  
L-glutamine  2 mM  
Sodium selenite  40 ng/mL  
Heparin sodium  10 U/mL  
Corticosterone  10 ng/mL  
db-cAMP 0.5 mM [Calbiochem] 
GDNF 2 ng/mL [PeproTech] 
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I -vi i  Complete formulation of DMEM:F-12 
DMEM:F-12, no glutamine, no HEPES [GIBCO; ThermoFisher Scientific; #21331] 
Components Molecular 
weight 
Concentration 
(mg/mL) 
mM 
Amino acids 
Glycine 75.0 18.750 0.250 
L-Alanine 89.0 4.450 0.050 
L-Arginine hydrochloride 211.0 147.500 0.700 
L-Asparagine-H2O 150.0 7.500 0.050 
L-Aspartic acid 133.0 6.650 0.050 
L-Cysteine hydrochloride-H2O 176.0 17.560 0.100 
L-Cystine 2HCl 313.0 31.290 0.100 
L-Glutamic Acid 147.0 7.350 0.050 
L-Histidine hydrochloride-H2O 210.0 31.480 0.150 
L-Isoleucine 131.0 54.470 0.416 
L-Leucine 131.0 59.050 0.451 
L-Lysine hydrochloride 183.0 91.250 0.499 
L-Methionine 149.0 17.240 0.116 
L-Phenylalanine 165.0 35.480 0.215 
L-proline 115.0 17.250 0.150 
L-Serine 105.0 26.250 0.250 
L-Threonine 119.0 53.450 0.449 
L-Tryptophan 204.0 9.020 0.044 
L-Tyrosine disodium salt dehydrate 261.0 55.790 0.214 
L-Valine 117.0 25.850 0.221 
Vitamins 
Biotin 244.0 0.004 1.434×10-5 
Choline chloride 140.0 8.980 0.064 
D-Calcium pantothenate 477.0 2.240 0.007 
Folic acid 441.0 2.650 0.006 
Niacinamide 122.0 2.020 0.017 
Pyridoxine hydrochloride 206.0 2.000 0.010 
Riboflavin 376.0 0.219 5.824×10-4 
Thiamine hydrochloride 337.0 2.170 0.006 
Vitamin B12 1355.0 0.680 5.018×10-4 
i-Inositol 180.0 12.600 0.070 
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Inorganic salts 
Calcium chloride (CaCl2) (anhyd.) 111.0 116.600 1.050 
Cupric sulfate (CuSO4-5H2O) 250.0 0.001 5.2×10-6 
Ferric Nitrate (Fe(NO3)3”9H2O) 404.0 0.050 1.238×10-4 
Ferric sulfate (FeSO4-7H2O) 278.0 0.417 0.002 
Magnesium chloride (MgCl2) 
(anhyd.) 
95.0 28.640 0.301 
Magnesium sulfate (MgSO4) 
(anhyd.) 
120.0 48.840 0.407 
Potassium chloride (KCl)  75.0 311.800 4.157 
Sodium bicarbonate (NaHCO3) 84.0 1200.000 14.286 
Sodium chloride (NaCl) 58.0 6995.500 120.612 
Sodium phosphate dibasic 
(Na2HPO4) (anhyd.) 
142.0 71.020 0.500 
Sodium phosphate monobasic 
(NaH2PO4-H2O) 
138.0 62.500 0.453 
Zinc sulfate (ZnSO4-7H2O) 288.0 0.432 0.002 
Other components 
D-Glucose (dextrose) 180.0 3151.000 17.506 
Hypoxanthine Na 159.0 2.390 0.015 
Linoleic acid 280.0 0.042 1.500×10-4 
Lipoic acid 206.0 0.105 5.097×10-4 
Phenol Red 376.4 8.100 0.022 
Putrescine 2HCl 161.0 0.081 5.031×10-4 
Sodium pyruvate 110.0 55.000 0.500 
Thymidine 242.0 0.365 0.002 
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Appendix II: Buffer recipes 
I I - i  MACS buffer 
Buffer used for processing PBMCs for magnetic-activated cell sorting (MACS) 
DPBS  [Life 
Technologies] 
BSA 0.5 %  
EDTA 2 mM  
I I - i i  Radioimmunoprecipi tat ion assay (RIPA) buffer 
Buffer used to prepare some cell lysates 
Tris-HCl 25 mM; pH 7.6 [Sigma] 
NaCl 150 mM  
NP-40 1.0 %  
Sodium deoxycholate 1.0 %  
Sodium dodecyl sulphate (SDS) 0.1 %  
cOmplete protease inhibitor cocktail 1 × [Roche] 
I I - i i i  10× Tris/Borate/EDTA (TBE) buffer (1 L) 
Buffer used to prepare agarose gels for electrophoresis of DNA fragments 
Tris base 100 g [Sigma] 
Boric acid 55 g  
0.5 M EDTA 40 mL  
ddH2O to 1 L  
I I - iv Lysis Buffer 
Lysis solution used to prepare lysate samples for Western blotting or dot blotting 
 Western blotting Dot blotting  
PBS 1 × 1 ×  
Triton X-100 1.0 % 0.5 %  
Tris − 50 mM; pH 7.4 [Sigma] 
Sodium deoxycholate 0.5 % 0.5 %  
NaCl − 150 mM  
SDS 0.1 % −  
Nonidet P-40 (NP-40) 1.0 % −  
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Benzonase 0.25 U/μL 0.25 U/μL [Novartis] 
cOmplete protease inhibitor 
cocktail 
1 × 1 ×  
I I -v Sample buffer (5×) 
Buffer added to lysates in preparation for loading gels for Western blotting 
Tris-HCl 0.625 M; pH 6.8  
Glycerol 50 %  
SDS 10 %  
Bromophenol blue  trace  
β-mercaptoethanol 10%  
I I -vi  Tr is/Glycine/SDS Running buffer [National Diagnostics] 
Buffer used for running SDS-PAGE  
Tris 25 mM  
Glycine 192 mM  
SDS 0.1 %  
I I -vi i  Electroblott ing buffer [National Diagnostics] 
Buffer used for transferring proteins from polyacrylamide gel to membrane 
Tris-HCl 25 mM; pH 8.0  
Glycine 192 mM  
Methanol 20 %  
I I-v i i i  Tropix assay buffer [Appl ied Biosystems] 
Buffer used for washing immunoblots before developing AP-conjugated secondary 
antibody signals 
Tris-HCl 20 mM; pH 9.8  
MgCl2 1 mM  
I I - ix Duol ink In Situ Wash Buffer A [Ol ink Bioscience] 
Buffer used for PLA probe and oligonucleotide ligation reaction wash steps in Duolink 
In Situ PLA 
Tris 0.01 M  
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NaCl  0.15 M  
Tween-20 0.05 %  
HCl to pH 7.4  
I I -x Duol ink In Situ Wash Buffer B [Ol ink Bioscience] 
Buffer used for RCA reaction wash steps in Duolink In Situ PLA 
NaCl  0.1 M  
Tris 0.2 M  
HCl to pH 7.5  
I I -xi  FACS buffer 
Buffer used for flow cytometry cell suspension and some wash steps in IFC 
PBS 1 ×  
Azide  0.02 %  
BSA 1.00 %  
I I -xi i  MSD buffer 
Buffer used for preparation of samples for quantitation of HTT using MSD assay 
Tris 20 mM; pH 7.5  
NaCl  150 mM  
EDTA 1 mM  
Ethylene glycol-bis(β-aminoethyl 
ether)-N,N,N',N'-tetraacetic acid 
(EGTA) 
1 mM  
Triton X-100 1 %  
Phosphatase inhibitor I and II 1 × [Sigma] 
cOmplete protease inhibitor cocktail 1 ×  
Phenylmethylsulfonyl fluoride (PMSF) 0.5 mM  
NaF 10 mM 
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Appendix III: Publications and presentations relating to this Thesis 
I I I - i  Art ic le publ ished in Journal of Neurochemistry 
Title: Laquinimod dampens hyperactive cytokine production in Huntington's disease 
patient myeloid cells 
Authors: Lucianne Dobson1, Ulrike Träger1, Ruth Farmer2, Liat Hayardeny3, Pippa 
Loupe3, Michael R. Hayden3, Sarah J. Tabrizi1  
Author affiliations: 1 Department of Neurodegenerative Diseases, UCL IoN and NHNN, 
London, UK. 2 Department of Medical Statistics, London School of Hygiene & Tropical 
Medicine, London, UK. 3 Teva Pharmaceuticals, Research and Development, Netanya, 
Israel. 
Date: June 2016 | Volume: 137 | Issue: 5 | Pages: 782-794 | doi: 10.1111/jnc.13553 
Article:  
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I I I - i i  Poster presented at Faculty of Brain Sciences Postgraduate 
Research Symposium 
Date: 8 March 2016 
Location: University College London, London, United Kingdom 
Title: Investigation into pathogenic neuronal-myeloid cell interactions and rescue of 
hyper-reactive immune responses in Huntington’s disease  
Authors: Lucianne Dobson1 (presenting author), Ralph André1, Ulrike Trӓger1, Rhia 
Ghosh1, Liat Hayardeny2, Sarah J. Tabrizi1 
Author affiliations: 1 Department of Neurodegenerative Diseases, UCL IoN and NHNN, 
London, UK. 2 Teva Pharmaceuticals, Research and Development, Netanya, Israel. 
Abstract: Huntington’s disease (HD) is a genetic neurodegenerative condition 
hallmarked by presence of intracellular mutant huntingtin (mHTT) aggregates, 
neurodegeneration and loss of striatal medium spiny neurons. mHTT is ubiquitously 
expressed, so several non-neuronal pathologies also occur, including innate immune 
system dysfunction leading to elevated release of proinflammatory cytokines from HD 
myeloid cells. To investigate the direct effects of immune dysfunction on 
neurodegeneration in HD, a novel human neuronal-microglial cell model of HD was 
developed and characterised. Neurons expressing mHTT (HD neurons) had 
significantly more death compared to neurons expressing normal HTT (control 
neurons), indicating toxicity of the HD model. When in co-culture with control neurons, 
non-stimulated microglia were neuroprotective, while stimulated microglia were 
neurotoxic. However, in co-culture with HD neurons, both non-stimulated and 
stimulated microglia reduced neuronal death levels, indicating that microglia protect HD 
neurons from toxicity induced by mHTT expression. HD microglia were found to 
release higher levels of IFNү, IL-2, IL-10 and IL-12 compared to HV microglia. Also, 
unlike HV microglia, HD microglia released high levels of brain-derived neurotrophic 
factor when stimulated. However, no significant differences were observed between the 
effects of HD or HV microglia on neuronal survival. Additionally, novel 
immunomodulatory drug laquinimod was found to dampen dysfunctional hyper-reactive 
cytokine release in HD patient myeloid cells.  
Poster: 
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I I I - i i i  Poster presented at European Huntington’s Disease Network 
Plenary Meeting and publ ished in Journal of Neurology 
Neurosurgery & Psychiatry 
Dates: 19 September 2014 - 21 September 2014 
Location: Hesperia Tower Hotel in Barcelona, Spain 
Title: Laquinimod reduces hyper-reactive proinflammatory cytokine release from human 
primary Huntington’s disease myeloid cells 
Authors: Lucianne Dobson1 (presenting author), Ulrike Trӓger1, Liat Hayardeny2, Sarah 
J. Tabrizi1 
Author affiliations: 1 Department of Neurodegenerative Diseases, UCL IoN and NHNN, 
London, UK. 2 Teva Pharmaceuticals, Research and Development, Netanya, Israel. 
Publication citation: Dobson L, Träger U, Hayardeny L, et al. M13 Laquinimod Reduces 
Hyper-reactive Pro-inflammatory Cytokine Release From Human Primary Huntington’s 
Disease Myeloid Cells. J Neurol Neurosurg Psychiatry 2014;85:A98-A99.  
Abstract:  
Background Hyper-reactivity of the innate immune response is an early and active 
component of Huntington’s disease (HD) and is due in part to NFκB pathway 
dysregulation. There is evidence that the peripheral immune system plays a disease-
modifying role in HD and that targeting it may slow disease progression. Laquinimod 
(LAQ) is an orally active immunomodulator that has beneficial effects in multiple 
sclerosis and is thought to act via the NFκB pathway. We investigated whether the 
compound could also reverse the hyper-reactive immune responses observed in HD. 
Aims Investigate the effects of LAQ on hyper-reactive HD myeloid cells.  
Methods Primary human monocytes were isolated from blood collected from 
symptomatic HD patients, premanifest HD gene-carriers (PreHD) and healthy 
volunteers. Cells were pretreated with 1μM or 5μM LAQ for 2 or 24 hours (h) before 
being stimulated with LPS for 24h. Cytokine release was measured by ELISA. IκB 
degradation kinetics, nuclear translocation of NFκB, and interactions between IKK and 
HTT were assessed in LAQ-treated cells.  
Results Twenty-four hour pretreatment with 5μM LAQ reduced cytokine release in 
manifest HD patient monocytes. This included IL-1β, IL-8, TNFα, IL-5, IL-13 and IL-10. 
Reductions in IL-6, IL-8, IL-10 and IL-13 release by preHD monocytes were also 
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observed using this LAQ dose. When using either 1µM LAQ or 2h pretreatment there 
was little evidence of a difference between active and control conditions in any of the 
patient subgroups. We did not observe any significant effect of LAQ on IκB degradation 
kinetics, NFκB translocation or interactions between IKK and HTT. 
Conclusions 5μM LAQ applied to HD monocytes for 24h reduces hyper-reactive 
cytokine production in response to LPS stimulation. The mechanism for this does not 
appear to be downstream of NFκB activation. We are currently working on elucidating 
the mechanism of action of LAQ and will go on to determine how this impacts on 
neuronal survival using neuronal-myeloid cell co-culture models. 
Poster: 
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I I I - iv Accepted abstract for podium presentation at Gordon Research 
Seminars 
Seminar: CAG Triplet Repeat Disorders 
Dates: 22 June 2013 - 23 June 2013 
Location: Waterville Valley Resort in Waterville Valley, New Hampshire, United States 
Title: Neuronal-myeloid cell co-culture models of Huntington’s disease 
Authors: Lucianne Dobson1 (presenting author), Ralph Andre1, Ulrike Traeger1, Liat 
Hayardeny3, Jennifer M. Pocock2, Sarah J. Tabrizi1 
Author affiliations: 1 Department of Neurodegenerative Diseases and 2 Department of 
Neuroinflammation, UCL IoN and NHNN, London, UK. 3$ Teva Pharmaceuticals, 
Research and Development, Netanya, Israel. 
Abstract: The innate immune system may modify the pathogenesis of several 
neurodegenerative diseases. In pre-manifest Huntington’s disease (HD) gene carriers, 
inflammatory markers in the blood are elevated up to 16 years before predicted onset 
of clinical symptoms, and macrophages and microglia are hyper-reactive throughout 
the disease course. The disease-causing mutant form of the huntingtin (HTT) gene is 
expressed in HD patient myeloid cells, suggesting a cell-autonomous mechanism for 
immune activation. Microglial hyper-reactivity could directly contribute to neuronal 
damage, targeting of which could restore a protective phenotype to slow down the 
neurodegenerative process. Peripheral immune hyper-reactivity may parallel central 
pathogenic events, acting as a potential non-invasive biomarker for disease 
progression. It is important therefore to elucidate the mechanisms involved in the 
interactions between the CNS and immune system in HD. To do this, human HD 
neuronal-myeloid cell co-culture models have been developed. Human neural stem 
cells (NSCs) isolated from foetal ventral mesencephalon (ReNcell VM) or striatum 
(STROC05) are being studied. These NSCs can be robustly differentiated into mature, 
electrophysiologically active, GABAergic and dopaminergic neurons. These neurons 
have been co-cultured with primary human macrophages isolated from control subjects 
or HD patients at different disease stages, using a variety of paradigms. Human blood-
derived macrophages have been characterised and data suggests they are a viable in 
vitro model of microglia, in both resting and stimulated (by LPS or neuronal cell debris) 
states, and in-depth analysis of cell-cell interactions is currently underway. Recent work 
by the Tabrizi group has shown a mechanistic link between the presence of mHTT in 
myeloid cells and a dysfunctional hyper-reactive phenotype, via direct interaction 
between the mutant protein and the NFkappaB pathway. Laquinimod (LAQ) is a novel 
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oral immunomodulatory drug proven to slow progression of disability and reduce 
relapse rate in relapsing-remitting multiple sclerosis. LAQ affects peripheral immune 
cells by down-regulating pro-inflammatory cytokines, tipping the Th1/Th2 cytokine 
balance towards anti-inflammatory cytokines. The compound is also thought to act via 
the NFkappaB pathway, and therefore we are currently conducting experiments looking 
at the effects of LAQ on HD and control myeloid cells to determine whether the hyper-
reactive phenotype we have previously observed can be reversed by the drug. We are 
looking at the effects of LAQ on cytokine release and signalling pathway dysfunction. 
Once the effects of the drug are established, it will be screened in neuronal-myeloid 
cell co-culture models for any neuronal protection effects via actions on the co-cultured 
myeloid cells. 
I I I -v Poster presented at Bri t ish Neuroscience Association Event 
BNA2013 
Event: Festival of Neuroscience  
Dates: 7 April 2013 - 10 April 2013 
Location: The Barbican Centre, London, United Kingdom 
Title: Neuronal-myeloid cell co-culture models of Huntington’s disease 
Authors: Lucianne Dobson (presenting author), Jennifer Parker, Ralph André, Sarah J. 
Tabrizi 
Author affiliation: Department of Neurodegenerative Diseases, UCL IoN and NHNN, 
London, UK 
Abstract: The innate immune system may modify the pathogenesis of several 
neurodegenerative diseases. In pre-manifest Huntington’s disease (HD) gene carriers, 
inflammatory markers in the blood are elevated up to 16 years before predicted onset 
of clinical symptoms, and macrophages and microglia are hyper-reactive throughout 
the disease course. The disease-causing mutant form of the huntingtin (HTT) gene is 
expressed in HD patient myeloid cells, suggesting a cell-autonomous mechanism for 
immune activation. Microglial hyper-reactivity could directly contribute to neuronal 
damage, targeting of which could restore a protective phenotype to slow down the 
neurodegenerative process. Peripheral immune hyper-reactivity may parallel central 
pathogenic events, acting as a potential non-invasive biomarker for disease 
progression. It is important therefore to elucidate the mechanisms involved in the 
interactions between the CNS and immune system in HD. To do this, human HD 
neuronal-myeloid cell co-culture models are being developed. Human neural stem cells 
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(NSCs) isolated from foetal ventral mesencephalon (ReNcell VM) or striatum 
(STROC05) have been immortalised with v-myc or c-myc carrying retroviruses and 
expanded long-term. HD and control cell lines are being created by stably transfecting 
NSCs with full length HTT with normal (15Q) or expanded, disease-causing (138Q) 
CAG repeats by retroviral transduction. HTT exon 1 cell lines will also be made by 
transfecting NSCs with N-terminal HTT fragments with 29 (wild-type), 71 (expanded) or 
129 (highly expanded) CAG repeats. The NSCs can be robustly differentiated into 
mature, electrophysiologically active, GABAergic and dopaminergic neurons, with 
~15% medium spiny neurons, which are the cells preferentially affected in HD patients’ 
striata. Human microglial cell lines will also be transfected with the same full length or 
exon 1 HTT constructs. Various co-culture paradigms will be created with HD and 
control neurons together with HD central (microglia) and peripheral (monocytes, 
macrophages) cells of the myeloid lineage. This represents a human primary in vitro 
model of the in vivo HD state, allowing study of neuronal-myeloid cell-cell interactions 
and representing a tool for the screening of potential therapeutic compounds. 
Poster: 
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I I I -vi  Poster presented at UCL Neuroscience Symposium 
Date: 22 March 2012 
Location: University College London, London, United Kingdom 
Title: Cellular pathobiology of Huntington’s disease 
Authors: Sarah J. Tabrizi and the Huntington’s disease research team. Presenting 
authors: Lucianne Dobson and Ulrike Träger 
Author affiliation: Department of Neurodegenerative Diseases, UCL IoN and NHNN, 
London, UK 
Abstract: Huntington’s disease (HD) is a fatal, inherited neurodegenerative disorder, in 
which the importance of the immune system is becoming increasingly recognised. We 
have demonstrated myeloid cell hyper-reactivity in HD patients and transgenic mouse 
models, contributing to elevated levels of inflammatory markers in plasma. These 
effects appear to be due to the cell intrinsic expression of mutant huntingtin (mHTT). 
Current work involves knocking-down HTT to investigate the intracellular signalling 
pathways that cause immune cell dysfunction. Quantification of mHTT in peripheral 
immune cells holds promise as a non-invasive disease biomarker for HD progression. 
Mutant HTT levels in peripheral immune cells differ significantly between pre-manifest 
and manifest HD patients, and are associated with disease burden scores and caudate 
atrophy rates in HD patients. Fragmentation of mHTT may explain the progressive 
increase in levels in these cells. To examine direct interactions between HD immune 
cells and neurons, co-culture paradigms with primary ex vivo cultures of HD patients’ 
peripheral myeloid cells or human microglia cell lines are being established. This is 
being facilitated by the development of novel human HD neural stem cells, which could 
provide an invaluable tool for the broader study of cellular aspects of HD pathogenesis.    
Poster: 
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Abstract
Huntington’s disease (HD) is a neurodegenerative condition
characterized by pathology in the brain and peripheral tissues.
Hyperactivity of the innate immune system, due in part to NFjB
pathway dysregulation, is an early and active component of HD.
Evidence suggests targeting immune disruption may slow
disease progression. Laquinimod is an orally active
immunomodulator that down-regulates proinﬂammatory cyto-
kine production in peripheral blood mononuclear cells, and in
the brain down-regulates astrocytic and microglial activation by
modulating NFjB signalling. Laquinimod had beneﬁcial effects
on inﬂammation, brain atrophy and disease progression in
multiple sclerosis (MS) in two phase III clinical trials. This study
investigated the effects of laquinimod on hyperactive proinﬂam-
matory cytokine release and NFjB signalling in HD patient
myeloid cell cultures. Monocytes from manifest (manHD) and
pre-manifest (preHD) HD gene carriers and healthy volunteers
(HV) were treated with laquinimod and stimulated with
lipopolysaccharide. After 24 h pre-treatment with 5 lM laquin-
imod, manHD monocytes released lower levels of IL-1b, IL-5,
IL-8, IL-10, IL-13 and TNFa in response to stimulation. PreHD
monocytes released lower levels of IL-8, IL-10 and IL-13, with
no reduction observed in HV monocytes. The effects of
laquinimod on dysfunctional NFjB signalling in HD was
assessed by inhibitor of kappa B (IjB) degradation kinetics,
nuclear translocation of NFjB and interactions between IjB
kinase (IKK) and HTT, in HD myeloid cells. No differences were
observed between laquinimod-treated and untreated condi-
tions. These results provide evidence that laquinimod dampens
hyper-reactive cytokine release from manHD and preHD
monocytes, with a much reduced effect on HV monocytes.
Keywords: cytokines, Huntington’s disease, inﬂammation,
laquinimod, neurodegenerative disease, NFjB.
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Huntington’s disease (HD) is a neurodegenerative condition
caused by a cytosine-adenine-guanine (CAG) repeat expan-
sion in exon 1 of the huntingtin gene (HTT) (The Hunting-
ton’s Disease Collaborative Research Group 1993) and is
characterized by progressive motor, cognitive and psychiatric
symptoms including involuntary movement disturbances,
dementia and depression. Symptoms display delayed onset
despite presence of mHTT throughout the entire lifetime, and
usually become manifest in middle age. Primary pathology
involves dysfunction and loss of the GABAergic medium
spiny neurons in the striatum as well as cortical neuronal
degeneration, and is hallmarked by presence of intra-nuclear
and cytoplasmic aggregates of mHTT. Many mechanisms
have been described to contribute to tissue damage leading to
neuronal degeneration in HD, including excitotoxicity,
mitochondrial dysfunction, production of free radicals,
impairment of protein degradation systems and transcrip-
tional dysregulation; leading to inﬂammatory processes that
cause microglial and astrocytic activation and neuronal loss
(Ross and Tabrizi 2011; Ellrichmann et al. 2013).
In the central nervous system (CNS), elevated levels of
inﬂammatory molecules are observed in postmortem HD
brain tissue (Bj€orkqvist et al. 2008). Substantial numbers of
activated microglia are seen in affected regions of the brain
such as the striatum and cortex (Sapp et al. 2001; Pavese
et al. 2006), and this correlates with loss of neuronal
function (Politis et al. 2011). Activated microglia are also
present in the brains of pre-symptomatic HD gene carriers
(Tai et al. 2007), and peripherally, inﬂammatory molecules
are elevated in blood plasma many years before disease onset
(Dalrymple et al. 2007; Bj€orkqvist et al. 2008; Wild et al.
2011), suggesting a possible active role of the innate immune
system during progression to symptomatic disease. Periph-
eral myeloid cells are the likely source of elevated systemic
levels of inﬂammatory molecules. HD patient monocytes and
macrophages produce increased levels of cytokines when
stimulated ex vivo (Bj€orkqvist et al. 2008), and are impaired
in their ability to migrate towards chemo-attractant stimuli
(Kwan et al. 2012b). These same dysfunctional phenotypes
are observed in both peripheral myeloid cells and microglia
isolated from HD mouse models (Bj€orkqvist et al. 2008),
suggesting that blood-derived myeloid cells may reﬂect the
pathological actions of microglia in the CNS in HD. It is also
possible that there is direct communication between the
peripheral immune system and the CNS in HD: peripheral
inhibition of kynurenine 3-monooxygenase, highly expressed
in peripheral immune cells, ameliorates neurodegeneration in
a HD mouse model by raising CNS levels of neuroprotective
metabolite kynurenic acid and preventing hyperactive
microglial activity (Zwilling et al. 2011).
Hyper-reactivity of the innate immune response in HD is
due partly to nuclear factor (NF)jB pathway dysregulation
(Khoshnan et al. 2004; Tr€ager et al. 2014). In HD myeloid
cells, dysregulation is observed upon activation of Toll-like
receptors (TLRs) using lipopolysaccharide (LPS), implicat-
ing a possible mechanism of dysfunctional signalling down-
stream of TLR4, the principal LPS receptor (Poltorak et al.
1998; Qureshi et al. 1999). In cultured cells expressing
mHTT and striatal cells from HD transgenic mice, mHTT
was found to interact with inhibitor of kappa B (IjB) kinase
(IKK) c subunit, leading to elevated NFjB activity and
increased NFjB-dependent gene expression (Khoshnan
et al. 2004). This was also observed in primary human
peripheral blood mononuclear cells (PBMCs), along with a
more rapid degradation of IjB following LPS stimulation in
HD monocytes compared to controls (Tr€ager et al. 2014).
While there are treatments that manage the severity of
symptoms in HD, there are no effective disease-modifying
therapies and consequently, novel approaches targeting
hyperactive immune cells have been investigated. Minocy-
cline, a caspase inhibitor, reduces IL-1b and inducible nitric
oxide synthase, and in the R6/2 mouse model of HD,
minocycline signiﬁcantly delayed disease progression (Chen
et al. 2000). A small study in HD patients has shown
minocycline to be safe and well tolerated (Thomas et al.
2004), however, the primary endpoint of a 25% improvement
in the total functional capacity score was not met in a
subsequent futility study (Huntington Study Group DOM-
INO Investigators 2010). More recently, dimethyl fumarate,
an immunomodulator approved as a treatment for relapsing-
remitting MS (Tecﬁdera, Biogen), has been shown to have
beneﬁcial effects on neuronal degeneration, motor functions
and survival time in R6/2 and YAC128 mouse models of
HD. Dimethyl fumarate is believed to exert its effects via
induction of nuclear factor E2-related factor 2, a transcription
factor which activates detoxiﬁcation pathways and subse-
quently protects against oxidative damage triggered by
inﬂammation (Ellrichmann et al. 2011).
Laquinimod is a novel oral immunomodulatory drug
which has been shown to reduce the proportion of astrocytes
with nuclear NFjB (p65/RelA) immune-reactivity in cupri-
zone-treated mice (Br€uck et al. 2012), and decrease cytokine
release from LPS-stimulated adult human microglia (Mishra
et al. 2014). Laquinimod effects on peripheral inﬂammatory
phenotypes have also been described. Laquinimod-treated
human PBMCs release lower levels of interleukin (IL)-17,
IL-3 and granulocyte colony-stimulating factor (Br€uck and
Wegner 2011). Mononuclear cells isolated from the spleen of
a laquinimod-treated MS rat model display evidence of a
shift from proinﬂammatory T helper (Th)1-activating to anti-
inﬂammatory and regulatory Th2/Th3-activating cytokine
expression proﬁle, with a laquinimod-induced change in
favour of the Th2 stimuli IL-4, IL-10 and transforming
growth factor beta (TGFb) and reductions in the Th1 stimuli
tumour necrosis factor alpha (TNFa) and IL-12 (Yang et al.
2004). Laquinimod has also been shown to promote splenic
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development of M2 polarized monocytes and dendritic cells
in mice, leading to reduced cellular production of Th1-
activating cytokines IL-6, IL-12 and TNFa with a corre-
sponding increase in Th2-activating anti-inﬂammatory IL-10
production (Schulze-Topphoff et al. 2012).
Affymetrix GeneChip arrays on PBMCs have shown
that laquinimod increases IjB expression whilst down-
stream NFjB genes are decreased (Gurevich et al. 2010),
and imaging ﬂow cytometry has shown laquinimod-
induced reduction in p65 translocation in primary murine
astrocytes (Br€uck et al. 2012), suggesting a potential role
of NFjB signalling in laquinimod mechanism of action. It
is therefore plausible that laquinimod could reverse the
hyperactive proinﬂammatory phenotype observed in HD
PBMCs, possibly by rescuing the dysfunctional NFjB
signalling in these cells. Intervention of peripheral inﬂam-
matory events has previously been shown to modulate
central neuropathology and disease progression in HD
(Zwilling et al. 2011; Bouchard et al. 2012; Kwan et al.
2012a), therefore an immunomodulatory drug such as
laquinimod is a potential candidate for slowing disease
progression in HD patients by affecting peripheral immune
cells. In addition, laquinimod has already been studied in
human immunomodulation and has a very good safety
proﬁle following clinical trials for the treatment of MS
(Comi et al. 2012; Filippi et al. 2014; Vollmer et al.
2014). Such studies have also provided evidence for
laquinimod-induced immunomodulation having beneﬁcial
effects on disease progression and brain atrophy in MS
(Comi et al. 2012). As inﬂammation has been implicated
in myelin, axonal and neuronal loss in HD pathology
(Ellrichmann et al. 2013), it is feasible that laquinimod
may slow disease progression and reduce brain atrophy
rate in HD through central and peripheral immunomodu-
latory mechanisms, as it has been shown to do in MS.
Therefore, the goal of this study was to determine whether
laquinimod down-regulates the hyper-reactive proinﬂamma-
tory phenotype of HD patient myeloid cells, and switches the
functional signatures of these cells away from M1 and
towards M2 polarization with a consequential shift in the
balance from Th1- to Th2-activating cytokine release. This is
the ﬁrst demonstration of the effects of laquinimod in HD
patient myeloid cells. The second aim was to elucidate a
possible mechanism of action of laquinimod in the periphery,
by assessing its possible effects on NFjB pathway dysreg-
ulation in HD patient myeloid cells. While a mechanism of
action involving the NFjB pathway has been shown in cells
of the CNS, it is not yet known whether laquinimod has the
same effect in the periphery. To this end, primary human
monocyte and macrophage cultures from HD patient sub-
groups and healthy volunteers were treated with laquinimod
in stimulated and non-stimulated conditions. Cytokine
release, IjB levels, NFjB translocation and IKKc-mHTT
interactions were examined.
Methods
Collection and classification of human samples
All human experiments were performed in accordance with the
Declaration of Helsinki and approved by University College London
(UCL)/UCL Hospitals Joint Research Ethics Committee. All blood
donors provided informed written consent for research on Hunting-
ton’s disease. Whole blood samples were collected from manifest
HD patients with early or moderate stage disease (manHD), pre-
manifest HD gene carriers (preHD) and healthy volunteers (HV).
ManHD samples were collected from six females and 13 males with
an average age of 55.32 years ranging from 27 to 70; preHD
samples were collected from six females and three males with an
average age of 47.45 years ranging from 33 to 62; HV samples were
collected from 10 females and ﬁve males with an average age of
47.95 years ranging from 25 to 68.
Primary human monocyte isolation
Whole blood samples were decanted into 50 mL heparinized tubes
(50 lL prescription grade heparin in standard 50 mL Falcon tubes).
25 mL whole blood was then carefully layered onto 20 mL
Histopaque-1077 (Sigma, Dorset, UK) and separated through the
gradient by centrifugation in a swinging bucket rotor at 400 g for
30 min at 21°C with no brake. The resulting PBMC layer was
removed with a Pasteur pipette from the plasma/Histopaque-1077
interface. PBMCs were washed in magnetic-activated cell sorting
(MACS) buffer [1 9 Dulbecco’s phosphate-buffered saline (Gibco,
Life Technologies, Paisley, UK); 0.5% bovine serum albumin
(Sigma); 2 mM EDTA (Sigma)] and pelleted out of wash solution
by centrifugation at 350 g for 10 min at 4°C. Cells were re-
suspended in 1 mL MACS buffer and 60 lL anti-CD14 MACS
MicroBeads (Miltenyi Biotec, Surrey, UK) was added to the
suspension, followed by quick vortex and 15 min incubation at 4°C.
Cells were then pelleted by centrifugation at 350 g for 5 min at 4°C,
and re-suspended in fresh MACS buffer before being applied to
MACS columns (Miltenyi Biotec) mounted on a magnetic separator
(Miltenyi Biotec). The ﬂow-through was discarded and magnetically
isolated CD14 + monocytes were plunged out of the columns into
separate collection tubes.
Cell culture
Primary human monocytes were seeded in Primaria culture dishes
(BD Falcon, BD Biosciences, Oxford, UK) at 3 9 105 cells/cm2,
and maintained in Roswell Park Memorial Institute medium 1640
(Gibco, Life Technologies); 10% foetal bovine serum (Gibco);
2 mM L-glutamine (Gibco, Life Technologies); 5 U/mL penicillin
and 5 lg/mL streptomycin (Gibco PenStrep solution) in 5% CO2
atmosphere at 37°C. Pre-testing has shown that this protocol
produces monocyte cultures of at least 95% CD14+ monocytes
and these were used in experiments from 1 to 3 days in vitro
(DIV). For some experiments, monocytes were differentiated into
macrophages with the addition of 20 ng/mL granulocyte macro-
phage colony-stimulating factor (GM-CSF, R&D Systems,
Oxford, UK) to the culture medium on seeding. Cells were
given a complete media change with addition of fresh GM-CSF
at 3 DIV and have been conﬁrmed by factor analysis to be fully
differentiated macrophages at 6 DIV and were used in experi-
ments at this stage.
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Cell treatments
Once the cells had adhered post-seeding, monocytes were treated
with doses of laquinimod ranging from 0 to 100 lM for 24 or 48 h
for toxicity analysis. For cytokine analysis, monocytes were treated
with 1 or 5 lM laquinimod for 2 or 24 h, or were untreated. Cells
were then given a media change, and relevant cultures were
stimulated with 1 lg/mL LPS (Sigma, #L6529) for 24 h. 10 ng/mL
interferon gamma (IFNc, R&D Systems) was added at the same
time as LPS as a priming agent. Three drug treatment durations, and
two drug concentrations were used: 2 and 24 h pre-treatments of 1
and 5 lM laquinimod (before stimulation, 2hPT and 24hPT
respectively) and 24 h 5 lM pre-treatment + 24 h continued
5 lM laquinimod treatment during LPS stimulation
(24hPT+24hCT). After LPS stimulation, culture supernatants were
collected, frozen and stored at 80°C. For western blot analysis,
monocytes received 24hPT with 5 lM laquinimod, or untreated,
followed by 1 lg/mL LPS stimulation over a time-course of 0–
60 min. For imaging ﬂow cytometry analysis, monocytes received
24hPT with 5 lM laquinimod, or untreated, before stimulation with
1 lg/mL LPS for 45 min. For proximity ligation assays, macro-
phages were treated with 5 lM laquinimod for 24 h, and then ﬁxed.
Cytotoxicity assay
Monocytes cultures from six HD patients and HV were treated, in
duplicate, with 0, 0.001, 0.01, 0.1, 0.5, 1, 5, 10, 50 or 100 lM
laquinimod for 24 or 48 h. Cell survival after laquinimod treatment
was assessed by CytoTox 96 Non-Radioactive Cytotoxicity Assay
(Promega, Southampton, UK), as per the manufacturer’s protocol,
and compared to viability of untreated cells.
ELISA analysis of cytokines
Cytokine levels in monocyte culture supernatants were measured
using MesoScale Discovery Human Th1/Th2 10-Plex Tissue Culture
Kit analysing 10 different cytokines simultaneously (IFNc, IL-1b,
IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p70, IL-13, TNFa), or Human
IL-6 Singleplex Kit, according to the manufacturer’s protocol.
Depending on cell treatment condition, for 10-plex analysis n = 9–
11 for HV, n = 9 for preHD and n = 10–14 for manHD, and for the
IL-6 singleplex analysis n = 13–15 for HV, n = 6–9 for preHD and
n = 15–19 for manHD. Cytokine level read-outs were normalized to
protein content per culture well, which was ascertained by lysing the
cultures with radioimmunoprecipitation assay buffer [consisting of
25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% Nonidet-P40, 1%
sodium deoxycholate, 0.1% sodium dodecyl sulphate and protease
inhibitor cocktail (Roche, West Sussex, UK)] and performing
bicinchoninic acid protein assays (Pierce, Life Technologies) on the
resulting lysates, according to the manufacturer’s protocol. IFNc
levels were not considered because of the addition of this cytokine as
a priming agent in the stimulated conditions.
Western blotting
Monocyte cultures from four manHD received 24hPT with 5 lM
laquinimod, or untreated, followed by LPS stimulation. Cell lysates
(made using radioimmunoprecipitation assay buffer) were harvested
at 0, 5, 15, 30 and 60 min time-points after stimulation. Protein
lysates were analysed by western blot using anti-IjB antibody
(1:500, Santa Cruz Biotechnology, Heidelberg, Germany) to
determine the rate of IjB degradation. All IjB readings were
normalized to the house-keeping protein glyceraldehyde 3-phos-
phate dehydrogenase (anti-GAPDH antibody, 1:3000, Sigma
Aldrich, Dorset, UK), and quantiﬁed by densitometry analysis of
three exposures using TotalLab TL100 image analysis software
(Sigma Aldrich). Western blotting and analysis were performed as
previously described in detail (Tr€ager et al. 2014).
Imaging flow cytometry
Monocyte cultures from seven manHD received 24hPT with 5 lM
laquinimod, or untreated, followed by 45 min LPS stimulation.
Monocytes were ﬁxed and probed with NFjB p65 XP antibody
(1:200, Cell Signaling Technology, New England Biolabs, Hertford-
shire, UK) followed by secondary anti-rabbit IgG phycoerythrin-
conjugated antibody (1 : 100, eBioscience Ltd., Hatﬁeld, UK). Cells
were stained in 1 lg/mL 40,6-diamidino-2-phenylindole (DAPI,
Sigma Aldrich) nuclear stain immediately prior to analysis. Samples
were run on ImageStreamX analyser (Amnis Corporation, Seattle,
WA, USA) to assess intra/extra-nuclear localization of p65 and
analysed using IDEAS Software (Amnis) to calculate percentage
translocated cells. Imaging ﬂow cytometry and analysis of images
were performed as previously described in detail (Tr€ager et al. 2014).
Proximity ligation assay
Monocytes from six manHD and preHD were seeded on 13 mm
coverslips at 5 9 103 cells/cm2, and differentiated into macro-
phages. Cells were treated with 5 lM laquinimod for 24 h, or
untreated, then ﬁxed in 4% paraformaldehyde and stained with
ﬂuorescent wheat germ agglutinin (WGA, Life Technologies) to
label membranes. Cells were stained with 1 lg/mL WGA for 5 min
at 37°C before washing ten times with phosphate-buffered saline.
Cells were then permeabilized, blocked and probed with mouse anti-
HTT antibody 4C9 (1 : 300, gift from Novartis, Basel, Switzerland)
and anti-IKKc antibody (1 : 100, Santa Cruz). Instead of using
ﬂuorescently labelled secondary antibodies, a proximity ligation
approach was undertaken, as per the manufacturer’s instructions
[Proximity Ligation Assay (PLA), Sigma]. Brieﬂy, samples were
incubated with secondary antibodies conjugated with PLUS and
MINUS DNA probes, which were hybridized and ligated before
ampliﬁcation of the DNA template in a rolling circle ampliﬁcation
reaction. Detection solution was added to identify ampliﬁed DNA,
and coverslips were mounted on glass slides in Duolink mounting
medium (Sigma Aldrich) containing 1 lg/mL DAPI. Signals were
detected using ﬂuorescent confocal microscopy. Positive interac-
tions appear as ﬂuorescent spots which were quantiﬁed as average
number of spots per cell using Volocity software (PerkinElmer,
Waltham, MA, USA). Each of the two negative controls was made
up of a single primary antibody with both PLUS and MINUS
secondary antibodies. The positive control was anti-IKKb (1 : 50;
Santa Cruz) and anti-IKKc primary antibodies with both secondary
antibodies, as these proteins are known to directly interact. PLA and
analysis of images were performed as previously described in detail
(Tr€ager et al. 2014).
Statistical analyses
All samples were labelled with an anonymized 5-digit number for
blinded analysis
Cytotoxicity assay data were statistically analysed in-house. One-
way ANOVA with Dunnett’s multiple comparison tests comparing
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all laquinimod treatment conditions to untreated were used to
analyse statistically signiﬁcant variations in the means.
Analysis of ELISA cytokine measurements was performed by an
independent statistician (RF). The data set was split into two –
stimulated and non-stimulated conditions – to perform statistical
analysis. Not every subject had a measurement for every condition
because of some samples failing quality control, leading to
unbalanced data. Data were log transformed prior to analysis
to improve normality assumptions. A linear mixed model was ﬁtted
to each of the subsets separately, assuming exchangeable correla-
tion, with robust standard errors to allow for misspeciﬁcation of the
covariance structure. Comparisons of interest were calculated using
linear contrasts. This approach allows for data from a subject to be
used even if some of the conditions are missing, under a missing at
random assumption. For the HD combined comparisons, a weighted
combination of preHD and manHD was used, based on the total
number of patients in those subgroups. All analyses were addition-
ally adjusted for age. Multiple comparison adjustments were not
made because of the small sample size and lack of independency in
cytokine activity, and this was taken into consideration when
reviewing the ﬁndings from these analyses. All results of cytokine
levels and statistical analysis of this data are graphically presented
and reported on the logarithmic scale. It is important to note that
natural differences in cytokine release from primary human
monocytes leads to highly variable data, and the sample size limits
the precision for which estimates of between condition and between
group differences can be made. Therefore, in cases where there is
absence of statistical evidence it is not possible to determine whether
this is because of no effect or that the random variation in
measurements masks any effect that may be present.
NFjB mechanism of action data was analysed in-house. IjB
degradation kinetics data were analysed using two-way repeated
measures ANOVA comparing treatment conditions (untreated or
laquinimod pre-treatment) over time post-LPS-stimulation. Two-
tailed, paired Student’s t-tests were used to compare untreated
versus laquinimod treatments for imaging ﬂow cytometry and PLA
data. For PLA analysis, all conditions were tested in six subjects,
however, the results for the laquinimod condition were removed for
one of the subjects for quality control reasons.
Results
Laquinimod is not toxic to ex vivo human monocyte cultures
First, it was important to determine whether laquinimod is
toxic to primary human monocytes in culture. Monocytes
were treated for 24 or 48 h with previously published doses
of laquinimod used to treat human PBMCs, 1 and 5 lM
(Br€uck and Wegner 2011), as well as a range of concentra-
tions either side. Laquinimod-treated cell survival was
assessed relative to untreated cells. None of the laquinimod
concentrations or treatment durations tested showed any
overt toxicity to the cells (Fig. 1). Conﬁdence intervals (CIs,
calculated at the 95% conﬁdence level) around the mean
percentage survival relative to untreated cells span 100%
survival in all laquinimod-treated conditions, and are gener-
ally narrow. In addition, none of the laquinimod treatment
conditions showed a statistically signiﬁcant difference in
percentage monocyte survival (p > 0.05). After the longest
laquinimod treatment duration of 48 h, 1 and 5 lM laquin-
imod resulted in an average of 99.84% and 97.54%
monocyte survival, respectively, relative to untreated cells.
The lower bound of the CIs for these results were 88.01% for
1 lM laquinimod and 86.84% for 5 lM laquinimod, there-
fore one can be conﬁdent that at these concentrations the true
cell survival relative to untreated is above 86%, which was
taken to be acceptable in terms of establishing a lack of
laquinimod toxicity. Previously published doses of 1 and
5 lM laquinimod were therefore used for subsequent
experiments, which is in accordance with physiological
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Fig. 1 Primary human monocyte survival following laquinimod treat-
ment. Monocytes treated with a range of laquinimod concentrations for
24 or 48 h. Laquinimod-treated monocyte survival expressed as a
percentage of untreated monocyte survival. Data points = mean
average of six biological repeats. Error bars = SEM. Concentrations
of 1 and 5 lM (boxed) were used in subsequent experiments.
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in vivo data for relevant plasma levels of laquinimod in
humans (Sennbro et al. 2006; Preiningerova 2009) and mice
(Brunmark et al. 2002).
Laquinimod reduces hyper-reactive cytokine release from
stimulated HD patient monocytes
HD monocytes and macrophages have been observed to
release elevated levels of the proinﬂammatory Th1-activating
cytokines IL-6, IL-8 and TNFa (Bj€orkqvist et al. 2008), and
laquinimod has been reported to drive a shift from Th1- to
Th2-activating cytokine production in human PBMCs
in vitro (Br€uck and Wegner 2011) and in mouse and rat
models of MS in vivo (Zou et al. 2002; Yang et al. 2004;
Br€uck and Wegner 2011). To determine whether laquinimod
can shift the hyper-reactive proinﬂammatory cytokine release
from HD myeloid cells by tipping the reactive cytokine
balance from Th1- to Th2-activating cytokine release, ex vivo
primary monocyte cultures from HV, preHD and manHD
were treated with laquinimod, or untreated, in non-stimulated
and stimulated conditions. Culture supernatants were col-
lected and production of the following cytokines was
measured: Th1-activating cytokines IL-1b, IL-6, IL-8, IL-
12p70, TNFa; Th2-activating cytokines IL-4, IL-5, IL-10,
IL-13, TNFa; and IL-2.
Baseline cytokine release in untreated monocytes
Levels of all cytokines, other than IL-6, were signiﬁcantly
higher (p < 0.05), or borderline, in manHD compared to HV
in monocyte cultures which had received no laquinimod
treatment or stimulation. IL-5, IL-8 and IL-13 were also
elevated in preHD compared to HV under these conditions.
While not all cytokines tested were higher in preHD
compared to HV, both preHD and manHD subgroups
showed similar trends, and combining the HD subjects
increased the power sufﬁciently to see a statistically signif-
icant (p < 0.05), or borderline increase in all cytokines tested
in HD compared to HV cultures (data not shown) suggesting
that HD monocytes inherently release higher levels of
cytokines.
Cytokine release in laquinimod-treated non-stimulated
monocytes
Monocytes from HV showed at least borderline signiﬁcant
evidence for an increase in Th1-activating cytokine IL-12
(p = 0.062) (Figure S1) and the Th2-activating cytokines IL-
4 (p = 0.009) and IL-5 (p = 0.002) (Figure S2), after 2hPT
with 1 lM laquinimod. After 24hPT with 1 lM laquinimod,
IL-4 and IL-5 levels were still estimated to be higher, but to a
lesser degree which was not statistically signiﬁcant. When
HV monocytes were treated with 5 lM laquinimod, there
was evidence of an increase in levels of the Th1-activating
cytokines IL-12 and TNFa (Figure S1) compared to
untreated: IL-12 was increased after 2hPT and
24hPT+24hCT (p = 0.036 and p = 0.026 respectively), and
TNFa was increased after 24hPT and 24hPT+24hCT
(p = 0.022 and p = 0.006 respectively). IL-2 and the Th2-
activating cytokines IL-4, IL-5, IL-10 and IL-13 were also
increased (Figure S2): IL-2 was increased after
24hPT+24hCT (p = 0.030), IL-4 was increased after
24hPT (p = 0.014), IL-5 was increased after 2hPT, 24hPT
and 24hPT+24hCT (p = 0.025, p = 0.002 and p = 0.007
respectively), IL-10 was increased after 24hPT+24hCT
(p = 0.004) and IL-13 was increased after 24hPT+24hCT
(p = 0.005). There was no evidence of a statistically
signiﬁcant effect of laquinimod treatment at any of the
concentrations or treatment durations on non-stimulated
preHD or manHD monocytes.
Cytokine release in non-laquinimod-treated stimulated
monocytes
In LPS(+IFNc)-stimulated conditions, there was some evi-
dence of an increase in IL-1b, IL-5 and IL-13 release in
manHD compared to HV monocytes. The log levels of these
cytokines in manHD were all estimated to be around 0.4
higher than in HV, with these differences being of at least
borderline statistical signiﬁcance. IL-4, IL-6 and IL-10 had
differences in similar magnitude but did not reach borderline
signiﬁcance. IL-8 levels were lower in preHD compared to
HV, with borderline statistical signiﬁcance. Overall there was
little statistical evidence of differences between HD sub-
groups and HV monocyte cytokine release in stimulated
conditions (data not shown).
Cytokine release in 1 lM laquinimod-treated stimulated
monocytes
There was no evidence of an effect of 2hPT with 1 lM
laquinimod in LPS(+IFNc)-stimulated HV monocytes. Fol-
lowing 24hPT at the same concentration, HV monocytes
showed a borderline signiﬁcant increase in Th1-activating
cytokine IL-8 (p = 0.064; Fig. 2) and a signiﬁcant increase in
Th2-activating cytokine IL-5 (p = 0.035; Figure 3) compared
to untreated cells. PreHD subjects showed decreases in Th1-
activating cytokines IL-6 and IL-8 (p = 0.069 and p = 0.004
respectively; Figure 2) compared to untreated, following
2hPT with 1 lM laquinimod. After a longer pre-treatment
duration, 24hPT, at the same concentration, IL-6 levels were
signiﬁcantly decreased compared to untreated (p = 0.028;
Figure 2). Like the preHD group, manHD monocytes also
showed a signiﬁcant decrease in IL-8 levels following 2hPT
with 1 lM laquinimod in stimulated cells (p = 0.005;
Figure 2). There was no statistical evidence of an effect of
1 lM laquinimod on stimulated manHD monocyte cytokine
release following 24hPT (Figures 2 and 3).
Cytokine release in 5 lM laquinimod-treated stimulated
monocytes
In HV monocytes, 2hPT or 24hPT with the higher laquin-
imod concentration of 5 lM resulted in no signiﬁcant effects
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on levels of cytokine release (p > 0.05 for all comparisons;
Figures 2 and 3). Levels of Th1-activating cytokine IL-6
were signiﬁcantly lower in HV monocytes which received
24hPT+24hCT with 5 lM laquinimod compared to untreated
(p = 0.004; Figure 2), and levels of Th2-activating cytokines
IL-5 and IL-13 were signiﬁcantly higher in the same
condition (p = 0.047 and p = 0.041 respectively; Fig. 3).
In the preHD group, although not always statistically
signiﬁcant, the estimates comparing treatments for 2hPT,
24hPT and 24hPT+24CT with the untreated condition
generally showed decreases in levels of cytokines. The
exceptions were IL-2 and IL-5, where the general trend
shows increases in cytokine levels following laquinimod
treatments, but these differences were small in magnitude.
Th1-activating cytokines IL-6 and IL-8 were reduced
(Fig. 2): IL-6 was reduced after 2hPT and 24hPT+24hCT
(p = 0.015 and p = 0.016 respectively), and IL-8 was
reduced after 24hPT (p = 0.015). Th2-activating cytokines
IL-10 and IL-13 were also reduced (Fig. 3): IL-10 was
reduced after 2hPT, 24hPT and 24hPT+24hCT (p = 0.037,
p = 0.015 and p = 0.004 respectively), and IL-13 was
reduced after 24hPT (p = 0.033).
In manHD monocytes, 2hPT with 5 lM laquinimod did
not show a statistically signiﬁcant change in cytokine levels
compared to untreated, however, the 24hPT effect was of at
least borderline statistical signiﬁcance for several cytokines,
with evidence of a reduction in the proinﬂammatory, Th1-
activating cytokines IL-1b (p = 0.022), IL-6 (p = 0.056), IL-
8 (p = 0.052) and TNFa (p = 0.007) (Fig. 2), and the Th2-
activating cytokines IL-5 (p = 0.053), IL-10 (p = 0.044) and
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Fig. 2 Th1-activating cytokine release in stimulated monocytes pre-
treated with laquinimod. Primary stimulated human monocyte cultures
from HV, preHD and manHD received 2hPT or 24hPT with 1 or 5 lM
laquinimod, or 24hPT+24hCT with 5 lM laquinimod. Levels of cytokine
release were measured in monocyte culture supernatants and
normalized to cell culture protein. Figure 2 displays results for the
Th1-activating cytokines and Fig. 3 displays results for IL-2 and the
Th2-activating cytokines measured. Columns = mean average log
cytokine level of biological repeats; error bars = SEM; *p < 0.05,
**p < 0.01.
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IL-13 (p = 0.052) (Fig. 3). In addition, for the cytokines IL-
1b, IL-10 and TNFa, 24hPT with 5 lM laquinimod resulted
in a statistically signiﬁcant reduction in cytokine release from
manHD monocytes that was not seen in HV. While not
statistically signiﬁcant, many of the other cytokines also
showed this trend. This could suggest that 24hPT with 5 lM
laquinimod has more of an effect on reducing cytokine
production in manHD monocytes than in HV monocytes.
After 24hPT+24hCT, there were decreases in the Th1-
activating cytokines IL-6 (p = 0.053), IL-12 (p = 0.028) and
TNFa (p = 0.009) compared to untreated in manHD mono-
cytes (Fig. 2). Although not statistically signiﬁcant, levels of
IL-2 and Th2-activating cytokines IL-4, IL-5 and IL-13 were
increased following 24hPT+24hCT (Fig. 3), going against
the trend seen with 2hPT and 24hPT.
A secondary analysis was performed to increase power and
look at the differences between HV and HD overall. When
manHD and preHD subgroup data were combined, 24hPT
with 5 lM laquinimod resulted in at least a borderline
signiﬁcant decrease in the Th1-activating cytokines IL-1b
(p = 0.006), IL-6 (p = 0.059), IL-8 (p = 0.005) and TNFa
(p = 0.003), and the Th2-activating cytokines IL-10
(p = 0.003) and IL-13 (p = 0.009) compared to the untreated
condition. In addition, the difference in change from the
untreated condition between grouped HD subjects and HV
was of at least borderline signiﬁcance for IL-1b (p = 0.062),
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IL-5 (p = 0.045), IL-10 (p = 0.008), IL-13 (p = 0.005) and
TNFa (p = 0.045), suggesting that 24hPT with 5 lM
laquinimod has a larger effect on reducing cytokine release
from HD cells than HV cells.
Laquinimod does not affect NFjB signalling in HD
monocytes
Laquinimod-induced down-regulation of proinﬂammatory
factors in monocytes has previously been shown to be
because of a switch from MI to M2 phenotype (Zou et al.
2002; Yang et al. 2004; Br€uck and Wegner 2011; Schulze-
Topphoff et al. 2012). The exact mechanism for this remains
unclear, although in astrocytes the down-regulation has been
shown to be a result of reduced NFjB activation (Br€uck
et al. 2012). In HD myeloid cells, the enhanced release of
proinﬂammatory factors is at least in part because of elevated
NFjB activation (Tr€ager et al. 2014), so investigations were
made into a role of the NFjB pathway in the observed
overall dampening of cytokine release from stimulated HD
monocytes pre-treated with laquinimod.
To determine whether laquinimod has the potential to
improve NFjB dysfunction in HD, the effect of the
compound on IjB degradation kinetics was assessed in HD
monocytes. IjB binds NFjB transcription factor p65 in the
cytoplasm, preventing its nuclear translocation. Degradation
of IjB, however, liberates p65, which then translocates into
the nucleus to modulate transcription (Hayden and Ghosh
2012). Consequently, monitoring IjB kinetics is an indirect
measure for monitoring p65 nuclear translocation; decreased
IjB levels indicates increased nuclear translocation of p65.
ManHD monocytes were stimulated with LPS, with or
without 24hPT with 5 lM laquinimod, and IjB levels were
measured by western blotting at 0, 5, 15, 30 and 60 min post-
stimulation. LPS stimulation resulted in the usual degrada-
tion pattern of IjB for HD monocytes (Tr€ager et al. 2014),
and laquinimod pre-treatment did not signiﬁcantly alter
(p = 0.566) IjB levels from the untreated condition over
time post-LPS stimulation (Fig. 4a). As IjB degradation
kinetics were not affected by laquinimod treatment, this
suggests that laquinimod may not alter nuclear translocation
of the NFjB transcription factor p65 in monocytes. How-
ever, because of the indirect method of measuring p65
translocation used, it was necessary to directly monitor
nuclear translocation using an alternative method before
ruling out an effect of laquinimod in this mechanism.
Imaging ﬂow cytometry was implemented to directly
assess p65 nuclear translocation. ManHD monocytes
received 24hPT with 5 lM laquinimod, or untreated, for
24 h before 45 min LPS stimulation. Monocytes were
labelled with anti-p65 antibody and DAPI nuclear stain,
and run through ImageStream to detect intra/extra-nuclear
localization of p65. NFjB translocation has previously been
shown to be pathologically enhanced in HD patient myeloid
cells, leading to a hyper-reactive response to LPS stimulation
and increased release of proinﬂammatory cytokines (Tr€ager
et al. 2014). 24hPT with 5 lM laquinimod did not signif-
icantly alter (p = 0.466) the extent of p65 translocation
compared to untreated in HD monocytes (Fig. 4b).
It has previously been shown in HD myeloid cells that
mHTT directly interacts with the c subunit of IKK, and it is
this dysfunctional interaction which may lead to the observed
increase in IjB degradation (Tr€ager et al. 2014). PLA was
conducted to assess the interaction between mHTT and IKKc
in HD macrophages after 24hPT with 5 lM laquinimod, or
untreated. Laquinimod did not signiﬁcantly alter (p = 0.552)
the number of observed positive HTT-IKKc interactions
(spots per cell) compared to untreated, suggesting that
laquinimod does not affect the interaction between mHTT
and IKKc in HD macrophages (Fig. 4c).
Discussion
Systemic levels of proinﬂammatory cytokines in HD gene
carriers are elevated many years before disease manifesta-
tion, and monocytes and macrophages are the likely source
(Bj€orkqvist et al. 2008). HD patient monocytes produce
higher levels of cytokines than HV monocytes when
stimulated ex vivo (Bj€orkqvist et al. 2008) and are impaired
in their ability to migrate towards chemoattractant stimuli
(Kwan et al. 2012b). There is evidence that systemic
inﬂammatory processes activate CNS microglia leading to
exacerbation of neurodegeneration pathology (Cunningham
et al. 2007; Perry 2007; Perry et al. 2007; Palin et al. 2008),
and peripheral immune challenges have been shown to
exacerbate disease progression in mouse models of HD
(Hsiao et al. 2013). Therefore, peripheral immune events
may directly inﬂuence neuroinﬂammation and neuropathol-
ogy in HD.
Laquinimod appears to alter hyperactivity of the peripheral
immune system in HD as shown by its reduction in cytokine
release from HD patient blood-derived monocytes. In non-
stimulated conditions, laquinimod showed signiﬁcant effects
on HV cytokines but not preHD or manHD cytokine levels.
In stimulated monocytes, laquinimod had an overall damp-
ening effect on cytokine release; however, these changes
were variable depending on the cytokine, subject group, and
laquinimod pre-treatment conditions. Laquinimod pre-treat-
ment reduced the release of nearly all cytokines from
stimulated preHD and/or manHD monocytes compared to the
untreated condition. This effect was most consistent follow-
ing 24hPT, and interestingly had an effect of larger
magnitude on HD monocytes than on HV monocytes, where
the changes (if any) in the HV group were relatively minor.
In particular, our data provides evidence for this for the Th1-
activating proinﬂammatory cytokines IL-1b, IL-8 and TNFa
and the Th2-activating cytokines IL-5, IL-13 and anti-
inﬂammatory IL-10. It is important to note that the natural
differences in cytokine release from primary human mono-
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Fig. 4 Laquinimod does not affect (a) IjB degradation kinetics, (b) p65
translocation or (c) IKKc-mHTT interaction in HD patient myeloid cells.
(a) IjB degradation kinetics in lipopolysaccharide (LPS)-stimulated HD
monocytes, with and without 24hPT with 5 lM laquinimod. IjB levels
measured using western blotting of cell lysates harvested at 0, 5, 15,
30 and 60 min post-LPS stimulation. Blots quantiﬁed using densitom-
etry giving a procedure deﬁned unit (p.d.u.) for comparison of
conditions. Columns = mean average p.d.u. of four biological repeats;
error bars = SEM. (b) Nuclear translocation of NFjB transcription
factor p65 in manHD monocytes 45 min post-LPS stimulation, as
assessed by imaging ﬂow cytometry. Monocytes received 24hPT with
5 lM laquinimod or untreated. Monocytes were probed for p65 (green)
and nuclei were stained with DAPI (pink), as can be seen in example
images all taken from the same untreated sample, and percentage
translocated cells assessed. Columns = mean average percentage
translocated cells from seven biological repeats; error bars = SEM. (c)
Interaction between HTT and IKKc in HD macrophages with or without
24 h 5 lM laquinimod treatment, as assessed by proximity ligation
assay (PLA). Cells imaged using ﬂuorescence confocal microscopy. A
direct interaction between the two proteins is presented as a
ﬂuorescent red spot, nuclei stained with DAPI (blue) and membranes
withwheat germ agglutinin (WGA) (green), as can be seen in example
images all taken from the same patient cells. Positive and negative
controls indicate success of the assay. Columns = mean average
spots per cell (untreated condition from 6 biological repeats, laquin-
imod condition from ﬁve biological repeats; ﬁve matched pairs); error
bars = SEM.
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cytes (HV and HD) leads to large variations in cytokine level
measurements, which introduces some limitations to this
system. Consequently, it is not always possible to determine
whether lack of a statistically signiﬁcant effect is because of
there being no effect or because of random variation in
measurements masking an effect that may be present.
Overall, the sample size limits the precision for which
between condition and between subject group differences can
be assessed. However, there is evidence that laquinimod does
have an effect on cytokine release from HD monocytes, and
that this effect may be different than the effect of laquinimod
on HV monocytes.
Cytokine level trends across laquinimod treatment condi-
tions are generally consistent in terms of laquinimod-induced
changes being greater in magnitude at the 5 lM drug
concentration and a longer pre-treatment duration. However,
this did not usually extend to the 24hPT+24hCT condition,
where in many cases a much smaller change from the
untreated condition occurred than would have been pre-
dicted, or there was even a change in the opposite direction.
Indeed, with the exception of IL-10, there were small
increases in the Th2-activating cytokines in the
24hPT+24hCT condition. Thus, it is important to note that
the 24hPT+24hCT condition may need to be considered
independently from the pre-treatment only conditions, as
laquinimod was present during stimulation. It is possible that
an alternative mechanism of action is at play under these
conditions, such as competitive binding or confounding cross
talk between intracellular signalling pathways.
We did not observe an overall shift in cytokine balance
from Th1- to Th2-activating cytokine release in HD mono-
cytes, which has been reported previously in MS (Zou et al.
2002; Yang et al. 2004; Br€uck and Wegner 2011; Schulze-
Topphoff et al. 2012). The shift in cytokine balance
previously reported was identiﬁed in systems quite different
than those used here. Zou et al. (2002) and Yang et al.
(2004) both describe a decrease in proinﬂammatory cytoki-
nes along with an increase in Th2-activating and anti-
inﬂammatory cytokines in vivo in rat models of MS
following 15 days of daily laquinimod administration. Zou
et al. found a decrease in the number of IFNc- and TNFa-
expressing cells, with an increase in the number of IL-4-
expressing cells in sciatic nerve sections, but in mononuclear
cells (MNCs) isolated from lymph node they only looked at
release of the proinﬂammatory cytokines, which decreased.
Yang et al. describe an increase in the number of spleen
MNCs expressing mRNA for the Th2-activating cytokines
IL-4, TGFb1 and IL-10 and a decrease in the number of cells
expressing mRNA for proinﬂammatory IL-12 and TNFa,
however, in PBMCs they report a decrease in the number of
cells expressing TNFa mRNA with no change in the other
cytokines. Schulze-Topphoff et al. (2012) also report their
ﬁndings in an in vivo animal model of MS, describing a
laquinimod-induced cytokine shift in cells isolated from
spleen. Br€uck and Wegner (2011) report a Th1- to Th2-
activating shift following daily laquinimod administration in
a MS mouse model, but in PBMCs isolated from HVs they
only describe decreases in proinﬂammatory cytokines. In our
model, we push isolated PBMCs towards an M1 phenotype
by stimulating them with LPS and IFNc. In this setting an
increase in Th2-activating cytokines was unlikely to be
observed, however, laquinimod pre-treatment did reduce
overall cytokine production, including those which promote
Th1 activation, suggesting that the functional signatures of
laquinimod-treated HD monocytes are somewhere between
the M1 and M2 polarization extremes following stimulation
(Martinez and Gordon 2014). Overall, our evidence for a
laquinimod-induced decrease in cytokine release from human
HD monocytes is supported by the current literature on
laquinimod effects in MS models. Our ﬁndings for lack of a
Th1- to Th2-activating shift in cytokine balance is also
consistent with the effects seen following laquinimod pre-
treatment of LPS-activated human microglial cultures, where
laquinimod signiﬁcantly reduced the secretion of the proin-
ﬂammatory cytokines TNFa, IL-1b, IL-12p70 and IL-6, and
the anti-inﬂammatory/regulatory cytokines IL-4, IL-10 and
IL-1ra (Mishra et al. 2014).
In the Bj€orkqvist et al. (2008) study comparing peripheral
cytokine levels in the plasma of HV and HD patient
subgroups, there were increased levels of both Th1- and
Th2-activating cytokines in HD compared to HV, and these
increases correlated with disease progression. The Th1-
activating cytokines IL-6, IL-8 and TNFa, and the Th2-
activating cytokines IL-4 and anti-inﬂammatory IL-10 were
elevated in HD patient plasma compared to HV plasma. A
combination of IL-6, IL-8 and IL-10 cytokine increases was
positively correlated with disease progression from preHD
through to manHD, and could also be used to discriminate
HV from HD gene carriers (both pre-manifest and manifest).
In this study, laquinimod shows dampening of the hyper-
reactive release of cytokines by HD monocytes, and this may
be a way of reducing the elevated plasma cytokine levels
observed in HD patients and the increasing levels in
advancing disease, both peripherally and in the brain.
It may seem counterintuitive to reduce potent proinﬂam-
matory factors such as IL-1b and TNFa whilst additionally
decreasing the key anti-inﬂammatory cytokine IL-10. How-
ever, IL-10 levels, which are shown to be high in HD
patients, are also abnormally elevated in Alzheimer’s disease
(AD) patient brains (Guillot-Sestier et al. 2015), and IL-10
has recently been highlighted as harmful in mouse models of
AD; increasing brain amyloid-b (Ab) accumulation, exacer-
bating memory impairment and suppressing microglial Ab
phagocytosis (Chakrabarty et al. 2015). As HD and AD
share similar pathologies of protein aggregation and neu-
rodegeneration, and are both diseases exacerbated by
dysregulated inﬂammation, it may be that the laquinimod-
induced reduction in IL-10 from HD peripheral myeloid cells
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is beneﬁcial, and may contribute to resolution of the innate
immune system cytokine balance.
Previous studies on laquinimod mechanism of action
present evidence for a role of the NFjB pathway in
astrocytes. Laquinimod reduced astrocytic NFjB activation
in cuprizone-treated mice and primary human astrocyte
cultures (Br€uck et al. 2012), and gene expression microar-
rays on laquinimod-treated PBMCs isolated from MS
patients revealed down-regulation of key genes downstream
of NFjB signalling (Gurevich et al. 2010). The results of
this study, however, do not support a role for laquinimod
mechanism of action downstream of NFjB activation in
primary human HD monocytes. Laquinimod did not affect
IjB degradation kinetics, nuclear translocation of p65 nor
IKKc-mHTT protein–protein interactions, from the untreated
condition. This is in accordance with work by Br€uck et al.
who found that NFjB activation was markedly reduced by
laquinimod in astrocytes, but not in microglia, the resident
myeloid cells of the CNS, in stimulated primary mouse
cultures (Br€uck et al. 2012).
In summary, 5 lM laquinimod applied to HD patient
peripheral myeloid cells for 24 h appears to reduce hyper-
reactive cytokine production in response to LPS stimulation.
This is true for Th1-activating proinﬂammatory cytokines
and Th2-activating cytokines including IL-10. Altering
peripheral immune responses modulates central pathology
and disease progression in HD, hence laquinimod is a
promising candidate for dampening the harmful effects of a
dysfunctional innate immune system in HD. The mechanism
for this does not appear to be downstream of NFjB
activation in these cells. Laquinimod mechanism of action
is currently under investigation.
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Supplementary figures 1 and 2 legend: Primary non-stimulated human monocyte cultures from HV, preHD and 
manHD received 2hPT or 24hPT with 1 or 5 µM laquinimod, or 24hPT+24hCT with 5 µM laquinimod. Levels of 
cytokine release were measured in culture supernatants and normalised to cell culture protein. Supplementary figure 
1 displays results for the Th1-activating cytokines and supplementary figure 2 displays results for IL-2 and the Th2-
activating cytokines measured. Columns = mean average log cytokine level of biological repeats; error bars = SEM; 
*p<0.05, **p<0.01. 
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SUPPLEMENTARY FIGURE 1: Th1-activating cytokine levels in non-stimulated
monocytes pre-treated with laquinimod
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SUPPLEMENTARY FIGURE 2 IL-2 and Th2-activating cytokine levels in 
non-stimulated monocytes pre-treated with laquinimod
